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Preface
‘Less then 200 years ago matter created by living organisms was
regarded to be distinct from non-living matter, like salts, minerals and
gases. It was with the discovery by Friedrich Wo¨hler in 1828 that a
biological molecule could be synthesized from inorganic compounds that
the inorganic and organic worlds joined. Wo¨hler tried to form am-
monium cyanate by combining the inorganic salts silver cyanate and
ammonium chloride, but found that urea was formed instead. Urea
was known to be produced by animals and excreted in large amounts
in the urine. In a strike it became evident the chemical reactions of
organic matter must obey the same principles as the reactions of the
inorganic compounds, which chemists at that time had been studying
extensively. If this was true it should be possible to study the biological
world in a similar way by applying a purely chemical point of view . . . ’
‘Introduction to Pharmaceutical Bioinformatics’
by Jarl E.S. Wikberg
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nologies, 2010, 7(2), 115 (*equal contribution of both authors, upon invita-
tion for the themed issue: Drug Discovery beyond the rule of ﬁve)
chapter 2: Transcription Factor Mimics describes the miniaturization
of basic region leucine zipper transcription factor proteins. Two models are
represented. First, a model developed in our group and therefore named ‘the
Madder mimic’ is discussed. In this study, a peptidosteroid model, which was
developed earlier (during the PhD thesis of D. Verzele) to improve pharmaco-
kinetic properties, was revisited and optimized through the incorporation of
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ﬂexible linkers. Though this dramatically complicated the synthesis, through
optimized protocols and the use of microwave assistance, the improved model
could be synthesized and DNA binding for the ﬁrst time shown. In the
second part, ‘the Morii mimic’, developed by the Morii group based on a
non covalent adamantane-cyclodextrin inclusion complex is described. It was
selected from literature as a reliable model for DNA-peptide cross-linking in the
next chapter and resynthesized during a research stay in the group of Prof. Morii.
• Peptidosteroid tweezers revisited: DNA binding through an optimized de-
sign. Carrette L.L.G., Morii T. & Madder A. (provisionally accepted in Eur.
J. Org. Chem.)
chapter 3: Furan-based cross-linking combines all results obtained with
the furan oxidation cross-linking methodology. It starts with a short introduction
of the methodology, developed in our group for DNA interstrand cross-linking.
This is then followed by a case study on naturally occuring furan-modiﬁed DNA.
The methodology was further shown to be compatible with RNA duplexes for
interstrand cross-linking. It was attempted to visualise interstrand cross-link
formation using DNA origami and a fast scanning atomic force microscope. The
main part and goal of this section is the extension of the methodology towards its
application on the DNA-protein interface. Using the transcription factor mimics
from the previous chapter this was ﬁrst attempted from a furan-modiﬁed peptide
to the DNA, then from furan-modiﬁed DNA to the peptide and ﬁnally from a
furan-modiﬁed protein to RNA.
• DNA Interstrand Cross-link Formation by using Furan as a Masked Reactive
Aldehyde. Carrette L.L.G., Gyssels E. & Madder, A. Curr. Prot. Nucl.
Acid. Chem. 2013, 54:5.12.1-5.12.16
• A synthetic oligonucleotide model to evaluate oxidation and cross-linking
propensity of natural furan modiﬁed DNA. Carrette L.L.G.* & Madder
A.* ChemBioChem 2014, 15(1), 103-107 (*co-corresponding authors), inside
cover.
3• Mildly inducible and selective cross-link methodology for RNA duplexes.
Carrette L.L.G., Gyssels E., Loncke J. & Madder A. Org. Biomol. Chem.
2014, 12, 931-935.
• Toxicity Inspired Cross-linking for Probing DNA - Peptide Interactions.
Carrette L.L.G, Morii T. & Madder A. Bioconj. Chem. 2013, 24(12),
20082014.
chapter 4: Method development describes three results associated with
solid phase synthesis, which is used to synthesize peptides and oligonucleotides:
a) the use of a colour test to show the presence of functional groups on a solid
support, b) an NMR based method for the concentration determination of
peptides and oligonucleotides and c) a novel coupling methodology to synthesize
functionalized oligomers on solid support from a single building block and
without protecting groups.
• NF-31 color test uncovers ‘hidden’ alcohol functionalities in PEG-based
resins for solid phase peptide synthesis. Carrette L.L.G., Verzele D. &
Madder A. Tetrahedron Lett., 2010, 51(16), 2106-2108.
• Multi-functionalized sequence-deﬁned oligomers from a single building
block. Espeel P.*, Carrette L.L.G.*, Bury K., Capenberghs S., Martens
J., Du Prez F. & Madder A. Angew. Chem. Int. Ed. 2013, 52(50), 13261-
13264 (*equal contribution of both ﬁrst authors).
Part 2: Experimental Part lists the general protocols and provides additional
supporting information (speciﬁc protocols and spectral data) for all sections of
the descriptive part, represented in the same order.
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Part I
Descriptive Part
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Chapter 2
Situation
To situate this work, I would like to begin with a manuscript written
at the start of this PhD thesis in 2010, reviewing the state of the art
in the ﬁeld concerning the goals that had been set for this PhD study:
• To prove DNA binding with our developed peptidosteroid tran-
scription factor model
• To obtain cross-linking from a DNA binding peptide to its DNA
target
This review is thus ideal for the situation of the research. It gives an
overview of peptidic transcription factor mimics binding duplex DNA
and thus acting on the DNA-protein interface and the available meth-
ods for cross-linking on this interface with their pros and cons.
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Introduction Aberrant modulation of gene expression at the transcriptional
level is at the origin of numerous diseases. By disregulating cell growth and trig-
gering cell proliferation, various oncoproteins carry out their biological functions
as transcription factors, crucially relying on their DNA-binding capacities. Ar-
tiﬁcial transcription inhibition or modiﬁcation is possible via various approaches
through diﬀerent interfaces (Fig. 2.1). Selective recognition between the reac-
tion partners on the interface is essential for success. Truncated mimics that lack,
for example, the activation domain while retaining the DNA-binding requirements
might interfere with DNA complexation of the malignant natural counterpart, dis-
rupt transcriptional induction and ultimately suppress the oncogenic activity.[1, 2]
This short review will treat such peptidic transcription factor mimics, acting on
the DNA-protein interface by binding the duplex, ultimately towards irreversible
9blocking via interface cross-linking. Besides the simple desire to mimic Nature,
these miniature probes hold potential for disentanglement of the molecular basis
of DNA-targeting by natural proteins.
Artiﬁcial transcription factor mimics: gradual expansion of the chem-
ical space Fifty years after the milestone discovery of the Watson and Crick
double-helical structure of DNA, the oﬃcial completion of the Human Genome
Project (HGP) in 2003 was another landmark event in the history of natural
sciences.[10, 11] Multidisciplinary research at the interface of various disciplines
became prerequisite to distill the ﬂood of new information and reap maximum re-
ward from the genome data. The nascent discipline of chemical biology approaches
biological problems from the chemist’s point of view and employs its ability to pro-
ﬁciently design, prepare and characterize tailor-made compounds, which can be
subsequently applied to probe biological systems in highly-controlled, well-deﬁned
experiments (reviewed in [12]). Organic synthesis occupies an indispensable po-
sition in the discovery process, enabling the craftful preparation of tailor-made
conjugates, not limited by the genetic code or the structures of the ribosomal ma-
chinery. Through sophisticated strategies, the rigorous control of molecular struc-
ture and function provides access to the vast expanse of chemical space.[13] The
targets of chemistry research in these days are no longer restricted to small drug-
like molecules. Much of the intellectual adventure and challenge has gradually
converged with biology and the size of aimed compounds has steadily increased.
The activity, selectivity and stability of biopolymers become controllable, and
they can be tailor-made like small organic compounds. Furthermore, chemical
protein synthesis has enabled the systematic development of proteins with en-
hanced potency and speciﬁcity as candidate therapeutic agents.[14] Consequently
eliciting a recent awareness within the pharmaceutical society for the unexplored
opportunities of the generally ignored chemical space (GICS), medicinal chemists
start thinking outside their Lipinski box.[15]
Despite the promising relevance of probing simpliﬁed peptide versions derived
from natural protein counterparts, progress has been remarkably slow, failing to
keep pace with the plethora of resolved complexes. The fragile balance between
structural minimization and biophysical outcome impedes rational design of down-
sized mimics, demanding devoted trial-and-error tuning of empirical constraints.
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Figure 2.1: Diﬀerent biological interfaces are involved in the processes of
transcription and translation. a) Typically several proteins have to associate to
obtain an active transcription factor and/or to form the transcription initiation complex
on the DNA. Disruption of these interactions can be modulated by small molecules,
which block the interaction.[3–5] b) Promising strategies exploiting the nucleic acid
interface aim at inhibition of translation. This can be achieved by blocking mRNA with
a short complementary RNA fragment (antisense RNA). Alternatively a double stranded
RNA fragment (small interfering RNA) or single stranded RNA fragment (micro RNA)
together with the RNA-induced silencing complex (RISC) can degrade mRNA.[6, 7]
c) The DNA-protein interface is an emerging site for new generation therapeutics.[8]
Interference can be achieved either at the protein level with decoys (small synthetic DNA
fragments that bind to the transcription factor by mimicking the speciﬁc DNA binding
site)[9] or at the DNA level by blocking the target site. The latter can be realized
by a small intercalating molecule, which slides in between DNA base pairs; a triplex
forming oligonucleotide, which binds in the major groove of DNA through Hoogsteen
interactions; a small molecule binding in the minor groove or a large molecule binding
in the major groove. In the latter approach, initial strategies focus on DNA-binding,
and at most inhibition of gene expression. By linking this DNA-recognizing domain to
an activating eﬀector domain, selective modulation of the transcription process could
ultimately be envisioned. While size of the compounds will probably hamper both
synthesis and permeability, fascinating examples have been disclosed for the (synthetic)
minor-groove binding Dervan polyamides[18-20] or (mostly, if not all biotechnologically-
engineered) major-groove targeting zinc ﬁngers.[25] Successes are most certainly related
to the exquisite control of recognition speciﬁcity, the modularity of systems and the
synthetic accessibility, as detailed hereafter.
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Minor Groove Recognition: synthetic polyamides Dervans
polyamides, based on the minor groove binder Distamycin A (Fig 2.2a),
can be regarded as peptides with each α-carbon replaced by a ﬁve membered
ring (Fig 2.2d). Natural Distamycine is a crescent shaped, small polyamide
with three pyrrole (Py) rings that binds AT rich sequences in the minor groove
selectively. Dervans group demonstrated that substituting pyrrole by imidazole
(Im) and introducing hydroxypyrrole (Hp), it became possible to recognise all
bases by a speciﬁc combination of two rings.[16] The genetic code was cracked.
As the Dervan peptides bind the minor groove in a 2:1 fashion, aﬃnity could be
further increased by linking two peptides.
Additional modiﬁcations introduce speciﬁc properties to the DNA binders.
Fusing a polyarginine to the tripyrrole increases binding aﬃnity and promotes
nuclear uptake even though these small molecules are already relatively cell
permeable.[17] Linkage of a Dervan peptide, binding in the regulating domain
of a gene, with the activator domain of a transcription factor allows for selective
transcriptional activation of that speciﬁc gene.[18] Conjugation with a natural
alkylating moiety, like CC-1065 or duocarmycin, increases the eﬃciency and se-
lectivity of the DNA alkylation and can be used for gene silencing, as alkylated
coding regions cannot be read by RNA polymerase II.[19, 20] Most proteins bind
in the major groove (excluding the TATA box binding protein) but except for a
few cases were major groove protein binding is inhibited by minor groove bind-
ing Dervan peptides,[21] the latter are unsuitable for blocking the DNA-protein
interface, as it was shown that both can bind at the same time.
Figure 2.2 (facing page): Non-exhaustive, pictural overview of synthetic pep-
tidic groove binders, based on the natural DNA binding moieties distamycin
(a), zinc ﬁngers (b) or basic region leucine zippers (c). Based on distamycin,
Dervan developed hairpin minor groove binding polyamides of pyrrole (Py), imidazole
(Im) and hydroxypyrrole (Hp) (d). Small monomeric peptides can bind the major groove
as α-helix, if the associated entropic penalties are compensated via preorganization (e).
Hybrid conjugates of a tripyrrole sequence and a peptide monomer represent another
strategy to cope with thermodynamics. The former module assists in the major groove
recognition by the latter module which mimics either the atypical zinc ﬁnger, GAGA
(f) or the basic region leucine zipper GCN4 (g). Furnishing genuine mimics of natural
proteins, a ﬁnal approach consists in the combination of several major groove binding
peptides, such as homodimeric GCN4 (h) or heterodimeric cMyc-Max (i) sequences.
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Ultimately, to uniquely distinguish a site in the three gigabase human genome,
a recognition sequence of 16 base pairs is required. Although examples of
polyamides that can realise this exist, mismatch sequences will probably not dis-
rupt binding, due to the great binding aﬃnity of such a single molecule-DNA
binder.[22]
Major Groove Recognition: stabilised monomeric helices The ma-
jority of well-characterized families of native DNA-binding proteins rely on recog-
nition α-helices to make base contacts in the major groove. The overall shape
and dimensions of an α-helix allow it to ﬁt into the major groove in a number of
related, but signiﬁcantly diﬀerent ways. This variability explains the preference
of natural proteins for targeting this wider groove over the narrower minor one.
The design of peptides mimicking the DNA binding domain of such proteins
is not straightforward, as most α-helices lose the capability to fold and thus bind
DNA with high aﬃnity when removed from their natural context.
Various possible strategies have been described[23, and references cited
therein] and consist in the use of peptide fragments that stabilise an α-helix
(Fig 2.2e). Successful substitution of non-crucial amino acids with the helix pro-
moting alanine can be achieved. Helical structures can also be stapled by the
formation of a lactam bridge between lysine and aspartic acid, four positions fur-
ther in the chain. Alternatively one can make use of stable α-helices, as in the
small, well-folded avian pancreatic polypeptide (aPP), where an α-helix is sta-
bilised by hydrophobic interactions on one side of the helix. The other side of
this helix can then be used to graft residues required for DNA recognition and
binding.
Exploitation of minor groove conjugation for major groove recogni-
tion It was shown that the covalent attachment of peptides to the DNA back-
bone through a linker can compensate for the entropic cost associated with sec-
ondary structure formation and bind DNA as an α-helix. Next to intramolecular
binding to increase the aﬃnity for DNA, cooperative binding is another option.[23,
and references cited therein] This can be achieved by fusing intercalators or Der-
van peptides to the major groove binding peptide (Fig 2.2f and 2.2g). Combining
diﬀerent smaller DNA binding units, overall binding selectivity can be signiﬁcantly
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improved.
Engineered Zinc Fingers gripping the major groove In the area of
zinc ﬁnger transcription factors, an advanced level of insight and pairing control
has been achieved.[24] Whereas other DNA-binding proteins generally make use of
the 2-fold symmetry of the double helix, zinc ﬁngers are linearly linked in tandem
to recognize DNA stretches of varying lengths, with high discrimination ﬁdelity.
The ability to bind speciﬁcally to virtually any given DNA sequence, combined
with the potential of fusing polydactyl zinc ﬁnger peptides with eﬀector domains,
has led to the technology of engineering of chimeric DNA modifying enzymes
(equipped with e.g. methylase, nuclease, recombinase modules) and transcription
factors (simple blockage without eﬀector, repression vs. activation domains, and
chromatin remodeling factors as examples).[25] Opening the possibility of using
the engineered zinc ﬁnger-based factors as novel human therapeutics, ongoing suc-
cesses stimulated the creation of the ﬁrst biotech companies to exploit this new
platform (Sangamo BioSciences, Inc., Richmond, California; and later Gendaq
Ltd., as a spin-oﬀ of the MRC Laboratory of Molecular Biology, Cambridge, UK).
Interestingly, customized zinc ﬁnger constructs for given DNA sequences can now
be acquired commercially from Sigma-Aldrich, branded as Compo-Zr technology.
Table 1 includes an example of a Zinc ﬁnger construct for therapeutic applica-
tion. Although a vital sequel in the gradual expansion of the chemical space
covering artiﬁcial transcription factors, most (if not all) zinc ﬁnger designs are
biotechnologically-engineered and as such beyond the scope of present overview,
emphasizing on miniature constructs synthesized via bottom-up organic synthesis.
Despite numerous further studies and applications, ranging from genome anno-
tation tools to (pre-)clinical implementation, the interested reader is therefore
referred to excellent reviews recently disclosed in literature.[26, 27]
Artiﬁcial zipper miniatures seizing the major groove The α-helical
bZIP and b-HLH-ZIP motifs are among the simplest protein structures able to
bind the DNA major groove in a sequence-speciﬁc fashion. The simplicity and
tractability of the bipartite zipper-type proteins has made them attractive frame-
works for the design of artiﬁcial counterparts. The variety of designs exhibiting
native protein-like targeting of DNA-sequences by employing short basic region
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peptides, dissected from naturally occurring bZIP transcription factors, demon-
strates the potential of artiﬁcial miniatures as biomolecular recognition devices.
However, considering above discussion, the inherently-low DNA-binding aﬃnity
of short, isolated, natural basic region peptide monomers does not surprise. As
mentioned earlier, suppression of bZIP binding capacities by presenting so-called
monomeric reading heads illustrates the delicate balance between entropy and
enthalpy.
Research demonstrated that the basic region as such contains suﬃcient in-
formation for DNA recognition, provided helical structures are stabilized (vide
supra) or artiﬁcial dimerization is applied. Predominantly serving as a structural
scaﬀold to pre-organize the relatively small, N-terminal recognition α-helices, the
extended C-terminal dimerization domain can be replaced by various connectors,
both covalent and non-covalent.[23, and references cited therein][28] Since the
original disclosure of a cystine-bridged peptide dimer mimicking the homodimeric
yeast GCN4 leucine zipper protein, development of subsequent generation bZIP
miniatures has been intensely pursued. Early work of Schepartz et al. focused on
the chemical synthesis of (homodimeric) GCN4 mimics upon artiﬁcial dimeriza-
tion via formation of a non-covalent bis(terpyridyl)-iron(II) coordination complex.
Related contributions were further disclosed by Morii et al., typically employing
either a non-covalent β-cyclodextrin:adamantyl host-guest inclusion complex or
covalently bridged enantiomeric biphenyl derivatives as artiﬁcial dimerization in-
terfaces in a variety of homo- and heterodimeric GCN4-based designs.
The apparent hibernation in this research area notwithstanding, Mascaren˜as’
artiﬁcial GCN4 homodimer, represented in Fig. 2.2h, illustrates current state-
of-the-art in the comprehension of design principles and control over binding
properties for simultaneous DNA major groove targeting. Incorporation of a
photo-isomerisable azobenzene moiety allowed for generating a light-modulated
DNA-binding peptide.
Although sharing a similar mode of binding DNA target sites with the exten-
sively scrutinized bZIP-equivalents, artiﬁcial mimics of the basic helix-loop-helix
zipper (b-HLH-ZIP) transcription factors are conspiciously few. Despite the ex-
ceptional total chemical synthesis (172 residues) yielding a covalently-stitched
replica of the vertebrate cMyc-Max (proto-) oncoprotein achieved by Canne et
al. in 1995,[29] translation of this precedent towards miniature derivatives has
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been long overdue. Related to the bZIP and b-HLH-ZIP type proteins, the sin-
gular MyoD-MyoD bHLH-type mimic, reported by the Morii group[30] before
ﬁnally resorting to the GCN4 standard, conﬁrms the interest for corresponding
miniaturization eﬀorts.
Directly involved in human tumorgenesis and cancer, the pivotal cMyc
member of the Myc/Max/Mad network is a prominent example of how these
proteins are promising targets towards novel, potent, transcription-targeting
chemotherapeutica.[31] However, (1) the inﬂuence of loop-projecting DNA-
contacts, (2) the ambiguous role of loop-associated ﬂexibility, (3) the constrain-
ing/stabilizing interactions with essential accessory mediators of the transcrip-
tional machinery in vivo and (4) the seeming regulatory subtleness of the helix-
loop-helix transcription factor family conspire against the exploitation of their
peptide counterparts in design eﬀorts. In this respect, the heterodimeric Jun-
Fos bZIP oncoprotein bears special mentioning, combining a cMyc-like cancer
relevance with the GCN4-like structural tractability.
Although a decade passed since Mascaren˜as’ triggerable GCN4-GCN4 bZIP
contribution mentioned above, the contrasting void of helix-loop-helix counter-
parts stimulated initiatives from our own group. Recently, we achieved a ﬁrst
generation of down-sized b(-HLH-)ZIP models with emphasis on the therapeu-
tically relevant cMyc-Max combination.[32] Based on covalent restriction by a
steroid core with deﬁned geometrical properties (as depicted in Fig. 2.2i), the
orthogonal reactivity of the attachment points is an additional feature of the ar-
tiﬁcial linkage, permitting straightforward synthesis of not only homo- but also
heterodimer peptidosteroid conjugates.
Table 2.1 highlights some of the therapeutic developments directly derived
from the here discussed synthetic DNA binding peptidic constructs.
Cross-linking methods in development In order to block the DNA-protein
interface, the above described mimics need to compete with the natural DNA-
binding proteins. Capitalizing on previous successes at the protein-protein in-
terface, cross-linking moieties can be introduced to overcome the competition
problem.
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Table 2.1: Therapeutic developments of DNA-binding peptides
Table 2.2: Classiﬁcation of chemical strategies for cross-linking
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Exogenous bifunctional cross-linkers For cross-linking purposes, it is
most easy to add small reagents, like platina complexes, nitrogen mustards,
psoralen and reactive aldehydes (Fig. 2.3). In this case no modiﬁed DNA or
protein is required and their size allows easy penetration in cell and nucleus.
Most current chemotherapeutics belong to these compound classes and result
in DNA intra- or interstrand cross-linking. The impact of covalent attachment
of proteins was recognised more recently. It was shown that cisplatin, the best
known anticancer drug, cross-links nuclear matrix-bound transcription factors
and cofactors to DNA.[33]
Figure 2.3: Examples of exogenous bifunctional cross-linkers formaldehyde
(top), cis-platin (left), nitrogen mustard (right)
The problem with these external reagents is their lack of selectivity. Selec-
tivity can be dramatically increased by equipping either DNA or protein with
reactive groups. Alternatively, incorporation of more selective photoactivatable
cross-linking moieties has gained popularity. Over the years, an extensive col-
lection of cross-linking techniques has been developed, mainly to study transient
complexes between proteins or between proteins and DNA. Since it is not the
intention of this paper to give an exhaustive list, the reader is referred to more
specialized literature.[34–36] Table 2.2 intends to summarize the diﬀerent chemical
strategies for cross-linking.
DNA → Protein cross-linking Many examples exist in which nucleotides
are equipped with a reactive functionality, in order to form a covalent bond to
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a non-covalently bound protein (Fig. 2.4). In ﬁrst instance, it is possible to
modify the phosphate backbone, for example with pyrophosphate internucleotide
groups [37] or disulﬁde groups. In the last case a PSS-backbone (phosphoroth-
iosulﬁde) is formed, which can break and further react selectively with protein
cysteine groups. Cells treated with a PSS-oligonucleotide of the binding site
for NF-κB transcriptional factor underwent apoptosis.[38] Secondly, nucleotide
building blocks equipped with a reactive functionality (aldehyde, aziridine, alky-
lating moiety) can be used in automated DNA synthesis for the production of
reactive oligonucleotides.[39] Additionally, various approaches for postsynthetic
regioselective modiﬁcation to introduce reactive functionalities into DNA have
been described.[40] So called decoys, as depicted in Fig 2.1, have been developed
for irreversible cross-linking and inhibition of transcription proteins.[36]
Figure 2.4: Examples of cross-linking modiﬁcations in DNA for reaction
to proteins PSS-oligonucleotide (left), aldehydes (Crib) (middle), photoreactive 3-
triﬂuoromethyl-3-phenyldiazirine, benzophenon and phenylazide (right)
Protein → DNA cross-linking As for cross-linking to DNA, strategies
involving TFO (see Fig 2.1) for covalent blocking of the genome have been con-
sidered. Inhibition of transcription in cells was observed after application of a
psoralen-modiﬁed oligonucleotide and irradiation.[41]
Alternative approaches involving cross-linking peptides or proteins for achieve-
ment of covalent DNA blocking have received considerably less attention. The
most straightforward way to introduce a cross-linking functionality in peptides
or proteins involves cysteine side chain modiﬁcation. This was described for de-
termination of the orientation of a DNA binding motif within a complex[42] and
later applied for determination of other DNA-protein complexes. Furthermore,
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unnatural reactive moieties (examples in Figure 2.5) can be included during so-
lution or solid phase peptide synthesis. Even in proteins unnatural amino acids
can be introduced via the natural or mutated translation system.[43, 44] Recently
a photoactivatable cross-linking protein, obtained by genetically encoding for a
benzophenone containing amino acid was cross-linked to its DNA binding site.[44]
Figure 2.5: Examples of reactive moieties incorporated in peptides for con-
jugation to DNA Ruthenium complec [Ru(phen)(bpy’)(dppz)]2+ [51] (left), psoralen
[52] (middle), duocarmicin based (S)-CPI (cyclopropapyrroloindool) [53] (right)
Although application of speciﬁcally engineered proteins for DNA cross-linking
has thus proven feasible, the clear preference for the above described reverse ap-
proach can be explained in terms of the unpredictable inﬂuence of protein modiﬁ-
cation on DNA binding aﬃnity. The here described DNA binding peptides, being
potent candidates for mimicking their parent proteins, bring along new possibil-
ities in this area. As mentioned before, introduction of sequence selectivity to
DNA targeting agents does improve their eﬃciency as anticancer drug. Following
this trend, cross-linking transcription factor mimics might play an important role
in future cancer treatment.
Conclusions Illumination of the molecular mechanism by which cells adapt
their phenotype in response to external stimuli is a central objective in mod-
ern life sciences. The use of exogenous chemical approaches based on simpliﬁed
probes derived from natural proteins provides a potent alternative to interrogate
and decipher cellular behavior, supplementing biological methods (e.g. knock-out
organisms or expression proﬁles). Chemical biology is eliciting a paradigm change
in the way scientists approach therapy-directed biomedical questions and diagnos-
tics development, improving innovation and productivity towards drug discovery
of the future. Prominent practitioners of chemical biology research recently advo-
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cated the eminent role of this burgeoning ﬁeld in drug discovery, towards innova-
tive cures of the 21st century.[12] Harboring the potential to bridge fundamental
academic aspirations with pharmaceutical industry’s objectives, i.e. to genuinely
alter the perception of the pharmacologically achievable, this integrative discipline
oﬀers invaluable incentive to elicit uncovered therapeutic targets. The ultimate
goal remains the expansion of the diagnostic toolkit of biomarkers and the enrich-
ment of the limited arsenal of contemporary pharmacopeia. Corroborating the
relevance and opportunities presented in current review, a profound impact of
tailor-made bioconjugates, down-sized probes and small molecule libraries is an-
ticipated, and so-called ‘undruggable’ targets (and processes) such as (oncogenic)
transcription factors might accordingly shift into the realm of the medicinally con-
ceivable. Bayer’s acknowledgment for the fundamental research on transcription
regulation at a molecular level by Prof. Dr. Patrick Cramer (see links) illustrates
this change of mentality, while the 2006 Nobel Prize of Chemistry awarded to
Prof. Dr. Roger Kornberg (see links) conﬁrms the value of continuing eﬀorts.
Designed mimics of transcription factors are valuable to assess the implica-
tions of the exquisite recognition selectivity of natural transcription factors on
the control of gene expression, towards molecular dissection of the complex reg-
ulatory networks and functional annotation of genetic information. Primarily
unveiling fundamental details of the dynamic interplay between biomolecular sys-
tems, biomedicinal diagnostics and anti-gene chemotherapeutics might eventually
arise from elucidation of key interactions, interrogation of aberrant transcriptional
behavior, and identiﬁcation of new genetic targets. Recent progress in peptide
delivery systems and the prospect of developing peptidomimetic counterparts of
in vitro active derivatives seem to warrant the ultimate medicinal potential of
this research area. Tackling human disease in an early stage at the fundamen-
tal DNA-protein interface, the signiﬁcantly rewarding ends for cancer research
demonstrate the relevance and justify the means of ongoing endeavors.
Outstanding issues
• Although speciﬁc DNA recognition is claimed for most artiﬁcial transcrip-
tion factor mimics, critical interpretation of assay results is needed because
single target binding in a genome-wide context is yet to be veriﬁed.
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• In spite of the recent progress in structural and biochemical studies, a uni-
versal code for the recognition between proteins and nucleic acids via the
major groove has yet to be generalized.
• Despite the contemporary interest in compounds beyond the Lipinski rule
of ﬁve, the medicinal applicability will beneﬁt from ongoing miniaturization
eﬀorts.
Related articles [23, 54–57]
Links
• The PIN Database (Proteins Interacting in the Nucleus): http://pin.
mskcc.org/home.html.
• The Nobel Prize in Chemistry 2006 to Roger D. Kornberg (Stanford Univer-
sity, USA) for his studies of the molecular basis of eukaryotic transcription:
http://nobelprize.org/nobel_prizes/chemistry/laureates/2006/.
• Recently acknowledged at the Bayer website, Prof. Dr. Patrick
Cramer (LMU Munich, Germany) occupies a prominent role at the
forefront of transcription research, elucidating the chemical processes
which turn the building blocks of DNA into a living, biological pro-
cess: See (a) Podcast: http://www.podcast.bayer.com/module/podcast/
tv-research-en.xml; (b) 2009 Hansen Family Award: http://www.
research.bayer.com/edition-21/science_and_education.aspx.
• Sangamo BioSciences, Inc., biopharmaceutical company exploiting the zinc
ﬁnger technology: http://www.sangamo.com/.
• The Sigma-Aldrich CompoZrTMzinc ﬁnger technology oﬀer: http://www.
compozrzfn.com/.
• The Zinc Finger Database (ZiFDB): http://bindr.gdcb.iastate.
edu/ZiFDB (Fu et al. (2009) Zinc Finger Database (ZiFDB): a repository for
information on C2H2 zinc ﬁngers and engineered zinc-ﬁnger arrays. Nucleic
Acids Res. 37 (database), D279D283)
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• Zinc Finger Targeter (ZiFiT), a web-based tool to facilitate design of zinc
ﬁnger proteins: http://bindr.gdcb.iastate.edu/ZiFiT (Sander et al.
(2007) Zinc Finger Targeter (ZiFiT): an engineered zinc ﬁnger/target site
design tool. Nucleic Acids Res. 35 (web server), W599-W605)
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Chapter 3
Transcription Factor Mimics
3.1 Madder Mimic:
dipodal peptidosteroid
As introduced in the previous chapter there is an interest in DNA
binding peptides, based on natural transcription factors for probing the
DNA-protein interface and for potential biomedical applications. Our
group contributed in the ﬁeld with the design of a dipodal peptidosteroid
tweezer, an artiﬁcial major groove zipper with a cholic acid as dimer-
izing scaﬀold.[58] The reported design did however not result in DNA
binding and was therefore revisited and optimized. The following is the
full paper that describes the optimized design, the associated synthetic
challenges that were faced and met and the achieved selective DNA
binding.
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Introduction For few years, examples of non-Lipinski drugs from outside the
traditional small-molecule box have been emerging on the market.[59, 60] To
name one of over 50 approved peptide drugs, Roche’s Enfuvirtide, a 36-mer
peptide for HIV-fusion inhibition was approved in 2003. Clear advantages in
activity, selectivity, and toxicology[60] are the basis of their utility as alternatives
to low molecular weight drugs.[61] Indeed, more selective targeted interactions
can result in a better treatment for a disease with fewer side eﬀects. Such drugs
can therefore be desirable alternatives to current very toxic chemotherapeutic
agents, through direct selective interaction with a defective gene, or by selectively
blocking the interaction of a transcription factor (TF) with its promoter. TFs
play an important role in the regulation of gene expression, and it has been
shown that in cancers, there is typically an overexpression of a limited number
of these factors.[1, 2] This forms the basis for a new selective therapeutic
platform. Transcriptional modiﬁcation using artiﬁcial TF models has been
demonstrated with the well-known polypyrrole amides, developed by Dervan,
which show selective DNA minor-groove binding.[18–20, 62] However, a universal
pairing code for recognition between natural amino acids and nucleotides for
major-groove binding has not yet been established.[63–65]
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In this context, TF proteins have been studied intensively in order to
understand the remarkable binding selectivity and aﬃnity that they show for the
major groove of DNA in the complex cellular environment.[66] TFs typically bind
DNA cooperatively as tweezers, embracing the DNA helix with two α-helical
peptides that insert into the major grooves. The basic-region leucine zipper
(bZIP) TF family simply consists of two uninterrupted α-helices (Fig. 3.1, left).
The N-terminal basic-region peptides interact with the DNA through 20-30
mostly basic residues,[67] while the leucine-rich C-terminal part takes care of
dimerization and correct positioning of the basic-region peptides through the
formation of a coiled coil. By dissecting interesting areas (i.e., the DNA-binding
regions) from the folded protein chain and assembling them onto a scaﬀold to
obtain a similar geometry, protein properties can be transferred to smaller model
systems.[68] Pioneering work by Kim et al. demonstrated that the entire leucine
zipper part can be replaced by a smaller moiety to fulﬁll the dimerizing function
for GCN4, a member of the bZIP family. By adding a cysteine and a spacer
consisting of two glycines to the basic-region peptide, a miniature protein was
obtained through disulﬁde-bridge formation.[69] Since then, other examples of
GCN4 models have been reported, dimerizing the basic-region peptides through a
branched lysine,[70] a bridged biphenyl moiety,[71] a hostguest inclusion complex
(Fig. 3.2C),[72]an Fe complex,[73, 73] a photoresponsive azobenzene,[74] PNA
(peptide nucleic acids),[75] etc.[76–78] The reduction of the size from proteins
to peptides not only makes them synthetically accessible, allowing unnatural
modiﬁcations derived from the organic chemist’s imagination, but it also improves
issues with stability, delivery, and availability.[79]
Previously, we designed and synthesized a dipodal peptidosteroid as a TF
model of the cMyc-Max oncoprotein,[58] a transcription factor belonging to
the basic helix-loop-helix zipper (b-HLH-ZIP) family, a class of TFs related
to the bZIP family, containing an additional loop. Although the envisaged
molecule was obtained in good purity, DNA binding could not be achieved.
Visualization based on the PDB structures of the TF proteins (Fig. 3.1, middle)
showed that truncation of the α-helices to the basic-region peptides and direct
conjugation to the steroid scaﬀold does not permit adequate insertion of these
peptide helices into the DNA major groove. Despite a clear parallel positioning
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Figure 3.1: Design of a TF mimic of GCN4, a basic region leucine zipper TF (left)
by dissection the basic region peptides (middle) and immobilizing them through linkers
(Gaba-GG) on a smaller scaﬀold (deoxycholic acid) for dimerization (right) in side, front
and top view. The middle panel clearly shows the required divergence for insertion in
the major groove of the DNA and the steric encumbrance between the steroid and DNA
that would result from direct conjugation of the basic region peptides to the steroid.
of the two peptides, imposed by immobilisation onto the steroid scaﬀold, the
restricted divergence and steric encumbrance of such a constrained rigid model
prevents the right positioning of essential side-chain contacts and the induction
of α-helices, and thus DNA binding is hampered. This conﬁrmed the need
for a modiﬁed design, and prompted us to explore the potential beneﬁts of
a spacer moiety between the steroid scaﬀold and the basic-region peptides
(Fig. 3.1, right). Although the introduction of ﬂexible linkers into the design
meant that the synthetic route had to be thoroughly optimized, we now demon-
strate for the ﬁrst time selective DNA binding using these peptidosteroid tweezers.
Results and Discussion
Optimized model design The use of a steroidal cholic acid moiety was
inspired by the positive eﬀects of its amphiphilic nature on the biostability[80]
and bioavailability of an attached peptide,[81, 82] both of which are desirable for
the further development of TF models. Cholic acid is taken up in cells both by
active transport and by passive diﬀusion. Thus, cholic acid moieties have been
added as absorption modiﬁers[83] or covalently attached to enhance the uptake of
nanoparticles,[84] peptides, oligonucleotides, oligosaccharides, and small-molecule
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drugs.[85, 86] Depending on the number of cholic acid residues and their mode
of attachment, the passive diﬀusion is referred to as ﬂipase activity[87] or
umbrella transport.[88–93] Furthermore, cholic acid is perfectly suited to be
used as a scaﬀold in multivalent and cooperative molecular engineering, and it
has been extensively used for this purpose. In this context, these conjugates
are often referred to as cholaphanes..[94] Ceragenins, cholic-acid-based mimics
of antimicrobial peptides are less sensitive to degradation, and as such are
more suitable for clinical development.[82] Furthermore, they are smaller and so
synthetically more accessible.
Figure 3.2: A) Orthogonally protected, C-3, C-12 diamino-modiﬁed deoxycholic acid
scaﬀold; B) Proposed peptidosteroid model; C) Model described by Morii based on the
adamantane-cyclodextrin inclusion complex.[72]
To dimerize the two GCN4 basic-region peptides, an orthogonally protected
diamino steroid derived from commercially available deoxycholic acid (Fig. 3.2A)
was used.[95, 96] The two orthogonally protected amino groups allow the attach-
ment of two diﬀerent DNA-binding peptides, both ﬁxed in the α-orientation,
optimal for DNA binding, by the chirality of the rigid scaﬀold (Fig. 3.2B).
The distance of ca. 7 A˚ between the C-3 and C-12 anchoring points of the
steroid scaﬀold[97] is comparable to the radius of β-cyclodextrin (7.5 A˚) used
in the previously reported Morii model (Fig. 3.2C).[72] This distance also lies
well within the range of distances measured between anchoring points in other
previously reported models (Fig. 3.3). Direct attachment of the basic-region
peptides to the steroid scaﬀold, as previously reported,[58] did not result in
a DNA-binding construct. As can be derived from Figure 3.1, this can be
ascribed to the steric clash between the DNA duplex and the scaﬀold, which
interferes with the insertion of the peptides into the grooves of the DNA.
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Previous designs with other dimerizing units used two extra glycines and a
cysteine as a linker to avoid this problem.[69, 71, 75] We preferred to avoid the
use of oxidation-prone cysteine, and therefore a γ-aminobutyric acid (Gaba)
moiety was intro duced together with two glycines as a linker to provide the
necessary ﬂexibility. Moreover, the rotational freedom of the Gaba residue should
allow the peptides to more easily adopt a conformation required for DNA binding.
Figure 3.3: Representation of previously used models The choice for the C-3
and C-12 of deoxycholic acid as anchoring points was partly inspired by the compara-
ble distance spanned by previously reported models. Other examples next to the Morii
model (Fig. 3.2C), are given here. This illustrates that 7 A˚ lies well within the range of
distances measured between anchoring points in previously reported models. A) Mea-
sured distance of 3 - 7.8 A˚ (using ChemBio3D) for the bridged biphenyl moiety reported
by Morii [71]. B) Measured distance of 8-9 A˚ for the binding Z form of the azoben-
zene model reported by Mascarenas [74] (Figure taken from ref. [74]). C) Measured
distance of 11 A˚ for the Fe-complex reported by Schepartz [73, 98] (Figure taken from
ref. [73, 98]).
Additionally, an N-terminal cap, acetamido benzoic acid (Aba) was added
to the N-terminus of the peptide. This aromatic moiety allows convenient
UV-monitoring and concentration determination as an internal standard,[77]
while eﬃciently blocking the N-terminus during the introduction of the second
amino acid sequence (Fig. 3.4). We chose to immobilize earlier described and
well-studied GCN4 basic-region peptides as DNA-binding moieties from the
simple bZIP rather than b-HLH-ZIP TF family. This led to the optimized design
of the target compound (3.1.3) shown in Figure 3.4, with two peptides consisting
of a ﬂexible linker, the DNA-binding basic-region peptide of GCN4, and an
N-terminal cap.
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Figure 3.4: Synthesis approach for the generation of a dipodal peptidosteroid
TF model (3.1.3).
Synthesis For the synthesis, several solid supports were evaluated, as it is
known that the resin can have a major inﬂuence on the outcome of the synthesis
of such large constructs. The most recent PEG polymers have been reported
to eﬃciently reduce hydrophobic peptide aggregation through their increased
hydrophilic character.[99–101] However, as we have shown earlier, with these
more recently developed resins, monitoring of the completion of reactions can be
compromised.[102] Therefore, we opted for the PEG-grafted polystyrene Tentagel
support from Rapp.[103] A low loading (0.28 mmol/g) further ensures the
accessibility of the growing peptide chains through a pseudodilution eﬀect.[104]
The ﬁrst step in the synthesis involved attachment of the orthogonally pro-
tected C-3,C-12-diamino-modiﬁed steroid scaﬀold to the solid support by a
Holmes photosensitive nitroveratryl-based linker.[105, 106] This linker was cho-
sen as it allows semi-online monitoring of the reaction through a mild, fast,
orthogonal, and non-laborious cleavage. Coupling and deprotection were car-
ried out manually under standard Fmoc (9-ﬂuorenylmethoxycarbonyl) solid-
phase peptide synthesis (SPPS) conditions using PyBOP (benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexaﬂuorophosphate).
With the scaﬀold attached to the solid support, we went on to attach the
GCN4 basic-region peptides (Fig. 3.4). Although the same peptide was to be
introduced at both the C-3 and C-12 positions, attempted simultaneous synthesis
of both peptides proved unsuccessful (see experimental part). As the C-12
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position is sterically more hindered, reaction proceeds faster at the C-3 position,
further inhibiting reaction at the C-12 position. Therefore the ﬁrst peptide
should be attached at the C-12 position before going on to functionalize the C-3
position. This diﬀerentiation is enabled by the Boc (tert-butoxycarbonyl) vs.
Alloc (allyloxycarbonyl) selectivity. Furthermore, this orthogonality allows future
mimicry of heterodimeric rather than homodimeric TF proteins. The amine
at the C-3 position was carefully Boc-deprotected with TFA (triﬂuoroacetic
acid; 20% solution), to ensure orthogonality with the photocleavable linker. The
ﬁrst residues (i.e., Gaba and Gly) were coupled manually under standard Fmoc
SPPS conditions using PyBOP (4 equiv.), and the remainder of the sequence
was coupled in automated fashion using HBTU (N,N,N’,N’-tetramethyl-O-(1H-
benzotriazol-1-yl)uronium hexaﬂuorophosphate; 10 equiv.). The Aba capping
was again carried out manually with PyBOP (10 equiv.) to give monopodal
product (3.1.2) in high purity (Fig. 3.5).
Figure 3.5: RP-HPLC chromatogram (C4, 300A˚, 75-100% MeCN in 15 min)
of the product (3.1.2)
The scaﬀold was then Alloc-deprotected at C-3 (to give 3.1.4) for attachment
of the second peptide. Previously, we reported that 1 equiv. is necessary,
when using (apparently less active) commercially available catalyst. However,
with freshly prepared tetrakis(triphenylphosphine)-palladium, this deprotection
could be achieved using only a catalytic amount. The ﬁrst amino acid coupling
at the C-3 position (to give 3.1.5) is diﬃcult, due to steric crowding once a
peptide is attached to the C-12 position (Fig. 3.6A). Acceptable conversions
could only be achieved by double HATU (1-[bis(dimethylamino)-methylene]-1H-
1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexaﬂuorophosphate) mediated coupling.
A capping step was still required to fully convert the amino groups (Fig. 3.6B).
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As shown in Figure 3.6C, conversions with other coupling reagents were worse.
Coupling of the second amino acid again proceeded well with PyBOP. From
the third residue onwards, coupling was carried out using automated synthesis
equipment. The ﬁnal product was obtained after a ﬁnal manual capping step.
The ﬁnal photocleavage from the solid support had to be carried out before
the acidic side-chain deprotection to avoid peptide loss, due to the observed
sensitivity of the photocleavable linker to acidic conditions.
Figure 3.6: A) Coupling of the ﬁrst amino acid (Gaba) of the second pep-
tide at the C-3 position of (3.1.4) to obtain (3.1.5) is challenging. B) RP-HPLC
chromatograms (C4, 300A˚, 75-100% MeCN in 15 min) of the standard manual coupling
conditions for the ﬁrst residue of the second peptide at C-3. B1: using PyBOP: (3.1.5)
was obtained in poor yield. B2: Subsequent double HATU coupling gave almost com-
plete reaction. B3: The small amount of remaining (3.1.4) was capped. C) RP-HPLC
chromatograms (C4, 300A˚, 75-100% MeCN in 15 min) of double 10 min coupling with
4 equiv of diﬀerent coupling reagents to obtain (3.1.5). C1: with HATU, C2: with
HBTU, C3: with Oxyma.
The RP-HPLC chromatogram in Figure 3.7 shows that a mixture, rather
than one major product, was obtained. LCMS analysis further revealed that
no compound of the correct mass was present in the mixture. In view of our
earlier reported successful synthesis,[58] and because linear 50-mer peptides are
typically accessible by solid-phase peptide synthesis, failure of the synthesis
was unexpected. The generation of two, protected 25-mer peptide chains in
close proximity on a rigid steroid scaﬀold through ﬂexible GabaGG linkers,
thus seemed to be particularly sensitive to aggregation, which complicates
the synthesis under the conditions reported earlier. Intra- and especially
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intermolecular aggregation through hydrophobic forces can prevent access of
the reagents to the reactive sites, reducing the reaction rates of the coupling
and deprotection steps. The kinetic problems lead to incomplete reactions, and
thus result in mixtures of compounds with deletion sequences and prematurely
terminated sequences.[107–109] Detailed analysis of the intermediates revealed
that diﬃculties arose starting from the ﬁrst residue of the second peptide,
which was sterically encumbered by the ﬁrst peptide chain at C-12. Although
steric hindrance diminished as the peptide was extended, hydrophobic aggrega-
tion with the ﬁrst peptide increased as the length of the second peptide increased.
Figure 3.7: RP-HPLC chromatogram (C18, 100A˚, 0-100% MeCN in 15 min)
of the products obtained upon synthesis of (3.1.3) under conventional syn-
thesis conditions following the reaction scheme shown in Figure 3.4.
Optimistically, the mixture obtained can be considered as a library of close
derivatives of the envisaged target model compound, and thus a preliminary
crude electrophoretic mobility shift assay (EMSA) was carried out (Fig. 3.8). As
the EMSA analysis showed a faint but clear indication of speciﬁc binding, we
were encouraged to further pursue the challenging synthesis of this new model,
optimized for DNA binding. Moreover, as failure in peptide synthesis is most
often due to steric hindrance and aggregation, like in this case, the dipodal
structure proposed here constitutes a good model system for further optimisation
of SPPS conditions. The production of high molecular weight peptidic drugs, in
which chemical synthesis plays an important role,[59] is still an important factor
that hinders their transfer into clinical use.
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Figure 3.8: Preliminary EMSA experiment using CRE DNA in lanes 1-5 and
random DNA in lanes 6-10 with the peptidosteroid (3.1.3) in concentrations 0 nM, 75
nM, 150 nM, 225 nM and 300 nM in respectively lanes 1 and 6, 2 and 7, 3 and 8, 4 and
9 and 5 and 10.
Completing and Improving the Synthesis In a ﬁrst attempt to
improve the synthetic yield and quality of the product, cleavage and deprotection
conditions were carefully optimized.
For reaction monitoring and small-scale cleavage, a small lamp (1 mW/cm2)
was used with the reaction mixtures in small glass test tubes for 3 h. To maximize
the yield in the ﬁnal cleavage of the end product, a more powerful lamp was
desired. We found that by using a 15 mW/cm2 lamp irradiating for 1 h from
both above and below, with the resin spread out as a monolayer in a Petri dish to
minimize light scattering and shadowing eﬀects, maximal cleavage yields could be
obtained (optimisation described in detail in experimental part). With a stronger
lamp or a longer irradiation time, side reactions started to occur.
Side-chain deprotection was then carried out using a cocktail very similar to
the generally accepted but smelly reagent K (TFA, water, phenol, thioanisole,
and ethanedithiol).[110, 111] Care was taken to avoid side reactions by adding the
cooled cocktail to the peptide on ice. These conditions are drastically diﬀerent
from those described and used earlier, where cleavage mixture B (TFA, water,
TIS (triisopropylsilane and phenol), including a non-smelly trialkylsilane, was
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heated to 60◦C to achieve complete deprotection. But under these conditions, a
better result could be obtained (Fig. 3.9), and the target compound was present
in the product mixture, as identiﬁed by LC-MS analysis.
Figure 3.9: RP-HPLC chromatogram (C18, 100A˚, 0-100% MeCN in 15 min)
of the products obtained upon the synthesis of (3.1.3) under conventional
synthesis conditions following the reaction scheme shown in Figure 3.4, but cleaved
oﬀ under optimized and more mild conditions.
Further improvements were approached using microwave-assisted synthesis.
Microwave irradiation was ﬁrst introduced in peptide synthesis in 1992, using a
modiﬁed kitchen microwave, and improved coupling yields were obtained at ele-
vated temperatures.[112] It became an immensely popular technique, partly be-
cause of the controversial non-thermal special microwave-related phenomena.[109,
113] Today, supported by the excellent work of Kappe[108, 114, 115] through stud-
ies with accurate temperature control, it is possible to say that the improvements
can be attributed to thermal eﬀects. Still, microwave heating has favourable prop-
erties over conventional heating, including the absence of wall eﬀects caused by an
inverted temperature gradient, localized superheating, and its easy applicability
to vortexed solid-phase reactions, where stirring bars should be avoided, and the
processes preferably carried out in an automated fashion.[116, 117]
The current target molecule, with the challenging synthesis of the strongly
aggregating second peptide, provides a good test system to explore the potential of
microwave-assisted SPPS (MA SPPS), which could disrupt the aggregation in the
peptide synthesis through thermal agitation. A ﬁrst test consisted of the coupling
of the ﬁrst residue of this peptide, which required double HATU couplings under
conventional conditions (Fig. 3.6). Using microwave irradiation, however, this
coupling could be carried out with standard coupling reagents HBTU, PyBOP,
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and DIC (N,N’-di-isopropylcarbodiimide)/HOBt (hydroxybenzotriazole) to give
complete conversion, as was seen with HATU (Fig. 3.10).
Figure 3.10: RP-HPLC chromatograms (C4, 300A˚, 75-100% MeCN in 15
min) of (3.1.5) obtained by double couplings with 8 equiv of diﬀerent coupling reagents
at 75◦C.
Encouraged by this result, the remainder of the second peptide was also syn-
thesized under microwave-assisted conditions. The microwave-assisted synthesis
gave considerable savings in time and cost, but also the ﬁnal yield and purity of
the product were increased (Fig. 3.11). The target peptide was shown to be the
major product by LC-MS analysis. Thermal agitation was found to decrease the
overall aggregation and to reduce the steric hindrance at the diﬃcult to access
reaction sites.
Figure 3.11: RP-HPLC chromatogram (C18, 100A˚, 0-100%MeCN in 15 min)
of the products obtained upon synthesis of (3.1.3) following the reaction scheme
shown in Figure 3.4, with the synthesis of the second peptide under microwave-assisted
conditions.
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DNA binding achieved The product obtained after puriﬁcation (Fig. 3.12)
was subjected to an EMSA to test for binding aﬃnity to a DNA binding site of
the original TF (CRE: 5’-ATGACGTCAT-3’).[118] Figure 3.13 shows the results
of the experiment. It is clear that the target molecule binds the DNA to form
an upshifted complex with lower mobility. The observed smearing of the gel is
probably caused by non-speciﬁc interactions with the DNA by impurities that
co-eluted with the target molecule during RP-HPLC puriﬁcation.[119] Indeed,
with increasing peptide length, the relative diﬀerences between target and by-
products decrease, while the number of variations exponentially increase. This
causes strong overlap on HPLC, making puriﬁcation extremely tedious. The su-
perposition of both speciﬁc and unspeciﬁc binding modes (see experimental part)
makes the present dose response between the concentration of the peptide and the
peptide-DNA complex more diﬃcult to observe, especially at high peptide con-
centrations. The binding capacity was further compared with the earlier reported
GCN4 mimic developed by Morii [72] (Fig. 3.2C), of which an authentic sample
was produced (see next section). It can be seen that our cholic-acid-based dipodal
peptide shows an aﬃnity for the target DNA that is comparable to and slightly
higher than that of the earlier developed non-covalent dimer. This clearly shows
the potential of our current design for synthetically accessible DNA major-groove
binders.
Figure 3.12: RP-HPLC chromatogram (C18, 100A˚, 0-100% MeCN in 15
min) of the puriﬁed product (3.1.3)
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Figure 3.13: EMSA titration (8% acrylamide gel, with 0.2% TBE buﬀer) of the
dipodal peptidosteroid (left, see Fig. 3.2B) and Morii mimic (right, see Fig. 3.2C) to the
CRE binding site. Lane 1 and 6, 2 and 7, 3 and 8, 4 and 9, 5 and 10 contain respectively
0, 0.3, 0.45, 0.6 and 0.75 μM of the mimic (3.1.3) with 6% sucrose, 100 mM Tris pH
7.6, 20 mM KCl, 10 mM MgCl2, 2.5 mM EDTA and 0.167 μM DNA. Gels were stained
with SybrGold and visualized under UV light.
Conclusion The synthesis of closely immobilized peptides is challenging, due
to aggregation of the peptides during synthesis. This is particularly so in the
current case, with a rigid amphiphilic steroid moiety. The ﬂexibility required for
DNA binding provided by the insertion of Gaba-GG spacers led to a dramatic
increase in the steric entanglement of the protected peptides, and thus precluded
successful conventional synthesis. Microwave irradiation allowed to reduce these
interactions, resulting in a successful synthesis of the dipodal peptidosteroid with
increased purity and yield using standard coupling reagents, and additionally
in greatly reduced synthesis time. It was further shown that improvements in
the yield and purity could be obtained by altering the cleavage conditions. As
such, this investigation contributes to the understanding and improvement of
SPPS methods for diﬃcult sequences, where microwave irradiation can clearly be
beneﬁcial. Using these optimised SPPS conditions, we were able to produce an
optimised, more ﬂexible peptidosteroid tweezer as a TF model with demonstrated
DNA-binding properties.
Our next eﬀorts will focus on a more modular and convergent synthesis to
obtained this now qualiﬁed transcription factor model. The synthesis and pu-
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riﬁcation of smaller peptides is more cost-eﬃcient and will greatly simplify the
eﬀort.[58, 120] This is the desired approach to obtain compounds in the amounts
and purities required for the further development and validation of the current
model system.
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3.2 Morii mimic:
Ad-CD inclusion complex
The synthetically accessible, DNA binding transcription factor
model is an ideal system for modiﬁcation with a cross-linking moi-
ety as outlined earlier. However, because the optimization of synthesis
and design for the peptidosteroid model was an ongoing process dur-
ing the thesis, an alternative was desired for use in these experiments.
The previous section already mentioned and depicted the adamantane-
cyclodextrin inclusion complex based model described by Morii and co-
workers. An additional advantage of this model is its non-covalent na-
ture, which allows a reduction in size by half after cross-linking under
denaturating conditions as illustrated in Figure 3.14 and simpliﬁes its
analysis and characterization. This section will give some additional
and more detailed information on this model and its synthesis.
Figure 3.14: Advantage of the non-covalent nature of the Morii mimic After
cross-linking the complex can be denatured to reduce the size by half for more straight-
forward analysis.
General The Morii group introduced the non-covalent mimic based on the
adamantane (Ad)-cyclodextrin (CD) inclusion complex in 1993,[72] after the in-
troduction of a covalent mimic based on a bridged biphenyl moiety.[121] Diﬀerent
members of the bZIP transcription factor family were miniaturized, GCN4[72],
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EmBP1[122] and C/EBP[123]. Their DNA binding peptides could be synthe-
sized with Ad and/or CD and mixed into Ad-CD heterodimers that preferentially
bound to DNA sequences with correspondingly mixed binding half sites.[28] The
synthesis of the constructs was mainly pursued to address the question of how
DNA binding proteins work as dimers and what the signiﬁcance of the dimer for-
mation was. The inclusion complex allowed to test the eﬀect of diﬀerent guests
(Fig. 3.15) or thus diﬀerent aﬃnities for dimerization.[124]
Figure 3.15: Diﬀerent guests for the formation of peptide dimers through
an inclusion complex Amino acid sequence for the peptide (G23) and structures
of the modiﬁed C-terminal Cys residue (X). The cysteine residues were modiﬁed with
6-deoxy-6-iodo-β-cyclodextrin for G23Cd and with bromoacetyl derivatives of adaman-
tanemethylamine, aminoadamantane, aminonoradamantane, aminoethylnorbornane and
cyclohexylamine for the guest molecules G23Ad, G23NAd, G23NrA, G23Nb, and G23Ch
respectively. Taken from [124]
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When the host and guest molecule were each attached to a terminus of the
peptide, cooperative oligomers could be formed on repeating DNA binding half
sites as illustrated in Figure 3.16.[125]
Figure 3.16: Schematic representations showing the Ad-CD homooligomer
bound on the direct-repeat sequence of the DNA binding half-site. Bars
represent the basic region peptide. N and C indicate the N-terminal and C-terminal of
the peptide, respectively. Half-circles at the C-terminal and ﬁlled ovals at the N-terminal
represent β-cyclodextrin and the adamantane group, respectively. White arrows denote
the DNA binding half-site. Taken from [125]
Synthesis The synthesis of the non-covalent model based on the Ad-CD inclu-
sion complex and from hereon now named the Morii mimic, was resynthesized
under the supervision of Prof. Morii in his lab.[72]
Mono-6-deoxy-6-iodo-β-cyclodextrin (3.2.3) for modiﬁcation of the cysteine
thiol functionality in the peptides, was obtained by mono-tosylation of a primary
hydroxyl functionality of the cyclodextrin followed by SN2 substitution with NaI
(Fig. 3.17).
Figure 3.17: Modiﬁcation of β-cyclodextrin a. 0.5 equiv TosCl in dry pyridine at
rt for 2h, 45%; b. 10 equiv NaI in DMF at 70◦C for 2h, 40%.
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N-(bromoacetyl)-1-adamantanemethylamine (3.2.6) for the modiﬁcation of
the cysteine thiol functionality in the peptides, was obtained by activation of
bromoacetic acid as succinimide ester for reaction with adamantanemethylamine
(Fig. 3.18).
Figure 3.18: Modiﬁcation of adamantane a. DCC coupling (1.1 equiv) with hy-
droxysuccinimide (1 equiv) in dry EtOAc at 0◦C for 2h, 66%; b. 0.33 equiv adaman-
tanemethylamine, 0.66 equiv HOBt in dry DMF at 0◦C, allowed to heat up to rt
overnight, 41%.
Peptide synthesis was performed under standard conditions for long peptides,
using 10 equivalents of HBTU with HOBT as coupling reagent. Cleavage was
performed as described in the previous section under optimized conditions. The
obtained GCN4 peptides (3.2.7) were puriﬁed by RP-HPLC. Contrary to the
peptide depicted in Figure 3.15, a double glycine linker was added between the
basic region peptide and the cysteine, to also allow for dimers through a disulﬁde
bond as described by Kim.[69]
The puriﬁed peptides where reacted with the activated adamantane to obtain
Ad-GCN4 (3.2.8) or with the cyclodextrin moiety to obtain CD-GCN4 (3.2.9)
(Fig. 3.19) in phosphate buﬀer at pH 9 under inert conditions to avoid dissulﬁde
formation as much as possible. For modiﬁcation with activated adamantane, it
was found that the formation of side products could be minimized by reducing the
reaction time from the reported 1 h to 5 min on ice. Modiﬁcation with the less
activated cyclodextrin was more diﬃcult and required 7 h at room temperature,
after which all remaining starting material had been oxidized to form disulﬁdes.
The latter were reduced and reintroduced in the reaction to increase the yield.
The modiﬁed peptides were repuriﬁed on RP-HPLC. Upon combination of both
Ad- and CD-GCN4, an inclusion complex gives rise to the Morii mimic (3.2.10).
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Figure 3.19: Modiﬁcation of the GCN4 peptides and formation of the Morii
mimic through an inclusion complex
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DNA binding The DNA binding of the Morii mimic was already shown before
in comparison with the Madder mimic (Fig. 3.13). Binding was also quantiﬁed
by EMSA with 32P -labeled AP1 DNA, which is the natural pseudopalindromic
binding site of GCN4 protein. The radiolabelled DNA allows for very sensitive
radiodetection. Therefore only minimal amounts of DNA are required and the
equation for the dissociation constant (KD) can be simpliﬁed, to equal the con-
centration at half-binding. Judging from the result in Figure 3.20 the KD is about
150 nM. This is higher than the reported value of 30 nM for the palindromic CRE
binding site,[72] due to the preference of the Morii mimic for the latter binding
site.[124]
Figure 3.20: EMSA titration of the Morii mimic to 32P -labeled AP1 binding
site (8% acrylamide gel, with 0.2% TBE buﬀer). Lane 1 to 10 contain respectively 0, 1,
2, 5, 10, 20, 50, 100, 200, 500 nM of the mimic (3.2.10) with 6% sucrose, 100 mM Tris
pH 7.6, 20 mM KCl, 10 mM MgCl2, 2.5 mM EDTA and 4.88 pM DNA.
Chapter 4
Furan based Cross-linking
4.1 DNA
interstrand cross-linking
4.1.1 The methodology
The cross-linking methodology described here is inspired by the natural toxicity
of furan. Furan has been classiﬁed by the International Agency for Research on
Cancer (IARC) as a possible human carcinogen (class 2B), based on several reports
of toxicity in laboratory rats and mice. Furan is present in the environment, as
a contaminant from incomplete combustion, as well as in food, especially after
heat treatment.[126] Once in the body, furan is metabolized by cytochrome P450
enzymes to butenedial, which reacts quickly with nucleophiles in proteins and
nucleic acids,[127] resulting in the observed toxicity.
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To study DNA-damaging processes such as furan oxidation, and especially
the subsequent endogenous DNA repair mechanism, well-deﬁned model systems
are required. As extraction from biological systems is often troublesome, much
eﬀort has been devoted to synthesizing model substrates.[128] DNA ICLs are an
important form of DNA damage, not because of their abundance (they account
for less than 10% of all DNA damage), but because they represent the most toxic
lesions.[129] Furthermore, ICLs and their repair are of interest in the context of
chemotherapeutics and increasing resistance to them.
ICLs can be generated by addition of bifunctional cross-linkers (N-mustards,
mitomycin C, platinum) to double-stranded DNA[130], but selectivity in this ap-
proach can be problematic. Generation of ICLs by incorporation of a linked
dinucleoside during solid-phase synthesis[131] or by postsynthetic orthogonal re-
action between two modiﬁed ODNs through disulﬁde formation[132] and Huisgen
click reaction[133] has also been described. Because the latter requires modiﬁca-
tion of both strands in the desired duplex, use with natural DNAs for therapeutic
applications (e.g., antisense, antigene, plasmids, aptamers, RNA interference, al-
ternative splicing, decoy strategies), diagnostics (SNP detection), or structural
studies is not possible.
To allow reaction with unmodiﬁed DNA strands, a reactive functionality is
required. However, because the incorporation and handling of such modiﬁed re-
active ODNs are tricky, and premature reactions can occur, latent functionalities
are desirable. In this approach, furan was used for this purpose. Reminiscent
to what happens during in vivo furan metabolization, selective oxidation trans-
forms the furan into a reactive enal functionality, which allows it to react with
nearby nucleophiles (e.g., the exocyclic amine of cytidine) and form a cross-link.
Figure 4.1 illustrates the reaction mechanism for the formation of the stable cross-
linked ODN species.
Figure 4.1: Reaction mechanism for formation of a stable cross-linked ODN.
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In view of the general stability of the furan moiety before oxidation, handling
during synthesis and binding events is straightforward and no special protection
strategies or precautions need to be considered. This has led to the synthesis
and evaluation of several alternative furan-modiﬁed ODNs (Fig. 4.2), allowing
the ﬁnetuning of yield and selectivity.[134–139]
Figure 4.2: Summary of all the furan-modiﬁed nucleosides synthesized and
tested for ICL formation in our group
This was the background information from a protocol we wrote on
our established furan based method for DNA interstrand cross-linking
and forms the basis of the further investigations, which are the topic of
this thesis. The introduction of the protocol, describing the methodol-
ogy is furthermore given below. The protocols themself give a detailed
description on the synthesis and use of two furan-modiﬁed nucleoside
analogs. Basic Protocol 1 describes the synthesis of furan-modiﬁed 2’-
amino-2’-deoxyuridine (4.1.1 or nu1), which provides selective cross-
linking with complementary C bases (up to 30% isolated yield). The
Alternate Protocol describes synthesis of a more simple and ﬂexible
acyclic furan-containing nucleoside analog (4.1.2 or nu2), which is
less selective, but generates high quantities of ICL duplex species (up to
70% isolated yield). Incorporation of both modiﬁed phosphoramidites
in oligonucleotides is described in Basic Protocol 2, and cross-link for-
mation to an unmodiﬁed target DNA strand is described in Basic Pro-
tocol 3. As these protocols are lengthy and technical, they are not given
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here but are available at the end of the manuscript as Appendix.
This unit describes the use of furan-modiﬁed oligodeoxynucleotides (ODNs)
for cross-linking with the complementary nucleic acid strand to achieve site-
selective interstrand cross-links (ICL). Once incorporated into an ODN, the
furan moiety is selectively oxidized to a reactive 4-oxobutenal. If positioned
on the Watson-Crick base pairing interface in the DNA duplex, it will quickly
react with the exocyclic amine functionality of a complementary base on the
opposite unmodiﬁed strand, generating an ICL (Fig. 4.3). As the reactive
aldehyde functionality is only uncovered on triggered demand (for example,
after hybridization), nonspeciﬁc and oﬀ-target reactions are quasi excluded.
Essential in the cross-linking protocol is that the obtained aldehyde reacts with
an unmodiﬁed complement, allowing ICL formation with natural DNA target
sequences. The cross-linked species can be isolated in good yields and are very
stable.
4.1. DNA INTERSTRAND CROSS-LINKING 51
The furan moiety is readily incorporated into the necessary phosphoramidite
building blocks and does not interfere with solid-phase ODN synthesis. Given the
stability and commercial availability of a series of furan derivatives, the possibili-
ties for generating furan-modiﬁed analogs are numerous, and a range of diﬀerent
furan-modiﬁed nucleosides have already been synthesized and described.[134–139]
Cross-link yield and selectivity are strongly dependent on the exact structure of
the furan-modiﬁed nucleoside. In addition, there is a trade-oﬀ between duplex
stability and nucleobase availability on the one hand and cross-link yield and
selectivity on the other. Using rather simple but ﬂexible (and thus duplex desta-
bilizing) furan-modiﬁed nucleoside analogs like nu1, high yields of ICL duplex can
be obtained, with cross-linking to both complementary A and C bases. On the
other hand, when the furan moiety is introduced onto the more classical nucleoside
building block like nu2, cross-linking is completely selective for complementary
C bases.
Figure 4.3: Overview of furan-based interstrand cross-linking methodology.
Furan-modiﬁed nucleosides are converted to the corresponding phosphoramidites and
incorporated into ODNs under standard conditions. After hybridization with a suitable
complement, the furan-modiﬁed ODN is oxidized to generate a reactive 4-oxobutenal,
which reacts eﬃciently with the nucleophilic exocyclic amine of the opposite base.
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4.1.2 Case study: Kinetin
Kinetin (N6-furfuryladenine) is obtained after base excision repair
of furfuryladenine containing DNA. It has been associated with bene-
ﬁcial anti-aging eﬀects and is therefore being studied for the treatment
of cancer and degenerative diseases. In the context of our previous
work on furan-modiﬁed oligonucleotides for the formation of inter-
strand cross-links, known to be very toxic lesions, we were intrigued
by the absence of negative eﬀects of the kinetin modiﬁcation in DNA.
Therefore, kinetin-modiﬁed oligonucleotides were synthesized, through
a new, easy, post-synthetic approach and tested for duplex cross-linking
under our previously reported conditions. We here show that indeed
oxidation to a reactive intermediate takes place, which however de-
grades without cross-link formation. A tentative explanation for this
observed diﬀerence between the naturally occurring kinetin-containing
DNA and our previously synthesized furan-modiﬁed DNA is presented.
Figure 4.4: Kinetin originates from furan-modiﬁed DNA, which in principle
could form ICLs, but has beneﬁcial anti-aging eﬀects
Kinetin modiﬁcations are formed under oxidative stress and are
here shown to protect against this stress through their rapid oxidation.
This ﬁnding contributes to the general understanding of the mecha-
nism by which kinetin can exert its beneﬁcial eﬀects and can be of
interest to a large community, in view of the importance and appli-
cation potential for human health. Furthermore the fact that furan
oxidation in kinetin-modiﬁed DNA does not lead to toxic DNA inter-
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strand cross-links, underscores the importance of the positioning of the
furan moiety in our previously described methodology. On the other
hand, it reveals the potential of our furan based cross-linking to target
cells under high oxidative pressure (for example cancerous cells), as
these conditions can trigger furan oxidation. Such experiments will be
the subject of our continued investigation.
Introduction Furan moieties are formed upon degradation of natural DNA
and can further react by addition to nucleic acid bases. The presence of
furfuryl-modiﬁed adenine in cellular DNA[140, 141] has been detected in almost
all organisms, including humans.[142] As illustrated in Figure 4.5, these modiﬁca-
tions are formed under oxidative stress, characterized by the presence of increased
levels of reactive oxygen species (ROS) and responsible for aging and a number
of degenerative diseases including cancer.[143] Hydroxyl radicals attack the DNA
deoxyribose components at C5’, which leads to the spontaneous cleavage of the
DNA backbone and β-elimination, giving rise to furfural as a marker of oxidative
damage. Furfural can react with the exocyclic amine group of adenine in DNA
to form a Shiﬀ base, which is further reduced by an unknown mechanism to yield
a stable furan modiﬁcation in the DNA. The modiﬁed base can then be cut from
the DNA by repair enzymes; this generates kinetin (N6-furfuryladenine) and an
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abasic site, which is further repaired.[144]
Figure 4.5: Kinetin biosynthesis
Kinetin was the ﬁrst discovered cytokine plant hormone. Cytokines are
products of oxidative metabolism of the cell and thus biomarkers of oxidative
stress. They typically are N6-substituted adenine derivatives that control many
processes in plants.[145] Kinetin promotes cell division in plants and has been
associated with several anti-aging eﬀects such as retardation of leaf senescence
and modulation of the environmental stress response.[146] In insects, kinetin can
delay development and prolong the lifespan[147] and also in human ﬁbroblast
cells, kinetin was found to delay aging characteristics.[148] A detailed discussion
of all eﬀects of kinetin is beyond the scope of current report, but has been
extensively reviewed by others.[145, 149]
As a result of kinetin’s observed beneﬁcial eﬀects, it is currently being
used in the treatment of dermatological problems[150] and tested in relation
to neurodegenerative diseases.[151] It is further also being investigated as a
chemotherapeutic.[152, 153] Importantly, unlike several other anti-ageing factors,
kinetin does not promote carcinogenesis. The increased lifespan in cell cultures is
not associated with proliferative activity. Kinetin’s actual mechanism of action
is still unknown, but it is clear that kinetin functions as antioxidant and is
able to protect proteins[154] and DNA[155] from oxidative damage. Diﬀerent
hypotheses for its action exist; they include the prevention of radical formation
by participation in complex formation with iron[155] and scavenging properties
by for example free radical mechanisms.[156] It further induces maintenance and
repair mechanisms by forming a bulky lesion in the DNA.[145]
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We have previously reported the use of singlet oxygen, an ROS, for the
oxidation of a furan moiety in synthetic, modiﬁed oligonucleotides to generate
DNA interstrand cross-links (ICL) in a high-yielding and selective manner.[139]
Furan oxidation by NBS[134–138, 157] or ROS such as singlet oxygen[139] results
in a reactive 4-oxobutenal[127] intermediate that will quickly react with the
exocyclic amines of the opposite base, resulting in an ICL as shown schematically
in Figure 4.6. Hydroxyl radicals, responsible for the formation of kinetin have
also been reported to oxidize furan.[158] ROS are thus scavenged both during
the formation of the kinetin moiety as well as during the furan oxidation. Such
antioxidant behavior has been described for naturally occurring antioxidant furan
fatty acids (F acids), which were shown to scavenge hydroxyl radicals by oxida-
tion to diketones.[159] The 4-oxobutenal obtained in case of 2-modiﬁed furans
like kinetin, however is more reactive and could, similar to our synthetic furan-
modiﬁed oligonucleotides cause ICL, which are considered very toxic DNA lesions.
Figure 4.6: Outline of the earlier described furan oxidation cross-link
methodology Furan-modiﬁed nucleosides (for example 1) are synthesized and upon
conversion into the corresponding phosphoramidites incorporated into ODNs, using stan-
dard ODN synthesis conditions. After hybridization with a suitable complement, the
furan-modiﬁed ODN is oxidized to generate a reactive 4-oxobutenal, which will eﬃciently
react with the nucleophilic exocyclic amine functionality of the opposite base.
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To check the oxidation and subsequent cross-linking propensity of the nat-
urally occurring furan-modiﬁed oligonucleotide precursors of kinetin, they were
synthesized through a new fast synthesis protocol and oxidized according to our
standardized procedures.[157]
Results and Discussion
Synthesis The synthesis of kinetin-modiﬁed oligonucleotides has been
described before, but clear protocols remain vague. As the kinetin modiﬁcation
is not very stable under the acidic conditions of dimethoxytrityl removal, a
post-synthetic oligonucleotide modiﬁcation approach is desirable.[160] The
modiﬁcation of inosine with furfurylalcohol has been mentioned,[143] as well as
the reaction of furfurylamine with a 1,2,4-triazol-4-yl-modiﬁed adenosine,[160]
which needs to be synthesized.[161]
To avoid this need for synthesis, the commercially available activated building
block O6-phenyl-deoxyinosine-cyanoethyl phosphoramidite was used in this study
(Fig. 4.7). It fulﬁlls the role of convertible dA and can be handled and coupled in
exactly the same way as standard commercial phosphoramidites. It was ﬁrst de-
scribed by Verdine in his study for disulﬁde cross-linked oligonucleotides.[162, 163]
After synthesis, the oligonucleotide was cleaved from the controlled pore glass by
4 h treatment with concentrated NH3 solution. This further led to a partial de-
protection (benzoyl groups of adenosine and cytidine, isobutyryl group of guano-
sine) of the DNA (see Fig. 4.8). The obtained mixture was DMTr-deprotected,
puriﬁed over Sep-Pak into 5 fractions (see Fig. 4.9) of which the ﬁrst fraction
was ﬁnally treated with 1 M aqueous furfurylamine at 55◦C, to obtain complete
deprotection and furfurylamine modiﬁcation of the activated inosine (4.1.4 or
nu4). There is an optimal treatment time with furfurylamine for the partially
deprotected oligonucleotide. If treatment is too short, residual protection groups
remain and/or there is incomplete conversion of the inosine. Upon prolonged re-
action times formation of a side product occurs, as can be derived from the peak
splitting in Figure 4.10. The optimal time is between 30 and 40 h (Fig. 4.11 and
Fig. 4.12). The procedure should thus best be monitored by HPLC. The identity
of the obtained ODNs was conﬁrmed by mass analysis.
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Figure 4.7: Post-synthetic modiﬁcation to obtain a furfuryl-modiﬁed syn-
thetic oligonucleotide
Figure 4.8: HPLC chromatogram after aqueous NH3 treatment, before Sep-
Pak of ODN4.1.1, a test oligonucleotide
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Figure 4.9: HPLC chromatograms of the 5 Sep-Pak fractions of a test
oligonucleotide, ODN4.1.1,
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Figure 4.10: HPLC chromatogram after 18h/24h/36h/64h of furfuryl-
amine treatment, with zooms on the peaks in the last 2 chromatograms
of ODN4.1.1, a test oligonucleotide
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Figure 4.11: HPLC monitoring of the furfurylamine modiﬁcation reaction
(24h/30h/38h) of ODN4.1.1, a test oligonucleotide
Figure 4.12: HPLC monitoring of the furfurylamine modiﬁcation reaction
(24h/30h/38h) of ODN4.1.2
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Analysis of kinetin-modiﬁed duplexes To test for oxidation and ICL
formation, the previously described sequence used to develop our furan oxi-
dation ICL methodology was synthesized, but with replacement of nucleoside
nu3 (ODN4.1.4) with the kinetin modiﬁcation (nu4) (ODN4.1.2, see Table 4.1).
ODN4.1.2 was combined with its complement, varying the base opposite to the
kinetin modiﬁcation (ODN1-4). The unmodiﬁed analog of ODN4.1.2 (ODN4.1.3)
was used for comparison. The eﬀect of the kinetin modiﬁcation on duplex sta-
bility was examined by measuring the melting proﬁles, summarized in Table 4.1.
Clearly, introduction of the kinetin modiﬁcation destabilizes the A-T basepair.
This can be ascribed to the furan substituent on N6 preventing the formation of a
Watson-Crick hydrogen bond.[164] On the other hand, A-A and A-C mismatches
are stabilized with 4 and 5 degrees respectively upon introduction of the furfuryl
substituent, possibly because of a favourable stacking interaction with the furan
moiety or the formation of Hoogsteen bonds.
Table 4.1: Oligonucleotide duplexes for ICL formation with their Tm values
Duplex Base Tm Modiﬁed Base Tm ΔTm
pair (◦C) Duplex pair (◦C) (◦C)
ODN4.1.3-ODN1 A-T 52 ODN4.1.2-ODN1 nu4-T 45 -7
ODN4.1.3-ODN2 A-G 43 ODN4.1.2-ODN3 nu4-G 40 -3
ODN4.1.3-ODN3 A-A 37 ODN4.1.2-ODN3 nu4-A 41 +4
ODN4.1.3-ODN4 A-C 36 ODN4.1.2-ODN4 nu4-C 41 +5
With ODN sequences:
ODN4.1.1: 5’-CGG ATG nu4CG TCA TTT TTT TTC-3’
ODN4.1.2: 5’-CTG ACG Gnu4G TGC-3’
ODN4.1.3: 5’-CTG ACG GAG TGC-3’
ODN4.1.4: 5’-CTG ACG Gnu3G TGC-3’
ODN1: 3’-CAG TGC CTC ACG-5’
ODN2: 3’-CAG TGC CGC ACG-5’
ODN3: 3’-CAG TGC CAC ACG-5’
ODN4: 3’-CAG TGC CCC ACG-5’
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Interstrand cross-linking Oxidation of the furan moiety was performed
with NBS for all duplexes as described previously.[157] Adduct formation
would be expected with ODN3 and ODN4, in which an adenosine and cytidine
unit, respectively, are opposite the kinetin modiﬁcation in ODN4.1.2, through
reaction between the exocyclic amine and the oxidized furan moiety, both of
which are positioned in the major groove. This is illustrated for cytidine in
Figure 4.13.[138] Because thymidine does not possess an exocyclic amine and the
exocyclic amine of guanosine is positioned in the minor groove, no ICL formation
is expected in those cases. Nucleosides containing furan on the base have not
been used for ICL previously, so a selection of previously obtained data with
nu3-modiﬁed ODNs[138] is represented for comparison in Figure 4.14C. With all
furan-modiﬁed nucleosides previously used for ICL in our group, the highest ICL
formation yields were obtained upon cross-linking to cytidine.[134–138, 157]
Figure 4.13: Mechanism of adduct formation with dC.[138]
Figure 4.14 shows the results of the cross-link reaction. The PAGE experi-
ment (Fig. 4.14A) shows a small amount of cross-link reaction in case of ODN4
containing a complementary C, but much less than expected and typically ob-
tained with our methodology. Moreover, and in contrast to previously obtained
ICL products, the lower-mobility compound was too unstable to be isolated and
characterized upon HPLC analysis. The HPLC chromatograms of the cross-link
reaction between ODN4.1.2 and ODN4 with increasing equivalents of added NBS
(Fig. 4.14B) show that modiﬁed ODN4.1.2 is consumed by the oxidation reaction,
thus behaving as a scavenger, but this clearly does not lead to the formation of
a new main compound or conjugates. Neither was ICL formation observed for
the other duplexes (HPLC chromatograms in the experimental part) Stable toxic
ICLs are thus hardly being formed upon oxidation, and this could explain the
observed positive eﬀects of kinetin modiﬁcations in cells.
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Figure 4.14: Results of the ICL formation reaction A) Denaturating PAGE of
reaction mixture before and after the addition of 4 equiv NBS with ODN4.1.2-ODN4
in lanes 1 and 2, ODN4.1.2-ODN3 in lanes 3 and 4, ODN4.1.2-ODN2 in lanes 5 and
6, ODN4.1.2-ODN1 in lanes 7 and 8 respectively. B) HPLC of the cross-link reac-
tion mixtures with ODN4.1.2-ODN4 following the reaction after addition of increasing
amounts of NBS. C) For comparison, typically obtained results with nu3-modiﬁed ODN
(ODN4.1.4) as example: denaturating PAGE (left) and HPLC (right).[138]
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Visualisation A plausible explanation for the diﬀerence in cross-linking be-
havior between both furan-modiﬁed oligonucleotides (nu4 incorporation versus
nu3 incorporation) can be found in the positioning of the furan moiety of a kinetin
modiﬁcation in the major groove, away from the base pairing interface. A visu-
alization of this scenario, with local optimizations is represented in Figure 4.15A.
The furan moieties in the modiﬁed nucleosides that are used for cross-link forma-
tion can access the base pairing interface for reaction. The furan moiety of nu3,
for example, can position itself via its linker from the sugar in between the bases
(Fig. 4.15B), where it is possibly stabilized by stacking interactions.
Figure 4.15: Visualisation of the positioning of the furan moiety (in ball
and stick representation) in the duplex A) Visualisation of the duplex ODN4.1.2-
ODN1. The furan moiety points away from the Watson-Crick interface into the major
groove. B) Visualisation of the same duplex but modiﬁed with the nu3-A basepair for
cmparison. The furan moiety is located on the Watson-Crick interface.
Conclusion We here report on a new, fast and eﬃcient synthetic protocol for
the synthesis of naturally occurring kinetin-modiﬁed ODNs. The oxidation and
cross-linking propensity of these ODNs was evaluated. We found that the furan
moiety does indeed undergo oxidation, but in this case cross-linking is observed
only in a very small amount, if at all. We thus propose that the antioxidant
properties of kinetin are possibly linked to the oxidation potential of the furan
moiety, which scavenges ROS, without causing more damage in the form of ICLs.
4.1. DNA INTERSTRAND CROSS-LINKING 65
4.1.3 Towards extension of current methodology
The furan oxidation based cross-linking that was developed in our group works
very well. However, the practical applicability is somewhat limited to stabiliza-
tion of DNA duplexes as dumbbells[165, 166], the use of cross-linked duplexes for
the study of repair mechanisms and the use of an inducible probe for antigene
approaches. The latter however is strongly complicated by the localization of
the genome in the nucleus and its highly compact form, wrapped around histone
proteins as chromatin. Attempts have therefore been undertaken to expand the
furan oxidation cross-link methodology and these will be discussed in the next
sections of this chapter.
The ﬁrst and main goal was to apply the furan oxidation cross-link method-
ology to DNA-protein interactions. Like discussed in the introduction, two ap-
proaches (illustrated in Fig. 4.16) can be followed for this purpose. Modifying
proteins with a furan for cross-linking to their DNA target such as a transcrip-
tion factor could potentially block or activate transcription. Modifying the DNA
could be used to create cross-linking decoys, regulating gene expression by cova-
lent capture and blockage of transcription factors in the cytoplasm. Furthermore,
this technology could be applied for use in the study of transient DNA-protein in-
teractions by covalent stabilization. For this latter approach, the DNA is modiﬁed
with a furan containing nucleoside like for ICL formation. However because of this
similarity, competitive ICL can occur, while the cross-link reaction will proceed
through a diﬀerent reaction mechanism targeting amino acids. The alternative
approach starts by incorporating furan-modiﬁed amino acids in a protein or a
more synthetically accessible peptidic protein model and proceeds through a sim-
ilar cross-linking mechanism targeting the exocyclic amines of the bases of the
target nucleic acid. This second approach was therefore initially followed.
To further broaden the possibilities in this context, the selective incorporation
of furan moieties in proteins, rather than peptides, through amber suppression
was also attempted. The obtained furan-modiﬁed proteins were tested in furan
based labeling reactions.
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Figure 4.16: Illustration of the approaches to study furan oxidation based
DNA-protein cross-linking, modifying the DNA or a protein mimic
Secondly, the furan interstrand cross-linking was applied on RNA duplexes,
which is highly relevant in view of the recently found important role of RNA
in regulation[167, 168] and for antisense approaches, targeting RNA in the
cytoplasm. Though counterintuitive because of the completely diﬀerent struc-
ture, stiﬀness, stability and reactivity, both NBS and singlet oxygen based
furan oxidation cross-linking proceeded similar as before, apart from a diﬀerent
nucleoside preference in RNA context.
Lastly, an attempt was undertaken to visualize DNA interstrand cross-linking
using fast scanning AFM on DNA origami. These experiments help for the ap-
plication of the cross-linking approach on origami, which could be used in the
assembly of complex architectures (e.g. with proteins) on such DNA chips.
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4.2 DNA ← protein mimic
cross-linking
The idea to expand the furan based cross-link methodology to pep-
tides, was not new in our group and has been extensively explored by
Dr. Annelies Deceuninck.[169] Diﬀerent peptides with known DNA
binding behavior, have been synthesized with a furan modiﬁcation and
tested for cross-linking. Initially Dervan peptides (see Fig.( 2.1),
synthetic polyamides based on the natural minor groove binding dis-
tamycine A, were explored for the purpose, because of their easy syn-
thesis and their well studied programmable DNA recognition. While
selective oxidation of the furan moiety attached to a polypyrrole was
diﬃcult, no cross-link products could be observed. Therefore peptidic
alternatives were searched. A synthetic peptide (SPRKSPRK), based
on the SPPK motif SPK(R)K(R) from the histones of sea urchin
sperm, was reported to interact with DNA probably through β-turns,
stabilized by two hydrogen bonds. When no cross-linking was obtained,
the HMG-I/Y peptide, a fragment (TPKRPRGRPKK) of the eukary-
otic, non-histon chromosomal HMG-I/Y protein, was tested as an al-
ternative model. More structural data was available for rational de-
sign, but still no cross-linked product was observed. However, as these
three model peptides bind in the minor groove of A,T-rich DNA se-
quences, where no exocyclic amine for reaction is available, the search
for a good model system continued. A helix (VEDRTVDVHIRRL-
RKALEPG) from the PhoB transcription factor that inserts in the
major groove and was reported to bind DNA on its own, was mod-
iﬁed with furan for the purpose. However in view of the discussion
in the previous chapter, it can be understood that this simplistic ap-
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proach did not result in a good DNA binder. Because other major
groove binders were not easily synthetically accessible, the attention
was ﬁnally turned to threading intercalator peptides. A naphthalene
diimide (NDI)-bisintercalator was synthesized, but also in this case
no cross-linking was observed. The transcription factor mimics dis-
cussed and developed in the previous chapter were now considered for
obtaining proof of principle for DNA-protein cross-link formation.
4.2.1 Furan-modiﬁed amino acid
In order to extend our furan based cross-linking methodology to peptides, furan-
modiﬁed amino acids are required (Fig. 4.17). Fmoc protected furfurylamine
(Fmoc-aa1) is commercially available. In previous work,[169] furan was also
introduced N-terminally on the peptide by capping with 3-(2-furyl)propanoic
acid (aa2), obtained from 3-(2-furyl)acrylic acid by hydrogenation. To allow for
more diversiﬁcation and evaluation of a diﬀerent linker, additional furan-modiﬁed
amino acids were synthesized (Fig. 4.17): two furan-modiﬁed lysines and a furan-
modiﬁed glutamic acid.
Figure 4.17: Overview of furan-modiﬁed amino acids protected for use in
peptide synthesis
Initially Fmoc-aa3 was synthesized, from the standard available Fmoc-
Lys(Boc)-OH for peptide synthesis, by acid Boc deprotection, reductive ami-
nation with furfural and Boc reprotection, as illustrated in Figure 4.18. Al-
though the Fmoc protecting group is not completely acid stable, orthogonal de-
protection was possible using a 50/50 mixture of DCM and TFA for 15 to 60
min at rt. A convenient method for direct reductive alkylation of Fmoc pro-
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tected amino acids with pyridine, thiazole, imidazole was described by Levadala
and co-workers,[170] using the fast and high yielding alkylation conditions with
NaBH(OAc)3 of Abdel-Magid.[171] By appropriate stoichiometric manipulation
of the amino acids and aldehydes and allowing imine formation before addition of
NaBH(OAc)3, monoalkylated products (4.2.8) could be obtained in good yield.
The described reﬂux conditions for imine formation however were both found to
be destructive and unnecessary and were thus slightly adapted. The reaction
was most easily followed on TLC after a small scale reduction. Protection of the
secondary amine is necessary for its use in peptide synthesis. Boc deprotection
was chosen as it is an easy high yielding reaction, which in the end will result
in a deprotectable furan-modiﬁed lysine, best resembling the native lysine. The
dialkylated product is present in the reaction mixture as side product (10−15%).
Though it does not require a reprotection step, the double modiﬁcation may result
in a lower DNA aﬃnity due to sterical hindrance and will most probably result
in a very complex cross-linking mixture. Therefore it was not further tested.
Figure 4.18: Syntesis of Fmoc-aa3 (4.2.3) a. TFA/DCM 1/1 for 1h at rt; b. addi-
tion of 0.95 equiv furfural in MeOH for 5h at rt; c. Addition of 1.4 equiv NaBH(OAc)3
for another 4h; d. Quench the reaction with 1 equiv Boc2O and 0.1 equiv DMAP for
1.5h (unoptimized overall yield 46%).
The monoalkylated amino acid (4.2.3) was also never used, as the obtained
peptide modiﬁed with this furfuryllysine was thought to be able to react
intramolecularly after oxidation as illustrated in Figure 4.19, rather than forming
cross-links.
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Figure 4.19: Intramolecular side reaction of a peptide modiﬁed with the
synthesized furfuryllysine (4.2.3)
Alternatively, lysine can be modiﬁed with furfurylisocyanate to obtain (4.2.4)
(Fig. 4.17), starting with the Boc deprotection as illustrated in Figure 4.20.
Figure 4.20: Syntesis of Fmoc-aa4 (4.2.4) a. TFA/DCM 1/1 for 1h at rt; b. 2.1
equiv furfurylisocyanate, 2.1 equiv DIPEA in DMF at rt for 2h (unoptimized overall
yield 60%).
However when peptides were synthesized with this amino acid, the furan
moiety was cleaved oﬀ by nucleophilic scavangers during the acid cleavage and
side chain deprotection as illustrated in Figure 4.21. The ureum linker was indeed
already used before in the design of a furan-modiﬁed nucleoside (Fig. 4.21B),
but peptide and oligonucleotide synthesis conditions are drastically diﬀerent,
obviously inﬂuencing the outcome of the reactions.
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Figure 4.21: Unsuitability of the ureum linker for furan modiﬁcation of an
amino acid A) During the strongly acidic conditions for cleavage of the peptide from
the solid support and the deprotection of its side chains, nucleophilic scavangers can
cause cleavage of the furan moiety; B) Designed furan-modiﬁed nucleoside containing a
ureum linker, which is stable under the phosphoramidite and DNA synthesis conditions
Because the introduction of a longer linker between the amino acid and the
furan moiety might really enhance the cross-linking yield and furthermore because
the stability of the furan moiety under acidic cleavage and side chain deprotec-
tion conditions should be investigated,[172] yet another furan amino acid (4.2.5)
was synthesized. This time starting from glutamic acid rather than lysine, com-
bination with furfurylamine and typical peptide coupling reagents can generate
a stable peptide bond. Fmoc-Glu-OtBu (5.2.10) was bought, modiﬁed and tBu
deprotected, similar like the earlier described Boc deprotection, as shown in Fig-
ure 4.22.
Figure 4.22: Syntesis of Fmoc-aa5 (4.2.5) a. 1 equiv furfurylamine, 1.2 equiv
HBTU and 2 equiv DIPEA in DMF at rt for 2h; b. TFA/DCM 1/1 for 1h at rt
(unoptimized overall yield 56%)
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4.2.2 Positioning of the modiﬁcations in the mimic
To create the best possible scenario to achieve cross-linking, the position for
incorporation of the furan-modiﬁed amino acid was carefully selected.
As described before, basic region leucine zippers, like the GCN4 transcription
factor, bind DNA as a dimer of 2 uninterupted α-helices that dimerize through
the formation of a coiled coil (Fig. 3.1). An α-helix and more speciﬁcally a
coiled coil is prescribed by a characteristic 7 amino acid repeat, the 3-4 heptad
repeat denoted as a-b-c-d-e-f -g (represented as the typical helical wheel in
Figure 4.23.[173] Positions a and d, positioned 1 turn apart at the same side of
the helix are typically occupied by hydrophobic amino acids such as Leu (hence
the name leucine zipper), Ile, Val, and Ala. These residues cause the helix to have
a hydrophobic site. Two such helices dimerize through hydrophobic interactions
forming a shallow coiled coil. The residues at positions e and g are frequently
polar or charged and can strengthen the coiled coil by electrostatic interactions.
The basic regions extend as α-helices from the coiled coil and though the residues
are now mostly basic for interaction with the DNA, their position can still be
represented by the helical wheel. At the DNA interface, residues at position g
are facing directly towards the major groove, at positions c and d the residues
are just aside, one turn higher in the helix. The residues at the N and C termini
of the basic region are positioned below and above the DNA.
However, the best positioned residue N235, cannot be replaced as it plays
an essential role in DNA binding. Replacing it might thus compromise DNA
binding. Therefore the important interactions were identiﬁed based on the crystal
structures and literature.[118] Because the Morii mimic has higher aﬃnity for
the unnatural palindromic binding site CRE, experiments will be performed with
DNA containing this binding site rather than the natural pseudopalindromic
AP1 site. The two binding sites only diﬀer in the center, where the two binding
half sites (ATGAC) for the 2 peptides in AP1 overlap at the central C/G
basepair (5’-ATGACTCAT-3’), they are separated in CRE (5’-ATGACGTCAT-
3’). The interactions between the peptide and the DNA are thus merely the
same, except in the center where the DNA is bent to accommodate the extra
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Figure 4.23: Helical wheel representation of GCN4 A) Illustration on the for-
mation of a coiled coil; B) residues of GCN4 and their corresponding positions in the
helix. The residues that are at the DNA interface are on a gray background, the dashed
line accentuates position g, the position directly in the major groove, the dotted line
accentuates position c and d that are just aside, one turn higher in the helix.
basepair. Transcription factor mimics with a large dimerizing moiety, like an
adamantine-cyclodextrin inclusion complex, have a higher aﬃnity for the CRE
binding site as there is more space.
CRE: 5’- A T G A C G T C A T -3’
3’- T A C T G C A G T A -5’
AP1: 5’- A T G A C T C A T -3’
3’- T A C T C A G T A -5’
All of the residues, which make speciﬁc contacts with DNA can be found
in the residues 231-245: KRARNTEAARRSRAR, which are of course on the
DNA interface. Five amino acid residues, Asn235, Thr236, Ala238, Ala239 and
Arg243 make direct base contacts, seven amino acid residues, Arg232, Arg234,
Arg240, Arg241, Ser242, Arg243 and Arg245 further make hydrogen bonds to
the phosphate backbone. Other interactions occur through an extensive network
of solvent molecules (Fig. 4.24).
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Figure 4.24: The protein, DNA and the interactions of the GCN4 bZIP
CRE Complex, taken from Keller et. al. [118] A) GCN4-bZIP domain numbered
according to the full-length sequence. Residues that make one or more DNA contacts are
indicated: b, direct to base; w, via water to base; p, direct to phosphate; x, via water
to phosphate. B) Self-complementary, 18 bp palindromic CRE DNA with terminal
thymidine. A molecular and crystallographic 2-fold axis passes through the C-1G1
base step. The speciﬁc recognition sequence is marked with the bar. C) DNA-protein
interaction summary for one basic domain and DNA half-site. The location of the
2-fold axis is indicated. Direct and water (W) mediated interactions with bases are
shown as continuous lines, interactions with the phosphate backbone as broken lines
and hydrophobic interactions as dotted lines. Arrows indicate the direction of hydrogen
bonds.
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After combination of both criteria, as symmerised in Figure 4.25, only K231
and R232 remained as possible positions for modiﬁcation (Fig. 4.26). With vi-
sualization software it was possible to measure the distance of these residues to
the most proximate nucleophile of the DNA. This revealed K231 to be the better
option. This residue was replaced in a ﬁrst modiﬁed peptide bGCN4(K231aa1).
The interacting residues logically showed closer proximity. A239 interacts through
a hydrophibic interaction with a thymine methyl group. As the methylene of fur-
furylalanine (aa1) could replace this interaction, this residue was replaced in a
second modiﬁed peptide bGCN4(A239aa1).
Figure 4.25: Summary of the considerations for the incorporation of the
furan-modiﬁed residue based on both the involvement in essential interactions for
binding and the positioning. Non-ideal residues are crossed out with an ‘x’
Figure 4.26: Visualisation of DNA binding of GCN4 modiﬁed with oxidized
aa1 at position K231 (A) and A239 (B)
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4.2.3 Synthesis of furan-modiﬁed peptides
Two diﬀerent modiﬁed peptides were thus synthesized:
• bGCN4(K231aa1): DPAALaa1RARNTEAARRSRARKLQ
• bGCN4(A239aa1): DPAALKRARNTEAaa1RRSRARKLQ
The aa1-modiﬁed peptides were synthesized in a similar way as the unmodi-
ﬁed peptides before. Though oxidation and degradation of the furan moiety has
been described under acidic peptide cleavage and deprotection conditions,[174]
and observed when using aa1 or aa2 at the N terminus of a peptide,[172] cleavage
and deprotection of peptides internally modiﬁed with aa1 in our hands does
not present any problems. It was reasoned that the peptide protects an internal
furan moiety. Still, to minimize possible side reactions, the acidic cleavage and
deprotection coctails were added cooled on ice.
It was chosen to equip all peptides as described before with Ad, as this is the
most easy reaction and Ad-peptides are easier to analyze. To form dimers, these
peptides were then combined with the unmodiﬁed CD-peptide.
4.2.4 DNA binding
Unexpectedly, the furan modiﬁcation nearly completely abolished DNA binding,
as can be seen in Figure 4.27. Compared to the unmodiﬁed mimic it is clear
that the mimic modiﬁed with aa1 at K231, hardly binds to the DNA, while the
mimic modiﬁed with aa1 at A239 binds as a complex with lower electrophoretic
mobility. The same shifted band and thus complex can be observed in lane 3,
which contains only CD-peptide. CD-peptides can form CD-CD dimers on their
own,[72] giving rise to a complex with a slightly lower electrophoretic mobility
than Ad-CD dimers, due to the size. Typically, formation of this complex is
far less eﬃcient than the formation of the Ad-CD dimer. However, in this
case with furan-modiﬁed Ad-peptides that have a lower aﬃnity for the DNA,
dimerization with two unmodiﬁed CD-peptides was found to be dominating.
This is problematic for cross-linking as the resulting CD-CD dimer-DNA complex
does not contain a furan moiety. This is schematically represented in Figure 4.28.
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Figure 4.27: EMSA of the unmodiﬁed (top), A239 furan-modiﬁed (middle)
and K231 furan-modiﬁed (bottom) Morii mimic to 32P -labeled AP1 binding
site (native 8% acrylamide gel, with 0.2% TBE buﬀer). Lane 1 contains single stranded
AP1 and 2 the AP1 duplex without added peptides. Lane 3 and 4 contain 100 nM of
the CD and the AD peptide respectively. Lanes 5 to 9 contain 5, 10, 50, 100, 500 nM of
both AD and Cd peptides with 6% sucrose, 100 mM Tris pH 7.6, 20 mM KCl, 10 mM
MgCl2, 2.5 mM EDTA and 4.88 pM DNA.
Figure 4.28: DNA binding of the furan-modiﬁed mimic From left to right the
desired furan-modiﬁed GCN4 Ad-CD homodimer, the undesired GCN4 CD-CD homo-
dimer and the designed furan-modiﬁed Ad-CD heterodimer.
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To overcome the problem, heterodimers were formed through the inclusion
complex of Ad and CD on diﬀerent peptides, derived from diﬀerent bZIP pro-
teins, which thus bind diﬀerent DNA sequences. If an oligonucleotide composed
of the binding half sites for both proteins is used, then homodimerization be-
tween two cyclodextrine-modiﬁed peptides is not possible. Practically this was
achieved by combining the synthesized GCN4 furan-modiﬁed Ad-peptides with a
CD-peptide derived from EmpB1, another bZIP protein with a DNA duplex con-
taining one binding halfsite for both peptides, as illustrated in Figure 4.28. This
proved to be a very eﬃcient way to disseminate the undesired CD-CD dimeriza-
tion and thus reveal the real DNA binding properties (Fig. 4.29). Both modiﬁed
dimers bound to DNA, but compared to the modiﬁcation of the non-essential
lysine bGCN4(K231aa1), modiﬁcation of the central, essential alanine (A239aa1)
strongly reduced the aﬃnity.
Figure 4.29: EMSA of the unmodiﬁed (top), A239 furan-modiﬁed (middle)
and K231 furan-modiﬁed (bottom) Morii mimic to 32P -labeled CECRE DNA
(conditions see Fig. 4.27).
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4.2.5 Cross-link tests
Figure 4.30: Illustration of the aim of DNA ← protein mimic cross-linking
The oxidation of the furan moiety in the Ad-peptides with NBS was monitored
by mass analysis of the reaction mixture (without buﬀer to improve ionisation)
after 5, 15, 30, 45 and 60 min. It was found (Fig. 4.31) that 1 equivalent of
NBS led to complete oxidation (+16 Dalton) of the peptide (mass: 3108 Dalton)
to the keto-enal (mass: 3124 Dalton) of the peptide after 5 minutes. After two
hours another equivalent of NBS was added, which led to over-oxidation to the
acid (+32 Dalton) (mass: 3140 Dalton).
Cross-link formation was then monitored by denaturing PAGE with 32P-
labelled DNA. Under these conditions, only the formation of a covalent bond
can give rise to a shifted band. Many diﬀerent conditions were applied (diﬀerent
concentration, buﬀer, reaction times, equivalents NBS, NaCNBH3 reduction or
not, . . . ), but a shifted band was never found.
The absence of cross-linked product in the gel shift experiments was double-
checked with HPLC on both peptide (C18 column with TFA buﬀer) and DNA
level (diﬀerent oligo columns with TEAA buﬀer). Oxidation of the peptide in
water with one equivalent of NBS indeed yielded the oxidized product, a little
bit of overoxidation and a little bit of remaining start product as can be seen in
Figure 4.32, exactly the same as determined before with MS. But to obtain such
a clean chromatogram from the reactive 4-oxobutenal is suspicious. The oxidized
compound remained stable for over 10 hours in buﬀer and did not react with dif-
ferent added nucleophiles like propylamine, cytidine mono phosphate, adenosine
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Figure 4.31: Maldi-MS spectra of the oxidation of Ad-bGCN4(K231aa1)
(mass 3108 Dalton). A) From top to bottom after 5, 15, 30, 45 and 60 min with 1 equiv
of NBS in mQ water; B) From top to bottom after 5 and 120 min with 1 equiv of NBS,
then 1 extra equiv of NBS was added and this was monitored after 30 and 120 min.
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triphosphate, glutathione, . . . with diﬀerent amounts of equivalents, during dif-
ferent reaction times, in diﬀerent buﬀers, at diﬀerent pH and temperature. This
led to the conclusion that the NBS treatment had not really oxidized the furan.
In the construct two very oxidation sensitive thioether bonds, connecting Ad and
CD to the peptides are present.[175, 176] The oxidation reaction had thus been
optimized to generate a sulfoxide derivative, the till then assumed overoxidized
product had an oxidized furan present next to the sulfoxide, rather than the
originally assumed acid.
Figure 4.32: HPLC Chromatogram of the oxidation of Ad-bGCN4(K231aa1)
(C18, 20-80% MeCN from 0.5% TFA buﬀer) before (red) and after (black) oxidation.
Optimization of the oxidation conditions thus had to be repeated. To make
sure a reactive 4-oxobutenal moiety was generated, it was trapped with hydrazine
forming an aromatic product that absorbs at 280 nm. Figure 4.33 shows the
reaction progress as monitored by HPLC at 214 and 280 nm. Before reaction
there is a single peak at 214 nm that does not absorb at 280 nm, as there are
no aromatic moieties in the peptide. Upon oxidation, the starting material
disappears and new products are formed. After quenching with hydrazine, there
is clear formation of a product that absorbes at 280 nm. Moreover, if the peptide
was treated by only hydrazine, no reaction occurs (Fig.4.34A). If NBS and
hydrazine are added at the same time, again no reaction occurs (Fig.4.34B) as
the reagents react with each other. The aromatic product is only formed if NBS
is added before hydrazine to oxidize the furan. The reaction was repeated in this
order (Fig.4.34C) and shows excellent reproducibility. The formed product could
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also be identiﬁed by mass analysis.
Figure 4.33: Veriﬁcation of the presence of 4-oxobutenal by reaction with
hydrazine reaction scheme (top), HPLC chromatograms (C18, 100A˚, 0-50% MeCN
from 0.1% TFA buﬀer in 25 min) A) peptide Ad-bGCN4(A239aa1) before oxidation; B)
peptide Ad-bGCN4(A239aa1) after oxidation; C) peptide Ad-bGCN4(A239aa1) after
oxidation and reaction with hydrazine (bottom). This clearly shows the formation of an
aromatic product (asorbing at 280 nm) from an unstable oxidized intermediate.
However, despite the now proven oxidation, cross-link reactions still did not
result in any observable covalent DNA-peptide adduct formation as shown in
Figure 4.35. Only some degradation occured upon oxidation, the exact same
traces, with broadening and additional peaks were observed in a blanc reaction
without mimic.
Though unfavorable positioning and/or linking cannot be completely excluded,
the results strongly suggest that the involvement of the targeted exocyclic amines
in Watson-Crick base pairing in the highly organised duplex, strongly reduces
their reactivity towards cross-linking. This rationale is further supported by the
reported use of aldehydes for the detection of single stranded regions of DNA
[177] and their use to elucidate RNA folding pathways.[178] Figure 4.36 depicts
the diﬀerence between ICL and the targeting of double stranded DNA with a
furan-modiﬁed peptide. While the reactive moiety on a peptide has to intrude in
and interfere with the highly organized duplex structure for DNA← protein cross-
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Figure 4.34: Additional experiments for the veriﬁcation of the presence of
4-oxobutenal by reaction with hydrazine A) treatment with only hydrazine; B)
treatment with NBS and hydrazine at the same time; C) treatment with NBS before
treatment with hydrazine (check reproducibility of the reaction). The trace of the reac-
tion mixture is presented in black, the trace of the unreacted Ad-bGCN4(A239aa1) is
superposed in light gray.
Figure 4.35: Cross-linking experiments. The top HPLC trace is before and the
bottom trace after furan oxidation of K231-modiﬁed Morii mimic (which is not visible
in the HPLC chromatograms) bound to the CECRE duplex. No cross-link formation
can be observed.
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linking, the nucleophile of the base opposite to the furan-modiﬁed ODN is readily
available for ICL. Moreover, in current research with triplex cross-linking (cfr.
unpublished results of Ellen Gyssels) it was found that furan cross-linking is only
established from the triplex forming oligonucleotide to a duplex, when the furan
modiﬁcation is incorporated at the extremity of the TFO and thus positioned at
the distorted transition from triplex to duplex. It was further shown that through
introduction of distortions in the triplex region by mismatches and increased
temperature, triplex cross-linking yield could be increased. The introduction of
distortions in the target duplex for the cross-link reaction with the peptide was
attempted, by introducing a mismatch in CECRE (CECRE mis: 5’-CGG ATT
GCG TCA TCT TTT TTC-3’) or a ﬂipout base in CECRE comp (CECRE ﬂip:
5’-GAA AAA AAC ATG ACG CAA TCC G-3’) or by increasing the reaction
temperature. However these distortions to improve the cross-link formation, also
disturb the binding of the mimic and thus causing the adverse eﬀect. It had to
be concluded that cross-linking with our furan-based approach to dsDNA was not
eﬃcient and that the mimic was not a good model system for further investigation
with forced cross-link formation.
Figure 4.36: ICL vs. cross-linking from a modiﬁed peptide to double
stranded DNA (modiﬁed residues indicated in yellow). In A the oxidized furan moiety
faces an unpaired C base, while in B the oxidized furan moiety faces a Watson-Crick
base paired C base.
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4.3 DNA → protein mimic
cross-linking
The cross-link formation should thus be approached from the
other side. Indeed, to form DNA-peptide cross-links, there are two
options: modiﬁcation of the peptide or modiﬁcation of the DNA. The
ﬁrst approach was initially followed to keep the same cross-linking
mechanism, targeting the exocyclic amines of the DNA bases. How-
ever, this proved diﬃcult. To succeed in the other way around, the
amine functionalities of lysine side chains now have to be targeted.
Moreover and more importantly, competitive interstrand cross-linking
should be avoided. A furan moiety facing away from the Watson
Crick interface, into the major groove where the peptide binds is thus
required.
Around this time in my project, thesistudent E. De Wilde, was
attempting ICL with a nucleoside modiﬁed with furan on the base . . .
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Introduction The interaction of proteins with nucleic acids is essential for
cellular functioning, as they are responsible for the regulation and execution
of many biological processes, including folding, replication, transcription, and
degradation. Understanding the remarkable selectivity and aﬃnity of DNA
binding proteins for their targets in the complex cellular environment is a major
challenge, driven by the ambition to design drugs that can compete in such
interactions.[68, and references therein] In an attempt to decipher the DNA-
protein recognition code, analysis of crystal structures and modiﬁed proteins
has been greatly aided by the use of bifunctional cross-linking moieties, causing
covalent locking of the interactions. Photoactivatable functionalities[179–182]
such as phenylazides, diazirines, and benzophenones have been exploited for
DNA-protein cross-link (DPC) generation, but lack selectivity for identiﬁcation of
the amino acid residues responsible for selective recognition at the DNA-protein
binding interface, as the generated reactive species can target any amino acid.
Further, due to the occurrence of high-energy intermediates, the resulting struc-
tures are not always representative of the actual structure in the absence of the
cross-link. Finally, obtained DPC yields are in general rather low (10-20%).[183]
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In order to probe the DNA-protein interface use of a cross-linking mechanism
requiring the presence of proximal nucleophilic side chain functionalities can be
considered as a viable alternative.
Aldehydes, representing sensitive functionalities reactive toward nucleophiles,
common occur in the environment and are endogenously generated by metabolic
activation and lipid peroxidation. As a result of random adduct formation with
DNA and proteins, they are mutagenic and cytotoxic, respectively.[184, 185]
Aldehydes are also known to covalently trap proteins onto DNA exploiting
the nucleophilic side chain functionalities of proteins.[186–189] Consequently,
externally added formaldehyde is routinely used for random DPC formation
in chromatin immunoprecipitation experiments.[190] However, for site-selective
formation of a DPC, oligonucleotides (ODNs) containing a suitably positioned
aldehyde moiety are required. Abasic sites, which are toxic DNA lesions
resulting from oxidative damage that ring-open to aldehydes[191] and can as
such subsequently form DPCs, can be locally generated in DNA by action of
uracil-DNA glycosylase on a correctly positioned deoxyuracil or by photolysis
of a protected precursor.[192, 193] Introduction of other aldehyde functionalities
into ODNs has been achieved through oxidation of a diol with NaIO4. DPC
formation after oxidative conversion of ODNs with diols replacing the sugar[194]
or diols attached to the 2-position[195, 196] or the base[197] have been reported.
In the latter case 5-formyldeoxyuridine (fdU) is generated, an abundant naturally
occurring form of thymidine damage in DNA,[198, 199] proposed to be involved
in the formation of DPCs.[200, 201] Unfortunately the synthesis of these diol
building blocks[194–197] with extended protection schemes is lengthy. Aromatic
aldehydes can be introduced without protection[202] or through postsynthetic
Suzuki-Miyaura coupling with 5-iodocytosine[203] as they are less reactive.
However, the lower reactivity is a disadvantage in subsequent cross-linking
reactions with nonactivated nucleophiles.
Figure 4.37: Furan oxidation
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Inspired by the toxic metabolic activation of furan into 4-oxobutenal
(Fig. 4.37),[127] we report here on the use of easily accessible furan-modiﬁed
ODNs for site-selective DPC formation. The furan moiety represents a latent
functionality, which can be oxidatively activated on demand to release the re-
active aldehyde. Furan incorporation in ODNs is straightforward as the small
aromatic moiety is stable under both nucleotide and ODN synthesis conditions.
Moreover, various furan derivatives are commercially available, allowing modular
construction of diﬀerent furan-substituted nucleoside derivatives. We have pre-
viously shown that in a nucleic acid context, selective activation by oxidation to
generate a reactive aldehyde is possible and can be carried out after duplex for-
mation, thus minimizing nonspeciﬁc oﬀ-target reactions and causing site selective
cross-link formation.[134, 135, 138, 139] Due to the obtained high yield and selec-
tivity, the furan-oxidation methodology has recently been accepted as a general
procedure to achieve DNA interstrand cross-linking.[157] Additionally, very re-
cently, the usefulness and wider applicability of the furan-oxidation methodology
has been illustrated by Summerer and co-workers in the cross-linking of genetically
modiﬁed proteins incorporating a furan-amino acid toward RNA targets.[204]
Here, using nucleoside nu5 (4.3.1) (Fig. 4.38) rather than our previously devel-
oped furan-modiﬁed building blocks, we describe for the ﬁrst time cross-linking to
non-nucleic acid targets, considerably expanding the scope of the furan-oxidation
cross-linking methodology and opening the way to a much broader application of
furan-based probes.
Figure 4.38: Furan-modiﬁed nucleoside nu5
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Results & Discussion Previously we developed several furan-modiﬁed nucleo-
sides for eﬃcient DNA interstrand cross-linking (ICL).[134, 135, 138, 139, 157]
For the formation of DPCs we decided to study a nucleoside (nu5) modiﬁed on
the base, which positions the furan moiety away from the Watson Crick interface
into the major groove where the recognition helices of proteins bind. In view of
this diﬀerent speciﬁc positioning of the furan moiety, it was ﬁrst veriﬁed that
no competitive ICL formation took place upon oxidation of the furan-modiﬁed
ODN in a duplex with its complementary strand (see experimental section for
spectral data).
To apply furan-oxidation based cross-linking in a DNA-protein context, one
must further take into account that oxidation or modiﬁcation of methionine,
tryptophan, tyrosine, histidine, and cysteine residues can occur.[176, 205] How-
ever, proteins bind DNA through recognition helices, protein fragments especially
rich in alanine, leucine, and arginine that have a high helix propensity[206]
complemented with asparagine, glutamine, aspartate, glutamate, and arginine for
speciﬁc interactions with the DNA.[65] Arginine, lysine, and histidine as charged
residues further interact with the DNA backbone. These residues are highly
conserved across DNA binding proteins,[207, 208] illustrating their relevance.
Oxidation of the earlier mentioned oxidation sensitive residues that are not
conserved and do not interact with the DNA bases should thus not interfere to
a major extent with DNA binding selectivity and aﬃnity and are not expected
to complicate eﬃcient DPC formation. In the absence of proximal nucleophiles,
aldehyde-modiﬁed ODNs have earlier been shown to undergo self-destruction
through several degradation processes within the aqueous buﬀer medium, further
reducing the chances for collateral damage.
To study and deliver proof of concept for the possibility of cross-linking at
the DNA-protein interface, a previously developed GCN4 transcription factor
mimic was used as test system.[72] GCN4 is a transcription factor from yeast
belonging to the basic region leucine zipper family. This transcription factor
family features 2 uninterrupted α-helices that dimerize through a coiled coil
and N-terminally interact with the DNA through 2 basic region peptides, or
recognition helices.[173] The model system chosen here consists of these two
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DNA binding basic region peptides modiﬁed with either a cyclodextrin (CD)
or adamantane (Ad) moiety to form a dimer through an inclusion complex (as
shown in Figure 4.39), which retains DNA binding selectivity and aﬃnity of the
original protein. This miniaturization allows easy synthetic access, through solid
phase peptide synthesis. It further allows a more straightforward analysis of
conjugation products.
Figure 4.39: Illustration of the DNA binding protein mimic of GCN4 showing
two lysines (lys 231 and 246) of the Ad-CD homodimer in close contact with two thymines
(T) in the DNA binding site CRE:CRE comp (adapted from pbd structure 2DGC).[118]
The synthesis of nu5 and its incorporation into ODNs using phosphor-
amidite chemistry was described by Greco and co-workers for its ﬂuorescent
properties.[209] Wicke and co-workers obtained nu5-modiﬁed ODNs by a
postsynthetic modiﬁcation.[210] It was further demonstrated that nu5 is
amenable to enzymatic incorporation into DNA.[211] For the purpose of current
investigation, furan-modiﬁed nucleoside nu5 was incorporated using standard
phosphoramidite protocols in the palindromic CRE DNA binding site of GCN4,
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consisting of two interaction half sites 5’-ATGAC-3’ (numbered -5 to -1 in
Figure 4.39) for the two DNA binding peptides. To induce minimal duplex
destabilization and thus avoid loss in binding aﬃnity, initially thymidine residues
were considered for substitution by nu5. The base pair nu5-A was found to be
as stable as the Watson-Crick T-A base pair, as judged from melting temperature
measurements. The observed small changes in melting temperatures upon the
introduction of nu5 (Tm(CRE1) = -1
◦C, Tm(CRE2) = 0◦C, Tm(CRE3) =
-3.1◦C) indicate minimal destabilization of the duplex by the modiﬁcation.
Visualization (using PDB structure 2DGC)[118] shows thymidines T-4 and
T2 in proximity to the two lysines (246 and 231, respectively) of the major
groove binding peptide (Fig. 4.39). T-4 and T2 were thus replaced by nu5,
in CRE1 en CRE2, respectively. From this visualization it was, however, also
clear that guanosine G-3 is closest in proximity to lys 246. These moieties
are involved in a water mediated amino acid-base contact.[118] Therefore, an
additional sequence, CRE3, was synthesized and combined with a similarly
mutated complementary strand CRE3 comp to equally obtain a nu5-A base pair.
Binding of the GCN4 mimic to the furan-modiﬁed CRE binding sites was veri-
ﬁed using electrophoretic mobility shift assay (EMSA) binding studies (Fig. 4.40).
Figure 4.40: EMSA of the binding of the GCN4 mimic to CRE and furan-
modiﬁed CRE variants CRE1, CRE2, and CRE3. Lanes 1 to 5 contained in-
creasing amount of protein mimic, respectively, 0, 0.42, 0.84, 1.25, and 1.67 μM peptide
versus 0.167 μM DNA duplex in lanes 1, 2, 3, 4, and 5.
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The result of the furan oxidation cross-link reaction for the DNA-protein
mimic complexes as analyzed on RP-HPLC is shown in Figure 4.41. The top
chromatogram shows the reaction mixture containing duplex CRE:CRE comp
and 5 equivalents of GCN4 mimic. Under the analysis conditions, only ODNs
show up in the chromatogram. After addition of 4 equivalents of NBS to
chemically cause furan oxidation, followed by NaCNBH3 reduction to shift the
equilibrium and stabilize the formed Schiﬀ base,[212] the bottom chromatograms
were obtained. In all cases, the furan-modiﬁed ODN disappears, while comple-
ments remain unmodiﬁed. For CRE1 no sharp new signal can be observed, only
some impurities originating from degradation of the furan-modiﬁed ODN. This is
in accord with the earlier observations of Ebright and co-workers, who showed a
non-nucleophilic alanine residue to be closest to T-4, based on photo-cross-linking
with bromouracil mutations.[213] However, for CRE2, a new small but clear
signal appears. The new signal is clearly most important for CRE3, featuring
closest proximity between the furan-modiﬁed nucleotide and lysine. A clear
relation between cross-link yield and nucleophile proximity is observed. Although
in all cases an A base is located opposite modiﬁed nucleoside nu5, diﬀerent
product yields are obtained for the three duplexes, with a maximum yield (HPLC
based) of 50% in the case of close interaction. This clearly indicates the formation
of a distance dependent DPC. The complementary ODN was not consumed
during the reaction in contrast to what is observed during ICL formation with
other studied furan-modiﬁed nucleosides (see Appendix).[134, 135, 138, 139, 157]
Furthermore, mutation of the complementary ODN to include nu5-C and even
nu5-T (which has no exocyclic amine for ICL formation) base pairs, has a minor
inﬂuence on the product yield (for CRE3 see Fig. 4.42, for CRE1 and CRE2 see
experimental part). Observed small variations are believed to be due to small
Figure 4.41 (facing page): Cross-linking experiments. The top part of the ﬁgure
illustrates the positioning of oxidized nu5 in the DNA with respect to the lysine residues
protruding from the protein mimic into the major groove. Images obtained from the
pdb structure 2DGC using the Discovery Studio visualization software from Accelrys,
the color code for the bases is as follows A = red, T = blue, G = green, and C =
magenta. The bottom part shows the HPLC traces before and after furan oxidation for
the duplexes of CRE1, CRE2, and CRE3 bound by the GCN4 protein mimic (which is
not visible in the HPLC chromatograms).
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changes in the binding stability and positioning of the protein mimic to the
slightly diﬀerent target DNA duplex. To conﬁrm the formation of a cross-link
between the modiﬁed oligonucleotide and the target peptide, the product was
isolated by puriﬁcation on HPLC (Fig. 4.43).
Figure 4.42: RP-HPLC chromatograms of the DPC reaction mixture with
the duplex of CRE3 with the complementary ODN containing A, T and C opposite
to the modiﬁed nucleotide, from top to bottom
Figure 4.43: RP-HPLC chromatogram of the puriﬁed DPC of CRE3
The cross-linked product is clearly present in the mass spectrum (Fig. 4.44,
DPC). Still, despite the HPLC puriﬁcation, additional compounds can be
observed in the mass spectrum. These are minor impurities eluting at the same
retention or result from partial degradation of the sample during mass analysis.
These impurities are strongly overrepresented in the mass spectra because
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the ODN-peptide conjugate is very diﬃcult to ionize. ODNs and peptides
have completely opposite ionizing characteristics, which mutually impede their
ionization. This is especially important in cases where both peptide and ODN
are equally contributing to the total mass, like in this case.[214] Therefore,
every contaminant that is present in the sample will ionize better than the
target, contributing to and even dominating the mass spectrum. The sample
was therefore subjected to nano LC-MS, separating the sample just before mass
analysis. Deconvolution of the spectra obtained during elution of the reaction
product gave the spectrum shown in Figure 4.45, with the target mass (10431
Da). The observed mass of the formed cross-linked product corresponds to the
calculated molecular weight of the reduced conjugate of CD-modiﬁed peptide
and furan-modiﬁed ODN (10431 Da) (Fig. 4.46).
Figure 4.44: MS spectrum of the puriﬁed DPC of CRE3
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Figure 4.45: Spectrum obtained by deconvolution of the spectra during elu-
tion of the product
Figure 4.46: Illustration of mass changes during DPC formation
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To verify the necessity of proximity between the generated enal function-
ality and the target lysine residue, the cross-linking experiment with CRE3
was repeated at high salt concentration. While duplex stability is generally
enhanced under such conditions,[215] DNA-protein complex formation will be
compromised.[216] The experiment under these conditions indeed resulted in
hardly any cross-link formation, owing to the destabilization of the DNA-protein
mimic complex (Fig. 4.47B). Similarly, a control experiment in the absence of
protein mimic did not yield cross-linked product (Fig. 4.47C). This also again
conﬁrms the absense of ICL formation with nu5. (This experiment was also
performed with CRE2, see experimental part for data.)
Figure 4.47: HPLC-traces of the cross-link reaction mixture of CRE3:CRE3
comp after NBS addition A) under standard conditions; B) under high salt conditions;
and C) in the absence of protein mimic.
On reviewers request, additional control experiments were performed in the
absence of a peptide-oligonucleotide duplex complex, using a random peptide
(Fig. 4.48) or just the single stranded furan-modiﬁed oligonucleotide (Fig. 4.49).
Complex formation and thus proximity is clearly prerequisite for eﬃcient DPC
formation, as no major product peak can be observed in the HPLC chromatogram
with random Rev peptide. The small amount of product formed can be explained
as originating from the proximity that results from unspeciﬁc electrostatic inter-
actions between the positively charged peptide and the negatively charged DNA.
98 CHAPTER 4. FURAN BASED CROSS-LINKING
In case there is only the single stranded oligonucleotide modiﬁed with furan,
no interaction with the mimic occurs and the furan-modiﬁed oligonucleotide
degrades.
Figure 4.48: RP-HPLC chromatograms of the cross-link experiments of
CRE3 and its complement with a random Rev peptide, before (top) and af-
ter (bottom) addition of NBS.
Figure 4.49: RP-HPLC chromatograms of the cross-link experiments of
CRE3 without its complement with the GCN4 protein mimic, before (top)
and after (bottom) addition of NBS.
Clearly, if no proximal nucleophile for selective reaction is present, random
degradation of the modiﬁed ODN takes place, deactivating the cross-linking
moiety. Furthermore, omitting the reduction step, the cross-linked complex was
shown not to be stable (Fig. 4.50).
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Figure 4.50: HPLC-traces of the cross-link reaction mixture of CRE3:CRE3
comp after NBS and NaCNBH3 addition and 3 weeks of storage (top) without NaCNBH3
addition and 3 weeks of storage (bottom).
Current ﬁndings can be rationalized mechanistically as illustrated in Fig-
ure 4.51. The major product of furan oxidation with NBS is the highly reac-
tive oxobutenal, which degrades in the absence of proximal nucleophiles. The
degradation mechanism is unclear and diﬃcult to study due to the reactivity of
the formed intermediate. We believe that this reactivity allows the aldehyde to
react in many diﬀerent ways. Besides that, non-reacted aldehyde-modiﬁed DNA
can be retained on RP-silica, explaining the absence of clear product formation
during HPLC analysis. A furan brominated species, resulting from competitive
electrophilic aromatic substitution, is only formed as a minor side product. In
the presence of proximal primary amines from amino acid residues, the reactive
aldehyde functionality forms a Schiﬀ base that can be selectively reduced with
NaCNBH3 to generate a DPC.[183, 188, 194–197, 203] Alternatively, in the case
of a diﬀerently positioned furan as shown in earlier work focusing on interstrand
cross-linking,[134, 135, 138, 139, 157] stable adducts can be formed with proximal
nucleic acid bases, generating ICLs. It is clear that carefully planned diﬀerential
positioning of the furan moiety on the nucleoside allows switching from ICL to
DPC formation.
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Figure 4.51: Mechanism of the furan-oxidation methodology for the forma-
tion of DPCs
Conclusion In conclusion, we have illustrated the use of furan as inducible
DNA to protein cross-link forming moiety, inspired by the toxicity of furan. The
stability and general availability of the small aromatic heterocycle allows for easy
incorporation into ODNs. Selective oxidation then generates a very reactive alde-
hyde that engages in a speciﬁc reaction with proximal nucleophiles or degrades
in their absence. This renders this type of furan containing ODNs particularly
useful as interaction or distance scanning probes for the study of DNA-protein
interactions. We’ve shown that positioning of the furan moiety on the base,
allows nu5 to selectively produce DPCs in high yield. As the applicability of
furan-based cross-linking has recently been clearly established in a biological
context by us[139] and others[204] for nucleic acid targets, current expansion
toward amino acid side chains in protein targets now considerably broadens the
application area of the methodology for cross-linking and bioconjugation.
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Additional experiments A small amount of full lenth GCN4 dimer protein
was oﬀered by Prof. Morii. This sample was used for a real DNA-protein
cross-linking reaction. However with current analysis methods the reaction
mixture could not be analyzed. The protein blocked the DNA column, and also
its analysis on typical PAGE gels did not yield results from which conclusions
could be drawn. The addition of sodiumdodecylsulphate (SDS) helped to resolve
the gels, but not enough sample was available to optimize the analysis conditions
for reportable results.
DPC formation was also attempted with nu4, which was introduced earlier
as the other base modiﬁed nucleoside, not causing ICL formation due to the
positioning of furan in the major groove. As the base, position and linker
is diﬀerent, visualisation identiﬁed a diﬀerent residue to be most suited for
substitution (CRE4 = ODN4.1.1). The substitution of this adenosine did not
disturb duplex formation or peptide binding (Fig. 4.52).
Figure 4.52: EMSA of the binding of the GCN4 mimic to CRE and furan-
modiﬁed CRE variant CRE4 Lanes 1 to 5 contained increasing amount of protein
mimic, respectively, 0, 0.42, 0.84, 1.25, and 1.67 μM peptide versus 0.167 μM DNA
duplex in lanes 1, 2, 3, 4, and 5.
As judged from the HPLC traces (Fig. 4.53A), the furan oxidizes without
the formation of a new species. PAGE experiments showed a very small amount
of cross-linked products (Fig. 4.53B). This behaviour is very similar to the
behaviour seen earlier with nu4 in ICL formation. Unfortunately, it thus looks
like DPC formation is not a general mechanism with base modiﬁed nucleosides,
though additional sequences should be tested to prove this.
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Figure 4.53: Results of the DPC formation reaction with nu4. A) HPLC traces
after increasing addition of NBS and NaCNBH3 for duplex of CRE4 bound by the GCN4
protein mimic (which is not visible in the HPLC chromatogram). B) Denaturating PAGE
of the same reaction mixture before and after the addition of 4 equiv NBS and reduction
with NaCNBH3 in lanes 1 and 2 respectively.
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4.4 RNA
interstrand cross-linking
Though the inability to cross-link to double stranded DNA was ini-
tially considered a negative result and a disadvantage, over time this
has been more and more considered as a feature that could be used
for structural elucidation in complex systems and to distinguish sin-
gle from double stranded DNA e.g in topoisomerases. But therefore
the hypothesis has to be conﬁrmed. Currently, thesis student Andreas
Baudot is analyzing DPC formation with a furan-modiﬁed Rev peptide
to its binding site RRE (Rev Responsive Element) RNA. This model
system is based on the strong interaction between a short syntheti-
cally accessible peptide and an RNA hairpin,[217, 218] that is highly
distorted with ﬂipout bases, a loop and a mismatch as potential cross-
link targets (Fig. 4.54). This is also in interest for our collaboration
with Prof. Morii, as the RRE Rev interaction is central in his ribo-
nucleoprotein sensors. Their stabilization through a covalent bond is
desirable.[219]
Figure 4.54: RRE-Rev interaction The distorted RRE hairpin, with a G-G mis-
match, 2 ﬂipout bases (bulges) and a loop (left) and with the Rev peptide binding in
close proximity to these distortions (right)
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As RNA had never been used in our group before, nor was it thus
ever used in furan cross-linking reactions, an exploratory study was
conducted on RNA interstrand cross-linking, which is actually very
relevant on its own in view of a series of potential applications.
Introduction While protein targets have dominated the pharmaceutical
industry for over 100 years, targeting RNA is a promising alternative. With
the recent FDA approval of Mipomersen[220], the second antisense drug of ISIS
to reach the market after Fomivirsen,[221] the possibilities in this new area
of drug discovery have been validated.[222] It was previously shown that the
antisense eﬀect obtained through a steric blockage can be enhanced by a covalent
linkage, transforming the transient inhibitory eﬀect to a permanent one.[223]
Moreover, it is becoming increasingly clear that genetic expression is regulated
by a large number of RNAs next to mRNA (lncRNA, miRNA, siRNA, snoRNA)
which are the subject of current investigations and constitute new therapeutic
targets.[167, 168] Cross-linking is further a well-established and widely used
method to obtain secondary and tertiary structural information.[224] To study
new RNA interactions, novel methods are continuously being developed, like
CHART (capture hybridization analysis of RNA targets) with puriﬁcation based
on hybridization.[225] Such methods could beneﬁt from covalently reinforced
hybridization for the ﬁsh out purposes. Finally also RNA aptamers (nucleic acid
4.4. RNA INTERSTRAND CROSS-LINKING 105
based selective binders obtained through in vitro selection) like Pegaptinap,[226]
are emerging as therapeutics. Currently, these go through a long develop-
ment process of post-selection modiﬁcation, to increase metabolic stability,
without compromising binding aﬃnity. Resistance to nucleases could be in-
creased by cross-linking,[165, 166] next to stabilization of the secondary structure.
Diﬀerent methodologies for cross-linking of RNA duplexes have been re-
ported. Cross-linking through selective click reactions[227–229] or through
disulﬁde formation[230] is less relevant for current applications, as these methods
require modiﬁcation of both strands of the duplex. To attack a natural and thus
unmodiﬁed target, a reactive moiety e.g. halocarbonyl[231], aziridine[232] or
other strained rings[233] is required. These modiﬁcations however, typically lack
suﬃcient stability resulting in low yields and oﬀ-target reactions.[234] Better
results are obtained when a reactive cross-linking moiety is induced from a stable
precursor. Psoralens have for this reason been extensively used. They react with
thymine residues upon UV irradiation,[235] but UV light is highly energetic and
can generate collateral damage. An alternative cross-linking strategy, which is
induced by oxidative deprotection of a reactive vinyl group, was described by
Sasaki.[236]
Our group developed a cross-linking methodology for DNA-DNA du-
plex interstrand cross-linking, inspired by the metabolic activation of furan
(Fig. 4.55).[134–136, 138, 157] We’ve shown that furan moieties can be easily
incorporated in oligodeoxynucleotides (ODNs) in view of the stability and
wide commercial availability of furan derivatives. Furan-modiﬁed ODNs can
be activated by oxidation to a very reactive oxobutenal that quickly reacts
with the exocyclic amine of the opposite base resulting in selective and high
yielding interstrand cross-link (ICL) formation. To increase its applicability
and usefulness, the furan oxidation cross-linking approach should be applicable
to RNA duplexes. However in view of the diﬀerent structure and reactivity,
this is counter intuitive. N-Bromosuccinimide (NBS), used to oxidize the
furan moieties, has indeed been reported to react with the electron-rich C5
position of uracil nucleosides.[237] Furthermore, the extra 2’-OH, renders RNA
considerably more nucleolyticaly labile and additionally inﬂuences the nucleotide
106 CHAPTER 4. FURAN BASED CROSS-LINKING
puckering. Nucleotides assume the north (C3’-endo) pucker, rather than the
south (C2’-endo) pucker of deoxynucleotides. As a result an RNA-RNA duplex
adopts an A-type duplex shape, which is diﬀerent from the typical B-type duplex
for DNA-DNA duplex.[238, 239] This diﬀerent shape causes substituents to be
positioned diﬀerently and thus possibly behave diﬀerently.[226] Lastly, RNA and
especially 2’OMe RNA-RNA duplexes[238] are thermally more stable than DNA
duplexes.[239, 240] Perturbation of such a more stiﬀ duplex to achieve ICL is
expected to be challenging.
Results and discussion For the experiments a 12-mer 2’OMe RNA probe
(ON4.4.1) was used (Fig. 4.55). The diﬀerent behavior of DNA versus RNA
is already illustrated by the stability of the respective duplexes (Table 4.2):
DNA-DNA (Tm = 41
◦C), DNA-RNA (Tm = 39◦C) and 2’OMe RNA-RNA (Tm
= 82◦C) of the unmodiﬁed ON4.4.1 or ODN4.4.1 and its complement, ON4 or
ODN4.
Figure 4.55: Principle of furan oxidation interstrand cross-linking. Furan-
modiﬁed nucleosides nu3 (4.1.3) or nu6 (4.4.1) are incorporated in an ON or ODN
during synthesis. After hybridization with natural RNA complements, the furan is
oxidized to a very reactive ketobutenal that will quickly react with the exocyclic amine
of the opposite base forming an ICL.
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Table 4.2: Duplexes used for cross-linking
duplex type furan-modiﬁed single strand complement single strand
2’OMe RNA/ RNA ON4.4.1*/ON4.4.2/ON4.4.3 ON4/ON5/ON6
DNA/RNA ODN4.4.1*/ODN4.4.2/ODN4.4.3 ON4/ON5/ON6
DNA/DNA ODN4.4.1*/ODN4.4.2/ODN4.4.3 ODN4/ODN5/ODN6
*these sequences are the unmodiﬁed analogs, with U/T
Figure 4.56: Illustration of the initial screen to identify the furan-modiﬁed nucleo-
sides most suited for use in RNA ICL formation.
Furan-modiﬁed nucleosides nu3 and nu6 were selected from a range of furan
modiﬁcations available in our group after an initial screen (Fig. 4.56). Both were
incorporated in the 2’OMe RNA sequence resulting in ON4.4.2 and ON4.4.3
respectively and in the corresponding DNA sequence resulting in ODN4.4.2
and ODN4.4.3 respectively. Incorporation of the furan-modiﬁed nucleoside
does not compromise DNA-DNA duplex formation. ΔTm for nu3 = -4
◦C and
ΔTm for nu6 = +8
◦C). In a mixed DNA-RNA duplex, both modiﬁcations are
destabilizing (ΔTm for nu3 = -8
◦C and ΔTm for nu6 = -2◦C). Surprisingly, in
the 2’OMe RNA-RNA duplex, severe destabilizations (ΔTm for nu3 = -31
◦C
and ΔTm for nu6 = -22
◦C) were observed (a summary of all Tm values is
available in Table 4.3). This local destabilization is presumably beneﬁcial for
cross-link formation in the otherwise very stiﬀ duplex. In all cases, nu6 is less
destabilizing than nu3, probably due to stacking interactions of the phenyl
moiety, though it is unable to form Watson-Crick base pairs.[136] To allow
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evaluation of the cross-link selectivity, two additional targets were tested. The
ﬁrst, ON5 is identical to ON4 thus complementary to the probe, but with a U
opposite to the furan-modiﬁed nucleotide or thus without an exocyclic amine to
react in an ICL reaction. The other target, ON6 was completely randomized
apart from the central CCC opposite to the furan-modiﬁed nucleotide.
Table 4.3: Melting temperatures of the diﬀerent duplexes
target
ON4 ODN4 ON5 ODN5 ON6
probe Tm ΔTm Tm ΔTm Tm ΔTm Tm ΔTm Tm ΔTm
(◦C) (◦C) (◦C) (◦C) (◦C) (◦C) (◦C) (◦C) (◦C) (◦C)
ON 82 n.d. 73 n.d. 39
4.4.1
ON 51 -31 n.d. 53 -20 n.d. 20 -19
4.4.2
ON 60 -22 n.d. 59 -14 n.d. 20 -19
4.4.3
ODN 39 41 40 44 n.d.
4.4.1
ODN 31 -8 37 -4 34 -6 37 -7 x
4.4.2
ODN 37 -2 49 +8 38 -2 45 +1 x
4.4.3
n.d. = not determined
x = no duplex formation
Figure 4.57 shows the result of the cross-link reactions through a denaturing
PAGE experiment. It is clear that the desired cross-linking from ON4.4.2 to
ON4 occurs in good yield (HPLC based: 42% for ON4.4.2 and 24% for ON4.4.3).
Despite the diﬀerent duplex structure and positioning of the substituent, cytidine
is targeted like in DNA. The south pucker of nu3 that was determined by NMR,
is thus likely maintained in the RNA duplex, like it was in the DNA duplex.
The cross-link reaction with nu3 proceeds in much higher yield than with nu6.
This can be explained by the competitive bromination reaction on the furan
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moiety, that occurs in case of an extended aromatic system like nu6[136] and
clearly generates a signiﬁcant side product (Fig. 4.58). Other, brominated side
reactions, like expected on the C5-uridine were not detected in the cross-linked
species or in residual DNA and RNA.
Figure 4.57: Denaturing PAGE results of the cross-link reaction. 2’OMe RNA
probes containing furan-modiﬁed nucleoside nu3 or nu6 (ON4.4.2 and ON4.4.3) were
annealed to the targets ON 4-6, after which NBS was added in portions. For each duplex
the reaction mixture before and after addition of 4 equiv NBS was analyzed.
Figure 4.58: A) Oxidation mechanism of nu6-modiﬁed furan with NBS and the
undesired side reaction leading to bromination. B) Comparison of the RP-HPLC
traces of the cross-link reaction with nu3 en nu6 before and after NBS oxidation. (Br
= brominated side product)
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The selectivity of the cross-link reaction is remarkable. In case of ON5, when
no exocyclic amine is available directly opposite to the modiﬁed nucleotide,
no cross-linking is observed. This implies that the ICL formation is highly
speciﬁc for the opposite base and that no reaction occurs with any present
neighboring cytidines. Further, as expected also in case of the randomized ON6
that does not form a stable duplex, no cross-linking is observed. (PAGE and
RP-HPLC data for RNA-RNA, DNA-RNA and DNA-DNA ICL formation in
supporting information). These examples clearly illustrate the requirements for
ICL formation: a stable duplex and a proper nucleophile in the base opposite
the furan moiety. If not, the probe undergoes self-destruction, thus avoiding
oﬀ-target reactions. Interestingly, with nu3 both the yield and selectivity are
better than previously observed in DNA-DNA ICL formation (HPLC yield
26% versus 42% in a 2’OMe RNA-RNA duplex), making this a very interesting
modiﬁcation for application in RNA context.
Though NBS oxidation proceeds unexpectedly without damage and can be
easily performed, it has limited applicability in vivo. The use of singlet oxygen,
generated by low energetic red light irradiation of methylene blue, for oxidation
of furan was recently demonstrated by us for DNA ICL formation.[139] It allows
biocompatible furan based cross-linking under spatiotemporal control. During
the course of the here described experiments our red light activation methodology
was used by Summerer for protein-RNA cross-linking,[204] further illustrating its
broad applicability. The possibility of red light activation for RNA ICL formation
is demonstrated in Figure 4.59. It can be observed that after 15 min of irradiation
with nu3 a considerable amount of ICL is formed (yield based on HPLC: 39%).
Increased irradiation times can further increase the cross-link yield, though it
also allows for side reactions to occur on the product, visible by the appearance
of a smear on the gel. Depending on the application, the irradiation time can
be kept short for high selectivity or increased for higher yield. Though there
is no NBS bromination side reaction under these oxidation conditions, nu6 was
again found to be lower yielding than nu3 (yield based on HPLC: 6% for nu6).
As opposite results were obtained in a DNA duplex context,[240] the inﬂuence
of diﬀerent duplex structure on ICL formation and the importance of a proper
choice of furan building block for the context is evidenced.
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Figure 4.59: Denaturing PAGE results after diﬀerent irradiation times from the
cross-link reaction mixture of ON4.4.2 (left) and ON4.4.3 (right) to ON4 using singlet
oxygen.
Conclusion We here report on the ICL formation between a furan-modiﬁed
2’OMe RNA-probe and an unmodiﬁed target RNA, using 2 diﬀerent furan-
modiﬁed nucleoside analogues. In the current RNA context, both NBS and
biocompatible red light irradiation are fast and eﬃcient triggers to induce
cross-linking. The furan oxidation methodology can thus be used as an inducible
tool for selective cross-linking in stiﬀ and reactive RNA duplexes. Though
cytidine is targeted in both DNA and RNA duplex structures, the eﬃciency of
the furan-modiﬁed nucleosides was found to be reversed (Table 4.4). Current
study illustrates the superiority of building block nu3 for selective and high
yielding cross-linking in an RNA context.
Table 4.4: Cross-link yields (%)
DNA-DNA DNA-RNA 2’OMe RNA-RNA
sequences ODN4.4.2 ODN4.4.3 ODN4.4.2 ODN4.4.3 ON4.4.2 ON4.4.3
ODN4 ODN4 ON4 ON4 ON4 ON4
NBS, 25◦C 17 36∗ 35 18 34 19
NBS, 37◦C 26 28 n.d. n.d. 42 24
1O2 15
∗ 57∗ n.d. n.d. 39 6
n.d. = not determined
∗ Determined based on HPLC analysis at 50◦C
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Note Interestingly, by putting all the cross-link yields together, we found that
the cross-link area and thus the yield as determined by HPLC analysis is depen-
dant on the column temperature of the RP-HPLC analysis (Fig. 4.60). The area
decreases with increasing temperature, probably due to instability of the formed
cross-link. All HPLC chromatograms and yields used throughout the thesis are
based on analysis at 60◦C, unless mentioned otherwise.
Figure 4.60: RP-HPLC chromatograms of the cross-link reaction mixture of
ODN4.4.2 and ODN4 as target with 4 equiv NBS at 25◦C, analyzed at A) 60◦C; B)
50◦C and C) 40◦C.
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4.5 Furan-modiﬁed protein
for cross-linking
For a chemist synthesizing peptides, incorporation of unnatural
amino acids is quite simple and straightforward: synthesizing a modi-
ﬁed amino acid analogue and incorporating it during the stepwise solid
phase peptide synthesis. The chemist is however limited by the size of
the protein that can be synthesized and has to be creative in protein
mimicry with peptide fragments. As can be concluded from the discus-
sion before, the synthetic access to a good model system is not always
that easy and the model is inferior to the protein in binding aﬃn-
ity and selectivity, which limits the possibilities for achieving cross-
linking. Ideally furan-modiﬁed amino acids could also be introduced
in proteins, for example in polymerases like illustrated in Figure 4.61
that grip around a single stranded DNA template to assist in the syn-
thesis of a new DNA strand. This system could thus serve to proof
that cross-linking to single stranded DNA is possible and to show that
our methodology can be extended to proteins.
Figure 4.61: Polymerase κ Structure of polymerase κ complexed with DNA, insert-
ing dATP opposite an 8-oxoG DNA lesion (left). Zoom on the structure showing the
interaction of the protein with the single stranded DNA template, with 2 residues threo-
nine 44 and phenylalanine 49 (red) in close proximity and suited for replacement with a
furan-modiﬁed amino acid to achieve cross-linking (right)
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Chemical modiﬁcation of amino acid side chains in proteins is
possible, but can lead to nonselective and nonquantitative derivatiza-
tion. It therefore often requires extensive mutagenesis to remove re-
dundant labeling sites and/or puriﬁcation to eliminate labeled contami-
nants. Incorporation of modiﬁed amino acids during protein synthesis
is desired. To explore this possibility, I visited the group of Profes-
sor Thomas Carell in Munich from November 21st till December 15th
2011.
4.5.1 Biochemical incorporaton of modiﬁed amino acid
analogs in proteins
The biological synthesis of proteins is performed by the ribosomes, which trans-
late messenger RNA (mRNA) into proteins using the genetic code. Each triplet
of nucleotides (or codon) codes for the incorporation of one of the twenty natural
amino acids or the termination of the sequence. There are 3 so-called stopcodons:
UAG (”amber”), UAA (”ochre”) and UGA (”opal”). Amino acids, the building
blocks for the protein synthesis are recognized (with the help of aminoacyl tRNA
synthetases) and transported to the mRNA by their transfer RNA (tRNA) that
can bind to the codon for the amino acid through an anticodon. The ribosome
regulates this process (illustrated in Figure 4.62), as it reads through the mRNA
and chains together the arriving amino acids into the target protein.
To incorporate unnatural amino acids, it is possible to chemically misacylate
nonsense tRNA with the desired amino acid and perform an in vitro translation.
This is however not easy and the protein yield is typically rather low. Working in
cell media, is often more easy and higher yielding. One option is to grow bacteria
on media in which the encoded amino acid is replaced by a structural analogue,
for example an amino acid with its 15N-labeled analogue [241] or methionine
by selenomethionine [242]. But, this leads to non-quantitative incorporation
throughout multiple sites in the protein and requires the use of auxotrophic
strains, which cannot synthesize the amino acid.
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Figure 4.62: Illustration of the biological synthesis of proteins from Campbell
and Reese’s Biology, copyright c©2005 Pearson Education, Inc.
To really expand the genetic code, there should be a unique tRNA-codon
pair, with its own aminoacyl tRNA-synthetase for the modiﬁed amino acid. If
the tRNA is not recognized by endogeneous synthetases and the synthetase does
not recognize endogeneous tRNA, the modiﬁed amino acid will only be incor-
porated at the site with the unique codon.[243] A system this clever has been
developed in nature to incorporate the 21st and 22nd amino acids, respectively
selenocysteine and pyrrolysine (shown in Fig. 4.63). These are not generated
through post-translational modiﬁcations like many other unnatural residues, but
are directly incorporated into the mRNA on the stopcodons UGA and UAG
respectively.[244–246] The pyrrolysyl-tRNA synthetase and its tRNACUA can be
hijacked by chemists for the same purpose.
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4.5.2 Amber suppression by pyrrolysine analogs
Amino acids that are similar enough to pyrrolysine, to be recognised by the
pyrrolysyl tRNA synthetase and pyrrolysyl tRNA of Methanosarcina mazei can
thus be incorporated on an amber stop codon in proteins.[247, 248] Comparison
of the successful analogs (Fig. 4.63) with the not so successful ones (Fig. 4.64),
allowes postulating of some typical features for success:
• clearly a suitable spacer (butylene) is required, with a properly sized and
shaped hydrophobic substituent (not necessarily cyclic) that can be accom-
modated in the hydrophobic pocket of the enzyme
• a hydrogen bond acceptor (N or O) is also required in the vicinity of the
N-carbonyl group. It is not required to have it in a ring, as carbamates are
well incorporated, but if it is in a ring the placement is important
• the stereocenter of the side chain is clearly important as the proline and
THF derivatives are well incorporated, but their isomers are not
• aromatic moieties (thiophene, phenylalanine) are not incorporated
If the similarity is not good enough for substrate recognition by the synthetase,
the latter can be mutated to allow more diverse pyrrolysine analogs, with typically
a smaller or bigger hydrophobic moiety (Fig. 4.65). This work was pioneered
by Yokoyama and Chan. Yokoyama mutated Tyr384 of the synthetase to Phe
and Tyr306 to Ala for eﬃcient incorporation of N-(o-azidobenzyloxycarbonyl)-
L-lysine [249], Emine from the Carell group mutated Tyr384 to Phe too, but also
Tyr306 to Gly and Ile401 to Arg for the incorporation of a norbornene carbamate-
L-lysine [250].
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Figure 4.63: Residues well accepted by the pyrrolysine synthethase and
tRNA and thus successfully incorporated in proteins
Figure 4.64: Residues not well accepted by the pyrrolysine synthethase and
tRNA and thus not successfully incorporated in proteins
Figure 4.65: Residues accepted by mutated pyrrolysine synthethase and thus
successfully incorporated in proteins
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4.5.3 Synthesis of pyrrolysine-like furan-modiﬁed amino
acids
Two furan-modiﬁed lysines (aa4 and aa5, depicted in Fig. 4.17) were synthesized
for their incorporation during peptide synthesis. aa4 (4.5.1) seems conform with
the required features for recognition by the pyrrolysine synthetase. Morover this
amino acid was unsuited for the harsh conditions of SPPS, but could be suited
for more mild incorporation in culture. For this purpose, removal of the Fmoc
protecting group was required. This was achieved by dissolving the product in
DMF with 10% piperidine at room temperature, as illustrated in Figure 4.66.
Immediately the product falls out of the solution as a white powder, which was
ﬁltered after 30 min with yields close to 100%.
Figure 4.66: Fmoc deprotection to obtain aa4 (4.5.1) 10% piperidine in DMF
for 30 min at rt (yield 95%).
Additionally a new furan-modiﬁed amino acid aa6 (4.5.2) was synthesized as
illustrated in Figure 4.67, showing stronger structural resemblance to pyrrolysine
(shown in Fig. 4.63). Like before, the synthesis started from the commercial
Fmoc-Lys(Boc)-OH (4.2.6) commonly used for Fmoc solid phase peptide
synthesis, by acid Boc deprotection. The furan moiety was introduced by amide
formation with furoic acid, activated as pentaﬂuorophenyl ester (4.5.3). Also
similar as in the previous synthesis, the reaction sequence was completed by a
Fmoc deprotection.
4.5. FURAN-MODIFIED PROTEIN FOR CROSS-LINKING 119
Figure 4.67: Synthesis of aa6 (4.5.2) a. TFA/DCM 1/1 for 1 h at rt; b. 1 equiv
furoic acid, 1.2 equiv pentaﬂuorophenyltriﬂuoroacetate and 1.2 equiv pyridine in DMF
at rt for 1 h; c. 1.2 equiv furoic acid, 1.2 equiv HOBt and 1.2 equiv DIPEA in DMF at
rt for 2 h; d. 10% piperidine in DMF for 30 min at rt (overall unoptimized yield 83%
The two furan-modiﬁed pyrrolysine analogues with diﬀerent linker length (aa4
and aa6) were both synthesized in an easy 3 step synthesis that is high yielding
and easily scalable. Such short synthesis is required for amino acids to be incorpo-
rated in proteins as they have to be added to cell cultures in high concentrations
of 1-10 mM.
4.5.4 Initial evaluation with Yellow Fluorescent Protein
The incorporation of unnatural amino acids by the pyrrolysyl-tRNA synthetase
and its tRNACUA in Yellow Fluorescent Protein (YFP) can be easily evaluated
by monitoring its ﬂuorescence with confocal microscopy. Without incorporation
of the amino acid at the amber codon position engineered in the middle of
the protein, this stop codon causes termination of the protein. This results
in a truncated, non-ﬂuorescent protein. The obtained ﬂuorescence intensity
thus parallels the incorporation eﬃciency. The incorporation of both amino
acids was tested against the wild type synthetase and 2 of its mutated variants,
by Yokoyama (Tyr384Phe-Tyr306Ala) and one by Emine of the Carell group
(Tyr384Phe-Tyr306Gly-Ile401Arg).
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Cultures with 0, 2, 5 and 10 mM of the furan-modiﬁed amino acid were ex-
amined. The results are shown in Figure 4.68. Unfortunately the wild type
synthetase could not incorporate aa4, but somewhat unexpected especially in
view of the described bad results with the thiophene-modiﬁed amino acid,[248]
aa6 was incorporated by the wild type synthetase in good yield. The mutated
synthetases gave lower yields. The Yokoyama mutant incorporated both aa6 and
aa4, and again aa6 was better than aa4, but in lower yield than the wild type.
Emine’s mutant had very low yield with aa4, aa6 was not incorporated. For more
confocal ﬂuorescent images, see the experimental part.
Figure 4.68: Confocal microscope images The incorporation eﬃciency of aa4 (left)
and aa6 (right, with zoom) by the wild type synthetase in YFP at 5 mM.
Based on these results, it was decided to continue with the wild type syn-
thetase and aa6. This was next used with a dual plasmid system: one plasmid
constitutively expresses the synthetase and tRNA, the second plasmid contains
the protein engineered with an amber codon at the desired position controlled
by a lac repressor. This increases the ﬂexibility in protein choice and allows for
higher yields. The expression was again examined at 0, 2 and 5 mM of amino
acid concentration with confocal microscopy. The incorporation was better at 5
mM. Therefore this concentration was selected for further use.
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4.5.5 Proof of concept with Thioredoxin A as testprotein
Because YFP is expressed only in low yield, its isolation is troublesome. For
characterization, it is more rewarding to express another protein. With the dual
plasmid system, this only requires to change the second plasmid with the en-
gineered protein. Thioredoxin A (TrxA), a small (13 kD) and stable electron
transfer protein that is expressed in better yield, was chosen for this purpose.
It was mutated with an amber stop codon to replace Asn65, which is located at
the surface and therefore suitable to proof the furan incorporation and also test
subsequent modiﬁcation reactions (Fig. 4.69).
Figure 4.69: Thioredoxin A, with Asn65 indicated in yellow
Due to the limited amount of furan-modiﬁed amino acid available in this test
phase, the protein expression was limited to a 1 l culture. This yielded 87 μg of
protein (an additional 87 μg of protein were obtained in a less pure fraction) after
puriﬁcation over a Strep column. Visualisation by SDS-PAGE revealed that two
main products were obtained with masses corresponding to the target protein and
its dimer. For a more accurate mass determination a full protein LC-MS analysis
was performed. The obtained mass proved the incorporation of the furan-modiﬁed
amino acid in the protein, as the calculated average mass of the furan-modiﬁed
oxidized TrxA without the starting methionine is 13039.95 Dalton, and a mass
of 13039.7 Dalton was found (Fig. 4.70). The average mass of unmodiﬁed TrxA
without the starting methionine is 12933.8 Dalton. The correct position of the
furan modiﬁcation in the protein was veriﬁed by analysis of a tryptic digest of the
product.
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Figure 4.70: Mass spectrum of the furan-modiﬁed TrxA (top) and corresponding
deconvoluted mass spectrum (bottom)
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4.5.6 Labeling reactions
Before starting the cross-linking reactions, it is desired to test the reactivity of
the furan moiety and the compatibility of the reaction conditions on proteins.
Therefore, labeling reactions as illustrated in Figure 4.71 were performed on the
TrxA test protein.
Figure 4.71: Labeling of TrxA Through oxidation of the furan (a) with 10 or 5
equiv NBS and reaction with 50 equiv phenylhydrazine (b) or ﬂuoresceinamine (c) with
subsequent NaCNBH3 reduction (d) or through Diels-Alder reaction with 50 equiv ﬂu-
oresceinylmaleimide (e) or through reaction with 50 equiv PTAD (f)
The furan was oxidized with 10 equivalents NBS as if for a cross-linking
reaction in 0.1 M phosphate buﬀer pH 7, but then quenched with an excess
of added phenylhydrazine to form a stabilized aromatic system. Oxidation
with 10 equivalents is a large excess, and was initially chosen to guarantee
furan oxidation in addition to the oxidation of a number of sensitive residues
in the protein (2 tryptophans and 1 methionine). Though most of the protein
had reacted, LC-MS analysis was not able to clearly characterize a reaction
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product. Probably oxidation-degradation rather than a labeling reaction had
proceeded. The reaction was therefore repeated with only 5 equivalents of NBS
and quenched by phenylhydrazine or ﬂuoresceinamine. The latter forms a Shiﬀ
base that is stabilized by NaCNBH3 reduction to an amine. Also in this case,
no labeled products were detected by LC-MS, but now a lot of starting material
was remaining.
To avoid the protein degradation issue caused by the oxidation, a Diels-Alder
reaction with 50 equivalents ﬂuorescein-5-maleimide was attempted. These
reactions were performed in 0.1 M phosphate buﬀer of pH 6, as it has been
reported that these reactions proceed more eﬃciently and chemoselectively at
slightly acidic pH. [251] The reaction was analysed by SDS-PAGE and checked
for ﬂuorescence (Fig. 4.72). One strongly ﬂuorescent band was observed at the
level of the product. This band was cut from the gel and subjected to in gel
trypsin digest to identify the formed ﬂuorescent product. The modiﬁcation
could however not be identiﬁed. The reaction was repeated to duplicate the
result, but this time no ﬂuorescent products were formed. Finally the recently
developed furan labeling using 4-phenyl-1,2,4-triazole-3,5-dione (PDAT)[252] was
tested. Also in this case, full protein LC-MS analysis was performed, but labeled
products could not be identiﬁed.
The expression of proteins with furan-modiﬁed amino acids was
thus, for the ﬁrst time shown possible. With the observed strongly
ﬂuorescent product, promising results were further obtained in terms
of protein labeling. Due to strong time constraints, as a result of
the short research stay, this result could not be repeated, conﬁrmed
or optimized. On the other hand, the electronic properties of the
furan in the pyrrolysine analog are strongly altered due to the electron
withdrowing eﬀect of the directly attached carbonyl group. This alters
the reactivity of the furan so that proposed labeling reactions for
electron rich furans are unlikely to proceed. Therefore it would be best
to ﬁnd another furan pyrrolysine analog and repeat these experiments.
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Figure 4.72: SDS-PAGE of labelling reaction with ﬂuoresceinylmaleimide
15% SDS-Laemmli-gels, ran for 1h at 150 V and visualized using blue LED incident
light source of 460 nm (left) and with protein staining solution (right) lane 1 contains
the mass ladder, lane 2 the wild type TrxA, lane 3 the wild type TrxA after reaction
with the maleimide, lane 4 the furan-modiﬁed TrxA and lane 5 the furan-modiﬁed TrxA
after reaction with the maleimide. The TrxA monomer and dimer are indicated. The
ladder represents 250, 148, 98, 64, 50, 36, 22, 16, 6 and 4 kDa.
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The potential of our furan oxidation methodology was picked up by
Prof. Summerer, specialized in genetic encoding of unnatural amino
acids. Inspired by one of our furan ICL papers, he carried out sim-
ilar experiments with an alternative furan-modiﬁed lysine derivative
(depicted in Fig. 4.73) that could be incorporated into proteins by mu-
tation of the pyrrolysine synthetase. The furan-modiﬁed protein was
then cross-linked to binding RNA.[204] This further strengthens our
previously formulated hypothesis concerning the importance of nucle-
obase located nucleophile availability, as with these results cross-linking
to distorted RNA has been proven possible.
Figure 4.73: Results by Prof. Summerer A) Design of the experiment: incorpo-
ration of a furan-modiﬁed lysine into Tat-peptide for cross-linking with singlet oxygen
by red light irradiation to TAR RNA; B) PAGE results of the cross-link experiments
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4.6 Visualisation
of furan based DNA interstrand cross-linking
The highly organised nature of double stranded DNA, has made
its targeting by our furan-oxidation cross-linking approach very tricky
in the course of this study. However, the programmability of DNA,
through its sequence and the Watson-Crick base pairing, is a very in-
teresting property. It allows for the rational design of very selective
antisense drugs, based on the genomic information as discussed before.
It also allows for the construction of nanostructures. DNA nanotech-
nology was pioneered by Seeman in 1982.[253] Since then all kinds of
DNA scaﬀolds, origami, devices, motors, [254] walkers and spiders
[255] have been developed. A clever property of these assemblies is
that each position of the structure has a precise address by means of
its sequence code. The Morii group used this to site speciﬁcally posi-
tion proteins on a nanostructure, using sequence-speciﬁc DNA-binding
zinc ﬁnger proteins as illustrated in Figure 4.74.[256] To stabilize this
interaction, our furan based cross-link methodology is currently being
tested in the Morii group. In collaboration with the Sugiyama group,
DNA-origami was used to visualise and optimize the formation of a
DNA ICL.
Figure 4.74: Immobilisation of zinc ﬁnger proteins on a DNA nanostructure
by the Morii group.[256] Cartoon representation of the DNA origami (left); AFM
image of the DNA origami: open squares can be clearly observed, small white dots
indicate immobilised Zinc Finger protein (right).
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4.6.1 DNA Origami
Scaﬀolded DNA origami was introduced in 2006 by Rothemund [257], using DNA
and its well known properties, to fabricate two-dimensional DNA nanostructures
of arbitrary shape, like the example in Figure 4.75, by self-assembly following a
staightforward and versatile design scheme.
Figure 4.75: DNA origami smiley shape, taken from Rothemund.[257] From
left to right: A) Folding path with dangling curves and loops represent unfolded se-
quence. B) Diagrams showing the bend of helices at crossovers (where helices touch)
and away from crossovers (where helices bend apart). Color indicates the base-pair in-
dex along the folding path (red is the 1st base, purple the 7,000th). C) AFM image of
165 nm x 165 nm. D) AFM image with scale bar 100 nm
The design process consists of ﬁve steps, illustrated in Figure 4.76, which can
be strongly simpliﬁed with computer assistance, for example with the open-source
software package caDNAno.[258] In the ﬁrst step the desired shape is approx-
imated by a geometrical model, build from an even number of parallel double
helices. Secondly, a single, long scaﬀold strand (M13mp18, a single stranded
circular viral genome) is folded along all the double helices, so introducing peri-
odic crossovers between the diﬀerent helices. In the next step hundreds of staple
strands’ are generated. These are complementary to the DNA scaﬀold strand
(generating the helices) and create extra crossovers between strands for stability.
In the two ﬁnal steps, the design is examined and reﬁned to minimize strain and
to strengthen the structure.[259]
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Figure 4.76: DNA origami design, taken from Rothemund.[257] A) A shape
(red) approximated by parallel double helices (idealized by cylinders) held together by
periodic crossovers (blue). B) A scaﬀold (black) runs through every helix and forms
more crossovers (red). C) As ﬁrst designed, most staples (coloured DNA strands) bind
two helices and are 16-mers. D) Similar to C with strands drawn as helices. Red
triangles point to scaﬀold crossovers, black triangles to periodic crossovers with minor
grooves on the top face of the shape, blue triangles to periodic crossovers with minor
grooves on bottom. Crosssections of crossovers (1, 2, viewed from left) indicate backbone
positions with coloured lines, and major/minor grooves by large/small angles between
them. Arrows in C point to nicks sealed to create green strands in D. Yellow diamonds
in C and D indicate a position at which staples may be cut and resealed to bridge the
seam. E) A ﬁnished design after merges and rearrangements along the seam. Most
staples are 32-mers spanning three helices.
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4.6.2 Single-molecule analysis using DNA Origami
With the addressability through the unique sequences, DNA origami is thus a
great platform for the precise placement of a variety of functional molecules.
In combination with atomic force microscope (AFM) with nanoscale resolution,
this allows for single-molecule analysis. Contrary to commonly used analysis
methods, which measure the bulk average, single molecule analysis can focus
on the properties, behavior and trajectory in real time (with high speed AFM
that allows recording of 15 images per second) of a single molecule in complex
biological processes. Moreover, contrary to chip technology, these assays can
be performed in solution. This has been used to elucidate the recognition
and folding of biomolecules, like the puzzling human telomeric G-quadruplex
and to study and visualize DNA robots and machines, label-free biomolecular
recognition, chemical and enzymatic reactions, as reviewed in [260]. This is just a
starting point, as this ﬁeld is still in its infancy, but it is showing rapid progress.
4.6.3 The project
Figure 4.77: Cartoon representation of the prior art in the Sugiyama
group.[261] The ‘ﬁve-well DNA frame’ consists of an origami tile with ﬁve cavities,
carrying ﬁve diﬀerent double stranded DNA sequences in these cavities. These DNA
sequences can be used for detailed analysis of sequence selectivity, like alkylation by a
Dervan peptide modiﬁed with an alkylating moiety and biotin. The biotin is used for
streptavidin labeling, which can be observed by AFM.
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Outline Based on a report of the visualization of single molecule alkylation
that used a frame-like DNA origami scaﬀold incorporating various dsDNA
substrates (bridges) into the cavities (illustrated in Fig. 4.77),[261] an attempt
was undertaken to visualize the formation of ICLs through our furan methodology
as illustrated in Figure 4.78A. For this purpose the bridges were designed using
nicked dsDNA with sticky ends. At low temperatures the sticky overhang of 9
base pairs in length, is stable enough to form a closed bridge over the cavity. In
this duplex furan interstrand cross-linking can be achieved, stabilizing the bridge,
which can thus be maintained also at higher temperatures. A non-modiﬁed
control nicked dsDNA bridge, will not form an ICL and will thus open at higher
temperatures as illustrated in Figure 4.78B. A shorter overhang of 7 base pairs is
less stable and can thus also open at lower temperatures, this should thus result
in a lower cross-linking yield. In the central cavity a dsDNA bridge without
nicks was annealed, as control to ensure a closed bridge. Exact sequences of the
bridges can be found in the experimental part.
For the modiﬁcation, the acyclic, phenyl stabilized furan-modiﬁed nucleoside
(nu6) (Fig. 4.78C), introduced by Kristof Stevens [136] and shown to be most
suited for singlet oxygen oxidation by Marieke Op de Beeck [139] was chosen. This
will allow for cross-link tests triggered by both NBS and visible light. The latter
has a broad potential with sensitizers for singlet oxygen production immobilized
on the origami.[262]
Synthesis The acyclic, phenyl stabilized furan-modiﬁed nucleoside was con-
verted over weekend to its phosphoramidite with the mild 2-cyanoethyl N,N,N’,N’-
tetraisopropylphosphoramidite in the presence of diisopropylammonium tetra-
zolide as activating species, rather than the standard β-cyanoethyl chlorophos-
phoramidite, which did not result in the formation of the phosphoramidite.[136]
The obtained phosphoramidite was manually incorporated in the designed
37-mer oligonucleotide I-2 (ODN4.6.1: 5’-ACG Gnu6G T-GC TTC CGG TAC
TAC GCC CAG ATG AGC TAC T-3’). Probably due to the length of the ODN
(37-mer), additional RP-HPLC puriﬁcation was required to obtain the desired
purity (Fig. 4.79).
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Figure 4.78: Design of the origami A) This design uses the ‘5-well frame’, with 5
diﬀerent dsDNA sequences annealed in its cavities. Cavity I and III carry the furan-
modiﬁed oligonucleotide (I-2 and IV-2 respectively, which are identical), with a 7 base
pair overlap in I and a more stable 9 base pair overlap in III. Well II and V are the
identical control cavities, with an oligonucleotide (II-2 and V-2 respectively, which are
identical) with a T instead of the furan-modiﬁed residue. In cavity III there is no furan
modiﬁcation and no nick in the DNA. The sequence of the overhang of oligonucleotides
1 and 3 in each cavity is unique, in order to anneal at the desired position in the origami
frame. The sticky end is formed between 2 and 4 in each cavity. Oligonucleotide 4 is
the same in the four cavities. The length of the diﬀerent oligomers in number of bases is
88 for oligonucleotides III-1 and III-2, 51 for I-1, II-1, IV-1 and V-1, 46 for I-3 and II-3,
44 for IV-3 and V-3, 42 for I-4 (= II-4, IV-4 and V-4), 37 for I-2 (= IV-2) and II-2 (=
V-2). B) When the origami tile is kept on ice, all dsDNA bridges should be annealed
or closed, like the control in cavity III. Under these conditions the cross-linking reaction
is performed. During analysis the tiles are not cooled anymore, which causes the non
cross-linked nicked bridges (cavity II and V) to open, while the cross-linked bridges
(cavity I and IV) stay closed. Due to the shorter sticky end in cavity I and II compared
to cavity III and IV, the DNA bridge will partly open even on ice, which will result
in a lower cross-link yield. C) The acyclic, phenyl stabilized furan-modiﬁed nucleoside
(nu6).
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Figure 4.79: I-2, the designed furan-modiﬁed 37-mer ODN4.6.1 RP-HPLC
chromatogram from Clarity column with a gradient from 0.1 M TEAA-buﬀer to 30%
MeCN in 30 min at 60◦C, before (top) and after puriﬁcation (bottom).
The modiﬁed oligonucleotide was annealed together with the other bridge
forming oligonucleotides in the pre-assembled ﬁve-well frame (Fig. 4.80). This
two-step method (Fig. 4.81) is preferred over the one-step assembly of both frame
and bridges from an enormous mixture, to reduce the risk of mismatches. The
ﬁve-well frame is thus ﬁrst assembled by the combination of the M13mp18 long
single stranded DNA and all the designed staple strands in the annealing buﬀer
and puriﬁed by gelﬁltration. The bridges were all assembled separately following
the same protocol. The frame was ﬁnally combined with 4 equivalents of the
bridges, which can insert in the frame by the 5’-overhangs complementary to
both edges of the cavity. This mixture was mildly heated to allow insertion of
the bridges in the frame and then cooled very slowly, overnight. This very slow
process was shown to be necessary, as faster cooling give inferior results without
inserted bridges, as shown in Figure 4.82. The origami was again puriﬁed by
gelﬁltration.
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Figure 4.80: Five-well frame. AFM images from the assembled ﬁve-well frame
Figure 4.81: Principle of the construction of the bridged ﬁve-well origami.
In a ﬁrst step the ﬁve-well frame and all the bridges are all seperately annealed, then
the duplex bridges are incorporated in the ﬁve-well frame by self-assemmbly.[261]
Figure 4.82: Five-well frame with inserted bridges. AFM images from the as-
sembled ﬁve-well frame with bridged, after annealing in 35 min, leaving most of the
cavities empty (left) and overnight, ﬁlling most of the cavities with a bridge (right)
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Cross-linking A fresh origami stock was prepared before every experiment.
Both NBS and singlet oxygen were used to oxidize the furan. The latter was
generated by irradiation of the sample with methylene blue with monochromatic
red light for 30 or 60 minutes. The oxidation was performed on ice, to ensure
closed bridges or thus duplex sticky ends.
Looking at the AFM images, shown in Figure 4.83, it is very diﬃcult, if
not impossible to see the diﬀerence between the open and closed bridges as
even the non-nicked control in the middle often looks open. In an attempt to
make visualization easier, because perhaps the bridges do not open under room
temperature, the Mg2+ concentration of the washing solution and/or the AFM
solution was lowered. The lower salt concentration should cause destabilization
of the duplexes and thus opening of the bridges. However under such conditions
the origami did not attach to the mica surface anymore. Magnesium ions are
required to neutralize the negative surface charge of the mica, and avoid repulsion
of the similarly charged origami.
As an alternative method to check for cross-linking, denaturating PAGE was
performed. The samples (blanc, NBS, 1O2 30 min and 60 min) were denatured
by heating with formamide and loaded on a gel. The obtained result is shown
in Figure 4.84. The M13mp18 long template strand could not penetrate in the
gel and remained on the bottom of the wells. Due to the enormous amount of
staple strands (160, varying in length from 32 to 71 bases) and bridge strands (20,
varying in length from 37 to 51 bases), it was however impossible to clearly follow
the reaction (between a single 37 mer and 42-mer, forming a single 79-mer).
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Figure 4.83: AFM images of the cross-link reactions on DNA origami A) The
origami without cross-linking as reference; B) The origami after the cross-linking with
NBS; C) The origami after the cross-linking with 1O2: 30 min (left) and 60 min (right)
4.6. VISUALISATION OF FURAN BASED CROSS-LINKING 137
Figure 4.84: PAGE of the cross-link reactions on DNA origami The obtained
bands on the polyacrylamide gel from the electrophoresis experiment, show the over-
whelming presence of bridges and staples. The mass ladder consists of a mixture of
oligonucleotides with 64, 56, 44, and 32 basepairs
Conclusion The furan-modiﬁed DNA was prepared and could be incorporated
in the origami. It was however impossible to visualize the cross-linking reac-
tion using this speciﬁc design. An improved design could solve this problem and
should thus be investigated. Moreover, optimization of the cross-link conditions
is required, due to the very small amount and especially the very low concen-
tration of the furan-modiﬁed DNA in the origami (0.01 μM) compared to the
used concentrations in our standard protocol (20 μM). Transfer of the amount
of equivalents of sensitizer or NBS, results in very low concentrations that could
disturb the kinetics of the reaction, while transfer of the concentration of sensi-
tizer or NBS, will result in DNA degradation due to the very high excess. For
applications on origami, like the covalent immobilization of proteins on origami
by the Morii group or for example in vivo, this needs to be further investigated.
138 CHAPTER 4. FURAN BASED CROSS-LINKING
Chapter 5
Solid Phase Methodology
Development
This ﬁnal chapter combines some results that are not directly
related to the scope of this thesis, the binding and cross-linking of
peptides and oligonucleotides, but focus on the used methodology to
synthesize them. Oligomers are typically synthesized in repetitive
steps from protected monomers, as represented in Figures 5.1 and
5.2.
After deprotection of a coupled monomer, the next monomer can
be added for a new synthesis cycle. This process can be dramatically
simpliﬁed, as ﬁrst noted by Merriﬁeld[263], by attachment of the
growing oligomers to a solid support, which allows for easy puriﬁ-
cation by ﬁltration and washing and is the basis for automation.
Both peptides and oligonucleotides are now routinely synthesized on
solid support, polystyrene or polyethyleneglycol and controlled pore
glass respectively. The last step of the synthesis thus consists of
cleaving the oligomer from the support and deprotecting it, removing
semi-permanent protecting goups.
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Figure 5.1: General representation of Solid Phase Peptide Synthesis
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Figure 5.2: General representation of Solid Phase Oligonucleotide Synthesis
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In solid phase synthesis it is very important that the reactions
are quantitative, as remaining starting material is like the product,
attached to the support and thus transferred to the following reaction.
By adding reagents in large excess, the reaction is driven to comple-
tion, while the excess is easily removed by ﬁltration. To monitor the
progress of the reaction, it is not possible to use TLC or MS, without
intermediate cleavage from the resin. Colour tests were developed
to partially circumvent this problem. Indeed, if the coupling step
was complete, no reactive functionalities remain for coupling with
a dye. Completion of the reaction can thus be visualized. Unless,
if undeclared functionalities of the support are able to interfere like
shown in the ﬁrst section of this chapter.
The second section presents an NMR based method and its
advantages for quantiﬁcation of very small quantities of synthesized
macromolecules, which is available through collaboration with the
NMR Structure Analysis unit of Prof. Martins.
Though solid phase synthesis is a highly streamlined automated
process, the protection-deprotection scheme makes the process in-
eﬃcient. Furthermore a diﬀerent monomer has to be used (and
sometimes synthesized) for every diﬀerent, desired functionality. In
collaboration with the Polymer Chemistry Research group of Prof.
Duprez, we developed a new coupling methodology for the preparation
of functionalized, sequence-deﬁned oligomers with a novel backbone
from a single readily available thiolactone-containing building block,
without protecting groups on solid phase (section 5.3).
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5.1 Color test
Introduction Solid phase synthesis of highly hydrophobic peptide sequences is
often problematic due to intramolecular aggregation of the peptide and hydropho-
bic interactions involving the solid support. Aggregation phenomena can have a
severe negative inﬂuence on the reactivity of the free N-terminus, leading in subse-
quent reactions to deletion sequences and eventually premature termination.[108]
The exact chemical composition of the resin material plays a major role and in-
teraction with the solid support depends strongly on its hydrophobicity. With
this in mind, the development of new and more performant solid supports has
been and still is an active ﬁeld of research. People have actively sought for solu-
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tions by the development of new advanced solid supports which consist of 100%
polyethyleneglycol (PEG), like the example depicted in Figure 5.3. This type
of resin is less hydrophobic than the traditional polystyrene (PS) and PS based
resins. Therefore the PEG-resins allow a better solvation of the growing pep-
tide chains, making them perfectly suited for high purity synthesis of diﬃcult
hydrophobic, highly structured and also poly-arginine sequences.[101, 108, 264]
These resins have good swelling properties in about any solvent. This springs
from the vicinal arrangement of carbon oxygen bonds throughout the chain in
the unique structure of PEG. It assumes helical structures with gauche interac-
tions between the polarized bonds. Three helical arrangements of PEG featuring
a low energy conformation exist. The ﬁrst exposes the oxygen atoms to the en-
vironment and is thus quite hydrophilic. In the second low energy conformation,
the oxygen atoms are oriented towards the interior of the helix, which is therefore
largely hydrophobic. The third possesses an intermediate polarity. For this rea-
son PEG displays an amphipathic nature and swells in both polar and non polar
solvents.[265] PEG-resins are also thermally, mechanically and chemically very
stable as they are exclusively built up from primary ether bonds. Moreover, they
are easy to handle in the dry state, thus facilitating weighing and transfer.[264]
Figure 5.3: General representation of NovaPEG or ChemMatrix R©resin
structure: 100% cross-linked PEG.[264, 266, 267]
The synthesis of peptides on solid phase could only be conveniently and gen-
erally applied with the development of colorimetric tests. These allow monitoring
the coupling eﬃciency of amino acid coupling, without the need for cleavage from
the solid phase.[268, 269] Next to the widely used Kaiser[270] and TNBS[271]
tests our group made a contribution in this area with the development of p-
nitrophenylester NF31 (Fig. 5.4), which allows reliable monitoring of coupling re-
actions even with very sterically hindered primary and secondary amines.[272, 273]
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Figure 5.4: Structure of p-nitrophenylester NF31.
Combining the accuracy of sensitive color tests with the improved properties
of new types of resins oﬀers a way to improve the quality of diﬃcult and not well-
behaved peptide sequences. Clearly, next to the importance of the speciﬁc and
optimized structure of the base polymer for improved properties of SPPS beads,
the presence of a speciﬁc functionality on the resin is important for attachment of
the desired sequence. Amine groups are generally used for this purpose, leading
to stable amide bonds, but allowing for cleavage at the end of the synthesis by
the introduction of suitable linker moieties. However it is important to be aware
of residual functionality present on the beads, not deliberately introduced for
attachment purposes but rather present as a result of the speciﬁc polymerization
strategy used for construction of the resin. We here report on the presence of
‘non-declared’, residual, free hydroxyl groups in solid supports consisting of 100%
PEG leading to background coloration with the sensitive NF-31 test.
Results and discussion In the course of our recent endeavors in the synthesis
of large dipodal peptide constructs featuring long chains of more than 20 amino
acids, we were faced with severe problems in achieving the desired purity. As
described above, recent papers report on the exclusive capacities of PEG-based
resins in ‘diﬃcult’ peptide sequences.[101, 108, 264] This prompted us to turn
our attention to this novel type of resins. Before embarking on the synthesis of
the actually desired large peptide constructs, a series of test reactions was run to
verify and establish suitable basic peptide synthesis conditions on this new type
of resin. During the simple synthesis of a small peptide, when using NovaPEG,
a 100% PEG-based resin from Novabiochem, TNBS tests were negative. But to
our great surprise, our regularly applied NF-color test never indicated complete
coupling. Despite prolonged reaction times or multiple couplings, red coloration
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Table 5.1: Color tests on resin after coupling reaction with N-Fmoc-glycinea
a N-Fmoc-glycine (4 equiv) was coupled with PyBOP (4 equiv) and DIPEA (8 equiv)
for two times 2 h in DMF.
b No coupling reaction was performed on the Wang resin, the color tests were performed
on the unmodiﬁed resin.
of beads was continuously observed, pointing towards the presence of unreacted
functionalities. Using identical conditions on TentaGel, a PS-based resin, color
tests indicated complete couplings (see Table 5.1).
In view of the positive reports on the performance of these PEG based resins,
it was considered highly unlikely that it was impossible to obtain 100% eﬃciency
on this novel resin during simple coupling reactions. Based on the structure of
the resin, the presence of free hydroxyl groups was considered to oﬀer a possi-
ble explanation for the unexpected positive color tests. Containing a reactive
p-nitrophenyl ester functionality, NF-31 has shown to also allow for the detection
of alcohols provided slightly diﬀerent test conditions are applied.[274] Using these
conditions, more intense red beads were obtained (see Table 5.1), as would be
expected if hydroxyl groups were present. To further test this hypothesis, TNBS
and NF-31 tests were carried out on the diﬀerent types of resin, after applying
a capping procedure with acetic acid anhydride, as illustrated in Table 5.2. To
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Table 5.2: Color tests after capping with acetic acid anhydride
For the capping procedure: 6 equiv acetic acid anhydride and 6 equiv DIPEA were
added to the solid support in DMF. For the washing procedure: the solid support was
washed four times with 0.1 M NaOH.
obtain a complete reaction of all present functionalities and associated disappear-
ance of the red color, a longer reaction time was required than used in the standard
protocol for the capping of amines, hinting toward the presence of another less
nucleophilic functionality. In turn, after treatment of the resin with an aqueous
0.1 M NaOH solution, the originally observed red color reappeared. In view of
the inherent diﬀerence in base sensitivity of an amide versus an ester bond, this
experiment conﬁrms the presence of free hydroxyl groups on the PEG-based resin.
The speciﬁc and beneﬁcial characteristics of the NF 31 test, especially its
increased performance and sensitivity for secondary, sterically hindered and aro-
matic amine functionalities (as compared to more classical TNBS or Kaiser test)
have initiated its use in a variety of cases where ‘diﬃcult’ peptide sequences are
desired.[275–278] Furthermore, in view of the growing importance of the incor-
poration of unnatural (and often diﬃcult to couple) building blocks in peptide
chains and the often improved results obtained when using the novel PEG-based
resins, one should be aware that the combination of this novel well-performing
resins with OH-sensitive color tests can give rise to false positive results, im-
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peding a correct interpretation of coupling progress and leading to the entirely
unnecessary application of double couplings and concurrent waste of precious
building blocks. The presence of free hydroxyl groups can further also interfere
in other reactions. When determining coupling eﬃciencies by UV absorbance of
the piperidine benzofulvene adduct [279] for example, amino acids coupled on the
free hydroxyls and their subsequent Fmoc deprotection with piperidine, will give
rise to wrong results.
Since schematic and graphical representations of aminomethylated NovaPEG
and ChemMatrix resins in catalogs [266]and papers [108, 267] describing the ben-
eﬁts of their use in diﬃcult peptide synthesis, often omit to depict residual free
hydroxyl functionalities (Fig. 5.3), it is important to realize that they are present
and might interfere with some of the processes carried out on the resin.
Conclusion In conclusion, we have been able to understand and show why the
application of the highly sensitive NF-31 test during SPPS on novel PEG-based
resins (sold under popular brand names as Nova-PEG or ChemMatrix R©) gives rise
to diﬃcult interpretation of coupling progress. We have demonstrated that the
presence of remaining free hydroxyl functionality leads to misleading background
coloration of the resin when checking reaction progress.
Although the presence of free hydroxyl groups does not necessarily lead to
associated problems during SPPS, one should be careful when following reactions
using sensitive color tests as to avoid unnecessary application of multiple coupling
procedures or use of increased excesses of precious reagents.
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5.2 NMR based quantiﬁcation as a valuable solu-
tion for quantiﬁcation of non-UV active com-
pounds and mixture analysis
with Katelijne Gheysen and Prof. Jose Martens
Introduction Upon synthesis of biomolecules like DNA and peptides, quan-
tiﬁcation of the acquired amount of material is indispensible to further test and
determine activity, binding aﬃnity and biological properties. Typically the ob-
tained amounts are too low to be measured accurately on the standard laboratory
analytical balance; moreover possible salt formation during synthesis makes these
measurements unreliable. For the concentration determination of proteins, dif-
ferent indirect biochemical methods have been developed, mostly based on mea-
surement of an optical signal resulting from binding to or hydrolysis of a reactive
dye.[280, 281] Unfortunately this often requires specialized instruments and in-
tensive manual handling as careful sample preparation and calibration have to
be performed. These methods are also mostly destructive for the sample and
are not always applicable to smaller synthesized peptides. Therefore UV spec-
trometry is routinely applied for the determination of concentrations.[282] It is
cheap and easy provided the extinction coeﬃcient of the compound is known at
representative conditions of solvent, pH, ionic strength and concentration.[283]
However, this is not possible for molecules without chromophoric groups, such as
peptides without aromatic amino acids[284] or that are extensively modiﬁed with
additional aromatic groups.
It is common knowledge that NMR is perfectly suited for the determination
of concentrations, in view of the direct proportionality of signal intensity to the
number of resonating nuclei.[285] As this method does not require chromophores
or other speciﬁc structural entities on the target molecule it is thus broadly ap-
plicable. Moreover, the technique is not destructive and additional information
about sample purity and identity is generated. However, its implementation has
been hampered for a long time by the need of good internal standards, which
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have to be carefully selected taking in account solubility, chemical interaction,
spectral overlap and relaxation time. Recently, this tedious search could be
eliminated by the development of alternative ways for referencing, by the gen-
eration of an electronic NMR-like signal, ERETIC (Electronic Reference To ac-
cess In vivo Concentrations)[286] and by use of an external standard, PULCON
(PUlse Length -based CONcentration measurements).[287] For the latter tech-
nique, which is more practical in routine applications than the former, automatic
post-acquisition QUANTAS (QUANTiﬁcation by Artiﬁcial Signal) software was
developed and implemented for Bruker TOPSPIN software, facilitating its prac-
tical implementation.[288]
In spite of the described advances, rendering the technique perfectly applicable
to standard NMR apparatus, this method still has not found introduction into
the synthesis laboratory. We therefore here report on a comparative study where
the use of PULCON with the QUANTAS software was validated against UV as a
straightforward means for concentration determination for a series of representa-
tive samples, ultimately illustrating its usefulness for non-UV active compounds
and mixtures.
Discussion In order to validate the possibilities of NMR for concentration
determination in our laboratories a series of test experiments was set up with
stock solutions of three standards, DAPI and tryptophan in water and estradiol
in methanol. The envisaged concentrations were respectively 7.50, 15.00 and
3.00 mM. Measurements were performed using UV and NMR on the same day
and with minimal diﬀerential manipulations. For each compound a quantitative
1D-1H NMR spectrum with full relaxation was recorded. Subsequently all
signals with adequate resolution were integrated and scaled upon the artiﬁcial
QUANTAS signal. As illustrated in Table 5.3, the obtained concentrations
with both methods were in good correlation for the latter two standards. With
QUANTAS concentrations of 15.16 ± 0.09 mM for tryptophan and 2.67 ±
0.04 mM for estradiol were obtained, whereas the UV measurements resulted
in concentrations of respectively 15.10 ± 0.05 mM and 2.69 ± 0.04 mM. The
concentration for the ﬁrst standard, DAPI, on the other hand was lower when
measured with NMR than with UV (respectively 6.45 ± 0.21 mM and 8.57
± 0,03 mM). This inconsistency illustrates a risk associated with UV based
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concentration measurements. The use of reported extinction coeﬃcients requires
data from the exact molecule, in the same solvent and at the same concentration.
If not, higher or lower concentrations can result in diﬀerent association behaviour,
resulting in diﬀerent absorption values. Not taking into account the concentration
dependency of the extinction coeﬃcient in this case, clearly results in deriving
a higher UV concentration value for the DAPI standard. As such, this initial
validation already illustrates the beneﬁts of using QUANTAS instead of UV.
Table 5.3: Summary of the concentrations, obtained with NMR and UV
aconcentrations represented in mM, concentration of the oligonucleotide taking into
account length,b length and compositionc or the length, composition and sequenced
Sample Concentrationa
envisaged
determined
by NMR
determined
by UV
Standards
- DAPI 7.50 6.45 ± 0.21 8.57 ± 0.03
- tryptophan 15.00 15.16 ± 0.09 15.10 ± 0.05
- estradiol 3.00 2.67 ± 0.04 2.69 ± 0.04
oligonucleotide 2.00 1.83 ± 0.03 1.58 ± 0.02b
1.69 ± 0.03c
1.66 ± 0.02d
peptides
- AcNH-ILPEI-COOH 5.00 4.42 ± 0.25 X
H2N-RSSVGSQS-COOH 5.00 2.98 ± 0.17 X
mixture
- oligonucleotide 0.90 0.80 ± 0.01 0.83 ± 0.01
- tryptophan 1.50 1.52 ± 0.05 13.12 ± 0.20
The methodology was then tested on representative samples from our groups
that are typically more diﬃcult to quantify. Initially the concentration of a
commercial oligonucleotide, 5’-GCA CAC CGT CAG-3’, was determined. For
DNA, UV concentration determination represents the standard procedure. It
is routinely performed in many laboratories, since oligonucleotides are used as
probes, templates and binding sites both in biological and chemical setups. It
has been noted that dissolving commercial lyophilised DNA and determining its
concentration by UV hardly ever matches the predetermined concentration, thus
illustrating the need for accurate concentration measurement before any further
experiments. Three diﬀerent methods have been described to calculate extinction
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coeﬃcients of DNA based on the nucleotides it consists of; taking into account
only the length,[289] the length and composition[290] or the length, composition
and sequence.[291] The latter so-called nearest neighbour method, is considered
the most accurate and is thus the most popular. It was however earlier shown
that experimentally determined extinction coeﬃcients are better suited for exact
concentration measurement as the calculated extinction coeﬃcients introduce an
additional uncertainty of 20%.[292] This uncertainty is even more pronounced
in the case of DNA with synthetic modiﬁcations that are not considered in
the extinction coeﬃcient calculation. This approximation is often necessary
if the contribution of the modiﬁcation and its inﬂuence on the behaviour of
the oligonucleotide as a whole is not known. Using the extinction coeﬃcients
calculated with the oligonucleotides length, length and composition and length,
composition and sequence, UV measurements found a concentration of respec-
tively 1.58 ± 0.02 mM, 1.69 ± 0.03 mM and 1.66 ± 0.02 mM. NMR determined
a concentration of 1.83 ± 0.03 mM. Considering the earlier mentioned additional
20% uncertainty, UV measurements and NMR measurements fall within the
same range. Considering that quantitative NMR integration is independent of
molecular features, except for the number of protons counting for a signal, it can
be considered more accurate.
In a next series of experiments, we turned our attention to the concentration
determination of peptides. Extinction coeﬃcients can be derived from the
constituting amino acids, provided aromatic moieties are present. As this is not
the case for many of the peptides synthesized in our laboratory, we hitherto often
faced problems when trying to quantify the obtained amounts of material. In
an attempt to test the described methodology also in this peptide context, we
submitted two representative non-UV active peptides to concentration determi-
nation with QUANTAS. In ﬁrst instance, the pentapeptide AcNH-ILPEI-COOH,
previously synthesized for a study concerning caspase activity, was selected.[293]
As at the time of the experiments its concentration could not be determined
using UV, estimation of concentration was based on the weight of the sample and
thus determined to be 5.00 mM. The concentration obtained with QUANTAS
was found to be 4.42 ± 0.25 mM which is in rather good agreement with the
previous estimated value. Secondly, an octapeptide (H2N-RSSVGSQS-COOH)
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synthesized during the development of an artiﬁcial estrogen receptor mimic was
tested.[294] In this case, the determined concentration was 2.98 ± 0.17 mM,
which is much lower than the earlier estaminated value of 5.00 mM based on
the weight. However, examination of the purity of both peptide samples (ca.
96% and 74% as determined from HPLC analysis) showed that whereas the
ILPEI peptide was very pure (Fig. 5.5a), the octapeptide, though appearing as
one main signal in the HPLC chromatogram (Fig. 5.5b), does contain traces of
various impurities. These impurities contribute to the total weight of the sample,
therefore leading to overrated reaction yields. This further illustrates another
signiﬁcant advantage of the QUANTAS protocol namely that impurities can be
readily observed when recording the quantitative 1D spectrum and avoided in
the quantiﬁcation.
As is clearly illustrated here for the octapeptide case, a great merit of
QUANTAS compared to UV measurements is the possibility to determine the
concentration of active or desired compounds in contaminated samples. It can be
further deduced that QUANTAS can thus be used in the straightforward deter-
mination of the concentration of diﬀerent compounds constituting a mixture. To
illustrate this added value of the QUANTAS technique, a mixture was prepared
of the tryptophan standard and the commercially available oligonucleotide (with
calculated concentrations of respectively 1.50 and 0.90 mM). Former results
have shown that NMR as well as UV measurements resulted in the correct
concentrations when the compounds were separately dissolved. Using UV, the
oligonucleotide concentration within the mixture was determined to be 0.83 ±
0.01 mM with the nearest neighbour method. The tryptophan concentration
on the other hand could not be determined, as the oligonucleotide dominates
the absorption found (13.12 ± 0.20 mM). Indeed, inspection of the absorption
in the range 500 to 200 nm reveals only one absorption signal corresponding to
the absorption of the oligonucleotide with a maximum at 260 nm (Fig. 5.6). No
absorption signal for tryptophan can be distinguished separately and its concen-
tration can thus not be determined, though it slightly contributes undetected
to the absorption of the oligonucleotide. Using QUANTAS NMR, no problems
were encountered and the concentrations of both substances could easily be
determined (0.80 ± 0.01 mM for the oligonucleotide and 1.52 ± 0.05 mM for
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Figure 5.5: Chromatogram (top) and NMR spectrum (bottom) of a) AcNH-
ILPEI-COOH and b) the octapeptide. The chromatograms were recorded at 214
nm on a Agilent 1200 Series HPLC, Luna column C18, 100 A˚(250 x 4.6 mm, 5μm) from
100% 0.1 TFA in water to 100% MeCN in 15 minutes to examine the purity of the
peptides. In the 1D-1H NMR spectrum from the octapeptide, the signals belonging to
impurities can easily be identiﬁed according to their lower concentration (ranging from
0.24 mM to 1.19 mM but the number of protons counting for the signals is unknown).
The NMR signal at -1 ppm is the artiﬁcial QUANTAS signal. The impurities are denoted
with *.
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tryptophan). This illustrates that QUANTAS is not just a reliable fast and
convenient method for concentration determination, but also further allows the
accurate determination of the concentration of a compound in a contaminated
sample or of compounds in mixtures.
Figure 5.6: UV-spectrum (left) and 1D-1H NMR spectrum (right) of the
Trp/oligonucleotide mixture. The UV spectrum shows the typical absorption of
an oligonucleotide with maximum at 260 nm. The tryptophan contamination is not
distinguishable from the oligonucleotide signal. In the NMR spectrum on the other
hand, clearly separated resonances for both compounds can be identiﬁed: ∗ are signals
belong to Trp and • represent aromatic signals from the oligonucleotide. The NMR
signal at -1 ppm is the artiﬁcial QUANTAS signal and the sample was contaminated
with ethanol.
Conclusion In conclusion, we have tested and implemented QUANTAS in our
laboratory as a viable alternative for UV concentration determination of synthetic
biomolecules on standard NMR equipment. This allows us to obtain accurate
data for standard and synthetically modiﬁed oligonucleotides, UV and non-UV-
absorbent peptides, contaminated samples and mixtures. Furthermore, it is a
practical method that requires less manipulation and is less prone to mistakes
and misinterpretations than UV based quantiﬁcation.
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5.3 Coupling Method
Two decades of progress in the ﬁeld of living and controlled polymeriza-
tions, combined with the elaboration of eﬃcient conjugation reactions, have
greatly contributed to the elegant preparation of functionalized macromolecular
architectures.[295–298] However, these state-of-the-art methodologies, while
providing a high degree of structural and topological control, are inadequate
tools for controlling the polymer microstructure. Crucial parameters like primary
structure (i.e. monomer sequence) and tacticity largely remain unmastered by
current man-made approaches. Expectations for the next generation of synthetic
polymers include performance as single chains, ability to fold and self-regulate,
5.3. COUPLING METHOD 157
and ability to sense speciﬁc molecules and/or catalyze reactions.[299–306] These
precisely functionalized linear polymers should exhibit sharply deﬁned and
tailored structureactivity relationships analogous to Nature’s delicately engi-
neered macromolecules. Therefore, progress towards reliable sequence-controlled
polymerization, enabling the preprogrammed distribution of multiple functional
groups along the backbone, is drawing attention in a growing number of research
groups worldwide.[307–311]
Pioneering eﬀorts to control the primary structure of functionalized polymers
have been based on several approaches, using diﬀerent reactivity ratios of vinyl
monomers,[312, 313] spatial prearrangement of monomers on a (macromolecular)
template[314–318] or, as recently demonstrated, the action of a small-molecule
machine.[319] Other attempts use (automated) sequential addition of building
blocks on a solid[320, 321] or liquid[322–324] support, leading to sequence control
as a result of iterative coupling steps, thereby omitting the need for preorganiza-
tion. These methods, established for peptide[263, 325] and oligonucleotide[326]
synthesis, present considerable drawbacks for sequence controlled polymeriza-
tion: they generally require the use of protecting groups, and the restricted
number of readily available building blocks (‘monomer alphabet’) equipped
with the appropriate functional handle can further hamper the preparation of
tailor-made functionalized sequences. The development of new chemical methods
for chain elongation, often on a solid support, that result in sequence-deﬁned
(macro)molecular structures with unique backbones and side chain functionali-
ties, or fragments thereof that could be combined to obtain sequence-controlled
polymers,[311] is therefore highly desirable.
Herein, we report on a new coupling strategy for the controlled generation
of sequence-deﬁned multifunctionalized oligomers on solid support by using
thiolactone-based chemistry. This protecting group free approach was inspired
by the ‘submonomer’ synthetic method for the preparation of functionalized
peptoids.[327–329] Although the generated oligomers are small in size, recon-
stitution approaches could further allow the synthesis of larger chains featuring
the designed and repetitive display of carefully selected and well-positioned
functional entities.
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Figure 5.7: Two-step iterative method for the synthesis of functionalized
oligomers on solid support: aminolysis of the resin-bound thiolactone followed by
coupling of a thiolactone-containing building block that selectively reacts with the gen-
erated thiol.
The synthetic scope of thiolactones as reactive precursors for thiols in
various polymeric systems was recently reported by the group of Prof. Du
Prez[330–334] and other groups.[335, 336] These cyclic thioesters are susceptible
to selective aminolysis, releasing a thiol and thus providing a functional handle
for subsequent eﬃcient conjugation reactions.[337, 338] From this, we reasoned
that immobilization of a thiolactone unit on a solid support should enable
chain extension after on-resin aminolysis. Indeed, using a judiciously selected
thiolactone building block to reinstate the thiolactone functionality would
allow the start of a next iterative reaction sequence (Fig. 5.7). This two-step
aminolysis/chain extension method does not make use of any protecting groups
and relies on a single thiolactone-containing building block for chain extension.
Most importantly, a myriad of functionalities can be introduced by using the
corresponding readily available amines.
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The main requirement for this approach is the preparation of a suitable
thiolactone-based building block for chain extension. Since such a reactant
will typically be used in high excess when applying solid-support methods, its
synthesis has to be high yielding on a multigram scale. Diﬀerent building blocks
(Fig. 5.8) were designed and could be synthesized in a one-step procedure, with a
straightforward puriﬁcation, from the readily available racemic DL-homocysteine
thiolactone (performed by Dr. P. Espeel, see experimental part). Together with
compound 5.3.1, which is used for the initial loading of a thiolactone unit onto
a suitable solid support, building blocks 5.3.2 and 5.3.3 were evaluated as chain
extension moieties.
Figure 5.8: Thiolactone-containing building blocks for loading (5.3.1) and
chain extension (5.3.2 and 5.3.3).
As the repetitive aminolysis and chain extension steps occur in basic medium,
an acid-labile linkage was foreseen for ﬁnal cleavage from the solid support.
Consequently, the carboxylic acid functionalized thiolactone linker (5.3.1) was
coupled to a 2-chlorotrityl resin using standard conditions (see experimental
part).[339] The thiolactone building block for chain extension should be equipped
with a functional handle to allow reaction with the on-resin generated thiol pref-
erentially in a nucleophilic fashion. Therefore, we have chosen N-(2-bromoacetyl)
homocysteine-γ-thiolactone (5.3.2) and N-(acryloyl) homocysteine-γ-thiolactone
(5.3.3), which are susceptible to thio-bromo substitution and thiol-Michael
addition, respectively.
Building blocks 5.3.2 and 5.3.3 were subsequently tested in the aminol-
ysis/chain extension method. Aminolysis of the resinbound thiolactone was
performed by overnight treatment of the swollen resin with an excess of benzy-
lamine in CH2Cl2, thus guaranteeing full thiolactone conversion. LCMS analysis
of the sample after acidic cleavage revealed quantitative consumption of the
160 CHAPTER 5. SOLID PHASE METHODOLOGY DEVELOPMENT
thiolactone, but only the corresponding disulﬁde of the expected thiol could be
identiﬁed (Fig. 5.9a). This inevitable disulﬁde formation during aminolysis is
independent of the identity of the amine because the corresponding disulﬁde
was detected for a variety of (functionalized) amines (see below). As a free
thiol is required for the subsequent coupling step, a ﬁrst attempt to avoid
disulﬁde formation involved lowering the amine concentration. However, the
thiolactone conversion was negatively inﬂuenced while the disulﬁde remained
the dominant reaction product. The disulﬁdes formed could be partially cleaved
in a postaminolysis treatment by using dimethylphenylphosphine (Me2PhP)
as a reducing agent (Fig. 5.9b). However, their complete reduction and the
subsequent conservation of the obtained resin-bound thiols appeared challenging.
The synthetic strategy was thus adapted to consider the resin-bound disulﬁdes
generated upon aminolysis as stable intermediates. With respect to the two-step
iterative method (Fig. 5.7), reduction of the disulﬁde by phosphine treatment
followed by immediate in situ reaction of the generated thiol[340] with the
next monomer building block is indeed an alternative for the proposed chain
extension. However, these conditions were found not to be applicable when using
building block 5.3.2 owing to the incompatibility of a bromide leaving group
with a trialkylphosphine. On the other hand, considering chain extension by
using building block 5.3.3, the phosphine reagent can fulﬁll a dual role: both as a
reducing agent for the disulﬁde generated upon the aminolysis and as an eﬃcient
catalyst for the thiol-Michael addition.[341, 342] Cleavage of the resin-bound
disulﬁde and Michael addition of the thiol to acrylamide 5.3.3 could indeed be
successfully performed in the presence of an excess of Me2PhP and building block
5.3.3, as demonstrated by the HPLC trace of the obtained conjugated product
(Fig. 5.9c).
To demonstrate the general potential of this methodology in terms of
versatility and tolerance towards functional groups, a small library of func-
tionalized sequences was prepared by two iterations of the elaborated two-step
method. A random selection of nonfunctionalized primary or secondary amines
(n-propylamine, benzylamine, and pyrrolidine) for the ﬁrst ring-opening step
and functionalized primary amines (allylamine, propargylamine, furfurylamine,
and N-(3-aminopropyl) morpholine) for the consecutive aminolysis allowed
5.3. COUPLING METHOD 161
Figure 5.9: LC-MS analysis of cleaved samples after a) aminolysis of the resin-
bound thiolactone with benzylamine, generating the corresponding disulﬁde, b) on-resin
reduction of the formed disulﬁde by phosphine treatment, and c) on-resin reduction
of the formed disulﬁde and sequential one-pot chain extension through thiolacrylamide
conjugation. Inserts: ESI-MS spectra of the dominant species (negative mode).
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for the synthesis of six functionalized dimers (Figure 5.10a and experimental
part). By reversing the order in which the amines were employed, the isomeric
sequences for each combination were obtained in good purity, thus illustrating
the possibility to control the sequence without signiﬁcant interference from the
introduced functional groups. (Figure 5.10b and experimental part). Diﬀerent
functional handles could consequently be incorporated into a single, longer
oligomeric motif through the application of an extra aminolysis/chain extension
cycle. This was demonstrated by extension of the benzylaminepropargylamine
sequence (Figure 5.10c) through a third iteration using furfurylamine during
the aminolysis, thus yielding a multifunctionalized sequence-deﬁned oligomer
suitable for orthogonal modiﬁcation.[138, 252, 334, 343, 344]
To further deﬁne the scope and limitations of the described method, the max-
imum number of repetitions of the synthetic cycle to generate longer sequences
was determined. While the consecutive overnight reactions in the current method
render the overall process time-consuming, it was demonstrated that heating
through microwave irradiation signiﬁcantly reduces the reaction times of both
steps (Fig. 5.11). This accelerated microwave-assisted method was applied to the
preparation of two pairs of structurally related trimer and tetramer sequences in
good purity. Attempts to extend the tetramer to a multifunctionalized pentamer
were only partially successful because side reactions tend to become predominant
(Fig. 5.12).
The trimers and tetramer were puriﬁed and subjected to HRMS (Figures in
experimental part) and 2D NMR (500 and 700 MHz) analysis, thus enabling
full characterization of the obtained oligomeric species (performed by Dr. Pieter
Espeel, see Appendix B). The appearance of amide NH resonances in the
1H-NMR spectra (d=7.88.5 ppm) is highly speciﬁc (like a ﬁngerprint) for each
oligomer as a result of the signiﬁcant inﬂuence of the amine residue on the chemi-
cal shifts of the amide protons in both the side chain and the backbone (Fig. 5.13).
In summary, a thiolactone-based approach for the solid supported preparation
of multifunctionalized sequence deﬁned oligomers was successfully developed. The
elaborated two-step iterative method, consisting of an on-resin aminolysis and
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Figure 5.10: LC-MS analysis of the functionalized oligomers originating from
repetitive on-resin aminolyses, using diﬀerent (functional) amines, and chain
extensions: a) benzylamine and propargylamine, b) propargylamine and benzylamine,
and c) benzylamine, propargylamine and furfurylamine. Inserts: ESI-MS-spectra of
dominant species (negative mode).
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Figure 5.11: LC-MS analysis of two reaction sequences (aminolysis with ben-
zylamine and subsequent chain extension), using conventional overnight reactions at
ambient conditions (top) or a microwave-assisted accelerated protocol (bottom).
subsequent chain extension through Michael addition, does not require protect-
ing groups and relies on the use of a single, readily available thiolactone acry-
lamide building block. Several functionalized short (up to tetrameric) sequences
were obtained by consecutive use of a variety of commercially available amines.
The obtained sequence deﬁned motifs featuring a unique backbone and a prepro-
grammed organization of functional side chains were fully characterized by NMR
spectroscopy and HRMS. These species could potentially exhibit particular fold-
ing and self-association properties, predominantly determined by the nature of the
functionalized amines. In this regard, high-throughput automation and control
Figure 5.12 (facing page): LC-MS analysis of the functionalized oligomers
originating from repetitive on-resin aminolyses, using diﬀerent amines,
and chain extensions: a) trimer: 3-morpholinopropylamine - 2-methoxyethylamine
-benzylamine; b) tetramer: 3-morpholinopropylamine - 2-methoxyethylamine - benzy-
lamine - furfurylamine; c) pentamer: 3- morpholinopropylamine - 2-methoxyethylamine
- benzylamine - furfurylamine - benzylamine; d) pentamer: 3- morpholinopropylamine
- 2-methoxyethylamine - benzylamine - furfurylamine - n-octylamine. All samples were
prepared via the microwave-assisted protocol and were analyzed as crude mixtures after
cleavage from the resin.
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Figure 5.13: The amide signals in the 1H-NMR spectra (500 MHz,
[D6]DMSO) of two structurally related trimeric species.
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over the stereochemistry, induced by the use of enantiomerically pure building
blocks, will be further explored. Moreover, through further application of thiolac-
tones as latent thiol functionalities and installation of appropriate functional end
groups, these short heterotelechelic fragments are susceptible to periodic polymer-
ization, a process expected to aﬀord larger sequence-controlled polymers. This
promising reconstitution approach[311] will be the focus of our future research
eﬀorts.
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Chapter 6
Conclusion & Perspectives
(English Summary)
DNA-protein interactions were the focal point of the work in this PhD project.
These interactions are essential for cellular life and are at the basis of several
biological processes like folding, replication, transcription, and degradation. The
selectivity and aﬃnity of these interactions is remarkable, as they allow DNA-
binding proteins to ﬁnd their target in the complex cellular environment. It is
a major challenge to improve our understanding of these interactions, which is
driven by the ambition to design drugs that can compete in such interactions.
Here, DNA-protein interactions were studied using protein models and furan
oxidation-based cross-linking.
169
170 CHAPTER 6. CONCLUSION & PERSPECTIVES
6.1 Protein Models
Protein models consist of the minimal DNA binding peptide fragments taken
from a protein. By assembling relevant peptide fragments on a scaﬀold, a desired
geometry can be obtained (Fig. 6.1). If this geometry corresponds to that of the
protein, its function can be mimicked. As such, these models allow to isolate and
study important interactions in detail. These models are also easy to use in a
variety of applications because of their synthetic and analytical simplicity.
Figure 6.1: Protein models are obtained by assembling relevant peptide fragments
of the protein on a scaﬀold.
6.1.1 Madder Model
A dipodal peptidosteroid model, developed in our group for enhanced pharmaco-
kinetic properties, was revised and optimized. Through the incorporation of
ﬂexible linkers in the design, the geometry of the natural transcription factor
protein could be better approached and for the ﬁrst time with a peptidosteroid,
selective DNA binding could be achieved. The increased ﬂexibility did promote
aggregation, which drastically complicated the synthesis. To obtain the peptido-
steroid, optimization of the synthesis conditions with microwave irradiation was
required. The synthesis on its own was thus of interest to evaluate the potential
of microwave irradiation in solid phase peptide synthesis. Further research
will focuss on a more convergent synthesis approach and the analysis of the
pharmacokinetic properties.
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Figure 6.2: Madder Model Schematic representation of the dipodal peptidosteroid
(left), HPLC trace of the puriﬁed construct after successful synthesis using microwave
assistance (middle) and the polyacrylamide gel showing a supershift due to binding with
the DNA target (right).
6.1.2 Morii Model
The Morii model, based on an adamantane-cyclodextrin inclusion complex,
was chosen from several model systems reported in literature because of its
non-covalent nature. For use in cross-link reactions, this is an advantage as it
allows simpliﬁcation through the use of smaller fragments. Therefore, this model
was used in the next chapter.
Figure 6.3: Morii Model Schematic representation of the non-covalent adamantane-
cyclodextrin dipodal peptide (left) and the polyacrylamide gel showing a supershift due
to binding with the DNA target (right).
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6.2 Furan Oxidation Based Cross-Linking
The DNA-protein interaction was further studied by furan oxidation based
cross-linking. This methodology is inspired by the toxicity of furan. In the
liver, furan is oxidized into a very reactive butenedial, which covalently links
biomolecules to each other, with for example formation of DNA ICLs. By
synthesizing furan-modiﬁed oligonucleotides (ODNs), which is easy due to the
relative stability of the furan and its commercial availability, this principle was
successfully developed in our group for the controlled formation of DNA ICLs in
a selective and high yielding manner (Fig. 6.4). Over the years, a whole range
of furan-modiﬁed nucleosides has been synthesized and tested, resulting in a
toolbox with diﬀerent selectivity and yield (Fig. 6.5). In general however, the
use of synthetic DNA ICLs is limited and has few applications besides their role
in the study of DNA repair enzymes that cause resistance to chemotherapeutics.
Therefore our group was interested to further explore the possibilities. The
covalent enforcement of the transient DNA-protein interaction allows for more
easy study and analysis. Moreover, a covalent and thus permanent blockage
could have therapeutic applications.
Figure 6.4: Furan oxidation based DNA interstrand cross-linking The Furan
methodology was developed and successfully applied for DNA interstrand cross-linking.
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Figure 6.5: Furan oxidation Mechanism of cross-link formation (left). Furan-
modiﬁed nucleosides for ICL formation, a toolbox for diﬀerent selectivity and yield
(right).
To apply the furan cross-linking methodology on this interface, two diﬀerent
approaches can be followed as illustrated in Figure 6.6: modify the DNA like
before to target proteins or modify proteins to target DNA like before. Modifying
the DNA on the one hand, could be used to create cross-linking decoys regulating
gene expression by covalent capture and blockage of transcription factors in the
cytoplasm. Modifying DNA binding proteins on the other hand, like transcription
factors, with a furan for cross-linking to their natural DNA target could block
the DNA an thus also block transcription.
Figure 6.6: Diﬀerent approaches for furan based cross-linking on the DNA-protein
interface.
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6.2.1 DNA → protein cross-linking
In case of reaction from furan-modiﬁed DNA to a bound protein, competitive ICL
should be avoided. This was possible by using nu5, which features a furan on the
base (Fig. 6.7). This furan is positioned away from the Watson-Crick base pairing
interface, into the major groove of the DNA where proteins bind. Therefore, nu5
did not give signiﬁcant levels of ICL formation. It was rationalized that in this
case, DPCs (DNA-protein cross-links) are formed through a Schiﬀ base, which
can be stabilized by NaCNBH3 reduction (Fig. 6.8 top).
Figure 6.7: Furan-modiﬁed nucleoside for use in the synthesis of furan-modiﬁed
ODNs, which were tested for cross-linking to their natural binding protein.
DPC formation could be observed after combination of the transcription
factor model with its nu5 modiﬁed DNA binding site, oxidation and reduction
(Fig. 6.8 bottom). This was also conﬁrmed by mass analysis. Interestingly,
diﬀerential positioning of nu5 in the duplex resulted in diﬀerent cross-link yields,
which decreased with increasing distance. As such furan-modiﬁed ODNs can be
used as distance scanning probes.
Kinetin-modiﬁed DNA, that occurs in natural DNA as a result of oxidative
stress is also base modiﬁed with a furan (nu4). It was shown that this furan-
modiﬁcation reacts under oxidative stress, functioning as antioxidant, but does
not lead to the formation of toxic DNA ICLs. The formation of DPCs could not
be shown in this case.
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Figure 6.8: DNA → protein cross-linking. Mechanism (top), HPLC trace be-
fore and after furan oxidation and reduction (bottom left), detail of the DNA-protein
interaction with the oxidized furan (bottom right).
6.2.2 DNA ← protein cross-linking
Alternatively, the protein model can be modiﬁed with furan for cross-linking to
the DNA bases. For the furan-modiﬁcation of the mimic, several furan-modiﬁed
amino acids were synthesized next to commercial furfurylalanine, to assess the
inﬂuence of linker length and type (Fig. 6.9). Finally, tests were performed with
aa1, as aa3 has a risk for intramolecular reactions, aa4 is unstable under the
applied peptide synthesis conditions and aa6 has an electron poor deactivated
furan. aa5 remains to be tested.
Figure 6.9: Furan-modiﬁed amino acids for the synthesis of furan-modiﬁed pep-
tides, which were tested for cross-linking to their natural DNA binding site.
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Furfurylalanine was incorporated at 2 diﬀerent positions in the peptide,
both directed towards the nucleophilic functionalities in the DNA with which
it should react. Care was taken to conserve essential residues, to avoid loss of
binding aﬃnity. The peptides could be synthesized under standard synthesis
conditions. Although oxidation and degradation of the furan moiety had
been described under acidic peptide cleavage and deprotection conditions, no
problems were encountered. Oxidation of the furan was checked by trapping the
reactve 4-oxobutenal with hydrazine. DPC formation (under a range of diﬀerent
conditions) however, was not observed. Only some degradation occured upon
oxidation, like shown in Figure 6.10.
Figure 6.10: DNA ← protein cross-linking. Mechanism (top), HPLC trace before
and after furan oxidation (bottom left), diﬀerence between ICL where reaction takes
place with the opposite ODN and DPC where reaction has to occure with a duplex
(bottom right).
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Though unfavorable positioning and/or linking cannot be completely ex-
cluded, the results led to the hypothesis that it is rather diﬃcult to cross-link to
duplex DNA. The involvement of the targeted exocyclic amines in Watson-Crick
base pairing in the highly organized duplex, strongly reduces their reactivity
towards cross-linking. This hypothesis is further supported by the reported use
of aldehydes for the detection of single stranded regions in DNA and their use
to elucidate RNA folding pathways. The diﬀerence between ICL and DPC is
depicted in Figure 6.10. While the reactive moiety from the peptide has to
intrude in and interfere with the highly organized duplex structure for DPC
formation, for ICL formation the reactive moiety is part of the duplex. Therefore
the base opposite the furan-modiﬁcation is unpaired and thus readily available
for reaction. The introduction of distortions in the target duplex (by means of
a mismatch, a ﬂipout base or a temperature increase) to facilitate cross-linking
was not possible as this disturbed binding of the model, which is dentrimental
for the cross-link reaction. It could thus be concluded that cross-linking with the
furan oxidation-based methodology is not eﬃcient towards duplex DNA and that
the use of a protein model is not ideal for further investigation with facilitated
cross-link formation.
Though initially considered a negative result and a disadvantage, this is more
and more considered as a feature that could be used for structural elucidation
in complex systems and to distinguish single from double stranded DNA e.g in
topoisomerases. To prove this hypothesis, cross-linking from a furan-modiﬁed
protein to a single stranded ODN is required. Currently, 2 possibilities are under
investigation. Cross-linking from a protein to an RNA hairpin, which is more
distorted by mismatches, ﬂipout bases and a loop (Fig. 6.11, left) should be
possible. Also cross-linking from a protein that binds single stranded DNA,
like polymerases should work. After initial experiments in our group and the
successful experiments by Prof. Summerer, it is now also clear that furan can be
incorporated in proteins by amber supression and recombinant expression. This
paves the way for a good many new possibilities.
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Figure 6.11: Model systems for proving the hypothesis that furan based
cross-linking can diﬀerentiate between single and double stranded ODN/ON
RRE RNA-Rev peptide interaction (left), polymerase associated with the single stranded
template DNA (right).
6.2.3 RNA ICL
To test the mildness and generality of the methodology, to prepare for protein-
RNA cross-linking and because RNA is becomming an increasingly important
therapeutic target, RNA ICL formation was examined. Rather suprisingly, it was
found that RNA sustained the oxidation conditions well and that high cross-link
yields were achieved. The diﬀerent duplex shape was reﬂected in a diﬀerent
furan-modiﬁed nucleoside preference. In this case, the best results in yield and
selectivity were obtained with nu3 (cfr. for DNA ICL better yields were obtained
with nu6 than with nu3).
Figure 6.12: RNA ICL met X = nu3. RP-HPLC trace of the RNA ICL reaction
before and after NBS oxidation (left). Denaturating PAGE gel with three diﬀerent
targets: complementary RNA with a C or a U opposite nu3 and a randomized non-
complementary RNA with a C opposite nu3 (right).
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6.3 Methodology Optimalisation
Next to the original goals in DNA-protein context, which constitute the main
theme of this work, some results were accomplished in the optimalization of solid
phase methodology.
• The previously developed NF31 color test was shown to detect residual OH
groups in novel solid phase resins.
• The potential of NMR for the concentration determination of biomacro-
molecules was tested in collaboration with the NMRSTR group.
• In collaboration with the PCR group, specialized in thiolacton chemistry,
a new and versatile solid phase coupling methodology for the synthesis of
sequence controlled oligomers was developped (Fig. 6.13).
Figure 6.13: Two-step iterative method for the synthesis of functionalized
oligomers on solid support: aminolysis of the resin-bound thiolactone followed by
coupling of a thiolactone-containing building block that selectively reacts with the gen-
erated thiol.
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Conclusion
The initial goal of this PhD work, to design a cross-linking transcription factor
mimic with possible therapeutic applications, was not achieved. Cross-linking
to a dubble stranded DNA helix appeared to be particularly challenging. The
synthesis of the dipodal peptidosteroid mimic was however optimized and DNA
binding achieved for the ﬁrst time. Furthermore, the work described in this
thesis has contributed to a better understanding of and insight in the furan
oxidation methodology and signiﬁcantly extended its applicability. Next to
furan incorporation in ODNs for DNA interstrand cross-link formation, RNA
interstrand cross-link formation was shown to be also possible in ON duplexes.
Furan-modiﬁed duplexes can, with the choice of an appropriate modiﬁed nucleo-
side, also be used for the formation of DPCs. Furan has also been incorporated
in peptides. DPC formation could not be shown in this case, but there are high
expectations for the cross-linking in not-duplex complexes. Finally, it has been
demonstrated that furan modiﬁcations can be site selectively incorporated in
proteins, which opens up enormous possibilities.
Figure 6.14: Summary of the extended applicability of the furan cross-linking
approach showing the diﬀerent available modiﬁcations (text in blue) and targets (text
in orange).
6.3. METHODOLOGY OPTIMALISATION 181
Perspectives
Now, the following steps should persue the use of the methodology in relevant
applications and in a biological context. With this purpose in mind, it is important
to deal with concentration related issues and use of a biocompatible oxidation
method. The production of singlet oxygen by red light irradiation of sensitizers
has been developed for DNA ICL formation and was shown to be compatible with
RNA ICL formation. Moreover, tests for DPC formation have been conducted
and this was the method used for the reported RNA-protein cross-linking. Singlet
oxygen can however still cause a lot of collateral damage. Theoretically reasonable
and more selective alternatives, for which initial tests have been performed are the
oxidation by cytochrome P450 that is responsible for the natural oxidation of furan
in the liver [345–347] and electrochemical oxidation.[348–350] Especially the latter
method holds a lot of potential. Because furan has a lower oxidation potential
than the DNA/RNA bases,[351–353], a current will only ﬂow (at the correct
potential) in the presence of unoxidized furan. Moreover, the use of electrodes
allows local applications.[354] The use of biological triggers for furan oxidation
like oxidative stress (e. g. in cancerous cells) is an other interesting possibility.
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Chapter 7
Nederlandstalige
Samenvatting
De interactie tussen DNA en prote¨ınes stond centraal in het uitgevoerde
doctoraatswerk. Deze interactie is essentieel voor cellulair leven, aangezien ze
aan de basis ligt van verschillende biologische processen, zoals opvouwing, repli-
catie, transcriptie en degradatie. De selectiviteit en aﬃniteit die DNA bindende
prote¨ınes toelaat hun target te vinden in de complexe cellulaire omgeving is uiterst
opmerkelijk. Inzicht hierin verkrijgen is een interessante uitdaging, gedreven door
de ambitie om geneesmiddelen te ontwikkelen die kunnen interfereren in deze in-
teractie. De DNA-prote¨ıne interacties werden hier bestudeerd aan de hand van
prote¨ıne modellen en furan-oxidatie gebaseerde cross-linking.
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7.1 Prote¨ıne Modellen
Prote¨ıne modellen zijn opgebouwd uit de minimale DNA bindende peptide frag-
menten van een prote¨ıne. Door relevante peptide fragmenten te combineren op
een scaﬀold, kan een gewenste geometrie bekomen worden (Fig. 7.1). Indien
deze geometrie gelijkaardig is aan die van het prote¨ıne, kan de functie nagebootst
worden. Deze modellen laten zo toe de belangrijke interacties te isoleren en in
detail te bestuderen. Deze modellen zijn ook gemakkelijk voor gebruik in allerlei
toepassingen door hun synthetische en analytische eenvoud.
Figure 7.1: Prote¨ıne modellen worden bekomen door relevante peptide fragmenten
correct te combineren op een scaﬀold.
7.1.1 Madder Model
Een dipodaal peptidosteroide model, ontwikkeld in onze groep voor verbeterde
farmacokinetische eigenschappen, werd herzien en geoptimaliseerd. Door het
toevoegen van ﬂexibele linkers aan het ontwerp, kon de geometrie van het
natuurlijke transcriptiefactor prote¨ıne beter benaderd worden en werd selectieve
DNA binding met een peptidostero¨ıde voor het eerst gerealiseerd. De toegenomen
ﬂexibiliteit bemoeilijkte de synthese wel zodanig dat de condities geoptimaliseerd
moesten worden. Microgolf assistentie bleek een oplossing te bieden en daarom
was de synthese op zich ook interessant om de mogelijkheden van microgolf
geassisteerde vaste fase peptide synthese te evalueren. Verder onderzoek zal
zich richten op een meer convergente synthesestrategie en de analyse van de
farmacokinetische eigenschappen.
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Figure 7.2: Madder Model Schematische voorstelling van het dipodaal peptidos-
teroide (links), HPLC trace van het opgezuiverde construct na successvolle synthese
met microgolf assistentie (midden) en de polyacrylamide gel die een supershift vertoont
door binding met de DNA bindingssite (rechts).
7.1.2 Morii Model
Het Morii model, gebaseerd op een cyclodextrine-adamantaan inclusie complex,
werd geselecteerd uit de verschillende modelsystemen beschreven in de literatuur
omwille van zijn niet-covalente natuur. Voor het gebruik in cross-link reacties
is dit een voordeel omdat dit een vereenvoudiging toelaat, er kan immers met
kleinere fragmenten gewerkt worden. Om die reden werd dit model dan ook
gebruikt in het volgende hoofdstuk.
Figure 7.3: Morii Model Schematische voorstelling van het niet covalente
adamantaan-cyclodextrine dipodaal peptide (links) en de polyacrylamide gel die een
supershift vertoont door binding met de DNA bindingssite (rechts).
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7.2 Furan Oxidatie Gebaseerde Cross-Linking
De DNA-prote¨ıne interactie werd verder bestudeerd door middel van furan
oxidatie gebaseerde cross-linking. Deze cross-link methode is ge¨ınspireerd op
de toxiciteit van furan. Furan wordt in de lever door oxidatie omgezet tot het
heel erg reactieve buteendial, dat biomoleculen covalent aan elkaar linkt door de
vorming van bijvoorbeeld DNA interstrand cross-links (ICL). Aan de hand van
de synthese van furan gemodiﬁceerde oligonucleotiden (ODNs), wat eenvoudig
is door de relatieve stabiliteit en commercie¨le beschikbaarheid van furan, kon
dit principe in onze groep gebruikt worden voor de gecontroleerde en selectieve
vorming van DNA ICLs met hoge opbrengst (Fig. 7.4). Doorheen de jaren,
werd een hele reeks furan gemodiﬁceerde nucleosiden gesynthetiseerd en getest,
wat geleid heeft tot een reeks aan varianten met verschillende selectiviteit en
opbrengst (Fig. 7.5). In het algemeen heeft het gebruik van artiﬁcie¨le DNA
ICLs echter weinig toepassingen buiten hun gebruik in de studie naar DNA
herstelenzymen, die voor resistentie tegen chemotherapeutica zorgen. Daarom
was er interesse om de verdere mogelijkheden van de methode te verkennen en
onderzoeken. De covalente stabilisatie van de transiente DNA-prote¨ıne interactie,
laat een gemakkelijkere analyse en studie toe. Een covalente en dus permanente
blokkage zou tevens therapeutische toepassingen kunnen hebben.
Figure 7.4: DNA interstrand cross-linking gebaseerd op furan oxidatie De
furan methode werd ontwikkeld en succesvol toegepast voor DNA interstrand cross-
linking.
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Figure 7.5: Furan oxidatie Mechanisme voor de vorming van cross-links (links).
Furan gemodiﬁceerde nucleosiden voor ICL vorming, varianten voor verschillende selec-
tiviteit en opbrengst (rechts).
Om de furan cross-link methode op deze interface toe te passen kunnen 2
verschillende benaderingen gevolgd worden, zoals voorgesteld in Figuur 7.6: een
ODN wordt gemodiﬁceerd met furan zoals voor ICL vorming en reageert met een
natuurlijk DNA-bindend prote¨ıne. Zo wordt een cross-linkende decoy verkregen
die bv. transcriptiefactoren kan blokkeren in het cytoplasma. Anderzijds, kan
een DNA-bindend prote¨ıne gemodiﬁceerd worden met furan, voor reactie naar
een natuurlijke DNA bindingssite zoals bij ICL. Door het DNA zo te blokkeren
kan transcriptie ook verhinderd worden.
Figure 7.6: Verschillende benaderingen die kunnen gevolgd worden voor de
toepassing van furan gebaseerde cross-linking op de DNA-prote¨ıne interface
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7.2.1 DNA → prote¨ıne cross-linking
Voor reactie van het DNA naar een gebonden prote¨ıne, moet competitieve
ICL vermeden worden. Dit was mogelijk door gebruik te maken van nu5,
gemodiﬁceerd met een furan op de base (Fig. 7.7). Dit furan bevindt zich in de
grote groeve van het DNA, waar de prote¨ınen binden en weg van de Watson-Crick
base paring interface. Daarom veroorzaakt nu5 geen signiﬁcante ICLs. Er werd
gerationaliseerd dat DPCs (DNA-prote¨ıne cross-links) in dit geval gevormd
worden via een Schiﬀse base, die kan gestabiliseerd worden door NaCNBH3
reductie (Fig. 7.8 boven).
Figure 7.7: Furan gemodiﬁceerd nucleoside voor gebruik in de synthese van furan
gemodiﬁceerde ODNs, die dan getest werden voor cross-linking naar hun natuurlijk
bindend prote¨ıne.
DPC vorming kon vastgesteld worden na combinatie van het transcriptie-
factor model met zijn nu5 gemodiﬁceerde DNA bindingssite, oxidatie en reductie
(Fig. 7.8 onder). Dit werd ook bevestigd door massa analyse. Verschillende
positionering van nu5 in de duplex resulteerde in een duidelijk verschillend
cross-link rendement, dat afnam met toenemende afstand. Furan gemodiﬁceerde
ODNs kunnen dus gebruikt worden als afstand scannende probes.
Kinetine gemodiﬁceerd DNA, wat voorkomt in natuurlijk DNA ten gevolge
van oxidatieve stress is eveneens op de base gemodiﬁceerd met een furan (nu4).
Er werd aangetoond dat deze furan modiﬁcatie reageert onder oxidatieve stress
en dus werkt als antioxidant, maar niet leidt tot de vorming van toxische DNA
ICLs. De vorming van DPCs kon in dit geval niet aangetoond worden.
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Figure 7.8: DNA → prote¨ıne cross-linking. Mechanisme (boven), HPLC chro-
matogram voor en na furan oxidatie en reductie (linksonder), detail van de DNA-prote¨ıne
interactie met het geoxideerde furan (rechtsonder).
7.2.2 DNA ← prote¨ıne cross-linking
Alternatief kan het prote¨ıne model gemodiﬁceerd worden met furan voor cross-
linking naar de DNA basen (analoog als bij ICL). Voor de furan modiﬁcatie
van het model werden, naast het commercieel beschikbare furfurylalanine,
verschillende furan gemodiﬁceerde aminozuren gesynthetiseerd om de invloed
van linkerlengte en -type te kunnen inschatten (Fig. 7.9). De testen werden
uiteindelijk uitgevoerd met aa1, aangezien aa3 een risico inhield tot intramolec-
ulaire reacties, aa4 niet stabiel was onder de gebruikte peptide synthese condities
en aa6 te elektronenarm en dus gedeactiveerd was voor reactie. aa5 moet nog
getest worden.
Furfurylalanine werd ge¨ıncorporeerd op 2 verschillende posities in het peptide,
beide gericht naar de nucleoﬁele functionaliteiten in DNA waarmee het moet rea-
geren. Daarboven werden essentie¨le residuen behouden om de bindingsaﬃniteit
niet te reduceren. De peptiden konden gesynthetiseerd worden onder standaard
condities. Hoewel furan oxidatie en degradatie onder de zure condities voor
peptide afsplitsing en ontscherming beschreven is, werden geen problemen onder-
vonden. Oxidatie van het furan werd gecontroleerd door het 4-oxobutenal af te
vangen met hydrazine. Cross-link vorming (onder een hele reeks aan verschillende
condities) kon echter uiteindelijk niet worden geobserveerd. Oxidatie leidde enkel
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Figure 7.9: Furan gemodiﬁceerde aminozuren voor gebruik in de synthese van
furan gemodiﬁceerde peptiden, die dan getest werden voor cross-linking naar hun natuur-
lijke DNA bindingssite.
tot wat degradatie, zoals weergegeven in Figuur 7.10.
Figure 7.10: DNA ← prote¨ıne cross-linking. Mechanisme (boven), HPLC chro-
matogram voor en na furan oxidatie (linksonder), principieel verschil tussen ICL, waarbij
gereageerd wordt met een oligonucleotide en DPC, waarbij er met een duplex gereageerd
moet worden (rechtsonder).
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Hoewel een ongunstige positionering en/of linker niet uitgesloten kunnen
worden, leidden deze resultaten tot de hypothese dat het erg moeilijk is om te
cross-linken naar duplex DNA. De exocyclische amines waarmee in een cross-link
reactie gereageerd moet worden, zijn immers betrokken in Watson-Crick basepar-
ing en daardoor minder geneigd tot verdere reactie. Deze hypothese wordt verder
ondersteund door het gerapporteerde gebruik van aldehyden voor de detectie van
enkelstrengige regio’s in DNA en het ophelderen van RNA opvouwingspatronen.
Het verschil tussen ICL en DPC vorming is weergegeven in Figuur 7.10. Terwijl
de reactieve groep op het peptide moet indringen en de sterk georganiseerde
duplex moet verstoren voor DPC vorming, maakt bij ICL vorming het furan deel
uit van de duplex waardoor de base tegenover de furan modiﬁcatie ongepaard
en dus vrij beschikbaar is. Het verstoren van de duplex (door middel van een
mismatch, een ﬂipout base of een temperatuursverhoging) om de cross-linking te
faciliteren is niet mogelijk omdat de binding van het model dan wordt verstoord
en dit dan weer nefast is voor cross-linken. Er kon dus geconcludeerd worden dat
cross-linking met onze furan oxidatie gebaseerde methode niet eﬃcient is naar
duplex DNA en dat het gebruik van een modelsysteem niet ideaal is voor verder
onderzoek met verstoring van de duplex.
Hoewel dit oorspronkelijk als een negatief resultaat en een nadeel werd
beschouwd, wordt het meer en meer duidelijk dat dit een interessante eigenschap
van de technologie kan zijn die kan helpen in de opheldering van complexe
structuren of het onderscheiden van enkel- en dubbelstrengig DNA bv. in
topoisomerasen. Om deze hypothese te bewijzen, zou er een cross-link moeten
gevormd worden van een furan gemodiﬁceerd prote¨ıne naar een enkelstrengig
ODN. Hiervoor worden momenteel 2 mogelijkheden onderzocht. Enerzijds zou
de cross-linking van een prote¨ıne naar een RNA hairpin, dat meer verstoord is
met mismatches, ﬂipout basen en een loop (Fig. 7.11, links) kunnnen lukken,
anderzijds zou ook cross-linking van een prote¨ıne dat enkelstrengig DNA bindt,
zoals polymerase (Fig. 7.11, rechts) mogelijk moeten zijn. Deze experimenten
vormen het onderwerp van huidige studies. Na initie¨le testen in onze groep en de
succesvolle experimenten van Prof. Summerer, is het nu ook duidelijk dat furan
ook in prote¨ınen ge¨ıncorporeerd kan worden door middel van amber supressie
en recombinante expressie. Dit opent de weg naar heel wat nieuwe mogelijkheden.
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Figure 7.11: Modelsystemen voor het bewijzen van de hypothese dat furan
gebaseerde cross-linking het onderscheid kan maken tussen enkel- en dubbel-
strengig ODN/ON RRE RNA-Rev peptide interactie (links), polymerase geassocieerd
met het enkelstrengige templaat DNA (rechts)
7.2.3 RNA ICL
Om de algemeenheid en mildheid van de methodologie te testen, prote¨ıne-RNA
cross-linking voor te bereiden en omdat RNA een steeds belangrijkere thera-
peutische target wordt, werd RNA ICL vorming onderzocht. Eerder onverwacht
vonden we dat het RNA de oxidatiecondities goed doorstond en dat hoge
cross-link rendementen bereikt konden worden. De verschillende duplex vorm
werd wel weerspiegeld in een andere furan gemodiﬁceerde nucleoside voorkeur.
In dit geval gaf nu3 immers de beste resultaten qua rendement en selectiviteit
(cfr. bij DNA ICL werden betere opbrengsten verkregen met nu6 dan met nu3).
Figure 7.12: RNA ICL met X = nu3. RP-HPLC trace van de RNA ICL reactie
voor en na NBS oxidatie (links). Denaturerende PAGE gel met drie verschillende tar-
gets: complementair RNA met een C of een U tov nu3 en een gerandomiseerd niet
complementair RNA met een C tov nu3 (rechts).
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7.3 Optimalisatie van Methodologie
Los van de oorspronkelijke doelstellingen in een DNA-prote¨ıne context, die het
hoofdthema van dit werk uitmaken, werden een aantal resultaten behaald in de
optimalisatie van vaste fase methodologie.
• De eerder ontwikkelde NF31 kleurtest bleek residuele OH groepen in nieuwe
vaste fase resins te kunnen detecteren.
• Het potentieel van NMR voor de concentratiebepaling van biomacro-
moleculen werd getest samen met de NMRSTR groep.
• In samenwerking met de PCR groep, gespecialiseerd in thiolacton chemie,
werd een nieuwe en veelzijdige vaste fase koppelingsmethode voor de syn-
these van sequentie gecontroleerde oligomeren ontwikkeld (Fig. 7.13).
Figure 7.13: Twee-staps repititief protocol voor de synthese van gefunction-
aliseerde oligomeren op vaste fase: aminolyse van het thiolacton op de vaste fase,
gevolgd door de koppeling van een thiolacton bouwsteen dat selectief reageert met het
vrijgestelde thiol.
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Conclusie
Het oorspronkelijke doel van dit doctoraatswerk, het ontwerpen van een cross-
linkend transcriptiefactor model met mogelijke therapeutische toepassingen, werd
niet bereikt. Het bleek immers bijzonder moeilijk om naar een dubbelstrengige
helix te cross-linken. De synthese van het dipodale peptidosteroid model werd
echter geoptimaliseerd en DNA binding werd voor de eerste maal aangetoond.
Verder heeft het werk beschreven in dit manuscript bijgedragen tot een beter
begrip en inzicht in de furan oxidatie methode en de toepasbaarheid ervan
drastisch uitgebreid. Behalve de incorporatie in ODNs voor de vorming van DNA
interstrand cross-links, werd de mogelijkheid om RNA interstrand cross-links te
vormen aangetoond in ON duplexen. Furan gemodiﬁceerde duplexen kunnen,
met de keuze van een geschikt gemodiﬁceerd nucleoside, ook gebruikt worden
voor de vorming van DPCs. Furan werd ook ge¨ıncorporeerd in peptiden. DPC
vorming kon niet worden aangetoond in dit geval, maar er zijn hoge verwachtin-
gen voor cross-linking in niet-duplex complexen. Tenslotte werd aangetoond dat
furan modiﬁcaties ook selectief ge¨ıncorporeerd kunnen worden in prote¨ınes, wat
veel nieuwe mogelijkheden cree¨ert.
Figure 7.14: Samenvatting van de uitgebreide toepasbaarheid van de fu-
ran cross-linking technologie toont de verschillende mogelijkheden voor modiﬁcaties
(blauwe tekst) en doelwitten (oranje tekst).
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Perspectieven
De volgende stappen die nu gezet dienen te worden, moeten toelaten de meth-
ode te gebruiken in relevante toepassingen en een biologische context. Daarvoor is
het belangrijk om concentratie gerelateerde problemen te optimaliseren en om een
biologisch compatibele oxidatie methode te hanteren. De productie van singlet
oxygen door sensitizers met rood licht te bestralen werd ontwikkeld voor DNA
ICL en is ook compatibel met RNA ICL. Daarenboven zijn testen uitgevoerd
voor DPC vorming en was dit ook de methode die gebruikt werd voor de RNA-
prote¨ıne cross-linking. Toch kan ook singlet zuurstof nog heel wat schade veroorza-
ken. Meer selectieve alternatieven die theoretisch haalbaar zouden moeten zijn
en waarvoor initie¨le testen zijn uitgevoerd, zijn oxidatie door cytochroom P450,
dat instaat voor de natuurlijke oxidatie van furan in de lever [345–347] of elec-
trochemische oxidatie.[348–350] Vooral deze laatste methode heeft veel poten-
tieel. Aangezien furan een lagere oxidatiepotentiaal heeft dan de DNA/RNA
basen,[351–353] zal bij een correcte potentiaal enkel stroom vloeien zolang er on-
geoxideerd furan aanwezig is. Het gebruik van elektroden maakt tevens lokale
toepasingen mogelijk.[354] Het gebruik van biologische triggers, zoals oxidatieve
stress (bv. in kanker cellen) is een andere interessante mogelijkheid.
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Common solvents and chemical reagents were purchased from Sigma-Aldrich
or Acros Organics. Deuterated solvents were purchased from Euriso-top. Suppli-
ers for more specialized chemicals, are speciﬁed when used. The water used in
experiments was always milliQ grade (Sartorius Arium 611 DI).
8.1 Small molecules
NMR NMR 1H-, 13C- and 31P-NMR (Attached Proton Test, APT) spectra
were recorded on a Bruker Avance 300 at 300 MHz, a Bruker Avance 500 at
500 MHz or a Bruker Avance II 700 at 700 MHz. Chemical shifts are presented
in parts per million (ppm) relative to CDCl3 (7.26 ppm in
1H- and 77.2 ppm
in 13C-NMR respectively), CD3CN (1.94 ppm in
1H- and 118.26 / 1.32 ppm in
13C-NMR respectively) DMSO-d6 (2.50 ppm in 1H- and 39.51 ppm in 13C-NMR
respectively) or D2O (4.79 ppm in
1H-NMR) as internal standard. Coupling con-
stants (J) in 1H-NMR are given in Hz. The resonance multiplicities are described
as s (singlet), d (doublet), dd (doublet of doublets), t (triplet) or m (multiplet).
ESI-MS ESI-MS spectra were recorded with an electronspray ionization source
G1946C ES-MSD-single quadrupole type mass detector in positive or negative
mode for small molecules using 5 mM NH4OAc in H2O/MeCN (1/1) as eluens.
LC-MS Sometimes LC-MS was recorded rather than just MS. LC-MS was
performed on an Agilent 1100 Series with diode array detection, using a Phe-
nomenex Luna 100 A˚, C18(2) column (5 μm, 4.6 x 250 mm) or Kinetex C18
column (5 μm, 4.6 x 250 mm) hyphenated to an electrospray ionizing, single
quadrupole MS detector type VL. Linear gradient elution was applied from 0 to
100% buﬀer B in 15 minutes or 6 min respectively (buﬀer A: 5 mM NH4OAc in
H2O; buﬀer B: MeCN) with a ﬂow of 1.0 ml/min or 1.5 ml/min respectively at
35◦C.
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8.2 Peptides
Chemicals and reagents typical for peptide synthesis were purchased from
Novabiochem or Iris Biotech GmbH. DMF and NMP peptide grade were from
Biosolve.
Because SPPS of peptides is repetitive, the following section will describe the
diﬀerent steps performed, which are repeated throughout the project. The experi-
mental description will refer to these standard operating procedures.
8.2.1 Synthesis
Manual synthesis on small scale was carried out in polypropylene reactors (2, 5
or 10 ml MultiSyntech GmbH) with a Teﬂon frit to allow easy ﬁltration with a
vacuum pump (KNF lab, Laboport). The vessel was closed with septa. Reactions
on bigger scale were performed in glass reactors with a sintered glass funnel with
tap again for easy ﬁltration and washing. The reactions at room temperature
were performed on a shaker (Vibromatic, Selecta). Reactions with microwave
assistance were performed in semi-automated fashion with the Biotage Initiator+
SP WaveTM. Automated synthesis at room temperature was performed by a
robot equipped with vortexing unit Syro II (MultiSynTech GmbH) or with N2
bubbling PSSM-8 (Shimadzu).
In those cases the peptide is attached to the resin through a photocleavable
linker, all reaction steps are performed shielded from direct sunlight.
Swelling Before every reaction the resin has to be swollen. Dry resin was
allowed to swell for minimum 15 min by suspending it in an adequate volume (10
ml/g) of DMF or DCM with intermediate shaking. The solvent was removed by
ﬁltration. If the resin was still swollen from a previous reaction, this step can be
omitted.
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Washing After each reaction, excess reagents were ﬁltered oﬀ using vacuum.
The resin was then thoroughly washed to avoid contamination. In manual SPPS
the resin was washed with DMF (4x), MeCN or MeOH (4x) and DCM (4x).
About 10 ml/ 1 g resin was added to the resin, which was shaken for 20 s and
ﬁltered. In (semi-)automated SPPS, washing steps consisted of 9 cycles in which
the vessels were ﬁlled with DMF or NMP, shaken for 30-45 s and then emptied
under vacuum for 30-45 s.
Coupling Coupling reagents (PyBOP (benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexaﬂuorophosphate), HBTU (O-
Benzotriazole-N,N,N,Ntetramethyl-uronium-hexauoro-phosphate), HATU
(1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid
hexaﬂuorophosphate), DIC (diisopropylcarbodiimide), COMU ((1-Cyano-2-
ethoxy-2-oxoethylidenaminooxy)dimethylamino-morpholino-carbenium hex-
aﬂuorophosphate)) and Fmoc (9-Fuorenylmethoxycarbonyl) amino acids were
purchased from Iris Biotech GmbH or NovaBiochem: Fmoc-Gly-OH, Fmoc-
Thr(tBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Asp(tBu)-OH,
Fmoc-Leu-OH, Fmoc-Arg (Pbf)-OH, Fmoc-Pro-OH, Fmoc-Lys(Boc)-OH, Fmoc-
Gln(Trt)-OH, Fmoc-Asn(Trt)-OH, Fmoc-Ala-OH, Fmoc-Phe-OH.
In manual SPPS the protected amino acid and DIPEA were added to the
resin which was suspended in half of the total volume of DMF. After 15 min the
coupling reagent was added together with the other half of the DMF. The excess
of reagents typically is 4 equiv amino acid, 8 equiv DIPEA and 4 equiv coupling
reagent, but depends on the synthesis and will be mentioned for each case. The
mixture was ﬂushed with argon and shaken (400 U/min) at room temperature.
This procedure was repeated twice for about 2 h. In automated SPPS, 10 equiv
protected amino acid, 20 equiv DIPEA and 10 equiv coupling reagent HBTU
were all added at the same time from stock solutions of respectively 0.5 M, 1
M and 0.5 M in NMP (As HBTU is not soluble at high concentrations in NMP,
DMF was added till a concentration of 0.1%.) The mixture was allowed to react
for 1 or 3 h in open vessel, during which it was shaken every 15 min for 20 s.
With microwave assistance, the coupling reaction was performed with 10 equiv
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amino acid, 20 equiv DIPEA and 10 equiv of the coupling reagent in a minimal
amount of DMF at 75◦ for 5 min.
Fmoc deprotection In manual SPPS, a 20% piperidine/DMF solution was
added to the resin (10 ml/g) and the suspension was shaken for 2 min after which
it was ﬁltered and washed with DMF (4x). This step was repeated for 5 min and
once more for 15 min. The same procedure was followed in automated SPPS,
using 40% piperidine/DMF solution. During the reaction the suspension was
shaken every minute for 20 s. In between the cycles the resin was drained for 45
s and washed (6 cycles). Also Fmoc deprotection can be assisted by microwave
irradiation, using 30% piperidine/DMF for 1 min at rt followed by 3 min at
65◦C.
Capping For free amine functions, three diﬀerent capping procedures were
used throughout the work.
Acetic anhydride Acetic anhydride (6 equiv) and DIPEA (6 equiv) were
added in DMF and the reaction mixture was shaken for 30 min.
1-Acetylimidazole (AcIm) 1-acetylimidazole (AcIm, 10 equiv) was added
to the resin in DMF. The reaction was performed overnight, shaken at 400 U/min.
4-Acetamido benzoic acid (Aba) This capping is very similar to the
coupling of an amino acid. The reaction was performed overnight and with a
higher number of equivalents of Aba (10 equiv), PyBOP (10 equiv) and DIPEA
(20 equiv).
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Cleavage from resin
With rink linker Ice cold cleavage cocktail (TFA:water:phenol:
thioanisole:EDT (40:4:2.8:2:1) (1 ml/10 mg) was added dropwise and while
stirring to the sample cooled on ice. After 15 min, the icebath was removed and
the sample allowed to heat up to room temperature and left for 3 h. The sample
was then ﬁltered over a sintered glass ﬁlter into ice cold diethylether, resulting
in precipitation of the peptide. After centrifugation, the ether was decanted and
the residue dissolved in mQ water, which was extracted twice with ether and
then ﬁltrated over a membrane ﬁlter (optionally also ﬁltered over a sephadex
column) and puriﬁed by HPLC before lyophilisation.
With photocleavable linker The UV-cleavage from the resin has to be
performed before acid side chain deprotection as the photocleavable linker is not
stable in strong acidic conditions. For fast on-line monitoring, it is also possible
to analyze the side chain protected peptide by only performing the photocleavage.
The resin was suspended in MeCN or EtOH, a spatula tip in a small glass vial
(small scale) or a monolayer spread in a petridish (big scale). This was illuminated
with UV-light from the top 1 mW/cm2 at 365 nm (Bioblock Scientiﬁc) for 3
h, or from both top and bottom 15 mW/cm2 at 365 nm for 1 h respectively.
After evaporation of the sample under reduced pressure, side chain deprotection
is performed by acid treatment as described for cleavage with the rink linker.
Colour tests
TNBS Few resin-beads were transferred into a small glass tube. 3 drops of
1% TNBS in DMF and 3 drops of 10% DIPEA in DMF were added. The colour of
the beads was observed immediately, after 5 min and after one hour. Red beads
indicate the presence of free amine functions while colourless beads indicate their
absence.
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NF-31 Few resin-beads were transferred into a small glass tube. 100 μl of a
2 mM solution of NF-31 (homemade) in MeCN was added. The tube was heated
at 70◦C for 10 min. Afterwards the excess dye was washed away with DMF,
MeOH and DCM. After washing, red beads indicate the presence of free amine
functions, colourless beads the absence.
If next to the 100 μl of a 2 mM solution of NF-31 in MeCN, also 100 μl of a
0.2 M DMAP solution in MeCN is added, the presence of free hydroxyl groups
can be detected after 10 min at rt.
Kaiser Few resin-beads were transferred into a small glass tube. 1 or 2 drops
of ninhydrin (500 mg in 10 ml EtOH), phenol (80 mg in 20 ml EtOH) and KCN
(2 ml 0.001 M solution deluted to 100 ml with pyridine) were added. The tube
was then heated in a boiling water bath for 2 min. The generation of blue colour
indicates the presence of free amine functions, no colour the absence.
UV loading determination Between 5 and 7 mg of resin-beads were weighed
in a volumetric ﬂask. Depending on the transferred amount of resin, a volume
of 20% piperidine/DMF solution was added, to obtain a concentration between
0.1 and 0.15 mM. The deprotection occurs in 30 min, during which the ﬂask was
occasionally swirled. From the absorbance of the piperidinebenzovulvene adduct
measured on a photospectrometer at 300 nm, the exact concentration could be
determined with the formula obtained from a calibration curve: [concentration =
( absorbance + 0.047 ) / 8.0618]. The loading of the resin in mmol/g is than equal
to the product of the concentration and volume divided by the weighed mass.
8.2.2 Analysis
Mass Analysis Mass analysis was performed using ESI-MS, with a quadrupole
ion trap LC mass spectrometer, equipped with electrospray ionization (LCQ
ion trap ThermoFinnigan MAT) with MeOH/H2O 1/1 + 0.1% formic acid, in
positive mode at 250◦C. Further MALDI-TOF-MS spectra were acquired on a
Kratos analytical, AXIMA-LNR (Shimadzu) or a Voyager-DE STR Biospec-
trometry Workstation (Applied Biosystems) with a high-performance nitrogen
laser (337 nm) in positive mode using DHB matrix (2,5-dihydroxybenzoic acid
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(98.0% pure, 10 mg) + MeCN (500 μl) + H2O (470 μl) + TFAaq. (30 μl,
3%)) for protected peptides and α-HCA matrix (α-cyano-4-hydroxycinnamic
acid (99% pure, 10 mg) + MeCN (500 μl) + H2O (400 μl) + TFAaq. (100 μl,
3%)) for deprotected peptides, with internal or external mass standards (Applied
Biosystems or AnaSpec).
RP-HPLC Analysis Analytical HPLC was performed on an Agilent 1100 or
1200 Series with diode array detection. Protected and therefore hydrophobic
peptides were analysed using a Phenomenex Jupiter 300 A˚, C4 column (5 μm,
4.6 x 250 mm). After deprotection, the peptides were analysed using an Shinwa
Ultron VX C18 ODS (5 μm, 4.6 x 150 mm) Phenomenex Luna 100 A˚, C18
column (5 μm, 4.6 x 250 mm) or Jupiter 300 A˚, C18 column (5 μm, 4.6 x 250
mm). The optimal concentration for the samples is 1 mg/ml, of which 15 μl
was injected. Linear gradient elution was applied from 0 to 100% buﬀer B in 15
minutes (buﬀer A: 0.1% TFA in H2O; buﬀer B: MeCN) with a ﬂow of 1.0 ml/min
at 35◦C. Long protected peptides were eluted with a linear gradient from 75 to
100% buﬀer B in 15 min. Unless otherwise stated, all chromatograms shown
were detected at 214 nm and obtained as described above. Fractions could be
collected both manually and automatically. They were lyophilized in a Speedvac
concentrator (Thermoelectron Corporation Savant SPD111V).
LC-MS Analysis LC-MC was performed on an Agilent 1100 Series with diode
array detection, using a Phenomenex Luna 100 A˚, C18(2) column (5 μm, 4.6 x
250 mm) hyphenated to an electrospray ionizing, single quadrupole MS detector
type VL. Linear gradient elution was applied from 0 or 75% to 100% buﬀer B in
15 minutes (buﬀer A: 0.1% formic acid in H2O; buﬀer B: MeCN) with a ﬂow of
1.0 ml/min at 35◦C.
Concentration Analysis Concentrations were determined by UV-Vis mea-
surements with a Varian Cary 3E UV/Vis spectrophotometer.
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8.3 Oligonucleotides (ODNs)
Commercial unmodiﬁed oligonucleotides were purchased puriﬁed over a Gold
Cartidge from Eurogentec, IDT DNA Technologies or Gene Design, Inc.
8.3.1 Synthesis
Oligonucleotide were synthesized using standard phosphoramidite chemistry
(reagents from Glen research or Proligo), in an automated fashion, DMT-on
using an ABI 394 DNA-synthesizer at 1 μmol scale. A standard synthesis
protocol was used except for coupling of the modiﬁed residues. For the manual
introduction of these modiﬁed residues, the synthesis column was removed from
the DNA-synthesizer and small portions (0.05 ml/min) of the phosphoramidite
(0.06 M or 0.1 M if crude, 0.4 ml) and 4,5-dicyanoimidazole (1 M, 0.5 ml) solution
in dry MeCN, on molecular sieves for max. 20 min, were then alternately pushed
over the reaction column, during a total reaction time of 18 min. The column
was ﬂushed with acetonitrile (1 ml), and a mixture of Cap A (0.5 ml) and Cap
B (0.5 ml) was pushed over the column, after which it was ﬂushed again with
acetonitrile (1 ml). The column was reinstalled on the DNA synthesizer, and
automated synthesis was resumed.
Upon completion of the synthesis, the ODN was deprotected and cleaved
from the controlled pore glass by incubation at 55◦C overnight in concentrated
aqueous ammonia (28% NH4OH). Postsynthetic workup and puriﬁcation was
performed using Sep-pak (C18 cartidges from Waters). The cartridge was
activated by rinsing it with MeCN (10 ml) and an aqueous TEAA solution (5
mM, 10 ml). Next the oligonucleotide solution obtained from deprotection was
loaded onto the column, the eluent was collected into the vial containing the
ODN solution and brought back onto the column (3x). The column was then
rinsed with a diluted aqueous NH4OH solution (2.8%, 15 ml) and H2O (10 ml),
during which truncated sequences, not containing a DMTr-group are eluted from
the column. The DMTr-groups of the ODN remaining on the column were then
deprotected by rinsing the column with an aqueous TFA solution (1.5%, 10 ml).
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The column was again rinsed with H2O (10 ml), after which the ODN were
eluted with MeCN:H2O (2:8, 5 ml).
The purity of the ODN was checked by RP-HPLC and the identity checked
by ESI-MS or Maldi-MS.
32P -labeling of ODNs for radiodetection. The ODN to be labeled (10 pmol,
10 μM, 1 μl), was combined with adenosine 5’-triphosphate,[γ32P] (Perkin Elmer)
(10 pmol, 1.66 μM, 1 μl), T4 Polymer Kinase (New England Biolabs) (4 units,
0.4 μl), NE buﬀer for T4 polynucleotide kinase (New England Biolabs) (10x con-
centrate, 1 μl) and milliQ grade water (1.6 μl) in a low binding centrifugal tube
(BioScience, Inc). These tubes should be used throughout experiments with very
small amounts of radiolabeled ODNs. The sample was mixed by gentle tapping
and incubated at 37◦C for 30 min. After reaction, the labeled ODN was puri-
ﬁed by phenol extraction (40 μl 1x TE buﬀer and 50 μl phenol/CHCl3) and size
exclusion (with a Bio-Spin 6 column (Bio Rad)).
8.3.2 Analysis
Mass Analysis ESI-MS spectra were recorded with an electronspray ionization
source G1946C ES-MSD-single quadrupole type mass detector in negative mode
using H2O/MeCN (1/1) with 1% TEA as eluens. The mass spectra were decon-
voluted, i.e. the molecular weights of the compounds were reconstructed from
the spectra using the Agilent LC/MSD ChemStation software (version A.08014).
All MALDI-TOF-spectra were measured with an Applied Biosystems Voyager
DE STR Biospectrometer, with 3-hydroxypicolinic acid/ammoniumcitrate (9/1)
as matrix and dowex beads to desalt the sample.
RP-HPLC Analysis Oligonucleotides were analyzed through ion pairing
chromatography methods. Ion Pair Chromatography (IPC) is used to separate
ionic analytes on a reversed phase column. An Ion Pair (IP) reagent, like
triethylammonium acetate (TEAA), is added to modulate retention of the ionic
analytes, in this case oligonucleotides. The ion-pairing additive in the mobile
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phase is adsorbed on the stationary phase, and thus provides for charge-to-charge
interactions with negative charges contained on the oligonucleotide backbone.
As a result, an eﬃcient charge-based (length-based) oligonucleotide separation
is achieved. Gradient elution using an MeCN or MeOH eluent displaces both
ion-pairing agent and the oligonucleotides from the sorbent surface.
RP-HPLC analysis was recorded on an Agilent 1100 or 1200 system equipped
with a UV diode array detector set at 260 nm, using Phenomenex Clarity (250
x 4.6 mm, 5 μm) or Aeris Widepore (150 x 4.6 mm, 3.6 μm) columns at 60◦C
with eluent: 0.1 M TEAA (with 5% MeCN) and MeCN as mobile phase (linear
gradient: 0-30% MeCN in 15 or 30 min, 30-100% MeCN in 3 min).
Concentration Analysis Concentration of ODNs was determined with a
Trinean dropsense multichannel spectrophotometer. Extinction coeﬃcients were
calculated by the online IDT tool, replacing a modiﬁed nucleotide by a thymidine.
Thermal denaturation Melting temperature (Tm) studies were performed
using a Varian Cary 300 Bio equipped with a six-cell thermostated cell holder.
The curves were monitored at 260 nm with a heating rate of 0.3◦C/min. A 1
μM sample of 2 complementary ODNs was buﬀered in 10 mM phosphate buﬀer
of pH 7, with 100 mM NaCl. The oligonucleotide concentration was 1 μM for
each strand. Melting temperatures were calculated from the ﬁrst derivative of
the heating curves using the Cary 300 Bio software. The measurements were
performed in triplicate, upon which an average Tm value was calculated.
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8.4 Electrophoretic shift mobility assay (EMSA)
Binding of peptides to ODN duplexes were assessed by EMSA. DNA duplexes
for binding were prepared in 10 mM Tris buﬀer pH 8, with 100 mM NaCl and
1 mM EDTA by annealing (heating to 95◦ for 24 min and slowly cool down
over min. 2 h). For ﬂuorescent detection, equimolar amounts of both strands
was used, with radiodetection, twofold excess of the cold complementary strand
was used. The DNA concentration was dependant on the detection method,
0.167 μM in the loading sample was suﬃcient for ﬂuorescent detection with
Sybr Gold, for radiodetection an amount of DNA giving 4000 counts per minute
(cpm) in the loaded sample is desired. Increasing equivalents of peptide were
added to the DNA solution with a loading buﬀer to obtain solutions with 6%
sucrose, 100 mM Tris pH 7.6, 20 mM KCl, 10 mM MgCl2, 2.5 mM EDTA. The
binding mixtures were incubated on ice for 1 h, before 5 μl was loaded on the
gel. Polyacrylamide gelelectrophoresis experiments were performed on 10 x 10
cm 8% acrylamide:bisacrylamide (29:1) gels, (portions of 20 ml were prepared
with ammonium persulphate (200 μl, 10%, Merck), soniﬁcated, cooled down
and initiated with tetramethylethylenediamine (20 μl, Merck)) The experiment
ran with 0.2% TBE buﬀer (Merck) at 150 V and 4◦C for 45 min, after a prerun
under the same conditions for 30 min. DNA was visualized by ﬂuorescent
detection: 10 min of Sybr Gold (Life Technologies) staining and illumination in
an Autochemi imaging system (UVP) or radiodetection: after drying the gel at
80◦C for 30 min by 10 h irradiating of a phosphor screen (Molecular Dynamics,
Amersham Pharmacia Biotech) in a closed cassette on a Storm 820 phosphor
imager (Molecular Dynamics).
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8.5 Cross-linking experiments
8.5.1 DNA interstrand cross-linking
Formation The modiﬁed strands were mixed with their complements in
equimolar (1 nmol) amounts at 20 μM concentration in 10 mM phosphate buﬀer
(pH 7) and 100 mM NaCl. Duplexes were obtained by annealing (heating to
95◦C for 10 min, and then allowing very slow cool down to room temperature).
Temperatures during the whole reaction were kept constant in an Eppendorf
thermomixer comfort at 25◦C, while shaking at 900 rpm. To start the reaction,
1 equiv NBS (1 equiv, 1 nmol, 2 μl) of a freshly prepared stock solution was
added. This was repeated every 15 min until complete disappearance of the
modiﬁed oligonucleotide (typically 4 equiv over 1 h). Cross-linking with singlet
oxygen was carried out by adding 2.5 μM methylene blue and shining light with
a Euromex 100 W cold light source, equipped with a red light ﬁlter at maximal
irradiation intensity at 25◦C.[139] The reactions were monitored by RP-HPLC
and denaturing polyacrylamide gel electrophoresis (PAGE).
RP-HPLC Analysis For the RP-HPLC analysis of the cross-link mixtures,
the same conditions were used as for the analysis of the ODNs seperately.
Cross-linking yields based on HPLC were calculated by the ratio of the peak area
from the spectra after and before reaction, taking into account the extinction
coeﬃcients. These were calculated by the nearest neighbor method, replacing
the modiﬁed nucleoside with a thymidine. The extinction coeﬃcient of the
cross-linked duplex is taken to be 0.9 times the sum of the extinction coeﬃcients
of its composing sequences.
Denaturating PAGE Analysis A 20% polyacrylamidegel (acry-
lamide:bisacrylamide 19:1) with 1x TBE buﬀer (Merck) and 7 M urea was
used for all analyses. The gel was prerunned with 1x TBE as running buﬀer at
225 V, 25◦C for 30 min. A portion of the reaction mixture (2 μl) was mixed with
formamide (18 μl) to obtain 90% and loaded on the gel (5 μl). Gels were run with
1x TBE as running buﬀer at 225 V, 25◦C for 1.5 h and stained with SybrGold
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(1x, Life Technologies) for 10 min. Pictures were taken with an Autochemi
imaging system (UVP).
8.5.2 RNA interstrand cross-linking
Experiments and analysis were performed as described for DNA interstrand cross-
linking, but care was taken to avoid degradation of the more labile RNA.
• Working surface and equipment were cleaned and made RNA’se free with
RNaseZAP (Sigma Aldrich)
• Gloves and a mouth mask were worn when manipulating samples
• Samples were stored in freezer or on ice, time at rt was kept to a minimum
• Annealing was performed by heating the sample for 3 min at 80◦C before
incubation on ice for 1 h
8.5.3 DNA-peptide cross-linking
Formation Cross-linking reactions were performed on a 1 nmol (20 μM)
DNA scale. Duplex DNA was obtained by heating 1 nmol of the 2 constituting
oligonucleotides in phosphate buﬀer of pH 7 with 0.1 M NaCl and 0.02 M
MgCl2 to 95
◦C for 10 min, and then allowing very slow cool down to room
temperature. An amount of peptide should then be added to obtain complete
DNA binding and the mixture was incubated on ice for 1 h, to allow DNA-peptide
complex formation. Complete furan oxidation was achieved by the addition of
portions of NBS (1 equiv, 2 μl) to the complex on ice. Reaction progress was
monitored by HPLC, but this typically required 4 additions over the course
of 1 h. Finally the reaction was driven to completion and the product sta-
bilized by reduction of the formed imine to an amine with an excess of NaCNBH3.
RP-HPLC Analysis For the RP-HPLC analysis of the cross-link mixtures,
the same conditions were used as for the analysis of the ODNs seperately.
Cross-linking yields based on HPLC were calculated by comparing the peak area
from the spectra before and after addition of NBS, taking into account the ex-
tinction coeﬃcients and corrected for sampling. For the DNA, the extinction
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coeﬃcient was calculated by the nearest neighbor method, replacing the modiﬁed
nucleoside with a thymidine. For the cross-linked complex, the extinction coeﬃ-
cient of the aromatic Aba cap (remainder of the GCN4 peptide is not aromatic
and does not absorb at 260 nm) was additionally taken into account.
Denaturating PAGE Analysis An 8% polyacrylamidegel (acry-
lamide:bisacrylamide 37.5:1) with 1x TBE buﬀer (Merck) and 6 M urea
was used for all analyses. The gel was prerunned with 1x TBE as running
buﬀer at 225 V, 25◦C for 30 min. A portion of the reaction mixture (2 μl)
was mixed with formamide (18 μl) to obtain 90% and loaded on the gel (5
μl). Gels were run with 1x TBE as running buﬀer at 225 V, 25◦C for 35 min.
Visualisation was achieved by staining with SybrGold (1x, Life Technologies) for
10 min and pictures were taken with an Autochemi imaging system (UVP). Or
using radiolabels, after drying the gel at 80◦C for 30 min, by 10 h irradiation
of a phosphor screen (Molecular Dynamics, Amersham Pharmacia Biotech) in
a closed cassette and measurement on a Storm 820 phosphor imager (Molecular
Dynamics).
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8.6 Visualisation
The free software Discovery Studio from Accelrys was used for visualization. ODN
duplexes could be drawn directly in the software. Proteins (and the duplexes
they bind to) were taken from the PDB. Furan modiﬁcations could be added
with the tools from the software. Geometry optimizations were performed locally
around the furfurylamine modiﬁcation and over the complete sturcture with a
fast Dreiding-like forceﬁeld.
Chapter 9
Speciﬁc Material and
Methods
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9.1 Supporting Material for the Madder Mimic
9.1.1 Additional and speciﬁc methods
Peptide synthesis was performed according to the described methods on
amino TentaGel-resin (90 m, loading 0.28 mmol/g, Iris Biotech Gmbh).
For the manual couplings following speciﬁcations are additionally given: dou-
ble 2.5 h PyBOP, DIPEA couplings in a minimal amount of DMF under argon
atmosphere with 3 equiv of linker and PyBOP and 6 equiv of DIPEA for the
photosensitive linker (homemade), with 1.2 and 2.4 equiv for the scaﬀold (home-
made), with 4 and 8 equiv for Gaba and the 1st Gly. Capping at the end of the
peptide was performed overnight with 10 equiv of Aba, PyBOP and 20 equiv of
DIPEA. Intermediate capping after incomplete reactions was performed with 6
equiv of acetic anhydride and DIPEA for 30 min, or 10 equiv 1-acetylimidazole
overnight.
The microwave assisted synthesis (both coupling and Fmoc deprotection) was
performed as described in the general methods. For the test with diﬀerent cou-
pling reagents for the attachment of Gaba at the C3 position, 4 equiv of Gaba
and the coupling reagent and 8 equiv of DIPEA were used in a double 10 min
coupling reaction at 75◦C.
Boc deprotection 20% TFA in DCM (1 ml/100 mg resin) was added to the
resin. The suspension was shaken for 2 min, after which it was drained and washed
4x with DCM. This step was repeated but for 5 min and 15 min. The resin is
subsequently washed 4x with DCM, DMF, 10% piperidine in DMF, DMF, MeOH
and DCM.
Alloc deprotection Pd(PPh3)4 (1155.58 g/mol, 0.3 eq, homemade)), Bu3SnH
(291.06 g/mol, 1.092 g/ml, 10 eq) and morpholine (87.12 g/mol, 0.9955 g/ml, 90
eq) were added in dry DCM (1 ml/100 mg resin). This reaction mixture was
ﬂushed with argon, sealed and shaken (440 U/min) for 3 h. The reaction was
repeated twice.
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Cleavage from the resin
Previous, destructive ﬁnal cleavage and deprotection was performed
as described in the general procedure with UV irradiation for cleavage from the
resin. After lyophilisation of the obtained sample, reagent B (88% TFA, 5%
H2O, 2% TIS, 5% phenol) was added to the side-chain protected peptide. The
suspension was shaken at 60◦C for 3 h. The reaction was then quenched by
adding 300 μL of mQ H2O and the mixture was lyophilised. Alternatively the
TFA could be evaporated under argon. The side-chain deprotected peptide was
obtained as a white powder. This procedure was repeated twice. The peptide
was puriﬁed by precipitation in ice cold Et2O. After centrifugation for 10 min at
2000 rpm and 2◦C, the supernatans was removed. The puriﬁcation was repeated
3 times. The last Et2O was removed by evaporation under argon.
Optimized cleavage is described in the general procedures and includes
spreading the solid support as a monolayer in a pertidish, which is irradiated
from top and bottom by a stronger UV lamp (15 mW/cm2), for 1 h, the use of a
diﬀerent cleavage cocktail and cooling rather than heating of the mixture.
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9.1.2 Spectral Data
monodipodal peptide synthesis (3.1.2)
Formula: C295H432N52O61S6
Calculated Mass: 5871.1 (MW: 5875.3)
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Figure 9.1: RP-HPLC (75-100% MeCN in 15 min on C4, 300 A˚): r.t. = 17 min
Figure 9.2: MALDI of the fraction with r.t. = 16.8-17.5 min: 5369 [M(3.1.2)-
2xPbf+H]+, 5623 [M(3.1.2)-Pbf+H]+, 5777 [M(3.1.2)Boc+H]+
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Introduction of the 1st residue of the 2nd peptide (3.1.5)
Formula: C310H445N53O62S6
Calculated Mass: 6094.2 (MW: 6098.6)
(starting material (3.1.4):
Formula: C291H428N52O59S6
Calculated Mass: 5787.0 (MW: 5791.2))
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After coupling with PyBOP: .
Figure 9.3: RP-HPLC (75-100% MeCN in 15 min on C4, 300 A˚): r.t. = 15.5 min
(3.1.4) and 17.4 min (3.1.5)
Figure 9.4: MALDI of the fraction with r.t. = 15.3-15.9 min: 5538 [M(3.1.4)-Pbf+H]+,
5559 [M(3.1.4)-Pbf+Na]+, 5790 [M(3.1.4)+H]+, 5812 [M(3.1.4)+Na]+
Figure 9.5: MALDI of the fraction with r.t. = 17.1-17.9 min: 5593 [M(3.1.5)-
2xPbf+H]+, 5845 [M(3.1.5)-Pbf+H]+, 6120 [M3.1.5)+Na]+
222 CHAPTER 9. SPECIFIC MATERIAL AND METHODS
After double coupling with HATU: .
Figure 9.6: RP-HPLC (75-100% MeCN in 15 min on C4, 300 A˚): r.t. = 15.5 min
(3.1.4) and 17.4 min (3.1.5)
Figure 9.7: MALDI of the fraction with r.t. = 15.1-15.8 min: 5539 [M(3.1.4)-Pbf+H]+,
5560 [M(3.1.4)-Pbf+Na]+, 5697[M(3.1.4)-Boc+H]+, 5791 [M(3.1.4)+H]+
Figure 9.8: MALDI of the fraction with r.t. = 17-17.7 min: 5594 [M(3.1.5)-2xPbf+H]+,
5750 [M(3.1.5)-Pbf-Boc+H]+, 5847 [M(3.1.5)-Pbf+H]+, 6119 [M(3.1.5)+Na]+
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After capping with AcIm: .
Formula Capped: C293H430N52O60S6
Calculated Mass Capped: 5829.1 (MW: 5833.3)
Figure 9.9: RP-HPLC (75-100% MeCN in 15 min on C4, 300 A˚): r.t. = 16.2 min
(Capped) and 17.4 min (3.1.5)
Figure 9.10: MALDI of the fraction with r.t. = 15.9-16.6 min: 5580 [M(Capped)-
Pbf+H]+, 5736 [M(Capped)-Boc+H]+, 5854 [M(Capped)+Na]+
Figure 9.11: MALDI of the fraction with r.t. = 17.0-17.8 min: 5593 [M(3.1.5)-
2xPbf+H]+, 5844 [M(3.1.5)-Pbf+H]+, 6119 [M(3.1.5)+Na]+
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After direct double coupling with HATU .
Figure 9.12: RP-HPLC (75-100% MeCN in 15 min on C4, 300 A˚): r.t. = 13.9 min
(3.1.5)
Figure 9.13: MALDI of the fraction with r.t. = 13.6-14.5 min: 5862 [M(3.1.5)-
Pbf+Na]+, 6115 [M(3.1.5)+Na]+
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Introduction of the 2nd residue of the 2nd peptide (3.1.5)
Formula: C312H448N54O63S6
Calculated Mass: 6151.2 (MW: 6155.6)
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Figure 9.14: RP-HPLC (75-100% MeCN in 15 min on C4, 300 A˚): r.t. = 16.2 min
(Capped) and 16.8 min (3.1.6)
Figure 9.15: MALDI of the fraction with r.t. = 16.2-16.6 min: 5580 [M(Capped)-
Pbf+H]+, 5736 [M(Capped)-Boc+H]+, 5853 [M(Capped)+Na]+
Figure 9.16: MALDI of the fraction with r.t. = 16.6-17.2 min: 5650 [M(3.1.6)-
2xPbf+H]+, 5809 [M(3.1.6)-Pbf-Boc+H]+, 5903 [M(3.1.6)-Pbf+H]+, 5926 [M(3.1.6)-
Pbf+Na]+, 6058 [M(3.1.6)-Boc+H]+, 6177 [M(3.1.6)+Na]+, 6194 [M(3.1.6)+K]+
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After direct double coupling with HATU .
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Dipodal peptide synthesis (3.1.3)
Formula: C274H469N101O73
Calculated Mass: 6342.6 (MW: 6346.3)
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Initial synthesis conditions: .
Figure 9.17: RP-HPLC (0-100% MeCN in 15 min on C18, 300 A˚): mixture
MALDI of the sample and fractions does not give good MALDI spectra.
LC-MS (0-100% MeCN in 30 min on C18, 100 A˚): sharp peak at r.t = 10.3 min
(Fig. 9.17) is not peptidic in nature. Signiﬁcant peptides with highest molecular
weight are 5792 and 5890 Dalton, present at r.t. = 10.6 min. The following ﬁgures
are the mass spectrum at r.t. = 10.6 min (left) and the result of the deconvolution
(right) in which components A and B correspond to multiply charged ions of the
peptides with a mass of 5792 and 5890 Dalton respectively.
Figure 9.18: ESI-MS spectrum at r.t. = 10.6 min (left) and deconvolution to compo-
nents A (5792 Dalton) and B (5890 Dalton)
The results thus revealed how the synthesis was not completely successful.
The obtained chromatogram shows the impurity of the sample. The sharp peak
with a retention time of 10 minutes corresponds to a protecting group. The rest
of the chromatogram corresponds to peptides of diﬀerent weight according to LC-
MS. Between 10 and 15 minutes the most important contributing peptides are
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found with a molecular weight decreasing with higher retention time. No trace of
3.1.3 could be found. If it was present, then it was only in a trace level amount.
The peptides with the highest molecular weight that were present in a signiﬁcant
amount A and B, had a weight of 550 and 452 Dalton lower than 3.1.3. Most likely
this corresponds for B to an arginine, an alanine and two leucines and for A to
the same residues and an additional proline. There are only two leucines and one
proline in the sequence, so all of them are missing. Proline has been long known
to be a diﬃcult amino acid to couple and problems associated with leucine have
also been reported. Alanine and arginine both have six copies in the sequence,
so it is not clear which of these is missing. Possibly they are missing at diﬀerent
positions, which further increases the complexity of the obtained mixture.
Parallel attachment of the peptides: .
Figure 9.19: RP-HPLC (0-100% MeCN in 15 min on C18, 300 A˚): mixture and low
concentration
The chromatogram (Fig. 9.19) illustrates how hardly any product had been
formed, as the purity and yield were very low. The failure of this approach is not
totally unexpected. Due to sterical hindrance, the two positions on the scaﬀold
have a diﬀerent reactivity. The amine at position C12 is more sterically hindered
and will therefore react slower than the amine at position C3. Prolonging the
branch mainly at position C3 enforces the sterical hindrance and reduces the
reactivity even more, giving rise to extensive deletions in the branch at position
C12.
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Synthesis on NovaPEG (all PEG solid support): .
Figure 9.20: RP-HPLC (0-100% MeCN in 15 min on C18, 300 A˚): mixture
LC-MS (0-100% in 30 min on C18,100 ): sharp peaks at r.t.= 11.5 min and 12.4
min (Fig. 9.20) are not peptidic in nature. The peptide with highest molecular
weight is 5792, present at r.t. = 9.5 min. The following ﬁgures are the mass
spectrum at r.t. = 9.5 min (left) and the result of the deconvolution (right) in
which component A corresponds to multiply charged ions of the peptide with a
mass of 5729 Dalton.
Figure 9.21: ESI-MS spectrum at r.t. = 9.5 min (left) and deconvolution to component
A (5792 Dalton)
The ﬁrst sharp peak with a retention time of 10 min in the chromatogram was
already present in the previous chromatograms and corresponds to a protecting
group. According to ESI-MS, the other sharp peak with a retention time of 12
min does not correspond to a peptide either. For the comparison of the synthesis
on TentaGEL and NovaPEG, it can be concluded that the results are similar and
not good. Once more the same compound A, with a mass 550 Dalton lower than
the desired was the compound with the highest molecular weight present.
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Synthesis with optimized cleavage method: .
Figure 9.22: RP-HPLC (0-100% MeCN in 15 min on C18, 300 A˚)
LC-MS (0-100% in 30 min on C18,100 ): Everything is peptidic in nature
and the target mass is present as the main contributer in the major peak. The
following ﬁgures are the mass spectrum at r.t. = 8.8 min (left) and the result of
the deconvolution (right) in which component A corresponds to multiply charged
ions of the peptide with a mass of 6345.6 Dalton or the target mass.
Figure 9.23: ESI-MS spectrum at r.t. = 8.8 min (left) and deconvolution to component
A (6346 Dalton)
It is thus clear that the previously described and used cleavage conditions,
which include 3 h heating at 60◦C are destructive for the sample. More mild
cleavage conditions result in the target product, which is still contaminated due
to steric hindrance.
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Microwave assisted synthesis: .
Figure 9.24: RP-HPLC (0-100% in 15 min on C18, 300 A˚)
LC-MS (0-100% in 30 min on C18,100 ): Everything is peptidic in nature and
the target mass is the main contributer in the major peak. The following ﬁgures
are the mass spectrum at r.t. = 9.2 min (left) and the result of the deconvolution
(right) in which component A corresponds to multiply charged ions of the peptide
with a mass of 6346 Dalton or the target mass.
Figure 9.25: ESI-MS spectrum at r.t. = 9.2 min (left) and deconvolution to component
A (6346 Dalton)
The purity of 3.1.3 (Fig. 9.24) is improved with microwave assistance (com-
pare to Fig. 9.22)
234 CHAPTER 9. SPECIFIC MATERIAL AND METHODS
9.1.3 Electrophoretic mobility shift assay data
Method for preliminary data : DNA duplexes (CRE binding site: 5’-TGG
AGA TGA CGT CAT CTC GT-3’ and its complement or Random: 5’-GAA
AAT CAC CCA ACT GCA-3’ and its complement), obtained from Eurogentec
puriﬁed over gold cartridge) were combined with the mimic in buﬀer, to obtain
solutions for binding in 17.7 mM Tris buﬀer pH 7.5, 88.5 mM KCl, 1.77 mM
MgCl2, 1.77 mM EDTA, 0.09x glycerol, 0.02x nonoidet-P40 and 0.01x BSA.
These were incubated on ice for 30 min, before 17 μl was loaded on the gel.
Polyacrylamide gelelectrophoresis experiments were performed on 10 x 10 cm
10% acrylamide:bisacrylamide (37.5:1) gels, ran with 0.5% TBE buﬀer at 140
V and 4◦C for 80 min. Gels were stained for 10 min with SybrGold (Life
Technologies) and visualized with UV light.
Method for ﬁnal data : Performed as described in the general
procedure, with the DNA duplex for binding (CRE binding site): 5’-
CGGATGACGTCATTTTTTTTC-3’ and its complement.
There is a dose response similar to the one observed for the Morii model,
but smearing due to non-speciﬁc interactions is superposed onto it. To illustrate
this point, the intensity in the upshifted area was measured as illustrated in
Figure 9.26. The obtained values are given below. The intensity contained within
the rectangle indicated on the gel in lane 1 is the background intensity. It increases
in the second lane due to the upshifted DNA-protein complex (which contains
already more than half of the DNA). In lane 3 almost all the DNA is involved
in complex formation with the peptide. Upon addition of extra peptide, it is not
possible to form more complex because there is no free DNA left, but non-speciﬁc
interactions to the DNA-protein complex increase causing it to further smear out
over the gel. The total amount of DNA remains the same, and therefore the
measured upshifted intensity too. Without the smearing, all this intensity would
be focused in a single band and the dose response would thus be similar like
observed with the Morii model.
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• Lane1. Total intensity 3x105 (= Background)
• Lane2. Total intensity 3x106
• Lane3. Total intensity 4x106
• Lane4. Total intensity 4x106
• Lane5. Total intensity 4x106
Figure 9.26: Determination of the total upshifted intensity in the EMSA
experiment with the deﬁned upshifted areas shown and numbered from left to right.
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9.1.4 Optimization of the UV cleavage
A linear peptide was used to optimize the cleavage conditions:
Formula: C263H381N51O56S6
Calculated Mass: 5341.7 (MW: 5345.5)
The solid support with peptide (loading 0.109 mmol/g) was split in two and
suspended in EtOH. Both halfs were irradiated under diﬀerent lamp setups. Then
the diﬀerences in peptide yield and purity were determined:
• 49.6 mg solid support (or theoretical yield 28.9 mg peptide: 3 h irradiation
under a small lamp with 1 mW/cm2 after evaporation and ﬁltration of the
sample: 4.4 mg peptide or 15% yield
Figure 9.27: RP-HPLC (75-100% MeCN in 15 min on C4, 300 A˚) of the peptide after
a 3 h cleavage under a small 1 mW/cm2 lamp
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• 26 mg solid support (or theoretical yield 15.1 mg peptide): 3 h irradiation
top and bottom irradiation with a more powerful lamp with 15 mW/cm2
(cleaved sample was collected after 1 h, and after an additional 2 h.
After evaporation and ﬁltration of the sample: 5.8 mg peptide or 38% yield
(from 1 h) and 5.5 mg peptide or 36% yield (from 2-3 h). That is a total
yield of 75%.
Figure 9.28: RP-HPLC (75-100% MeCN in 15 min on C4, 300 A˚) of the peptide after
a 1 h cleavage from top and bottom irradiated by a 15 mW/cm2 lamp.
Figure 9.29: RP-HPLC (75-100% MeCN in 15 min on C4, 300 A˚) of the peptide after
a 2-3 h cleavage from top and bottom irradiated by a 15 mW/cm2 lamp
The purity after 1 h irradiation by the strong lamp is exactly the same as after
3 h irradiation of the small lamp, but with more than double yield and in a third
of the time. Further irradiation of the resin for an additional 2 h allows to double
the yield, but with some increased impurities due to the prolonged irradiation.
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9.1.5 Puriﬁcation of ﬁnal product
Formula: C274H469N101O73
Calculated Mass: 6342.6 (MW: 6346.3)
Figure 9.30: RP-HPLC (0-100% MeCN in 15 min on C18, 300 A˚) of the crude dipodal
peptidosteroid obtained by microwave assisted synthesis
9.1. THE MADDER MIMIC 239
Figure 9.31: ESI-MS: 1270.5 [M(3.1.3) + 5H]5+, 1058.5 [M(3.1.3) + 6H]6+, 907.7
[M(3.1.3) + 7H]7+,794.3 [M(3.1.3) + 8H]8+
The crude dipodal peptidosteroid obtained by microwave assisted synthesis
was puriﬁed by RP-HPLC, monitored at both 214 and 280 nm. The fraction at
retention time 7.5 min was collected (Fig. 9.32).
Figure 9.32: RP-HPLC (24-32% MeCN in 16 min on C18, 300 A˚) of the puriﬁcation
process
As can be seen from the HPLC trace, purity has dramatically improved upon
puriﬁcation (Fig. 9.33). Puriﬁcation of such large size constructs by RP-HPLC
tedius, as with increasing peptide length, relative diﬀerences between target and
by-products decrease while variations exponentially increase, this causes strong
overlap on HPLC. This explains why the product was not obtained perfectly pure
and why smearing during the EMSA occured.
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Figure 9.33: RP-HPLC (24-32% MeCNin 16 min on C18, 300 A˚) of the puriﬁed
product
MALDI of the obtained sample (without prior fraction collection!):
6338.4[M(3.1.3) +H]+
Figure 9.34: ESI: 1270.7 [M(3.1.3) + 5H]5+, 1059.0 [M(3.1.3) + 6H]6+, 907.9 [M(3.1.3)
+ 7H]7+, 794.6 [M(3.1.3) + 8H]8+
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9.2 Supporting Material for the Morii Mimic
9.2.1 Synthesis
Because these experiments were performed in the laboratory of Prof. Morii, Kyoto
University, Japan. Chemicals from diﬀerent suppliers (Wako Chemical, TCI,
Watanabe and Nacalai Tesque) and diﬀerent equipment were used. The synthesis
was performed according to the reported procedure from literature.[72]
Synthesis of mono-6-deoxy-6-iodo-beta-cyclodextrine
Step 1: monotosylation of beta-cyclodextrine (3.2.2) Before the start
of the synthesis, it is necessary to replace crystal water present in the β-
cyclodextrine (3.2.1) (1 equiv, 5 mmol, 5.675 g, 1135.00 g/mol, Wako Chemical)
by dry pyridine (Wako Chemical). This was done, by twice dissolving the
cyclodextrine in a small amount of pyridine (10 ml) and coevaporating it with
the present water. The present air in the ﬂask was also exchanged by N2. The
cyclodextrine crystals were dissolved in 100 ml dry pyridine. This is diﬃcult and
therefore was aided as much as possible by shaking, soniﬁcation, stirring and
heating. The obtained suspension was cooled down and stirred in an icebath
for 10 min before p-toluenesulfonylchloride (0.5 equiv, 2.5 mmol, 0.477 g, Wako
Chemical) was added. After addition, the solution was allowed to heat up
to room temperature. The reaction was ﬁnished after 90 min and quenched
with a little water and the solvent was evaporated. Puriﬁcation was based
on the diﬀerent solubility of modiﬁed and unmodiﬁed β-cyclodextrine. The
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unmodiﬁed cyclodextrine is slightly soluble in ice-cold water, while the modiﬁed
cyclodextrine is not. The majority of the cyclodextine excess could therefore be
removed by dissolving it in icecold water and ﬁltration. Because the solubility of
cyclodextrine is only limited, this step had to be repeated. The evolution was
monitored on TLC and showed that three ﬁltration steps give the desired purity.
The residue was recrystallised in water. After 2 days the white crystals were
ﬁltered oﬀ and dried overnight under vacuum (yield 45%).
Analysis
• Rf product: 0.53 (eluent NH3/H2O/EtOAc/isopropanol: 1/3/2/5)
• Chemical Formula: C49H76O37S
• Mass: 1288.4 (Exact), 1289.2 (MW)
• Maldi: 1311 [M + Na]+ (observed mass)
• 1H-NMR (d6-DMSO, 300 MHz): 7.7 (2H, d, 8 Hz), 7.4 (2H, d, 8 Hz), 5.8-5.7
(14H, m), 4.9-4.8 (7H, m), 4.6-4.4 (6H, m), 3.8-3.2 (42H, m), 2.4 (3H, s)
Step 2: substitution of the tosylate by iodine (3.2.3) The tosylated
cyclodextrine (3.2.2) (1 equiv, 0.8 mmol, 1 g, 1288 g/mol obtained in the previous
step) and NaI (10 equiv, 8 mmol, 1.25 g, 149.89 g/mol, Nacalai Tesque) were put
together in a 25 ml 2-neck ﬂask. Air was substituted by N2 and 5 ml of dry DMF
(Wako) was added. The mixture was stirred at 70◦C for 2 h.
Excess NaI and formed NaTos were ﬁltered oﬀ as salts, the ﬁltrate was
evaporated and redissolved in the smallest volume of eluent (5% HOAc in water)
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able to dissolve the compound for size exclusion chromatography (Sephadex
G-10, 7 g swollen in 21 ml of eluent for 3 h). Fractions were combined and
evaporated twice, to eliminate all HOAc, before freezedrying. (Indicative yield,
before recrystallization is 59%) The obtained product was reprecipitated in 3 ml
H2O/EtOH (2/1), ﬁltered and dried under vacuum (yield 40.0%).
Analysis
• Rf product: 0.47 (eluent NH3/H2O/EtOAc/isopropanol: 1/3/2/5)
• Chemical Formula: C42H69IO34
• Mass: 1244.3 (Exact), 1244.9 (MW)
• ESI: 1245.2 [M+H]+, 1267.2 [M+Na]+ (observed mass)
• 1H-NMR (d6-DMSO, 300 MHz): 5.8-5.6 (14H, m), 4.9-4.8 (7H, m), 4.6-4.4
(6H, m), 3.8-3.2 (42H, m)
Synthesis of N-(bromoacetyl)-1-adamantane methylamine
Step 1: Preperation of activated ester (3.2.5) The reagents bromo-acetic
acid (3.2.4) (2.0 g, 1 equiv, 14.2 mmol, 138.95 g/mol) and hydroxyl succinimide
(1.656 g, 1 equiv, 14.2 mmol, 115.09 g/mol) were combined in a 100 ml 3-neck
ﬂask, put under inert atmosphere and dissolved in dry ethyl acetate (40 ml),
aided by a little heating. The solution was cooled down to 0◦C and DCC was
added (3.268 g, 1.1 equiv, 15.9 mmol, 206.18 g/mol). After 2 h the reaction was
complete.
The formed urea was ﬁltered oﬀ with ice cold EtOAc. The ﬁltrate was washed
with 5% NaHCO3, 10% citric acid and water, dried on Na2SO4, and concentrated
under vacuum (yield 65.5%).
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Analysis
• Rf product: 0-0.05 (eluent hexane/EtOAc: 2/1)or 0.75 (eluens CH2Cl2 with
5% MeOH)
• Chemical Formula: C6H6BrNO4
• Mass: 234.9 (Exact), 236.0 (MW)
Step 2: Reaction of the activated ester with adamantanemethylamine
(3.2.6) Adamantanemethylamine (400 mg, 2.42 mmol, 1 equiv, 165.28 g/mol;
Wako) was put in a small ﬂask ﬁlled with N2, dissolved in dry DMF (4 ml; Nacalai
Tesque) and stirred in an ice bath. The activated ester (3.2.5) produced in the
previous step (1.7 g, 7.26 mmol, 3 equiv, 234.95 g/ml) and HOBt (741 mg, 4.84
mmol, 2 equiv, 153.14 g/mol; Watanabe) were weighed in a small ﬂask, put under
inert atmosphere and dissolved in dry DMF (8 ml; Nacalai Tesque) under stirring
in an ice bath. After 5 min, this solution was added to the adamantanemethy-
lamine solution. The mixture was left for 5 more min in the icebath and was then
allowed to heat till room temperature overnight.
The solvent was evaporated under vacuum, and the product redissolved in
50 ml EtOAc, extracted with 0.1% HCl and brine, dried on Na2SO4 and con-
centrated under vacuum. Puriﬁcation was obtained by column chromatography
(hexane/EtOAc: 2/1), after evaporating the product dissolved in 30 ml of DCM
on 500 mg of silica (yield 41%).
Analysis
• Rf product: 0.44 (eluent hexane/EtOAc: 2/1)
• Chemical Formula: C13H20BrNO
• Mass: 285.1 (Exact), 286.2 (MW)
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• LC-MS: 6.4 min (r.t. on kinetex), 286.1 [M+H]+ (observed mass) and 327.1
[?]
• 1H-NMR (CDCl3, 500 MHz): 6.54 (1H, s), 3.91 (2H, s), 2.94 (2H, d, 6 Hz),
1.98 (3H, m), 1.71 (3H, d, 12 Hz), 1.62 (3H, d, 12 Hz), 1.49 (6H, d, 2 Hz)
• 13C-NMR (CDCl3, 125 MHz): 165 (C), 52 (CH2), 40 (CH2 x3), 37 (CH2
x3), 34 (C), 30 (CH2), 28 (CH x3)
Synthesis of 26-mer GCN4 peptides (3.2.7)
The synthesis was performed in Japan and therefor the methodology diﬀers a
little from the described general procedures.
The 26-mer GCN4 peptides (DPAALKRARNTEAARRSRARKLQGGC)
were synthesized on a PSSM-8 automatic peptide synthesizer from Shimadzu,
on PAL PEG PS resin with low loading (0.180 mmol/g, Applied Biosys-
tems) using 10 fold excess of Fmoc (9-ﬂuorenylmethoxycarbonyl) amino acids
(Novabiochem), with 10 equivalents of HBTU (O-Benzotriazole-N,N,N’,N’-
tetramethyl-uronium-hexaﬂuoro-phosphate, Novabiochem) as coupling reagent
and HOBt (1-hydroxybenzotriazole) as additive from a 1 M solution and 20 equiv-
alents of diisopropylethylamine from a 2 M solution in DMF. Agitation was pro-
vided by N2 bubbling. Single couplings were performed during 30 min. Fmoc de-
protection was achieved in double 4 min treatments with 30% piperidine in DMF.
The peptide was capped manually with acetic anhydride using N-methylimidazole
as catalyst. Completion of the reaction was checked by Kaiser test. Final depro-
tection and cleavage from the solid support was achieved by addition of cold
cleavage mixture to the product cooled on ice. The cleavage cocktail consisted of
0.375 g of phenol, 0.5 ml of water, 0.25 ml of thioanisole, 0.125 ml of ethanediol
and 5 ml of TFA. After 15 min, the mixture was allowed to heat up to room
temperature and was left for 3 h. The pure peptide was obtained by precipitation
in cold diethylether, which was dissolved in water and extracted twice with ether,
ﬁltered over a sephadex column, puriﬁed by HPLC and lyophilised.
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Modiﬁcation of the peptides with Ad (3.2.8)
Figure 9.35: The adamantane-modiﬁed GCN4 peptide (Ad-GCN4) (3.2.8)
Adamantane, modiﬁed as bromoacetyl (3.2.6) was used to react with the
thiol group of the C-terminal cysteine of the GCN4 peptide (3.2.7) to obtain
Ad-GCN4 (3.2.8). Before reaction the peptides were reduced, by adding 2 ml
0.05 M of DTT in Tris buﬀer by pH 8 for 1 h at room temperature. DTT was
removed by size exclusion (Sephadex G10, 10% acetic acid). The modiﬁcation
reaction was performed in 600 μl phosphate buﬀer (0.5 M Na2HPO4, pH 9.1).
NaOH (1 M, 60 μl) was added and the solution was degassed, by stirring it
under reduced pressure and exchanging air for N2. The peptide (5 mg) was
dissolved in 200 μl of mQ H2O and added to the stirred buﬀer in an icebath.
N-(bromoacetyl)-1-adamantanemethylamine (5 mg) was dissolved in 200 μl DMF
and added too. The pH was checked with pH paper (to be 9) and the reaction
mixture was stirred on ice for 5 min. The reaction was quenched with 100 μl of
mercaptoethanol for 1 h, after 10 minutes the mixture was allowed to heat up to
room temperature. The mixture was neutralized with 100 μl of acetic acid and
puriﬁed by gelﬁltration (10% acetic acid, G10). The product was puriﬁed by
RP-HPLC.
Analysis
• Chemical Formula: C130H228N50O36S
• Mass: 3097.7 (Exact), 3099.6 (MW)
• Maldi: 3100.5 [M +H]+ (observed mass)
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Figure 9.36: RP-HPLC chromatogram of the adamantane-modiﬁed GCN4
peptide (puriﬁcation method: from 29.5 to 47% MeCN/H2O 50/50 with 0.1% TFA
from H2O with 0.1% TFA in 35 min on C18 column (150 x 4.6 mm) at rt)
Figure 9.37: MS spectra of the adamantane-modiﬁed GCN4 peptide (with
internal mass standard mix: 1297.51; 2094.46; 2466.72 and 3660.19 Da)
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Modiﬁcation of the peptides with CD (3.2.9)
Figure 9.38: The cyclodextrin-modiﬁed GCN4 peptide (CD-GCN4) (3.2.9)
β-cyclodextrin was monoiodated via a tosylate (3.2.3) to allow reaction with
the thiol group of the C-terminal cysteine of the GCN4 peptide (3.2.7) to
obtain CD-GCN4 (3.2.9). The method used for this reaction is very similar
to the adamantyl modiﬁcation reaction, but more equivalents of the modiﬁed
cyclodextrine and a longer reaction time are required. Before reaction the
peptides were reduced, by adding 2 ml 0.05 M of DTT in Tris buﬀer by pH 8 for
1 h at room temperature. DTT was removed by size exclusion (Sephadex G10,
10% acetic acid). The modiﬁcation reaction is performed in 600 μl phosphate
buﬀer (0.5 M Na2HPO4, pH 9.1). NaOH (1 M, 60 μl) was added and the solution
was degassed, by stirring it under reduced pressure and exchanging air for N2.
The pepetide (5 mg) was dissolved in 200 μl of mQ H2O and added to the stirred
buﬀer in an icebath. mono-6-deoxy-6-iodo-beta-cyclodextrine (45 mg, 35.03
μmol, 1245 g/mol, 20 equiv) was dissolved in 200 μl DMF and added too. The
pH was checked with pH paper (to be 9) and the reaction mixture was stirred
on ice. After 1 h the reaction was allowed to heat up to room temperature
and was left overnight until all residual unmodiﬁed peptide was dimerized as
disulﬁde. The reaction was not quenched like the Ad modiﬁcation reaction, but
the inert atmosphere was broken, the pH was adjusted from 9 to 8 with 10%
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acetic acid and puriﬁed by gelﬁltration (10% acetic acid, G10). The product was
puriﬁed by RP-HPLC. The peptide disulﬁde was also puriﬁed and after reduction
re-introduced in the modiﬁcation reaction.
Figure 9.39: RP-HPLC chromatogram of the cyclodextrin-modiﬁed GCN4
peptide (puriﬁcation method: from 26 to 39% MeCN/H2O 50/50 with 0.1% TFA from
H2O with 0.1% TFA in 26 min on C18 column (150 x 4.6 mm) at rt)
Figure 9.40: MS spectra of the cyclodextrin-modiﬁed GCN4 peptide (with
internal mass standard mix: 1297.51; 2094.46; 2466.72 and 3660.19 Da)
Analysis
• Chemical Formula: C159H277N49O69S
• Mass: 4008.9 (Exact), 4011.3 (MW)
• Maldi: 4012.0 [M +H]+ (observed mass)
Formation of the Ad-CD inclusion complex (3.2.10)
Upon mixing the two peptides together, a dimer was formed through an Ad-CD
inclusion complex, in this way mimicking the homodimeric transcription factor
GCN4.
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9.3 Supporting Material for the Case Study:
Kinetin
9.3.1 Synthesis of nu4-modiﬁed ODNs
O6-Phenyl dI-CE phosphoramidite (O6-Phenyl-5’-Dimethoxytrityl-
2’deoxyinosine, 3’-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite) (Glen
Research) was manually incorporated in an ODN during standard automated
phosphoramidite synthesis, as described for modiﬁed phosphoramidites in the
standard procedures. After synthesis ODNs were cleaved from the CPG by
treatment with concentrated NH3 solution (28% NH4OH) at room temperature
for 4h, rather than the typical overnight treatment at 55◦C. The obtained
mixture was DMTr deprotected and puriﬁed over Sep-Pak (Waters) into 5
fractions, which were analysed, lyophylised and then treated with 1 M aqueous
furfurylamine at 55◦C for at least 24h. The DNA was puriﬁed by removal of the
furfurylamine over a 3 kDa cut-oﬀ ﬁlter (Pall, Life Science or Amicon, Millipore)
by centrifugation.
Analysis
• ODN4.1.1 (5’-CGG ATGnu4CG TCA TTT TTT TTC-3’) observed mass
(deconvoluted) 6471.72 Da, calculated mass 6470.1 (Exact) and 6473.2
(MW) Da
• ODN4.1.2 (5’- CTG ACG Gnu4G TGC-3’) observed mass (deconvoluted)
3765.52 Da, calculated mass 3764.6 (Exact) and 3766.6 (MW) Da
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Figure 9.41: HPLC chromatograms of the nu4-modiﬁed ODNs ODN4.1.1 (top)
and ODN4.1.2 (bottom). RP-HPLC chromatogram from Aeris column with a gradient
from 0.1 M TEAA-buﬀer to 30% MeCN in 30 min at 60◦C
Figure 9.42: MS spectra of the nu4-modiﬁed ODNs ODN4.1.1 (left) and
ODN4.1.2 (right)
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9.3.2 HPLC chromatograms of the cross-linking mixtures
with kinetin modiﬁcation
Figure 9.43: HPLC of ICL reaction mixture of ODN4.1.2-ODN4 with 0, 1, 2,
3 and 4 equiv of NBS from top to bottom. No clear ICL product can be observed.
Figure 9.44: HPLC of ICL reaction mixture of ODN4.1.2-ODN3 with 0, 1, 2,
3 and 4 equiv of NBS from top to bottom. No clear ICL product can be observed.
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Figure 9.45: HPLC of ICL reaction mixture of ODN4.1.2-ODN2 with 0, 1, 2,
3 and 4 equiv of NBS from top to bottom. No clear ICL product can be observed.
Figure 9.46: HPLC of ICL reaction mixture of ODN4.1.2-ODN1 with 0, 1, 2,
3 and 4 equiv of NBS from top to bottom. No clear ICL product can be observed.
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9.4 Supporting Material for DNA ← Protein
Mimic Cross-Linking
9.4.1 Synthesis of furan-modiﬁed amino acids
Synthesis of Fmoc protected aa3
Step 1: Boc deprotection TFA (1 ml / 100 mg) was added to a suspension
of Boc-protected lysine (4.2.6) (468.55 g/mol) in DCM (1 ml / 100 mg). This
immediately dissolves the product. After 30 min, the reaction was complete. The
product (4.2.7) was worked up by evaporating under vacuum, and co-evaporation
with MeOH. The reaction yield was calculated as 168%, this is probably due to
TFA-salt formation.
Analysis
• Rf product: 0.22 (RP, eluent H2O/MeOH : 1/1 + 1% MeCOOH)
• Chemical Formula: C21H24N2O4
• Mass: 368.2 (Exact), 368,4 (MW)
Step 2 + 3: reductive amination and Boc protection In a multistep
one-pot reaction Boc-deprotected lysine (4.2.7) (50 mg, 5% molar excess, 0.1357
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mmol, 368.42 g/mol) was converted to the imine, reduced and Boc-reprotected.
The reaction was performed in MeOH (3.5 ml) to dissolve the starting material.
Furfural 99% (10.71 μl, 1 equiv, 0.12925 mmol, 96.02 g/mol, 1.159 g/mol) was
added. The reaction was followed on TLC after reduction on small scale, as the
formed imine decomposes on TLC. After 5 h NaBH(OAc)3 (40 mg, 1.4 equiv,
1.8095 mmol, 212.05 g/ml) was added.
Analysis
• Rf product: 0.14 (normal phase, CHCl3/MeOH 5/1)
After 4 h the reaction was quenched with Boc2O (32 μl, 1 equiv to starting
material, 0.1357 mmol, 218.55 g/mol, 0.95 g/mol, 29.657 mg), which was
activated with DMAP (2 mg, 0.1 equiv, 0.01357 mmol, 122.17 g/mol, 1.658
mg). After 45 minutes, the product is clearly formed. The reaction was ﬁnished
by evaporation after 1.5 h, with some start product remaining. The residue
was redissolved in 10 ml EtOAC and washed with 10% citric acid and brine,
dried over Na2SO4 and evaporated (crude yield 32.39 mg, 46%, mainly due
to the extensive sampling). The product (4.2.3) was puriﬁed by ﬂash column
chromatography (EtOAc/Hexane 3/1 + 0.3% acetic acid).
Analysis
• Rf product: 0.58 (normal phase, CHCl3/MeOH 5/1)
• Chemical Formula: C31H36N2O7
• Mass: 548.3 (Exact), 548.6 (MW)
• FAB: 549 [M + H]+; 571 [M + Na]+
• 1H-NMR (d6-DMSO): not measured, due to abandonned synthesis
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Synthesis of Fmoc protected aa4
Step 2: coupling reaction Fmoc-lysine-OH (4.2.7) (1.97 g, 5.34 mmol, 1
equiv, 368.4 g/mol) obtained as described before, was co-evaporated with DMF
to remove all TFA and H2O. 12.3 ml dry DMF was added to obtain a 0.43 M
solution. DIPEA (1.94 ml, 2.1 equiv, 11.11 mmol, 1.43 g, 129.25 g/mol, 0.742
g/ml) was added and air was exchanged for N2. The mixture was stirred in an
icebath, isocyanate (1.19 ml, 2.1 equiv, 11.11 mmol, 123.11 g/mol, 1.148 g/ml)
was added and after 10 minutes the suspension was allowed to heat up to room
temperature. The reaction was compleet after 1 h. The product (4.2.4) was
puriﬁed by reprecipitation (dissolve in chloroform and crash out with hexane)
and recrystalization (chloroform) and obtained in an unoptimized yield of 60%.
Analysis
• Rf product: 0.18 (eluent MeOH/CHCl3 : 1/5 + 1% MeCOOH)
• Chemical Formula: C27H29N3O6
• Mass: 491.2 (Exact), 491.5 (MW)
• FAB: 492 [M + H]+; 514 [M + Na]+
• 1H-NMR (d6-DMSO, 500 MHz): 12.5 (1H, s), 7.9 (2H, d, 7.5 Hz), 7.7 (2H,
d, 7.5 Hz), 7.6 (1H, d, 7.9 Hz), 7.5 (1H, d, 1 Hz), 7.4 (2H, t, 7.5 Hz), 7.3
(2H, t, 7.5 Hz), 6.4 (1H, dd, 1/3 Hz), 6.18 (1H, t, 5.7 Hz), 6.16 (1H, d, 3
Hz) 5.9 (1H, t, 6 Hz), 4.3 (2H, d, 7 Hz), 4.2 (1H, t, 7 Hz), 4.1 (2H, d, 5.7
Hz), 3.9 (1H, m), 3.0 (2H, q, 6/12 Hz), 1.7 (2H, m), 1.3 (4H, m)
• 13C-NMR (d6-DMSO, 125 MHz): 174 (C), 158 (C), 157 (C), 154 (C), 144
(C x2), 142 (CH), 141 (C x2), 128 (CH x2), 127 (CH x2), 126 (CH x2), 121
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(CH x2), 111 (CH), 107 (CH), 66 (CH2), 54 (CH), 47 (CH), 40 (CH2), 37
(CH2), 31 (CH2), 30 (CH2), 24 (CH2)
Synthesis of Fmoc protected aa5
Step 1: Amide bond formation Fmoc-Glu-OtBu (4.2.9) (1.5 g, 1 equiv,
3.53 mmol, 425.5 g/mol) was weighed in a 2 neck ﬂask, put under N2 atmosphere
and dissolved in 13 ml dry DMF. Furfurylamine (0.311 ml, 1 equiv, 3.53 mmol,
97.12 g/mol, 1.099 g/ml), 1.2 equiv of HBTU (4.23 mmol, 1.6 g, 379.25 g/mol)
and 2 equiv of DIPEA (7.05 mmol, 1.23 ml, 129.25 g/mol, 0.742 g/ml) was
added and the mixture was stirred at room temperature for 2 h. The reaction
was ﬁnished by evaporating the solvent, the residual yellow oil was dissolved in
EtOAc, washed 3x with 5% citric acid, 10% NaHCO3 and brine and dried over
Na2SO4. Pure product (4.2.10) was obtained in 98% yield
Analysis
• Rf product: 0.54 (eluent EtOAc/Hexane : 2/1)
• Chemical Formula: C29H32N2O6
• Mass: 504.2 (Exact), 504.6 (MW)
• FAB: 505 [M + H]+
• 1H-NMR (DMSO, 300 MHz): 8.3 (1H, t, 5.3 Hz); 7.9 (2H, d, 7.5 Hz); 7.7
(2H, d, 7.5 Hz); 7.6 (1H, d, 7 Hz); 7.5 (1H, d, 1 Hz); 7.4 (2H, t, 7.5 Hz); 7.3
(2H, t, 7.5 Hz); 6.4 (1H, dd, 1/3 Hz); 6.2 (1H, d, 3 Hz); 4.3-4.2 (5H, m); 3.9
(1H, m) 2.2 (2H, t, 7.5); 1.9 (1H, m); 1.8 (1H, m); 1.4 (9H, s) (impurity 8.3
(singlet superposed on amide signal))
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• 13H-NMR (d6-CDCl3, 125 MHz): 172 (C), 171 (C), 156 (C), 151 (C, small
but conﬁrmed by HMBC crosspeak, 144 (2x C), 142 (CH), 141 (2x C), 128
(2x CH), 127 (2x CH), 126 (2x CH), 120 (2x CH), 110 (CH), 107 (CH), 83
(C), 67 (CH2), 54 (CH), 47 (CH), 37 ((CH2)), 32 (CH2), 29 (CH2), 28 (CH3
x3)
Step 2: tertiairy butyl deprotection The obtained furan-modiﬁed glutamic
acid (4.2.10) obtained in the previous reaction was dissolved in DCM (1 ml
/ 100 mg) and cooled down in an icebatch. TFA (1 ml / 100 mg) was added
slowly while the mixture was stirred on ice. After 5 min the reaction was
allowed to heat up to room temperature. After 3 h, the reaction was ﬁnisched
by evaporation under vacuum. The product (4.2.5) was puriﬁed over a short
silica plug (MeOH/chloroform : 1/6 + 0.1% acetic acid) and obtained in an
unoptimized overall yield of 56%.
Analysis
• Rf product: 0.20 (eluent EtOAc/Hexane : 2/1)
• Chemical Formula: C25H24N2O6
• Mass: 448.2 (Exact), 448.5 (MW)
• FAB: 449 [M + H]+
• 1H-NMR (d6-DMSO, 500 MHz): 12.6 (1H, s); 8.3 (1H, t, 5.3 Hz); 7.9 (2H,
d, 7.5 Hz); 7.7 (2H, d, 7.5 Hz); 7.6 (1H, d, 7 Hz); 7.5 (1H, d, 1 Hz); 7.4
(2H, t, 7.5 Hz); 7.3 (2H, t, 7.5 Hz); 6.4 (1H, dd, 1/3 Hz); 6.2 (1H, d, 3 Hz);
4.3-4.2 (5H, m); 4.0 (1H, m) 2.2 (2H, t, 6.8); 2.0 (1H, m); 1.8 (1H, m)
• 13H-NMR (d6-DMSO, 125 MHz): 172 (C), 157 (C), 153 (C), 144 (2x C),
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142 (CH), 141 (2xC), 128 (2x CH), 128 (2x CH), 126 (2x CH), 121 (2x CH),
111 (CH), 107 (CH), 66 (CH2), 53 (CH, very small but conﬁrmed by HSQC
crosspeak), 47 (CH), 36 ((CH2)), 32 (CH2), 27 (CH2), Cq signal is missing
9.4.2 Synthesis of furan-modiﬁed peptides
Peptide synthesis was performed as described in the general protocol, using aa1
at positions K231 or A239 of the brGCN4 peptide. The subsequent modiﬁcation
with Ad, was performed as described above.
brGCN4(K231aa1)
Analysis
• Chemical Formula: C118H204N48O36S
• Mass: 2901.5 (Exact), 2903.3 (MW)
• Maldi: 2904.2 [M+H]+ (observed mass)
Figure 9.47: MS spectum of brGCN4(K231aa1) (with an internal mass standard
mix: 1297.5, 2094.5, 2466.7 and 3660.2 Dalton, before puriﬁcation)
brGCN4(A239aa1)
Analysis
• Chemical Formula: C121H211N49O36S
• Mass: 2958.6 (Exact), 2960.3 (MW)
• Maldi: 2961.4 [M+H]+ (observed mass)
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Figure 9.48: MS spectum of brGCN4(A239aa1) (with an internal mass standard
mix: 1297.5, 2094.5, 2466.7 and 3660.2 Dalton)
Ad-brGCN4(K231aa1)
Analysis
• Chemical Formula: C131H223N49O37S
• Mass: 3106.7 (Exact), 3108.5 (MW)
• Maldi: 3109.2 [M+H]+ (observed mass)
Figure 9.49: MS spectum of Ad-brGCN4(K231aa1) (with contamination of the
internal mass standard at 2466 Dalton)
Ad-brGCN4(A239aa1)
Analysis
• Chemical Formula: C134H230N50O37S
• Mass: 3163.7 (Exact), 3165.6 (MW)
• Maldi: 3166.6 [M+H]+ (observed mass)
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Figure 9.50: MS spectum of Ad-brGCN4(A239aa1) (with contamination of the
internal mass standard at 2466 Dalton)
9.4.3 DNA binding analysis
DNA binding analysis was performed as described in the general protocol, using
the radiolabeled 32P-DNA sequences AP1 (5’-CGGATGACTCATTTTTTTTC-
3’), CRE (5’-CGGATGACGTCATTTTTTTTC-3’) and CECRE (5’-
CGGATTGCGTCATTTTTTTTC-3’).
9.4.4 Analysis of furan oxidation by hydazine trapping
Ad-bGCN4(A239aa1) (0.75 nmol, 50μM) was oxidized with NBS (2 equiv, 5 μl)
on ice for 1 h. Then hydrazine was added (100 equiv, 5 μl). The mixture was
left on ice for 30 min, then it was shaken 750 rpm at 25◦C for another 30 min.
The control experiments followed the same protocol but A) omitted the NBS
oxidation step, B) added NBS and hydrazine at the sam time and C) exactly
reproduced these conditions.
Analysis
• Chemical Formula: C134H230N52O37S
vs. starting material (Ad-bGCN4(A239aa1)): C134H230N50O37S
• Mass: 3191.7 (Exact), 3193.7 (MW)
vs. starting material (Ad-bGCN4(A239aa1)): 3163.7 (Exact), 3165.6 (MW)
• Observed mass A: 3167 Dalton (Maldi); no reaction
• Observed mass B: 3167 Dalton (Maldi); no reaction
• Observed mass C: 3196 Dalton (Maldi); reaction
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9.4.5 Analysis of cross-link formation
Analysis of cross-link formation was performed as described in the general pro-
tocol. No spectral data is shown here due to the numerous attempts, all with
negative outcome.
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9.5 Supporting Material for DNA → Protein
Mimic Cross-Linking
9.5.1 Synthesis of nu5
Nucleoside nu5 was synthesized through a Stille cross coupling of stannylated
furan with commercially available 5-iodo-2’-deoxyuridine. DMTr protection and
conversion into the phosphoramidite, was carried out by M. Op de Beeck as
described in literature.[209]
9.5.2 Synthesis of nu5-modiﬁed CRE
The modiﬁed residue nu5 (4.3.1) was incorporated into the CRE (5’-CGG ATG
ACG TCA TTT TTT TTT TTC-3’) DNA binding site of the transcription factor
mimic of GCN4, replacing natural T (CRE1 and CRE2) or natural G (CRE3)
residues. The synthesis was performed as described in the general procedures.
Analysis
• CRE1 (5’-CGG Anu5G ACG TCA TTT TTT TTC-3’) observed mass (de-
convoluted) 6443.79 Da, calculated mass 6442.07 (Exact) and 6445.17 (MW)
Da with formula C209H263N67O132P20
• CRE2 (5’-CGG ATG ACG nu5CA TTT TTT TTC-3’) observed mass (de-
convoluted) 6443.85 Da, calculated mass 6442.07 (Exact) and 6445.17 (MW)
Da with formula C209H263N67O132P20
• CRE3 (5’-CGG ATnu5 ACG TCA TTT TTT TTC-3’) observed mass (de-
convoluted) 6418.53 Da, calculated mass 6417.06 (Exact) and 6420.16 (MW)
Da with formula C209H264N64O133P20
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Figure 9.51: RP-HPLC chromatograms of the nu5-modiﬁed CRE ODNs
Figure 9.52: MS spectra (top) and the deconvolution (bottom) of the nu5-
modiﬁed CRE ODNs (from left to right: CRE1, CRE2, CRE3)
9.5.3 Melting temperatures of the formed duplexes
Duplex Tm (
◦C) ΔTm (◦C)
CRE:CRE comp 60.7
CRE1:CRE comp (nu5) 59.7 -1
CRE2:CRE comp (nu5) 60.7 0
CRE3:CRE3 comp (nu5) 57.6 -3.1
CRE4:CRE comp (nu4) 54.5 -6.2
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9.5.4 Cross-linking
The reaction was performed as described in the general procedure. To achieve
full binding, 5 equivalents of protein mimic, or thus of both peptides (5 nmol)
were added to the duplex. Since NBS will quickly oxidize the thioether bonds in
Ad-GCN4 and CD-GCN4, 1 equiv of NBS should equal 11 nmol. The reduction
with NaCNBH3 (20 nmol) restored the thioether bonds.
9.5.5 Mass analysis of the formed product with CRE3
With the purpose of structural characterization, the obtained product was iso-
lated by puriﬁcation on HPLC (ﬁrst on a Clarity column (Phenomenex) and
then on an Aeris column (Phenomenex)). Mass spectra were obtained by using
a Nano-Acquity HPLC (Waters Corporation, Milford, MA) in-line coupled to a
Q-Tof Premier mass spectrometer (Waters Corporation). Therefore the puriﬁed
sample was dissolved in 5 mM ammonium acetate buﬀer of pH 5 and ﬁrst loaded
onto a trapping column (100 μm internal diameter 20 mm, packed in-house with
Reprosil-Pur Basic C18-HD, 5 μm) with 5 mM ammonium acetate in water con-
taining 1% MeCN pH 5. It was then further transferred onto the nano column
(75 μm internal diameter 150 mm, packed in-house with Reprosil-Pur Basic-C18-
HD, 3 μm) with 5 mM ammonium acetate in water pH 5. Material retained by
the C18 column was eluted using a linear gradient of 1.69% acetonitrile increase
per minute at a ﬂow rate of 300 nl/min and analyzed in MS mode. The mass
spectrometer was calibrated every 10 seconds using Leu-Enkephalin as lockmass.
Molecular weight of the conjugate was reconstructed from the m/z values of the
multiply charged ions using the mass deconvolution program of the instrument.
Analysis
• CRE3 - CD-GCN4 observed mass (deconvoluted) 10431.0 Da, cal-
culated mass 10426.0 (Exact) and 10431.4 (MW) Da with formula
C368H541N113O202P20S
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9.5.6 Additional Data
DPC under High Salt Conditions
Cross-linking was performed as described above using the CRE3 duplex, but at 1
M NaCl concentration.
DPC attempt in absence of GCN4 Mimic
A cross-linking experiment with CRE3 duplex in the absence of the GCN4 mimic
was performed under identical conditions as described before. A volume of MilliQ
water was added equal to the used volume of peptide, to ensure the same ﬁnal
concentration for the reaction and obtain the best comparable results.
DPC attempt without NaCNBH3 reduction
A cross-linking experiment with CRE3 duplex was performed under identical
conditions as described before, and afterward it was divided in two. Half of
the sample was reduced with NaCNBH3, the other half was left untreated. Both
samples were stored at 20◦C for 3 weeks and analyzed together.
ICL experiment with CRE2 in the absence of protein mimic
Additional cross-link reactions were performed with CRE2 and its complements
CRE comp, CRE2 compT and CRE2 compC. These ICL experiments were per-
formed as DPC experiments, described in the general protocol in the absence of
mimic. A volume of milliQ water was added equal to the normally used volume of
peptide, this assures the same ﬁnal concentration for the ICL and DPC reactions
and allows comparison of the obtained results. As can be seen in Figure 9.53
there is no ICL formation. The earlier observed product in presence of mimic,
thus requires the presence of the mimic.
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Figure 9.53: RP-HPLC chromatograms of the cross-link experiments of
CRE2 and its complements: CRE comp, CRE2 compT and CRE2 compC (left to
right) in the absence of GCN4 mimic, before (top) and after (bottom) addition of NBS.
Cross-link experiment with variation of the opposite base in comple-
mentary ODN
CRE1, 2 and 3 were each combined additionally with two alternative strands,
to allow positioning of a diﬀerent base opposite to the furan-modiﬁed residue
and obtain the base pairs nu5-C and nu5-T next to nu5-A. In case of ICL
these variations would drastically change the cross-linking yield, as T has no
nucleophilic amine to cross-link to. Cross-linking reactions and analysis were
performed under identical conditions as described before. Chromatograms after
oxidation are presented in Figures 9.54, 9.55 and 4.42, and show only minor
changes in the yield. The observed variation in yield can be explained by the
eﬀect of the introduction of mismatches in diﬀerent positions in the ODN on the
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binding aﬃnity of the GCN4 protein mimic and thus the DPC cross-linking.
Figure 9.54: RP-HPLC chromatograms of the DPC reaction mixture with
the duplex of CRE1 with the complementary ODN containing A, T and C opposite
to the modiﬁed nucleotide, from top to bottom
Figure 9.55: RP-HPLC chromatograms of the DPC reaction mixture with
the duplex of CRE2 with the complementary ODN containing A, T and C opposite
to the modiﬁed nucleotide, from top to bottom
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DPC experiments in the absence of a peptide - oligonucleotide duplex
complex
with a random peptide In an attempt to work with a model where com-
plex formation is completely avoided (CD-GCN4 homodimers have been shown
to bind the DNA similarly to Ad-CD heterodimers[72]), the cross-link reaction
was repeated with 5 equivalents of another peptide of similar length and com-
position (Rev-peptide: DTRQARRNRRRRWRERQRAAAAR). The experiment
was performed as before (ensuring similar reaction concentrations and obtain the
best comparable results).
with the single stranded furan-modiﬁed CRE3 The experiment was per-
formed as before, a volume of mQ water was added equal to the used volume of
CRE3 comp, to assure the same ﬁnal concentration for the reaction and obtain
the best comparable results.
9.5.7 Control ICL with nu5-modiﬁed test ODNs
(performed by M. Op de Beeck)
The behavior of nu5 in ICL formation was veriﬁed in a series of ICL experiments
with nu5-modiﬁed test ODNs (Test G, Test T, Test C, Test A).
Synthesis of nu5-modiﬁed test ODNs
Similarly as in the previously reported experiments with furan-modiﬁed
oligonucleotides[135, 138], the modiﬁed residue was incorporated in between two
identical bases, to assess the cross-linking selectivity. Four diﬀerent sequences
were thus synthesized, varying the bases ﬂanking the C5-modiﬁed uridine. All
four ODN sequences (Test G, C, T and A) could easily be obtained in good yield
and purity using the standard procedure for the manual incorporation of modiﬁed
residues.
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Analysis
• Test G (5’-CTG ACG Gnu5G TGC-3’) observed mass (deconvoluted)
3728.7 Da, calculated mass 3727.6 (Exact) and 3729.4 (MW) Da with for-
mula C120H148N45O73P11
• Test T (5’-CTG ACG Tnu5T TGC-3’) observed mass (deconvoluted) 3678.5
Da, calculated mass 3677.6 (Exact) and 3679.4 (MW) Da with formula
C120H150N39O75P11
• Test C (5’-CTG ACG Cnu5C TGC-3’) observed mass (deconvoluted) 3648.5
Da, calculated mass 3647.6 (Exact) and 3649.4 (MW) Da with formula
C118H148N41O73P11
• Test A (5’-CTG ACG Anu5A TGC-3’) observed mass (deconvoluted)
3696.5 Da, calculated mass 3695.6 (Exact) and 3697.4 (MW) Da with for-
mula C120H148N45O71P11
Figure 9.56: RP-HPLC chromatograms of the nu5-modiﬁed Test ODNs from
left to right Test G, Test T, Test C and Test A
Figure 9.57: MS spectra (top) and the deconvolution (bottom) of the nu5-
modiﬁed Test ODNs from left to right Test G, Test T, Test C and Test A
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ICL with nu5-modiﬁed test ODNs
The obtained modiﬁed ODNs were each combined with four diﬀerent commercial
complementary ODNs where the base opposite to the modiﬁed residue, N was
varied to be A, C, G or T:
Test G: 5’-CTG ACG Gnu5G TGC-3’ with 3’-GAC TGC CNC ACG-5’
Test T: 5’-CTG ACG Tnu5T TGC-3’ with 3’-GAC TGC ANA ACG-5’
Test C: 5’-CTG ACG Cnu5C TGC-3’ with 3’-GAC TGC GNG ACG-5’
Test A: 5’-CTG ACG Anu5A TGC-3’ with 3’-GAC TGC TNT ACG-5’
Cross-linking reactions were performed using the standard ICL protocol. The
resulting reaction mixtures were analyzed by RP-HPLC and the results shown in
Figures 9.58- 9.61. Since the reaction yield in all cases is absent or low, this was
not further investigated.
Figure 9.58: RP-HPLC chromatograms of ICL experiment of Test G and
complementary ODN with N = A, C, G and T (left to right) before (top) and after
(bottom) addition of NBS
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Figure 9.59: RP-HPLC chromatograms of ICL experiment of Test T and
complementary ODN with N = A, C, G and T (left to right) before (top) and after
(bottom) addition of NBS
Figure 9.60: RP-HPLC chromatograms of ICL experiment of Test C and
complementary ODN with N = A, C, G and T (left to right) before (top) and after
(bottom) addition of NBS
Figure 9.61: RP-HPLC chromatograms of ICL experiment of Test A and
complementary ODN with N = A, C, G and T (left to right) before (top) and after
(bottom) addition of NBS
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9.6 Supporting Material for RNA Interstrand
Cross-Linking
9.6.1 Synthesis of furan-modiﬁed nucleosides
nu3 (4.1.3) and nu6 (4.4.1) were synthesized as described by our group
before.[136, 138]
9.6.2 Synthesis of oligonucleotides (ONs) and
oligodeoxynucleotides (ODNs)
ODNs were synthesized as described in the general protocol. For the synthesis of
the ONs, 2’OMe phosphoramidites (Glen Research) were coupled using the same
automated protocol, but with the coupling time increased to 6 min.
Analysis
• ODN4.4.2: 5’-CTG ACG Gnu3G TGC-3’ (C123H153N46O74P11) observed
mass: 3799 Da (Mass-H) (Maldi-TOF MS) and 3799.5 Da (deconvoluted)
(ESI MS), calculated mass 3798.7 (exact) and 3800.5 (MW) Da
• ODN4.4.3: 5’-CTG ACG Gnu6G TGC-3’ (C121H150N43O71P11) observed
mass: 3683 Da (Mass-H) (Maldi-TOF MS) and 3682.5 Da (deconvoluted)
(ESI MS), calculated mass 3681.7 (exact) and 3683.4 (MW) Da
• ON4.4.2: 5’-C*U*G* A*C*G* G*nu3G* U*G*C*-3’ (*2’OMe-RNA)
(C131H169N46O84P11) observed mass: 4071 Da (Mass-H) (Maldi-TOF MS)
and 4071.8 Da (deconvoluted) (ESI MS), calculated mass 4070.7 (exact) and
4072.7 (MW) Da
• ON4.4.3: 5’-C*U*G* A*C*G* G*nu6G* U*G*C*-3’ (*2’OMe-RNA)
(C129H166N43O81P11) observed mass: 3955 Da (Mass-H) (Maldi-TOF MS)
and 3954.8 Da (deconvoluted) (ESI MS), calculated mass 3953.7 (exact) and
3955.6 (MW) Da
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Figure 9.62: ESI-MS spectra of ODN4.2.2 (left) and ODN4.4.3 (right)
Figure 9.63: ESI-MS spectra of ON4.2.2 (left) and ON4.4.3 (right)
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9.6.3 Cross-linking
The cross-linking reactions were performed as described in the general protocol,
but both at 25◦C and 37◦.
Analysis
• ON4.4.2-ON4 (C244H313N91O166P22) observed mass: 7855 Da (Mass-H)
(Maldi-TOF MS); calculated mass 7858 Da
• ON4.4.3-ON4 (C242H310N88O163P22) observed mass: 7777 Da (Mass-
2H+K) (Maldi-TOF MS); calculated mass 7741 Da
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Figure 9.64: Maldi Mass spectrum of ICL: ON4.4.2-ON4
Figure 9.65: Maldi Mass spectrum of ICL: ON4.4.3-ON4
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Cross-linking of ON4.4.2 (PAGE) .
Figure 9.66: PAGE of cross-link reaction of ON4.4.2 and RNA targets at 37◦C (left)
and 25◦C (right). Ladder consist of a mixture of 4 ODNs with masses 7182, 6457, 4319,
2096 Da
Cross-linking of ON4.4.2 to ON4 (RP-HPLC) .
Figure 9.67: RP-HPLC chromatograms of cross-link reaction of ON4.4.2 with ON4 as
target at 37◦C (top) and 25◦C (bottom).
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Figure 9.68: RP-HPLC chromatograms of cross-link reaction of ON4.4.2 with ON4
using singlet oxygen.
Cross-linking of ON4.4.2 to ON5 (RP-HPLC) .
Figure 9.69: RP-HPLC chromatograms of cross-link reaction of ON4.4.2 with ON5 as
target at 37◦C (top) and 25◦C (bottom).
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Cross-linking of ON4.4.2 to ON6 (RP-HPLC) .
Figure 9.70: RP-HPLC chromatograms of cross-link reaction of ON1 with ON6 as
target at 37◦C (top) and 25◦C (bottom).
Cross-linking of ON4.4.3 (PAGE) .
Figure 9.71: PAGE of cross-link reaction of ON4.4.3 and RNA targets at 37◦C (left)
and 25◦C (right). Ladder consist of a mixture of 4 ODNs with masses 7182, 6457, 4319,
2096 Da
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Cross-linking of ON4.4.3 to ON4 (RP-HPLC) .
Figure 9.72: RP-HPLC chromatograms of cross-link reaction of ON4.4.3 with ON4 as
target at 37◦C (top) and 25◦C (bottom).
Figure 9.73: RP-HPLC chromatograms of cross-link reaction of ON4.4.3 with ON4
using singlet oxygen.
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Cross-linking of ON4.4.3 to ON5 (RP-HPLC) .
Figure 9.74: RP-HPLC chromatograms of cross-link reaction of ON4.4.3 with ON5 as
target at 37◦C (top) and 25◦C (bottom).
Cross-linking of ON4.4.3 to ON6 (RP-HPLC) .
Figure 9.75: RP-HPLC chromatograms of cross-link reaction of ON4.4.3 with ON6 as
target at 37◦C (top) and 25◦C (bottom).
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9.6.4 Additional experiments
Initial screen
A range of furan-modiﬁed nucleosides has been developed and or tested by our
group for DNA ICL formation. The furan moiety has been used to replace the
sugar of the nucleoside or has been attached to it, on the 1’ or 2’ position,
through diﬀerent linkers (amide, urea and ether) and combined with diﬀerent
bases (uracil and adenine). The furan moiety can also be attached to the base.
Because an RNA-RNA duplex is structurally diﬀerent from a DNA-DNA
duplex, the properties of the diﬀerent furan-modiﬁed building blocks cannot be
assumed to be simply transferable. For the selection of the 2 most promising
furan-modiﬁed nucleosides to be used in this study, an initial screen was
performed with 5 furan-modiﬁed nucleosides, incorporated in the DNA sequence
5’-CTG ACG GXG TGC-3’ (available from previous experiments) and targeting
ON4 (5’-GCA CCC CGU CAG-3’). The combination of DNA and RNA in a
helix forms an intermediate duplex between A and B and can give an indication
of the behavior in pure RNA duplex.
The cross-link reaction was performed at 0◦C (initial mild conditions) by ad-
dition of 4 equiv of NBS as described before. Figure 4.56 shows the RP-HPLC
chromatograms before and after oxidation with NBS. The 2nd and 5th furan-
modiﬁed nucleosides were identiﬁed as the most promising and therefore selected
for further study in this context.
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Cross-link tests from DNA to the RNA targets
Cross-linking of ODN4.4.2 (PAGE) .
Figure 9.76: PAGE of cross-link reaction of ODN4.4.2 and RNA targets at 25◦C.
Cross-linking of ODN4.4.2 to ON4 (RP-HPLC) .
Figure 9.77: RP-HPLC chromatograms of cross-link reaction of ODN4.4.2 with ON4
as target at 25◦C. ICL indicates the cross-linked species, which consists of 2 pairs of
pseudo enantiomers
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Cross-linking of ODN4.4.2 to ON5 (RP-HPLC) .
Figure 9.78: RP-HPLC chromatograms of cross-link reaction of ODN4.4.2 with ON5
as target at 25◦C. Only remaining RNA2 can be observed after NBS treatment.
Cross-linking of ODN4.4.2 to ON6 (RP-HPLC) .
Figure 9.79: RP-HPLC chromatograms of cross-link reaction of ODN4.4.2 with ON6
as target at 25◦C. Only remaining RNA2 can be observed after NBS treatment.
Cross-linking of ODN4.4.3 (PAGE) .
Figure 9.80: PAGE of cross-link reaction of ODN4.4.3 and RNA targets at 25◦C.
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Cross-linking of ODN4.4.3 to ON4 (RP-HPLC) .
Figure 9.81: RP-HPLC chromatograms of cross-link reaction of ODN4.4.3 with ON4
as target at 25◦C. ICL indicates the cross-linked species and Br indicates the brominated
side product
Cross-linking of ODN4.4.3 to ON5 (RP-HPLC) .
Figure 9.82: RP-HPLC chromatograms of cross-link reaction of ODN4.4.3 with ON5
as target at 25◦C. Br indicates the brominated side product, none of the other visible
peaks could be correlated with a cross-linked species, but correspond to degradation
products.
Cross-linking of ODN4.4.3 to ON6 (RP-HPLC) .
Figure 9.83: RP-HPLC chromatograms of cross-link reaction of ODN4.4.3 with ON6
as target at 25◦C. Br indicates the brominated side product, none of the other visible
peaks could be correlated with a cross-linked species, but correspond to degradation
products.
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DNA ICL tests
Cross-linking of ODN4.4.2 to ODN4 (RP-HPLC) .
Figure 9.84: RP-HPLC chromatograms of cross-link reaction of ODN4.4.2 with ODN4
as target at 37◦C (top) and 25◦C (bottom). ICL indicates the cross-linked species, which
consists of 2 pairs of pseudo enantiomers
Cross-linking of ODN4.4.3 to ODN4 (RP-HPLC) .
Figure 9.85: RP-HPLC chromatograms of cross-link reaction of ODN4.4.3 with ODN4
as target at 37◦C. ICL indicates the cross-linked species and Br indicates the brominated
side product
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9.7 Supporting Material for Furan-Modiﬁed
Proteins
9.7.1 Synthesis of furan-modiﬁed amino acids
Synthesis of aa4 (4.5.1)
For previous steps, see section DNA ← protein mimic cross-linking.
Step 3: Fmoc deprotection A solution of 10% piperidine in DMF was added
to Fmoc protected aa4 (4.2.6) and stirred for 30 min. The product (4.5.1)
fell out of the reaction mixture as a white powder and was puriﬁed by ﬁtration
(Yield 95%).
Analysis
• Rf product: 0 (eluent MeOH/CHCl3 1/6 + 0.1% acetic acid)
• Chemical Formula: C12H19N3O4
• Mass: 269.1 (Exact), 269.3 (MW)
• LC-MS: 8.8 min (r.t.), 270.1 [M+H]+ (observed mass)
• 1H-NMR (300 MHz, D2O): 7.42 (1H, d, 1 Hz), 6.38 (1H, dd, 1/3 Hz), 6.23
(1H, d, 3 Hz), 4.24 (2H, s), 3.68 (1H, t, 6 Hz), 3.09 (2H, t, 6.7 Hz), 1.82
(2H, m), 1.48 (2H, m), 1.35 (2H, m)
• 13C-NMR (125 MHz, D2O: 175 (C), 160 (C), 153 (C), 142 (CH), 110 (CH),
106 (CH), 55 (CH), 39 (CH2), 37 (CH2) 30 (CH2), 29 (CH2), 22 (CH2)
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Synthesis of aa6
Step 1: Boc deprotecion Was described before, see section DNA ← protein
mimic cross-linking.
Activation of furoic acid .
Furoic acid (1 equiv, 1.5 g, 13.4 mmol, 112.08 g/mol), was dissolved in
DMF (25 ml), then pentaﬂuoraphenyl triﬂuoroacetate (1.2 equiv, 2.68 ml, 15.5
mmol, 280.08 g/mol, 1.63 g/ml) and pyridine (1.1 equiv, 1.19 ml, 14.7 mmol,
79.10 g/mol, 0.98 g/ml) were added. The mixture was stirred at rt for 2 h.
The reaction mixture was diluted in EtOAc (500 ml), washed with 0.05 M HCl
and 5% NaHCO3, dried over MgSO4 and concentrated under reduced pressure.
White crystals (4.5.3) were obtained in 99% yield.
Analysis
• Rf product: 0.71 (eluent DCM)
• Chemical Formula: C11H3F5O3
• Mass: 278.0 (Exact), 278.1 (MW)
• LC-MS: 18.22 min (r.t.), 279.1 [M+H]+ (observed mass)
Step 2: coupling reaction .
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The obtained Boc deprotected lysine (4.2.7) (1 equiv, 10.7 mmol) was
combined with the obtained activated furoic acid (4.5.3) (1.2 equiv, 12.8 mmol,
3.56 g, 278 g/mol), together with HOBt (1.2 equiv, 12.8 mmol, 1.73 g, 135
g/mol) and DIPEA (1.2 equiv, 12.8 mmol, 2.12 ml, 129.25 g/mol, 0.78 g/ml) in
DMF (35 ml). The coupling was performed at rt for 2 h. The reaction mixture
was then concentrated under reduced pressure and the product (4.5.4) puriﬁed
using column chromatography (CHCl3/MeOH 12/1 with acetic acid 0.46%).
Analysis
• Rf product: 0.45 (eluent MeOH/CHCl3 1/6 + 0.1% acetic acid)
• Chemical Formula: C26H26N2O6
• Mass: 462.2 (Exact), 462.5 (MW)
• LC-MS: 12.1-13 min (r.t.), 463.1 [M+H]+ (observed mass)
Step 2: Fmoc deprotection .
A solution of 10% piperidine in DMF was directly added to the product
optained in the previous step (4.5.4) and stirred for 30 min. The product (4.5.2)
falls out of the reaction mixture as a white powder and is puriﬁed by ﬁtration
(unoptimized overall yield 83%).
Analysis
• Rf product: 0 (eluent MeOH/CHCl3 1/6 + 0.1% acetic acid)
• Chemical Formula: C11H16N2O4
• Mass: 240.1 (Exact), 240.3 (MW)
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• ESI MS: 239.3 [M-H]−, 241.3 [M+H]+ (observed mass)
• 1H-NMR (500 MHz, D2O: 7.6 (1H, d, 1 Hz), 7.1 (1H, d, 3 Hz), 6.6 (1H,
dd, 3/1 Hz), 3.7 (1H, t, 6 Hz), 3.3 (2H, t, 7 Hz), 1.9-1.8 (2H, m), 1.6 (2H,
m), 1.5-1.3 (2H, m)
• 13C-NMR (125 MHz, D2O: 175 (C), 161 (C), 146 (C), 145 (CH), 115 (CH),
113 (CH), 55 (CH), 39 (CH2), 30 (CH2), 28 (CH2), 22 (CH2), 21 (CH2)
9.7.2 Biotechnology protocols
It is important to work sterile. Therefore the working space and hands are cleaned
with 80% EtOH. All experiments should be performed in the airﬂow of a bunsen-
burner ﬂame.
LB medium
Tryptone (10 g/l, Roth), yeast extract (5 g/l, Roth), NaCl (10 g/l) were dissolved
in distilled water (the pH should be 7.5, but it is typically 7 and can be used as
such) and autoclaved.
Agar plates
Agar-agar (15 g/l) wass added to LB medium and dissolved by heating in a
microwave. Before pouring in the petridishes it was cooled down till 56◦ in a
water bath and the appropriate antibiotics (1/1000) were added. Then this was
poured into a petridish, to just cover the bottom and cooled down for 2 h.
Transfection
1 μl of plasmid (pET DUET 1) (or 2 μl of a 2 plasmid system), was added to
T7 express competent cells (E. coli, New England Biolabs) on ice and left for 30
min before a heat shock of 45 s at 42◦C. LB medium (0.5 ml) was added and
the suspension was shaken at 37◦C for 1 h. Half of the cells was plated on agar
with the appropriate antibiotics, for storage. The other half was added to LB
medium (50 ml) with the appropriate antibiotics (50 μl of a 1000x stock). Both
were incubated overnight at 37◦C.
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Inocculation and induction of YFP expression
100 μl (1/50) of an overnight culture was added to LB medium (5 ml) with
(1/1000) of the appropriate antibiotics (5 μl). The amino acid can be added to
obtain diﬀerent concentrations. The cells are incubated at 37◦C, 200 rpm till
an optical density (OD) of 0.6 is reached. Then the expression is induced with
isopropylthio-β-galactoside (IPTG) (1/1000) (1 mM, 5 μl). After 4 h the cells
(10 μl) were monitored on a TCS SPE spectral confocal microscope (Leica) with
an inverse stand and the HCX FL APO 63x/140-0.60 oil objective (excitation:
488 nm).
Expression of TrxA
An overnight culture (50 ml from a swipe of a plate) of T7 express chemical
competent cells transfected with a plasmid for TrxA with an Amber mutation at
N65 and carbenicillin resistance and a constitutive plasmid with the pyrrolysyl-
tRNA synthetase and its tRNACUA and chloramphenicol resistance (OD 2.5)
was inoculated (1/50) two times in half a litre of LB medium with carbenicillin,
chloramphenicol and 5 mM of aa6 and was grown till OD 0.6 (over 9 hours).
Then IPTG was added to induce the expression at 18◦C overnight (16 h).
TrxA protein puriﬁcation
All puriﬁcation steps were carried out at 4◦C. The media were centrifuged at
4◦C and 8000 rpm for 15 min and decantated to harvest the cells. Cells were
resuspended in StrepA buﬀer (IBA) (10 mM Tris-HCl pH 8.0, 1 mM EDTA, 150
mM NaCl, 30 ml) supplemented with protease inhibitor mix (Roche). The cells
were lysed with a French Press and centrifuged at 4◦C and 18 000 rpm for 40
min. The supernatant was puriﬁed over a Strep-Tactin-Superﬂow column (IBA)
on KTA (Amersham Biosciences) equilibrated with StrepA buﬀer (1 ml/min, Flow
through, 7 colom volumes wash) in 5 ml fractions during elution with 100% Strep
B buﬀer (0.56 g/l d-desthiobiotin in Strep A buﬀer) The protein in fraction 2 and
fraction 3+4, was concentrated using an (Amicon Ultra 10K) centrifugal tube in
0.1 M phosphate buﬀer pH 8 with 0.1 M NaCl. The concentration was determined
with a nanodrop (2 = 6.13 mg/ml and 3+4 = 6.48 mg/ml), but was inaccurate
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due to DNA contamination (260/280 for 2 =1.49 and 3+4 = 1.7). Therefore a
Bradford Assay was performed with Protein Assay solution (Bio-Rad). This way
the concentration of 2 and of 3+4 was determined to be 1.56 g/L.
SDS-PAGE
The analysis of the proteins was performed on Laemmli gels. These consist of
the main separating gel of 12% acrylamide, 0.375 M Tris pH 8.8 and a small
collecting gel on top of 5% acrylamide 0.1 M Tris pH 6.8. The loading buﬀer
consisted of 0.045 M Tris-HCl, pH 6.8, 10% glycerol, 1% sodiumdodecylsulphate,
0.01% bromophenolblue a,d 0.05 M dithiotreitol. The running buﬀer was 25 mM
Tris, 192 mM glycin and 0.1% sodiumdodecylsulphate. The gel was run at 150 V
for about 50 min. The running time was derived with SeeBluePlus2 pre-stained
standard. The gels were washed 3 times in 100 ml distilled water before staining.
Staining was achieved with 20 ml Page Blue protein staining solution (Thermo
Scientiﬁc) for 60 min (or overnight) with gentle agitation and 5 min rinsing in
distilled water.
In Gel Trypsin digest
The desired bands were cut from the Coomassie Blue stained SDS-gel that had
been washed in water (2x, 10 min), on a sterile underground and further cut into
pieces of approximately 1 mm2. The obtained fragments were put in a centrifugal
tube and washed by incubation in 100 μl water for 15 min and shaking at 550
rpm at rt. The water was taken oﬀ and replaced with 100 μl of a 1/1 solution of
50 μM NH4HCO3 (200 mg in 50 ml)/MeCN. This mixture was shaken for 5 to
10 min at 550 rpm at rt. This was then replaced by 100 μl MeCN and shaken
for 10 min. The gel was rehydrated by 100 μl 50 mM NH4HCO3 and shaken for
10 min. To this mixture 100 μl MeCN was added and shaken for 10 min. This
was then replaced by 100 μl MeCN to shrink the gel pieces and shaken for 10
min, before it was removed and the sample dried in the speedvac. The protein in
the gel was then reduced and alkylated by adding 100 μl of a 1/1 solution of 10
mM dithiotreitol (7.7 mg in 5 ml)/50 mM NH4HCO3, this was heated till 56
◦ for
45 min. After cooling down, the solution was replaced by a freshly prepared 55
mM iodoacetamide (51 mg in 5 ml 50 mM NH4HCO3) solution. The mixture was
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shielded from light and shaken for 30 min at rt. The solution was replaced by 100
μl of a 1/1 solution of 50 μM NH4HCO3/MeCN and shaken at rt for 15 min. This
last step was repeated once more. Finally the solution was replaced by 100 μl
MeCN and shaken for 15 min, before it was removed and the sample dried in the
speedvac. The protein was digested by adding 100 μl freshly prepared enzyme (90
μl 25 mM NH4HCO3 with 10 μl enzyme trypsin or chymotrypsin (Promega) (10
ng/μl in 25 mM NH4HCO3)) and overnight incubation (without shaking) at 37
◦.
Afterwards, the peptide fragments could be extracted from the gel. The digest
solution was collected in a new centrifugal tube. 100 μl 25 mM NH4HCO3 was
added to the gel rests and soniﬁcated for 15 min. Then 100 ml MeCN was added
and again soniﬁcated for 15 min. The 200 μl solution was taken out and added
to the centrifugal tube with the digest solution. 100 μl 5% formic acid was added
to the gel rests and soniﬁcated for 15 min. Then 100 ml MeCN was added and
again soniﬁcated for 15 min. The 200 μl solution was taken out and added to the
centrifugal tube with the digest solution. The combined solution was evaporated
till dryness in the speedvac and then redissolved in 25 μl of 0.1% formic acid for
analysis.
Mass spectrometry
Mass spectra were recorded on the following machines: Thermo Finnigan LTQ-
FT (ESI-ICR) and Thermo LTQ-Orbitrap XL. For analytical HPLC separations
of protein and peptide samples with subsequent MS a Dionex Ultimate 3000
Nano HPLC was used. The puriﬁed intact protein was analyzed by HPLC-MS.
A self-packed nano C4 column (ReproSil Gold 300 A˚, 3μM) was used for HPLC
and mass spectrometry was performed on a LTQ-Orbitrap XL mass spectrometer
(Thermo). For the nano-HPLC-ESI-MS analysis the tryptic digested peptides
were loaded onto a Dionex C18 Nano Trap Column (100 μm), subsequently eluted
and separated by the self packed C18-AQ (Reprosil Pur, 3 μm, 120 ) column.
The obtained peptide fragment data was analyzed with the SEQUEST algorithm
implemented in the software ‘Xcalibur bioworks’ against the TrxA sequence.
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9.7.3 Additional Data
Confocal ﬂuorescent images with the wildtype synthetase
.
Figure 9.86: Wild type synthetase with an alkyn-modiﬁed amino acid (10 mM), for
reference (with zoom on the right)
Figure 9.87: Wild type synthetase with aa4 (5 mM)
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Figure 9.88: Wild type synthetase with aa6 (5 mM) (with zoom on the right)
Confocal ﬂuorescent images with the mutant synthetase of Yokoyama
.
Figure 9.89: Mutant synthetase of Yokoyama with aa4 (10 mM) (with zoom on the
right)
Figure 9.90: Mutant synthetase of Yokoyama with aa6 (10 mM) (with zoom on the
right)
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Figure 9.91: Mutant synthetase of Yokoyama with aa4 (left) and aa6 (right) (5 mM)
Confocal ﬂuorescent images with the mutant synthetase of Emine
.
Figure 9.92: Mutant synthetase of Emine with aa4 (left) and aa6 (right) (10 mM)
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Confocal ﬂuorescent images with the Dual plasmid system, with wild
type synthetase and aa6
.
Figure 9.93: Wild type synthetase in the dual plasmid system with aa6, 0 mM or
blanc (top), 2 mM (middle) and 5 mM (bottom) using maximum laser intensity (with
zoom on the right)
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Figure 9.94: Wild type synthetase in the dual plasmid system with aa6, 2 mM (top)
and 5 mM (bottom) using a lower laser intensity to see the diﬀerence (with zoom on the
right)
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SDS puriﬁcation
Figure 9.95: SDS-PAGE gel (12%): 1) Lysate (2 μl + 1 μl loading buﬀer), 2) Flow
Through (2 μl + 1 μl loading buﬀer), 3) Wash (8 μl + 2 μl loading buﬀer), 4) 7.5
μl SeeBlue Plus2 Pre-stained standard, 5-8) Fractions 1, 2, 3, 4 (16 μl + 4 μl loading
buﬀer).
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9.7.4 Labeling reactions
Oxidative
The protein (both furan-modiﬁed and blanc as control) was diluted to a 20 μM
solution in phosphate buﬀer of pH 7. NBS solution (10 equiv, 2 nmol, 1 μl, 3.5
mg/10 ml H2O, 177.98 g/mol) was added to the protein solution on ice. After
1 h, phenylhydrazine solution (50 equiv, 10 nmol, 1 μl, 9.85 μg/10 ml H2O,
108.14 g/mol) was added and left to react for 1 h. As control reactions, the same
procedure was followed with only oxidation and no quenching and with only
addition of phenylhydrazine without oxidation.
For analysis 30 μl of water was added to the samples to obtain 5 μM samples.
In a second attempt the reaction was repeated but oxidized with less NBS (5
equiv, 1 nmol, 1 μl, 3.5 mg/20 ml H2O, g/mol).
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Also, in a seperate sample the reaction was quenched by labeling with ﬂuo-
resceinamine (50 equiv, 1 μl, 1 mg/288 μl H2O, 347 g/mol) and reduction with
NaCNBH3 (10 equiv, 2 nmol, 1 μl, 12.36 mg/20 ml H2O, 62.8 g/mol). For
this reaction the amine was added together with the NBS or together with the
NaCNBH3.
Non-oxidative
The protein (both furan-modiﬁed and blanc as control) was diluted to a 20 μM
solution in phosphate buﬀer of pH 6. Fluoresceinylmaleimide (50 equiv, 10 nmol,
1 μl, 1 mg/234 μl H2O, 427.36 g/mol) was added to 10 μl and the mixture was
shaken overnight at room temperature.
The protein (both furan-modiﬁed and blanc as control) was diluted to a 20 μM
solution in phosphate buﬀer of pH 6. 4-phenyl-1,2,4-triazole-3,5-dione (PTAD)
(50 equiv, 10 nmol, 1 μl, 1 mg/571.5 μl H2O, 175.14 g/mol) was added to 10 μl
and the mixture was shaken overnight at room temperature.
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9.8 Supporting Material for Visualisation of Fu-
ran based Cross-Linking
9.8.1 Sequences of the bridges
• I-2 = IV-2: furan-modiﬁed ODN with nu6
• II-2 = V-2: control ODN with T instead of nu6
• underlined parts of the ODN insert into the ﬁve well frame
• italic parts of the ODN are the overlapping sticky ends
• I-4 = II-4 = IV-4 = V-4
7 nt sticky end (furan):
I-1: CGTTAGAATCAGAGCG-
CCACGGCACGGACCTGGTCTCTCGTATGAGTCCTG
I-2: ACGGnu6GT -GCTTCCGGTACTACGCCCAGATGAGCTACT
I-3: TGGAAGGGTTAGAACC-
AGTAGCTCATCTGGGCGTAGTACCGGAAGC
I-4: ACCCCGT -CAGGACTCATACGAGAGACCAGGTCCGTGCCGTGG
7 nt sticky end (control):
II-1: TTTCAATTACCTGAGC-
CCACGGCACGGACCTGGTCTCTCGTATGAGTCCTG
II-2: ACGGTGT -GCTTCCGGTACTACGCCCAGATGAGCTACT
II-3: CCGACTTGCGGGAGGT-
AGTAGCTCATCTGGGCGTAGTACCGGAAGC
II-4: ACCCCGT -CAGGACTCATACGAGAGACCAGGTCCGTGCCGTGG
control:
III-1: GCTGTTTCCTGTGTGA-
CCACGGCACGGACCTGGTCTCTCGTATGAGTC-CTGACGGGGTGC-
TTCCGGTACTACGCCCAGATGAGCTAC
III-2: CCATTAGCAAGGCCGG-
AGTAGCTCATCTGGGCGTAGTACCGGAA-GCACCCCGTCAG-
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GACTCATACGAGAGACCAGGTCCGTGCCGTGG
9 nt sticky end (furan):
IV-1: TCTAGCTGATAAATTA-
CCACGGCACGGACCTGGTCTCTCGTATGAGTCCTG
IV-2: ACGGnu6GTGC -TTCCGGTACTACGCCCAGATGAGCTACT
IV-3: AAAGGAATTACGAGGC-
AGTAGCTCATCTGGGCGTAGTACCGGAA
IV-4: GCACCCCGT -CAGGACTCATACGAGAGACCAGGTCCGTGCCGTGG
9 nt sticky end (control):
V-1: TAATTTCAACTTTAAT-
CCACGGCACGGACCTGGTCTCTCGTATGAGTCCTG
V-2: ACGGTGTGC -TTCCGGTACTACGCCCAGATGAGCTACT
V-3: GTACCGTAACACTGAG-
AGTAGCTCATCTGGGCGTAGTACCGGAA
V-4: GCACCCCGT -CAGGACTCATACGAGAGACCAGGTCCGTGCCGTGG
9.8.2 Synthesis of the furan-modiﬁed ODN
Available DMT protected intermediate of nu6
The DMT protected intermediate (4.6.1) (150 mg) was available from a previous
synthesis by Kristof Stevens.[136] Analysis on NMR indicated the sample to be
still of good quality.
Phosphoramidite synthesis of nu6
For the synthesis of the phosphoramidite (4.6.2) of the nucleoside (4.6.1),
it was shown that in case of similar glycerol nucleic acid modiﬁcations,
use of the standard α-cyanoethyl chlorophosphoramidite does not result in
formation of the phosphoramidite. The less reactive α-cyanoethyl N,N,N’,N’-
tetraisopropylphosphoramidite in the presence of diisopropylammonium tetra-
zolide as activating species is used because of the mildness and chemoselectivity
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of this phosphitylation reaction.
The DMT protected intermediate (4.6.1) (75 mg, 1 equiv, 0.136 mmol,
g/mol) was dissolved in fresh distilled CH2Cl2 (4 ml) under argon at-
mosphere. N,N-diisopropylammoniumtetrazolide (62.6 mg, 2.7 equiv,
0.368 mmol, g/mol) was added and stirred at room temperature. 2-
cyanoethyltetraisopropylphosphoramidite (82.1 mg, 2 equiv, 0.272 mmol,
g/mol) was added while cooling on an ice-bath and the reaction mixture was
allowed to stir 48 h at room temperature. When no further conversion occurred,
the reaction mixture was quenched with 5% NaHCO3 (4 ml) and then further di-
luted with CH2Cl2. The reaction mixture was extracted 4x with CH2Cl2 and the
combined organic phases washed with 5% NaHCO3 and brine. It (4.6.2) was then
dried on anhydrous Na2SO4, and the solvent was removed under reduced pressure.
Analysis
• Rf product: 0.4 (iso-octaan/ethylacetaat : 6/4)
• Chemical Formula: C44H51N2O7P
• Mass: 750.9 (MW)
• 31P -NMR (121 MHz, CDCL3): 149,48 and 149,31 ppm (product), 14.169
ppm (pentavalent phosphorous due to quenched excess reagent)
I-2 synthesis (ODN4.6.1)
Furan-modiﬁed ODN synthesis was performed as described in the general proce-
dure. Though in this case, the phosphoramidite and dicyanoimidazole solutions
were mixed and pushed together over the column. Also, no additional washing and
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capping steps were performed manually. Due to the length of the ODN (37-mer),
additional RP-HPLC puriﬁcation was required to obtain the desired purity.
Figure 9.96: RP-HPLC chromatogram of the deprotected ODN4.6.1 fractions after
Sep-pak puriﬁcation, analysed on Clarity column 0-30% MeCN from 0.1M TEAA-buﬀer
in 30 min at 60◦C
Figure 9.97: RP-HPLC chromatogram of the puriﬁed I-3 (ODN4.6.1), analysed on
Clarity column 0-30% MeCN from 0.1M TEAA-buﬀer in 30 min at 60◦C
Mass was determined in Japan with a Bruker Microﬂex KS-II, after desalting
using ZipTip (Millipore) with 5-hydroxypicolinic acid/diammonium citrate 5/1
matrix.
Analysis
• Chemical Formula: C364H458N134O221P36
• Mass: 11355.9 (Exact), 11361.4 (MW)
• Maldi: 11364.6 [M-H]−
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9.8.3 Origami related protocols
AFM measurements (performed by K. Hidaka)
AFM images were obtained using a fast-scanning AFM system (Nano Live Vision,
RIBM Co. Ltd., Tsukuba, Japan) with a silicon nitride cantilever (resonant
frequency = 1.0-2.0 MHz, spring constant = 0.1-0.3 N/m, EBD Tip radius <15
nm, Olympus BLAC10EGS- A2). The sample (2 μL) was adsorbed onto a freshly
cleaved mica plate ( 1.5 mm, RIBM Co. Ltd., Tsukuba, Japan) for 5 min at
rt and then washed three times using the same buﬀer solution. Scanning was
performed by tapping mode in the same buﬀer solution.
Denaturing PAGE
The samples were combined with formamide containing loading dye and heated
to 60◦C for 5 min. Then the samples were loaded on a gel (15% acrylamide gel
(37.5:1), 7% urea) preran at 150 V for 15 min and ran at 150 V for 2 h. The gel
was then stained for 10 min in fresh SybrGold solution. A mass ladder (mixture
of 64, 56, 44 and 32 base pairs) was added in a seperate lane.
Construction of ‘5-well frame’
An annealing mixture (20 μl) with 0.01 μM M13mp18 single stranded DNA
(NewEngland BioLabs) and 0.04 μM of all the staples was prepared in 20 mM
Tris buﬀer pH 7.6 with 1 mM EDTA and 10 mM MgCl2. Annealing was per-
formed with a thermocycler (ASTEC PC350) from 85◦C to 15◦C, decreasing 1◦C
per minute (70 min). The origami frame was puriﬁed with Sephacryl S-300 high
resolution (from GE Healthcare) with Micro Bio-Spin Chromatography Columns
(from Biorad).
Insertion of the bridges in ‘5-well frame’
Two possibilities were explored to insert the bridges in the 5-well frame: Annealing
from a mixture of M13mp18, staples and single stranded bridges and annealing
of double stranded bridges into an assembled 5-well frame.
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Annealing from mixture A mixture of all the bridge strands was made, to
have each bridge component in 0.2 μM concentration. 4 and 2 equivalents excess
were then combined with 0.01 μM M13mp18 single stranded DNA (NewEngland
BioLabs) and 0.04 μM of all the staples in 20 mM Tris buﬀer pH 7.6 with 1 mM
EDTA and 10 mM MgCl2. Annealing was performed from 85 to 15
◦C, decreasing
1◦C per minute (70 min). Gelﬁltration was performed as before.
Figure 9.98: AFM images of the 5-well frame with (4 equivalents of) bridges annealed
from a mixture
Figure 9.99: AFM images of the 5-well frame with (2 equivalents of) bridges annealed
from a mixture
Annealing of bridges in frame The frame was prepared as before. The
bridges 1 μM were each annealed separately in solutions of 20 mM Tris buﬀer
pH 7.6 with 1 mM EDTA and 10 mM MgCl2. Annealing was performed from 85
to 15◦C, decreasing 1◦C per minute (70 min). The annealed bridges were then
combined to a mixture with concentration of 0.2 μM. 2 and 4 equivalents of the
annealed bridges were added to the frame in 20 mM Tris buﬀer pH 7.6 with 1
mM EDTA and 10 mM MgCl2. Annealing was performed by heating the mixture
to 50◦C and cooling at 1◦C per minute till 15◦C (35 min). Gelﬁltration was
performed as described before.
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Figure 9.100: AFM images of the 5-well frame with (4 equivalents of) bridges annealed
into it from 55◦C in 35 minutes
Figure 9.101: AFM images of the 5-well frame with (2 equivalents of) bridges annealed
into it from 55◦C in 35 minutes
As this clearly does not result in nicely inserted bridges. The procedure was
optimized with an overnight annealing. This gives very nice looking origami with
bridges assembled in the 5-well frame. These conditions were thus used to prepare
origami for the subsequent cross-linking reactions.
Figure 9.102: AFM images of the 5-well frame with (4 equivalents of) bridges annealed
into it from 55◦C overnight
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9.8.4 Cross-linking
A fresh origami stock was prepared for every experiment (10 μl), as described be-
fore. Both NBS (4 equiv over the course of 1 h, 4x 1 equiv in 0.375 μl) and singlet
oxygen were used to oxidize the furan. The latter was generated by irradiation of
the sample with 4 nM of methylene blue with monochromatic red light of 661 nm
(JASCO HM-3) for 30 or 60 min. The oxidation was performed on ice, to ensure
closed bridges or thus duplex sticky ends.
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9.9 Supporting Material for Color Test
The reactions and subsequent color tests were performed according to the stan-
dard conditions. Prior to reaction dry resins are allowed to swell in DMF with
occasional swirling. For the coupling reaction 4 equiv of N-Fmoc-glycine (297.3
g/mol) and 8 equiv of DIPEA (129.3 g/mol, 0.782 g/ml) were added to the resin
which was suspended in half of the total volume of DMF (1.5 ml/mg). After 15
min, 4 equiv of PyBOP (520.4 g/mol) was added together with the remaining
necessary volume of DMF. The mixture was ﬂushed with argon and vortexed at
rt. This procedure was repeated twice for 2 h. In the standard capping procedure,
acetic acid anhydride (6 equiv) and DIPEA (6 equiv) were added to the resin in
DMF, which was vortexed for 30 min at rt. To obtain complete capping of the hy-
droxyl groups, reaction time was prolonged to 4 h. To cleave formed ester bonds,
the resin was washed four times for 20 s with an aqueous 0.1 M NaOH solution.
After each reaction, excess reagent was ﬁltered oﬀ using vacuum. The resin was
then thoroughly washed with DMF (4x), MeOH (4x), and DCM (4x).
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9.10 Supporting Material for NMR Concentra-
tion Determination
Preparation of standards and samples Tryptophan, estradiol, DAPI
and menthol were purchased from Sigma Aldrich and the oligonucleotide 5’-
GCACACCGTCAG-3’ from IDT DNA Technologies. The peptides AcNH-ILPEI-
COOH and the H2N-RSSVGSQS-COOH were synthesized in our lab in previous
projects.[293, 294] For all compounds, stock solutions of typically 3 ml were pre-
pared in D2O 99.9% (or CD3OD 99.96% for estradiol) using a balance with a
precision of 0.1 mg. For NMR measurements, the stock solutions could be used
as such, for UV measurements on the other hand all stock solutions had to be
diluted with Milli Q H2O (or MeOH for estradiol) to be within the analysable
range for UV spectrometry. This was every time repeated three times, to elimi-
nate random errors. The volumes of the volumetric ﬂasks were chosen as large as
possible to further reduce relative errors (exact dilution conditions are given for
each measurement).
UV measurements Measurements were performed on a Varian BioSpec UV-
Vis spectrophotometer, using the ‘Advanced Reads’ software. The background
was taken into account by zeroing with a blank solution and double beam mode
was used to correct for changes in background absorption. Concentration c was
derived from the measured absorption A following the law of Lambert-Beer, with
l the optical path length (1 cm) and the molar extinction coeﬃcient: A = lc.
To eliminate systematic errors, from each dilution three cuvettes of 1 ml were
ﬁlled and measured 5 times.
The conditions for the measurements were as follows:
• For the DAPI sample 0.95 ml of the 7.5 mM stock solution in D2O was
diluted 3 times with H2O to 250 ml and measured at λmax = 344 nm with
 = 27 000 1/(cm M).[355]
• For the tryptophan sample 0.95 ml of the 15 mM stock solution in D2O was
diluted 3 times with H2O to 100 ml and measured at λmax = 278 nm with
 = 5579 1/(cm M).[355]
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• For the estradiol sample 1.00 ml of the 3 mM stock solution in MeOD was
diluted 3 times with MeOH to 10 ml and measured at the λmax = 280 nm
with  = 2053.9 1/(cm M) (determined via calibration curve).
• For the oligonucleotide sample 0.150 ml of the 2 mM stock solution in D2O
was diluted 3 times with H2O to 50 ml and measured at λmax = 260 nm
with  = 120 000, 112 140 or 114 000 1/(cm M) (calculated taking in account
respectively length,[289] length and composition[290] and length, composi-
tion and sequence[291])
• For the mixture 0.15 ml of the stock solution of 0.9 mM oligonucleotide
and 1.5 mM tryptophan in D2O was diluted 3 times with H2O to 25 ml and
measured for the oligonucleotide at λmax = 260 nm with  = 114 000 1/(cm
M) and for the tryptophan at λmax = 278 nm with  = 5579 1/(cm M).
NMR measurements (performed by K. Gheysen) For the QUANTAS
calibration, tryptophan was used as the standard for water and menthol for
methanol. For both compounds, two stock solutions of 3 mM were independently
prepared and from each stock solution three samples were taken which were mea-
sured in duplicate. All quantitative 1H NMR measurements were performed with
a Bruker Avance-II spectrometer running TopSpin 1.3 software, equipped with a
5 mm TXI 1H-13C/15N probe z-gradient probe and operating at 700.13 MHz. The
temperature was set to 298 K throughout all the measurements. All spectra were
acquired in a quantitative way with a relaxation delay of 30 s and an acquisition
time of 3.34 s. The receiver gain was kept constant at 128. The 1D data were
accumulated from 8 to 64 scans and multiplied with an exponential function with
2.0 Hz line broadening, followed by fourier transformation and baseline correc-
tion. For the integration relative to the artiﬁcial QUANTAS signal at -1 ppm,
well resolved resonances were selected.
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9.11 Supporting material for coupling method
9.11.1 Synthesis of thiolactone-containing building blocks
(performed by Dr. P. Espeel)
Synthesis of linker 5.3.1 .
Figure 9.103: One-step synthesis of carboxyl-functionalized linker compound 5.3.1
An ice-cooled solution of DL-homocysteine thiolactone hydrochloride (7.0 g,
45.6 mmol) in H2O/1,4-dioxane (1/1, 100 ml) was treated with NaHCO3 (19.15
g, 227.9 mmol) and stirred for 30 minutes at 0◦C. Glutaric anhydride (10.4 g,
91.2 mmol) was added to the mixture in several portions. The reaction mixture
was allowed to reach room temperature overnight. The pH was adjusted (pH
= 1) by drop-wise addition of 12 M HCl. Brine (100 ml) was added and the
mixture was extracted with EtOAc (3 x 200 ml). The pooled organic fractions
were dried (MgSO4) and concentrated. The crude residue was puriﬁed by column
chromatography (silicagel, gradient elution: 100% CH2Cl2 to CH2Cl2/acetone :
6/4), yielding linker 5.3.1 as a white solid (8.1 g, 35.0 mmol, 76%).
Analysis
• 1H-NMR (300 MHz, DMSO-d6, ppm) 12.04 (s, 1 H), 8.17 (d, 1H, 8.1 Hz),
4.58 (ddd, 1 H, 12.7, 8.0, 7.2 Hz), 3.31 (m, 2 H), 2.40 (m, 1 H), 2.31 to 1.99
(m, 5 H), 1.71 (m, 2 H).
• 13C-NMR (75 MHz, DMSO-d6, ppm) 205.5 (C), 174.1 (C), 171.7 (C), 58.1
(CH), 34.2 (CH2), 32.8 (CH2), 30.1 (CH2), 26.7 (CH2), 20.5 (CH2).
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Figure 9.104: 1H-NMR spectrum (300 MHz, DMSO-d6) with peak assignment and
integration (top) and HPLC trace with MS analysis (negative mode) of the dominant
species (bottom) of the puriﬁed linker 5.3.1.
Synthesis of building block 5.3.2 .
Figure 9.105: One-step synthesis of building block 5.3.2
Procedure adapted from Rojas-Quijano, F. A.; Benyo, E. T.; Tircso, G.;
Kalman, F. K.; Baranyai, Z.; Aime, S.; Sherry, A. D.; Kovacs, Z. Chem. Eur.
J. 2009, 15, 13188-13200.
DL-homocysteine thiolactone hydrochloride (9.2 g, 60 mmol) and potassium
carbonate (25 g, 180 mmol) were dissolved in H2O (200 ml), and CH2Cl2
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(200 ml) was added. The biphasic reaction mixture was cooled to 0◦C and
a solution of bromoacetyl bromide (10.5 ml, 120 mmol) in CH2Cl2 (40 ml)
was added dropwise. The reaction was stirred at 0◦C for 30 minutes, then
allowed to warm to room temperature and stirred for 1 hour. The two layers
were separated and the organic layer was washed twice with 5% aqueous
citric acid (40 ml) and twice with H2O (40 ml) before drying over Na2SO4.
The solvent was then removed in vacuo to aﬀord 12.1 g (84%) of an oﬀ-white solid.
Analysis
• 1H-NMR (300 MHz, CD3CN, ppm) 7.08 (s, 1 H), 4.57 (app dt, 1 H, 12.8,
7.5 Hz), 3.84 (s, 2 H), 3.38 (app dt, 1 H, 11.4, 5.3 Hz), 3.27 (ddd, 1 H, 11.2,
7.1, 1.4 Hz), 2.56 (m, 1 H), 2.15 (m, 1 H).
• 13C-NMR (75 MHz, CD3CN, ppm) 205.8 (C), 167.4 (C), 60.0 (CH), 31.0
((CH2), 29.4 (CH2), 27.9 (CH2).
Figure 9.106: 1H-NMR spectrum (300 MHz, CD3CN) with peak assignment and
integration (top) and HPLC trace with MS analysis (positive mode) of the dominant
species (bottom) of the puriﬁed building block 5.3.2.
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Synthesis of building block 5.3.3 .
Figure 9.107: One-step synthesis of building block 5.3.3
An ice-cooled solution of DL-homocysteine thiolactone hydrochloride (7.0 g,
45.6 mmol) in H2O/1,4-dioxane (1/1, 100 ml) was treated with NaHCO3 (19.15
g, 227.9 mmol) and stirred for 30 minutes at 0◦C. Acryloyl chloride (8.3 g, 91.2
mmol) was added to the mixture in several portions. The reaction mixture was
allowed to reach room temperature overnight. Brine (100 ml) was added and the
mixture was extracted with EtOAc (3 x 200 ml). The pooled organic fractions
were dried (MgSO4) and concentrated. The crude residue was puriﬁed by column
chromatography (silicagel, gradient elution: 100% CH2Cl2 to CH2Cl2/acetone:
95/5), yielding building block 5.3.3 as a white solid (6.4 g, 37.3 mmol, 82%).
Analysis
• 1H-NMR (300 MHz, DMSO-d6, ppm) 8.45 (d, 1 H, 8.2 Hz), 6.23 (dd, 1 H,
17.1, 9.7 Hz), 6.12 (dd, 1 H, 17.1, 2.6 Hz), 5.65 (dd, 1 H, 9.7, 2.6 Hz), 4.70
(ddd, 1 H, 15.3, 8.2, 7.1 Hz), 3.42 (app dt, 1 H, 11.3, 5.3 Hz), 3.30 (ddd, 1
H, 10.9, 6.9, 1.4 Hz), 2.44 (m, 1 H), 2.09 (m, 1 H).
• 13C-NMR (75 MHz, DMSO-d6, ppm) 205.3 (C), 164.6 (C), 131.0 (CH),
126.2 (CH2), 58.2 (CH), 30.3 (CH2), 26.8 (CH2).
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Figure 9.108: 1H-NMR spectrum (300 MHz, DMSO-d6) with peak assignment and
integration (top) and HPLC trace with MS analysis (positive mode) of the dominant
species (bottom) of the puriﬁed building block 5.3.3.
9.11.2 Oligomer synthesis
Methods
Swelling Prior to the reactions, the solid support was allowed to swell in the
solvent, while shaking for at least 30 minutes.
Washing After each reaction, the solid support was washed with the solvent of
the reaction (4x), with DMF (4x), methanol (4x), CH2Cl2 (4x) and diethyl ether
(1x) and dried under vacuum for storage.
Loading The 2-chlorotrityl chloride resin (200 mg, 1.55 mmol/g) was loaded
with linker 5.3.1 (86.03 mg, 1.2 equiv rel. to resin) in dry CH2Cl2 (2 ml, 10 ml/1
g of resin) with DIPEA (0.26 ml, 4 equiv rel. to acid) and 10 vol% of DMF (0.2
ml), to facilitate the dissolution of the acid. The reaction mixture was shaken for
3 h. The resin was subsequently washed with a CH2Cl2/MeOH/DIPEA mixture
(17:2:1, 3 x 6 ml), CH2Cl2 (3 x 6 ml), DMF (2 x 6 ml), and CH2Cl2 (2 x 6 ml).
The resin was dried under vacuum. To determine the loading of the resin, the
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calibration curve for the carboxylic acid was prepared by UV spectrometry at
254 nm (Fig. 9.109). The eﬃciency of the immobilization of the thiolactone unit
according to the optimized procedure (vide supra) is 75%, resulting in a loading
of 1.16 mmol thiolactone units per gram resin.
Figure 9.109: Calibration curve for the carboxyl-functionalized linker1.
Cleavage The compatibility of the thiolactone ring with standard cleavage
conditions for 2-chlorotrityl chloride resins (1% TFA in CH2Cl2) was tested by
adding 0.5 ml of TFA in CH2Cl2 (1%) to 5 mg of loaded resin and shake for 2
h. The resin was ﬁltered, the solvent evaporated, and the residue dried under
vacuum. The product was dissolved in MeCN for LC-MS analysis. The results
were very similar to the LC-MS results of 1, conﬁrming the expected structure
of the product after the cleavage reaction.
For cleavage, 2 mg of solid support was thus suspended in 0.5 ml of 1%
triﬂuoroacetic acid (TFA) in CH2Cl2 and shaken for 2 h. The solid support was
then ﬁltered, the sample concentrated by evaporation and dissolved in MeCN for
LC-MS analysis.
Aminolysis: general procedure The resin is suspended in CH2Cl2 (10 mg
resin per 100 μL reaction mixture). The selected amine (50 equiv relative to
the resin-bound thiolactone) was added and this mixture is shaken overnight at
room temperature. The resin is washed with DMF (4x), methanol (4x), DCM
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(4x) and diethyl ether (1x) and dried under vacuum.
Chain extension: general procedure The resin is suspended in DMF (10
mg resin per 100 μL reaction mixture) then the building block 5.3.3 (10 equiv
rel. to the resin-bound thiolactone), PhMe2P (10 eq. rel. to the resin-bound
thiolactone), and 1 drop of H2O are added. This mixture is shaken overnight at
rt. The resin is washed with DMF (4x), MeOH (4x), CH2Cl2 (4x) and diethyl
ether (1x) and dried under vacuum.
Microwave-assisted accelerated protocol In order to speed up the overnight
aminolysis and chain extension reaction, both reactions were performed with mi-
crowave assistance, while all other reaction parameters were according to the
general procedures, except for the use of DMF as solvent in both reactions and
the limitation to non-volatile amines as the reactions are performed in an open
vessel. The aminolysis with benzylamine and subsequent chain extension were
performed on the swollen resin by heating at 70◦C for 2 h. These conditions were
applied for the preparation of longer sequences.
Analysis The oligomers were analysed as described in the general protocol for
peptides.
Puriﬁcation The crude samples were puriﬁed by reversed-phase HPLC. The
freeze-dried fractions were consequently subjected to NMR and HRMS analysis
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9.11.3 Additional data
Figure 9.110: LC-MS analysis of the functionalized oligomers originating from repeti-
tive on-resin aminolyses, using two (functional) amines, and chain extensions: pyrrolidine
- allylamine (top) and the reverse order sequence (bottom). Inserts: ESI-MS-spectra of
dominant species (negative mode).
Figure 9.111: LC-MS analysis of the functionalized oligomers originating from repeti-
tive on-resin aminolyses, using two (functional) amines, and chain extensions: pyrrolidine
- furfurylamine (top) and the reverse order sequence (bottom). Inserts: ESI-MS-spectra
of dominant species (negative mode).
9.11. SUPPORTING MATERIAL FOR COUPLING METHOD 321
Figure 9.112: LC-MS analysis of the functionalized oligomers originating from repet-
itive on-resin aminolyses, using two (functional) amines, and chain extensions: n-
propylamine - propargylamine (top) and the reverse order sequence (bottom). Inserts:
ESI-MS-spectra of dominant species (negative mode).
Figure 9.113: LC-MS analysis of the functionalized oligomers originating from repet-
itive on-resin aminolyses, using two (functional) amines, and chain extensions: n-
propylamine - allylamine (top) and the reverse order sequence (bottom). Inserts: ESI-
MS-spectra of dominant species (negative mode).
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Figure 9.114: LC-MS analysis of the functionalized oligomers originating from repet-
itive on-resin aminolyses, using two (functional) amines, and chain extensions: benzy-
lamine - N-(3-aminopropyl)morpholine (top) and the reverse order sequence (bottom).
Inserts: ESI-MS-spectra of dominant species (negative mode).
HRMS data High resolution mass spectra (HRMS) were collected using an
Agilent 6220 Accurate-Mass time-of-ﬂight (TOF) equipped with a multimode
ionization (MMI) source. Monoisotopic masses were calculated using MolE -
Molecular Mass Calculator v2.03.
9.11. SUPPORTING MATERIAL FOR COUPLING METHOD 323
Figure 9.115: HRMS analysis of depicted trimer sequence (A I), in positive (top) and
in negative (bottom) mode
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Figure 9.116: HRMS analysis of depicted trimer sequence (A II), in positive (top)
and in negative (bottom) mode
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Figure 9.117: HRMS analysis of depicted trimer sequence (B I), in positive (top) and
in negative (bottom) mode
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Figure 9.118: HRMS analysis of depicted trimer sequence (B II), in positive (top)
and in negative (bottom) mode
Appendix A
Current Protocols in Nucleic Acid
Chemistry
A.1 BASIC PROTOCOL 1: Synthesis of selective 2’-furan-
modiﬁed uridine nucleoside phosphoramidite
The sequence of reactions in this protocol was reported by Op de Beeck and Madder[138]
and is shown in Figure A.1. First, uridine is converted to 2,2’-O-anhydro-1-(β-D-
arabinofuranosyl)-uracil (2) by cyclization as described by McGee et al.[356] This
is converted to 2’-azido-uridine (3) by substitution [357], which yields the key in-
termediate 2’-amino-2’-deoxyuridine (4) after Staudinger reduction.[358] The furan
modiﬁcation is then introduced by treatment with furfurylisocyanate to give 5.
Finally, 5’-O-tritylation and 3’-O-phosphitylation yield the desired phosphoramidite
7, which is highly selective for ICL formation with C bases in the complementary strand.
All intermediate compounds up to the trityl-protected 6 are stable enough for
prolonged storage (under argon at -20◦C) and may be prepared in larger quantities.
In contrast, because the ﬁnal phosphoramidite 7 is very unstable, it is advisable to
prepare only the required quantity just prior to oligonucleotide synthesis. In addition,
phosphitylation should be performed under dry and inert conditions.
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Figure A.1: Synthesis of 2’-furan-modiﬁed nucleoside phosphoramidite 7.
a. (PhO)2CO, NaHCO3, DMF, 16 h, 115
◦C, 74%; b. LiF, Me3SiN3, DMF/TMEDA,
63 h, 110◦C, 72%; c. PPh3, MeOH, H2O, 3 h, 50
◦C, 89%; d. furfurylisocyanate,
DMF, 1 h, 96%; e. DMTrCl, pyridine, 17 h, rt, 79%; f. 2-cyanoethyl-N,N-
diisopropylchlorophosphine, DIPEA, 2.5 h, 0◦C, 50%.
Materials
• Uridine
• Diphenylcarbonate ((PhO)2CO)
• N,N-Dimethylformamide (DMF), extra dry, on molecular sieves
• Sodium bicarbonate (NaHCO3)
• Dichloromethane (CH2Cl2)
• Methanol (MeOH)
• Lithium ﬂuoride (LiF)
• Azidotrimethylsilane (Me3SiN3)
• Tetramethylethylenediamine (TMEDA)
• Ethyl acetate (EtOAc)
• Triphenylphosphine (PPh3)
• Toluene
• Furfurylisocyanate (Sigma-Aldrich)
• Pyridine, extra dry, on molecular sieves
• 4,4’-Dimethoxytritylchloride (DMTrCl)
• Saturated aqueous sodium bicarbonate (NaHCO3)
• Brine (saturated aqueous NaCl)
• Sodium sulfate (Na2SO4)
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• Isooctane
• Triethylamine (TEA)
• Diisopropylethylamine (DIPEA)
• 2-Cyanoethyl N,N-diisopropylchlorophosphoramidite
• 25-, 50-, and 100-ml round-bottom ﬂasks
• 10- and 25-ml oven-dried round-bottom ﬂask
• Liebig condensers
• No. 4 sintered glass ﬁlter
• Rotary evaporator
• Vacuum pump (dry ice + isopropanol)
• Distillation apparatus for CH2Cl2
• Additional reagents and equipment for TLC (Curr. Protoc. Nucl. Acid Chem.
APPENDIX 3D) and ﬂash chromatography (Curr. Protoc. Nucl. Acid Chem.
APPENDIX 3E)
Prepare 2,2’-O-anhydro-1-(β-D-arabinofuranosyl)-uracil (2)
1. Add 4.99 g uridine (1; 25.6 mmol) to a solution of 5.49 g (PhO)2CO (1 eq, 25.6
mmol) in 5.5 ml dry DMF in a 50-ml round-bottom ﬂask with a Liebig condenser.
Heat to 80◦C until a white turbid solution is obtained (∼2 h).
2. Add 0.046 g NaHCO3 (0.02 eq, 0.55 mmol) and stir at 115
◦C until uridine is
completely consumed (5 h to overnight). Monitor the reaction by TLC (Curr.
Protoc. Nucl. Acid Chem. APPENDIX 3D) using 8:2 (v/v) CH2Cl2/MeOH (Rf
1 = 0.2; Rf 2 = 0.12).
After ∼4 h, gas evolution subsides and a white precipitate forms.
3. Allow mixture to cool to room temperature, then isolate the white precipitate by
ﬁltration through a no. 4 sintered glass ﬁlter. Wash with 10 to 20 ml MeOH.
4. Partially evaporate the ﬁltrate on a rotary evaporator, then isolate the remaining
solid again by ﬁltration. Repeat the concentration/precipitation process twice
more.
2,2’-O-Anhydro-1-(β-D-arabinofuranosyl)-uracil (2) is obtained as a white powder
(yield 74%).
Prepare 2’-azido-uridine (3)
5. Add 0.62 g LiF (1.8 eq, 23.9 mmol) in dry DMF (13.3 ml) to a 50-ml round-bottom
ﬂask with a Liebig condenser and heat to 105◦C.
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6. Add 3.2ml Me3SiN3 (1.8 eq, 23.9 mmol) and 16.6 ml TMEDA (8.3 eq, 110.7 mmol)
and stir for 30 min.
7. Add 3.00 g 2 (13.3 mmol) and continue stirring for another 64 h. Monitor the
reaction by TLC using 8:2 (v/v) CH2Cl2/MeOH (Rf = 0.59).
8. Allow the reaction mixture to cool to room temperature, then concentrate by
rotary evaporation.
9. Dissolve the residue in 10 ml MeOH in a 100-mL round-bottom ﬂask.
10. Add 40 ml EtOAc to precipitate the majority of salts and starting material.
11. Remove solid residue by ﬁltration and wash with 40 ml of 1:4 (v/v) MeOH/EtOAc.
Collect and concentrate the ﬁltrate.
12. Perform a ﬁrst rudimentary puriﬁcation by ﬂash chromatography (Curr. Protoc.
Nucl. Acid Chem. APPENDIX 3E) using 4:1 (v/v) EtOAc/MeOH. Monitor
fractions by TLC as above (Rf = 0.59).
If the compound is not soluble in the eluent, evaporate the ﬁltrate on silica (10 ml)
before loading on the column.
13. Combine fractions containing product and remove solvent under reduced pressure
on a rotary evaporator to give a brown foam.
14. Repurify by ﬂash chromatography using 9:1 (v/v) CH2Cl2/MeOH, monitoring
fractions by TLC as above (Rf = 0.59).
15. Combine fractions containing product and remove the solvent under reduced pres-
sure on a rotary evaporator and then vacuum pump.
2’-Azido-uridine (3) is obtained as an oﬀ-white foam (yield 72%).
Prepare 2’-amino-2’-deoxyuridine (4) by Staudinger reduction
16. Prepare a solution of 0.406 g 3 (1.51 mmol) in 16.5 ml of 9:1 (v/v) MeOH/H2O
in a 50-ml round-bottom ﬂask with a Liebig condenser.
17. Add 0.434 g PPh3 (1.1 eq, 1.65 mmol) and stir at 50
◦C for 3 h. Monitor by TLC
in 8:2 (v/v) CH2Cl2/MeOH (Rf = 0.09).
18. Combine fractions that contain product and concentrate by rotary evaporation.
19. Purify the product by recrystallizing overnight in 15 ml toluene under reﬂux con-
ditions (110◦C).
2’-Azido-2’-deoxyuridine (4) is obtained as a yellowish powder (yield 89%). Best
results are obtained with overnight crystallization.
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Prepare furan-modiﬁed nucleoside 5
20. Dissolve 0.200 g 4 (0.82 mmol) in 8.2 ml dry DMF in a 25-ml round-bottom ﬂask,
and then cool in an ice bath.
21. Add 100 μl furfurylisocyanate (1.1 eq, 0.90 mmol) dropwise and then stir the cold
reaction for 1 h. Monitor by TLC using 9:1 (v/v) CH2Cl2/MeOH (Rf = 0.24).
22. Quench the reaction with 1 ml MeOH, then concentrate the product under vac-
uum.
23. Purify the residue by ﬂash chromatography using 95:5 (v/v) CH2Cl2/MeOH and
monitor fractions by TLC as above (Rf = 0.24).
24. Combine fractions containing the product and remove solvent under reduced pres-
sure on a rotary evaporator and then vacuum pump.
2’-Deoxy-2’-[3-(2-furyl)-2-azapropanamido)]uridine (5) is obtained as an oﬀ-white
foam (yield 96%).
Perform dimethoxytritylation to give 6
25. Dry 76 mg 5 (0.207 mmol) by co-evaporating three times with 1 ml dry pyridine
in an oven-dried 25-ml round-bottom ﬂask.
26. Dissolve in 2 ml dry pyridine and cool to 0◦C on ice.
27. Add 99 mg DMTrCl (1.4 eq, 0.29 mmol) and stir overnight at room temperature.
28. Monitor by TLC using 9:1 (v/v) CH2Cl2/MeOH (Rf = 0.43). If the reaction is not
complete, add another 35 mg DMTrCl (0.5 eq, 0.10 mmol) at 0◦C, and continue
stirring at room temperature for an additional 4 h.
29. When the reaction is complete, cool in an ice bath and quench with 100 μl MeOH.
30. Dilute with 10 ml EtOAc, then wash successively with 10 ml water, 10 ml saturated
aqueous NaHCO3, and 10 ml brine.
31. Extract the combined aqueous layers with 30 ml EtOAc.
32. Dry the combined organic layers on Na2SO4 and then concentrate by rotary evap-
oration.
33. Purify the residue by ﬂash chromatography using 70:29:1 (v/v/v)
EtOAc/isooctane/TEA and monitor fractions by TLC using 9:1 (v/v)
CH2Cl2/MeOH (Rf = 0.43).
The eluent should contain 1% TEA because the DMTr protecting group is
acid-sensitive. This eluent should also be used to pretreat the silica resin by
eluting 2 column volumes before the product is loaded on the column.
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34. Combine fractions containing product and remove the solvent under reduced
pressure on a rotary evaporator and then vacuum pump.
2’-Deoxy-2’-[3-(2-furyl)-2-azapropanamido)]-5’-O-(4,4’-dimethoxytrityl)uridine
(6) is obtained as an oﬀ-white foam (yield 79%).
Perform phosphitylation to give phosphoramidite 7
35. Dry 79 mg 6 (0.118 mmol) by co-evaporating twice with 1 ml toluene and once
with 1 ml freshly distilled CH2Cl2 in an oven-dried 10-ml round-bottom ﬂask.
36. Dissolve in 2 ml dry CH2Cl2 and cool to 0
◦C on ice.
37. Add 65 μl DIPEA (3 eq, 0.364 mmol) followed by 40 μl 2-cyanoethyl N,N-
diisopropylchlorophosphoramidite (1.5 eq, 0.179 mmol) and stir for 1.5 h at 0◦C.
Monitor by TLC using 8:2 (v/v) isooctane/EtOAc (Rf = 0.45).
38. Quench with 100 μl MeOH.
39. Dilute with 20 μl EtOAc and wash the organic phase once with 20 ml saturated
aqueous NaHCO3 and three times with 20 ml brine.
40. Dry the organic phase on Na2SO4 and concentrate by rotary evaporation.
41. Purify the residue by ﬂash chromatography using 55:44:1 (v/v/v)
EtOAc/isooctane/TEA and monitor by TLC as above (Rf = 0.45).
As the phosphoramidite is very sensitive, the puriﬁcation should be performed
swiftly, using 1% TEA in the eluent and pretreating the silica as in step 33.
42. Combine fractions containing product and remove solvent under reduced pressure
on a rotary evaporator and then vacuum pump.
2’-Deoxy-2’-[3-(2-furyl)-2-azapropanamido)]-5’-O-(4,4’-dimethoxytrityl)uridine
3’-(2-cyanoethyl N,N-diisopropylphosphoramidite) (7) is obtained as an oﬀ-white
foam (yield 50%).
A.2 ALTERNATE PROTOCOL: Synthesis of 2’-furan-
modiﬁed acyclic nucleoside phosphoramidite
The sequence of reactions in this protocol was reported by Stevens and Madder[135]
and is illustrated in Figure A.2. First, (4S)-(+)-4-(2-hydroxyethyl)-2,2-dimethyl-1,3-
dioxolane (8) is activated by tosylation to 9. This is converted by SN2 to the bromine
derivative 10. The furan modiﬁcation is then introduced by addition of lithiated furan
to give 11. Acid deprotection results in (S)-4-furan-2-yl-butane-1,2-diol (12). Finally,
5’-O-tritylation and 3’-O-phosphitylation yield the desired phosphoramidite 14, which
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is useful for high yield ICL reactions with complementary A or C bases.
Intermediates 9 and 1113 are stable enough for prolonged storage (under argon at
-20◦C). We are not sure about the stability of 10 and advise to use it immediately.
Phosphoramidite 14 is unstable and should be prepared only in the quantity needed
just before oligonucleotide synthesis. Phosphitylation should be performed under dry
and inert conditions.
Figure A.2: Synthesis of acyclic furan-modiﬁed phosphoramidite 14. a. pTsCl
(1.15 eq.), pyridine, 0◦C, 2.5 h, 91%; b. LiBr (5 eq.), DMF, 60◦C, 1 h, 76%; c. furan (2
eq.), BuLi (1.8 eq.), THF, -78◦ to 0◦C, 16 h, 62% over two steps; d. 4 M HCl, THF, 3 h,
0◦C, 89%; e. DMTrCl (1 eq.), pyridine, 0◦C, 1.25 h, 66%; f. (iPr2N)(NCCH2CH2O)PCl
(2.5 eq.), DIPEA, CH2Cl2, 1.5h, rt, 79%.
Materials
• (4S)-(+)-4-(2-Hydroxyethyl)-2,2-dimethyl-1,3-dioxolane (8; Sigma-Aldrich)
• Pyridine, extra dry, on molecular sieves
• p-Toluenesulfonyl chloride (pTsCl)
• Argon gas
• Ethyl acetate (EtOAc)
• Pentane
• 1 M and 4 M aqueous HCl
• Diethyl ether (Et2O)
• Saturated aqueous sodium bicarbonate (NaHCO3)
• Anhydrous sodium sulfate (¡eNa2SO4)
• N,N-Dimethylformamide (DMF), extra dry, on molecular sieves
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• Lithium bromide (LiBr),
made anhydrous by heating under vacuum for 1 min
• Isooctane
• Tetrahydrofuran (THF), extra dry, on molecular sieves
• Isopropanol
• Dry ice
• n-Butyllithium (n-BuLi)
• Hexane
• Furan
• 4,4’-Dimethoxytritylchloride (DMTrCl)
• Cyclohexane
• Methanol (MeOH)
• Triethylamine (TEA)
• Toluene
• Dichloromethane (CH2Cl2)
• Diisopropylethylamine (DIPEA)
• 2-Cyanoethyl N,N-diisopropylchlorophosphoramidite
• 25- and 50-ml two-neck ﬂasks
• 25- and 50-ml oven-dried round-bottom ﬂasks
• Rotary evaporator
• Vacuum pump (dry ice + isopropanol)
• Distillation apparatus for CH2Cl2
• Additional reagents and equipment for TLC (Curr. Protoc. Nucl. Acid Chem.
APPENDIX 3D) and ﬂash chromatography (Curr. Protoc. Nucl. Acid Chem.
APPENDIX 3E)
Prepare tosylate 9
1. Weigh 1.73 g (4S)-(+)-4-(2-hydroxyethyl)-2,2-dimethyl-1,3-dioxolane (8; 11.85
mmol) in a 25-ml two-neck ﬂask.
2. Add 1.5 ml dry pyridine and 2.59 g pTsCl (1.15 eq, 13.6 mmol), ﬂush the ﬂask with
argon, and stir at room temperature for 2.5 h. Monitor the reaction by TLC (Curr.
Protoc. Nucl. Acid Chem. APPENDIX 3D) using 1:1 (v/v) EtOAc/pentane (Rf
= 0.71).
A white suspension is formed after a couple of minutes.
3. Quench the reaction by pouring the mixture into 3 ml of 1 M aqueous HCl.
4. Extract product with 5 ml Et2O·
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5. Wash the organic phase three times with 5 ml of 1 M aqueous HCl and three times
with 5 ml saturated aqueous NaHCO3·
6. Dry with anhydrous Na2SO4 and evaporate under reduced pressure on a rotary
evaporator and then vacuum pump.
(S)-Toluene-4-sulfonic acid 2-(2,2-dimethyl-[1,3]dioxolan-4-yl)-ethyl ester (9) is
obtained as a colorless oil (yield 91%) and can be used for further reactions without
puriﬁcation.
Prepare (S)-4-(2-Bromo-ethyl)-2,2-dimethyl-[1,3]dioxolane (10)
7. Dissolve 1.99 g 9 (6.63 mmol) in 10 ml extra dry DMF in a 50-ml oven-dried
round-bottom ﬂask.
8. Add 2.54 g anhydrous LiBr (5 eq, 33 mmol). Slowly heat the mixture to 60◦C
with stirring, and then let stir another 1 h at 60◦C. Monitor by TLC using 2:3
(v/v) EtOAc/isooctane (Rf = 0.53).
9. Quench reaction by pouring the mixture into 25 ml ice water.
10. Extract product three times with 25 ml Et2O. Combine the organic phases and
wash with 75 ml water and then 75 ml saturated aqueous NaHCO3.
11. Dry the organic phase with anhydrous Na2SO4 and evaporate under reduced pres-
sure.
Product 10 is volatile (b.p. 90◦C/19 Torr). To prevent evaporation of the com-
pound, never turn on the heating water bath of the rotary evaporator.
12. Purify residue by ﬂash chromatography (Curr. Protoc. Nucl. Acid Chem. AP-
PENDIX 3E) using 1:5 (v/v) EtOAc/pentane and monitor fractions by TLC as
above (Rf = 0.53).
13. Combine fractions containing product and remove solvent under reduced pressure
on a rotary evaporator and then vacuum pump.
(S)-4-(2-Bromo-ethyl)-2,2-dimethyl-[1,3]dioxolane (10) should be used soon after
preparation.
Prepare (S)-4-(2-Furan-2-yl-ethyl)-2,2-dimethyl-[1,3]dioxolane (11)
14. Add 6 ml dry THF to a 50-ml two-neck ﬂask and cool to -78◦C in an iso-
propanol/dry ice bath.
15. While stirring, add 7.5 ml of 1.6 M n-BuLi in hexane and 0.9 g furan (2 eq, 13.25
mmol). Leave at -78◦C for another 15 min.
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16. Transfer ﬂask to a normal ice bath (0◦C) and leave for 2 h.
A white precipitate is formed.
17. During precipitation, co-evaporate the entire amount of bromide 10 three times
with 10 ml dry THF to ensure that it is dry for the next reaction.
18. Add dry 10 to the precipitate in the ﬂask and stir the reaction overnight at room
temperature. Monitor by TLC using 2:3 (v/v) EtOAc/isooctane (Rf = 0.56).
19. Quench the reaction by pouring into 25 ml ice water.
20. Extract product with 25 ml Et2O. Dry the organic phase with anhydrous Na2SO4
and evaporate under reduced pressure.
21. Purify residue by ﬂash chromatography using 1:10 (v/v) EtOAc/pentane and mon-
itor fractions by TLC as above (Rf = 0.56).
22. Combine fractions containing product and remove solvent under reduced pressure
on a rotary evaporator and then vacuum pump.
(S)-4-(2-Furan-2-yl-ethyl)-2,2-dimethyl-[1,3]dioxolane (11) is obtained as a dark
yellow oil (yield 62% over two steps).
Prepare (S)-4-furan-2-yl-butane-1,2-diol (12)
23. Dissolve the 0.309 g diol 11 (1.57 mmol) in 3 ml THF in a 25-ml round-bottom
ﬂask.
24. Add 1.5 ml of 4 M HCl while stirring in an ice bath (0◦C), then continue stirring
at 0◦C for 3 h. Monitor by TLC using 2:3 (v/v) EtOAc/pentane (Rf = 0.14).
25. Extract product with 10 ml EtOAc and then evaporate under reduced pressure.
26. Purify residue by ﬂash chromatography using 1:1 (v/v) EtOAc/pentane and mon-
itor fractions by TLC as above (Rf = 0.14).
27. Combine fractions containing product and remove solvent under reduced pressure
on a rotary evaporator and then vacuum pump.
(S)-4-Furan-2-yl-butane-1,2-diol (12) is obtained as a red oil (yield 89%).
Prepare (S)-1-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-4-furan-2-yl-
butane-2-ol (13)
28. Dry 0.212 g diol 12 (1.36 mmol) by co-evaporating three times with 5 ml extra
dry pyridine in an oven-dried 25-ml two-neck ﬂask.
29. Dissolve in 2 ml extra dry pyridine and cool to 0◦C on ice.
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30. Add 0.46 g DMTrCl (1 eq, 1.36 mmol) and stir for 1.25 h at 0◦C. Monitor by TLC
using 1:5 (v/v) EtOAc/cyclohexane (Rf = 0.4).
31. Add 1 ml MeOH and stir for 10 min at 0◦C.
32. Add 15 ml EtOAc and wash the organic phase three times with 20 ml saturated
aqueous NaHCO3·
33. Dry the organic phase with anhydrous Na2SO4 and evaporate under reduced pres-
sure.
34. Purify product by ﬂash chromatography using 12:87:1 (v/v/v)
EtOAc/cyclohexane/TEA and monitor fractions by TLC as above (Rf =
0.4).
The eluent should contain 1% TEA because the DMTr protecting group is
acid-sensitive. This eluent should also be used to pretreat the silica resin by
eluting 2 column volumes before the product is loaded on the column.
35. Combine fractions containing product and remove solvent under reduced pressure
on a rotary evaporator and then vacuum pump.
(S)-1-[Bis-(4-methoxy-phenyl)-phenyl-methoxy]-4-furan-2-yl-butane-2-ol (13) is
obtained as an oil (yield 66%).
Perform phosphitylation to give phosphoramidite 14
36. Dry 220 mg 13 (0.48 mmol) by co-evaporating twice with 2 ml toluene and once
with 2 mL freshly distilled CH2Cl2 in an oven-dried 25-ml round-bottom ﬂask.
37. Dissolve in 10 mL dry CH2Cl2·
38. Add 0.9 ml DIPEA (11.25 eq, 5.4 mmol) and 269 μl 2-cyanoethyl N,N diisopropy-
lchlorophosphoramidite (2.5 eq, 1.2 mmol) and stir for 2 h. Monitor by TLC using
1:7 (v/v) EtOAc/cyclohexane (Rf = 0.25).
39. Quench reaction by adding 20 ml saturated aqueous NaHCO3·
40. Extract product with 20 ml CH2Cl2·
41. Dry the organic phase with anhydrous Na2SO4 and evaporate under reduced pres-
sure.
42. Purify compound by ﬂash chromatography using 1:7 (v/v) EtOAc/cyclohexane
and monitor fractions by TLC as above (Rf = 0.25).
43. Combine fractions containing product and remove solvent under reduced pressure
on a rotary evaporator and then vacuum pump.
As the phosphoramidite is very sensitive, the puriﬁcation should be performed
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swiftly, using 1% TEA in the eluent and pretreating the silica as in step 34.
Diisopropyl-phosphoramidous acid-1-[bis-(4-methoxy-phenyl)-phenyl-methoxy]-4-
furan-2-yl-propyl ester 2-cyano-ethyl ester (14) is obtained as a colorless oil (yield
79%).
A.3 BASIC PROTOCOL 2: Synthesis of furan-containing
oligodeoxynucleotides
Phosphoramidites 7 and 14 are incorporated as a manual step in an otherwise standard
automated ODN synthesis. Preparation of coupling solution, manual coupling, and
postsynthetic workup steps compatible with the incorporated furan moiety are described
here.
Materials
• Furan-modiﬁed phosphoramidite 7 (see Basic Protocol 1) or 14 (see Alternate
Protocol)
• 4,5-Dicyanoimidazole (DCI)
• Acetonitrile (MeCN), extra dry, on molecular sieves
• Nitrogen and argon gas
• Controlled-pore glass (CPG) derivatized with desired 3’ nucleoside (Proligo)
• Unmodiﬁed phosphoramidites, conﬁgured for DNA synthesizer (Proligo): DMTr-
dABz, DMTr-dCBz, DMTr-dGiBu, and DMTr-T
• Activated molecular sieves
• Reagents for automated ODN synthesis, conﬁgured for DNA synthesizer (Proligo):
activator, oxidizer, cap A and B solutions, TCA deblock
• 50 mM aqueous ammonia (NH4OH)
• DMTr-selective cartridge (Sep-pak from Waters)
• Rotary evaporator
• Vacuum pump (dry ice + isopropanol)
• Microcentrifuge tube
• Additional reagents and equipment for automated DNA synthesis (Curr. Protoc.
Nucl. Acid Chem. APPENDIX 3C) and ODN puriﬁcation using a DMTr-selective
cartridge (UNIT 10.7)
NOTE: ODN synthesis should be performed under anhydrous conditions using oven-
dried glassware, needles, and syringes, or new plastic syringes and needles that have been
dried in a desiccator for 2 days.
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Synthesize ODN
1. Evaporate crude phosphoramidite 7 or 14 with dry MeCN on a rotary evaporator
and then dry overnight using a vacuum pump.
2. Prepare 0.5 ml of 1 M DCI activator solution (59 mg) per sequence in dry MeCN
with molecular sieves and ﬂush with argon.
3. Weigh the proper amount of CPG to obtain 1 μmol of the 3’ nucleoside in a column
and place the column in the synthesizer.
4. Follow standard setup procedures (diluting commercial phosphoramidites to 0.1
M in MeCN, priming lines, programming) for automated ODN synthesis (Curr.
Protoc. Nucl. Acid Chem. APPENDIX 3C) on a 1-μmol scale, using the furan-
modiﬁed phosphoramidite as the extra (ﬁfth) phosphoramidite. Install a clean,
dry, empty ﬂask in the ﬁfth phosphoramidite position, and prime this extra line
with the other lines. Program synthesis to leave the trityl group attached to the
last unmodiﬁed nucleoside.
5. Perform synthesis cycles using the unmodiﬁed phosphoramidites.
6. During automated synthesis, dissolve modiﬁed phosphoramidite at ∼0.06 M in
dry MeCN. Transfer 0.4 ml (per sequence) to a dried ﬂask and ﬂush well with
argon. No more than 30 min before incorporation, add 3 molecular sieves and
ﬂush again with argon.
7. When coupling of the modiﬁed phosphoramidite begins, interrupt the synthesizer
and remove the column.
8. Take 0.4 ml modiﬁed phosphoramidite in a dry syringe and 0.5 ml DCI activator
solution in another dry syringe. To perform manual coupling by the double-syringe
technique, place an empty dry syringe at one end of the column and, from the
other end, alternately push portions of amidite solution and activator solution
over the column. Never push more than 1 column volume at once.
Total coupling time is ∼20 min.
If desired, phosphoramidite 14 and the activator solution can be mixed in a single
syringe and added simultaneously over the column, and manual capping (step 9)
can be omitted. This is not recommended for 7, because the coupling eﬃciency
is very low. Aside from a lower reactivity caused by the sterical hindrance of the
2’-modiﬁcation of 7, the nucleophile present in the modiﬁed building block can at-
tack the activated phosphoramidite in a side reaction, deactivating it. Coupling
eﬃciency could be improved by adding the activator to the phosphoramidite in the
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presence of the growing ODN chain, rather than mixing activator and phosphor-
amidite beforehand. An extra manual capping step is performed for 7, because of
the coupling yield, to avoid a deletion sequence. Regular capping steps are per-
formed for both on the synthesizer.
9. Using the same double-syringe method, rinse the column with 1 ml MeCN, then
push 1 mL of 1:1 (v/v) cap A/cap B solutions over the column, and rinse again
with 1 ml MeCN.
10. Return the column to the synthesizer and resume automated synthesis.
Deprotect, release, and purify ODN
11. Remove the column containing the completed ODN from the synthesizer and the
CPG under a stream of nitrogen.
12. Pour the CPG into a microcentrifuge tube.
13. Deprotect and cleave the ODN from the CPG by adding 1 ml of 50 mM NH4OH
and incubating overnight at 55◦C.
14. Purify the ODN over a DMTr-selective cartridge (UNIT 10.7).
ODNs are best stored lyophilized at -20◦C, but they can be stored for years in
aqueous solution at -20◦C.
A.4 BASIC PROTOCOL 3: Selective formation of DNA
interstrand cross-links
Cross-link formation occurs upon oxidation of furan to the reactive 4-oxobutenal with
NBS in water. Under these speciﬁc and mild oxidation conditions furan is quickly
oxidized, while the DNA remains unaﬀected. The in-situ oxidation after hybridization,
strongly reduces unspeciﬁc site reactions. This protocol describes the formation and
analysis of ICL by RP-HPLC and denaturing PAGE.
Materials
• Furan-modiﬁed ODN (see Basic Protocol 2)
• Complementary ODN
• 100 mM (10x) phosphate buﬀer, pH 7
• 1 M (10x) NaCl
• Milli-Q-puriﬁed water
• N-Bromosuccinimide (NBS)
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• Acetonitrile (MeCN), HPLC grade, >99.9
• 0.1 M triethylammonium acetate (TEAA) buﬀer, pH 7
• Formamide
• GelRed stock solution (Biotium): 10,000x in dimethyl sulfoxide (DMSO)
• Microcentrifuge tube
• Eppendorf thermomixer
• Additional reagents and equipment for RP-HPLC (UNIT 10.5) and PAGE (Curr.
Protoc. Nucl. Acid Chem. UNIT 10.4 & Curr. Protoc. Nucl. Acid Chem.
APPENDIX 3B)
Activate furan-mediated cross-link formation
1. In a microcentrifuge tube, prepare a 50-μl ODN solution as follows: 1 nmol furan-
modiﬁed ODN, 1 nmol complementary ODN, 5 μl 100 mM phosphate buﬀer, pH
7 (ﬁnal 10 mM), 5 μl 1 M NaCl (ﬁnal 100 mM), Milli-Q-puriﬁed water to 50 μl.
2. Place in a thermomixer and heat from room temperature to 95◦C, thenmaintain
95◦C for an additional 10 min.
3. Turn oﬀ the thermomixer and allow sample to cool to room temperature over at
least 2 h.
Better annealing is achieved by turning oﬀ the thermomixer rather than removing
the sample, as this allows the sample to cool as slowly as possible.
4. If desired, remove several μl as reference material for later analysis by RP-HPLC
or PAGE.
5. Prepare a fresh solution of 500 μM NBS in Milli-Q-puriﬁed water.
6. While holding the annealed sample at 25◦C in the thermomixer, add 2 μl freshly
prepared NBS (1 eq) with shaking at 950 rpm. Repeat for a total of four additions
at 15-min intervals.
If samples were removed for analysis, the volume of NBS should be adjusted to
account for the reduced amount of furan-modiﬁed ODN.
Analyze cross-link formation by HPLC
7. Take 2 μl reaction mixture and dilute to 20 μl with Milli-Q-puriﬁed water in an
HPLC vial.
8. Analyze by RP-HPLC (UNIT 10.5) on a C18 column with a gradient of 5% to
30% MeCN in 100 mM TEAA buﬀer over 15 min at 50◦C and UV detection at
260 nm.
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Analyze cross-link formation by denaturing PAGE
9. Mix 2 μl reaction mixture with 2 μl formamide as loading buﬀer and analyze by
denaturing PAGE (Curr. Protoc. Nucl. Acid Chem. UNIT 10.4 & Curr. Protoc.
Nucl. Acid Chem. APPENDIX 3B).
Speciﬁc conditions depend on the length of ODN. For 12-mer ODNs, use a 20 x
20-cm 20% polyacrylamide gel (19:1 acrylamide/bisacrylamide) with 7 M urea and
run at 120 V overnight at 25◦C.
10. Stain the gel for 30 min with shaking in 100 ml water containing 10 μl GelRed
stock solution. Visualize ODNs by illuminating the gel with UV light in a black
box.
CAUTION: GelRed is an intercalator and is therefore toxic. Careful handling with
appropriate gloves is required.
Appendix B
NMR study of the Sequence
Controlled Oligomers
Samples Two pairs of structurally related oligomeric sequences (Table B.1) were
prepared using the microwave-assisted protocol (vide supra). The ﬁrst pair of
trimers A I & A II only diﬀer in the second amine residue as a diﬀerent amine
(2-methoxyethylamine in A I vs benzylamine in A II) was used in the second iterative
cycle. The second pair consists of a trimer B I and a tetramer B II; an additional
aminolysis (furfurylamine)/chain extension cycle starting from B I resulted in the
formation of B II. The crude samples were puriﬁed by preparative reversed-phase
HPLC. The freeze-dried fractions were consequently subjected to NMR and HRMS
analysis (vide infra). Oligomers A I & A II ( 1.3 mg each) were dissolved in 650 μL
DMSO-d6 in a 5 mm-NMR tube, prior to analysis using the Bruker 500 MHz Avance II
spectrometer. Oligomers B I & B II ( 1.5 mg each) were dissolved in 17 μL DMSO-d6
an transferred to a 1 mm-NMR tube, prior to analysis using the Bruker 700 MHz
Avance II spectrometer.
NMR experiments (performed by Dr. P. Espeel) Each sample was
analyzed by 1D-1H- and 2D-NMR (gCOSY, TOCSY, 1H-13C multiplicity-edited
gHSQC, 1H-13C gHMBC and NOESY). In the following, the preﬁx g, signifying
gradient-enhanced sequences, will be dropped. NMR experiments were performed
either at 500 MHz or 700 MHz, both using a Bruker Avance II spectrometer equipped
with a 5 mm TXI-Z 1H,13C,31P probe, respectively a 1 mm TXI-Z 1H,13C,15N
probe. The latter aﬀords a 5-fold higher mass sensitivity compared to a 5 mm
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Table B.1: Structural information of two pairs of related oligomeric sequences, trimers
A I, A II, B I & tetramer B II, subjected to NMR and HRMS analysis.
345
probe at the same ﬁeld. Used at 700 MHz, this aﬀords a 15-fold increase in signal
to noise compared to the 5 mm probe at 500 MHz, in addition to the obvious
improvement in resolution. The sensitivity advantage proved most interesting to
obtain 2D NOESY spectra of suﬃcient quality to support the assignment process,
given that limited quantities of material were available and that the nOe cross-peaks
generally consist at most of about 5% of the diagonal peak intensity. All measure-
ments were performed at 25◦C and used TopSpin 3.1 for acquisition and processing
of all data. All spectra including 1D-1H, 2D gCOSY, TOCSY (80 ms), NOESY
(300 ms), 1H-13C gHSQC and 1H-13C gHMBC (optimized for nJCH of 8 Hz) were
recorded using in a standard fashion with pulse programs available in the Bruker library.
Data analysis and peak assignment (performed by Dr. P. Espeel) The
1D-1H NMR spectra of A I, A II, B I & B II are shown respectively in Figure B.1,
B.2, B.3 and B.4.
The analysis of the obtained 2D-NMR data is illustrated by a selection of plots
(zoom) of the relevant, well-resolved spectra.
A detail of the 1D-1H NMR spectra of A I, A II, B I & B II (8.5 to 6.0 ppm)
with assignment of the amide N-H and aromatic signals of the amine residues is shown
in Figure B.5 and B.6.
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Figure B.1: 1D-1H-NMR spectrum (500 MHz, DMSO-d6) of trimer sequence A I.
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Figure B.2: 1D-1H-NMR spectrum (500 MHz, DMSO-d6) of trimer sequence A II.
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Figure B.3: 1D-1H-NMR spectrum (500 MHz, DMSO-d6) of trimer sequence B I.
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Figure B.4: 1D-1H-NMR spectrum (500 MHz, DMSO-d6) of tetramer sequence B II.
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Figure B.5: Details (8.5 to 6 ppm) of 1D-1H-NMR spectrum (500 MHz, DMSO-d6) of
A I (top) and A II (bottom).
351
Figure B.6: Details (8.5 to 6 ppm) of 1D-1H-NMR spectrum (500 MHz, DMSO-d6) of
B I (top) and B II (bottom).
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At ﬁrst glance, the aromatic protons (Figure B.5 and B.6) can be assigned by com-
parison of the obtained spectra. More importantly, each sequence is characterized by a
set of typical amide N-H signals (Hi in Figure B.5 and B.6), for which only tentative
assignment is possible by comparison of the 1D-1H NMR spectra. Additionally, stacked
plots of the respective gCOSY and TOCSY spectra (zoom) of bothA I & A II (Fig. B.7
and B.8) reveal a clear distinction between the amide N-H signals in the backbone (Ha,
Hb and Hc), at the thiolactone chain end (Hd) and those in the side chains (He, Hf
and Hg). Moreover, side chain amide N-H signals, originating from aromatic amines,
have a higher chemical shift than those from aliphatic amines. Similar conclusions can
be made from the corresponding COSY/TOCSY spectra of B I &B II (not shown here).
Despite the high degree of spectral crowding in the high-ﬁeld region, stacking the
COSY and TOCSY spectra of B I (Fig. B.9) facilitates further assignment of overlap-
ping signals. Furthermore, 5 well-resolved nOe contacts, involving amide protons, in B I
(Figure S21), allow for the connection of the speciﬁc amine residues to the backbone (nOe
4 and 5, Fig. B.10). Additionally, nOe contacts, bridging the amide C=O bonds in the
backbone, even enable partial elucidation of the oligomeric sequence, as nOe 1 connects
the amide NH, Ha, to a CH2 signal of the linker (Fig. B.10). Unfortunately, nOe 2 and
3 cannot be unambiguously attributed to fully conﬁrm the sequential build-up via NMR.
Due to the poor signal-to-noise ratio in the APT spectra, the 13C-chemical shift
values were extracted from the corresponding HSQC and HMBC spectra, the latter for
quaternary carbons. The carbons in aromatic residues can be readily assigned from
an overlay of the HSQC and HMBC spectra, as demonstrated for the sequence A I
(Fig. B.11, left). The amide C=O signals (1˜71 ppm) are linked to the speciﬁc amide
N-H signals in the well-resolved HMBC spectrum (Fig. B.11, right).
The remaining C=O carbons at both ends of the sequence (COOH and thiolactone
unit) can be assigned in a similar manner (B I, Figure S23). Furthermore, combining the
COSY/TOCSY spectra (Figure S20) and the gHSQC spectrum (Figure S24) of B I al-
lows for the assignment of all (CH)-, (CH2)- and (CH3)- carbons in the high-ﬁeld region.
This in-depth study of the obtained 2D-NMR spectra enables full characterization of
all obtained samples, as for each sequence, the chemical shift of all 1H- and 13C-atoms
was determined (Table B.3 to B.10), despite the spectral crowding in the high-ﬁeld
region.
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Figure B.7: Stacked plots of the COSY (red) and TOCSY (blue) spectra (500 MHz,
DMSO-d6) of A I reveal a clear distinction between the amide N-H signals in the
backbone (Ha, Hb and Hc), at the thiolactone chain end (Hd) and those in the side
chains (He, Hf and Hg).
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Figure B.8: Stacked plots of the COSY (red) and TOCSY (blue) spectra (500 MHz,
DMSO-d6) of A II (right) reveal a clear distinction between the amide N-H signals in
the backbone (Ha, Hb and Hc), at the thiolactone chain end (Hd) and those in the side
chains (He, Hf and Hg).
355
Figure B.9: Stacked plot of the COSY (red) and TOCSY (blue) spectra (700 MHz,
DMSO-d6) of B I to facilitate the assignment of high-ﬁeld protons. (5 to 1.5 ppm).
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Figure B.10: Stacked plot of the COSY (red) and the NOESY (blue) spectra (700
MHz, DMSO-d6) of B I. 5 nOe Contacts allow for the connection between side chain
residues and the backbone and the partial elucidation of the sequential build-up.
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Figure B.11: HSQC (red) and HMBC (blue) spectra (500 MHz, DMSO-d6) of A I.
The carbons in aromatic residues can be assigned from an overlay of the HSQC and
HMBC spectra (left) and the amide C=O signals are linked to the speciﬁc amide N-H
signals (right).
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Figure B.12: High-ﬁeld region of the HSQC spectrum showing multiplicity editing
(700 MHz, DMSO-d6) of B I
359
Table B.2: Determination of the 1H- and 13C- chemical shift values of B I
360 APPENDIX B. NMR STUDY
Table B.3: 1H - chemical shifts of trimer A I (500 MHz, DMSO-d6).
Table B.4: 13C - chemical shifts of trimer A I (125 MHz, DMSO-d6).
361
Table B.5: 1H - chemical shifts of trimer A II (500 MHz, DMSO-d6).
Table B.6: 13C - chemical shifts of trimer A II (125 MHz, DMSO-d6).
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Table B.7: 1H - chemical shifts of trimer B I (700 MHz, DMSO-d6).
Table B.8: 13C - chemical shifts of trimer B I (175 MHz, DMSO-d6).
363
Table B.9: 1H - chemical shifts of tetramer B II (700 MHz, DMSO-d6).
Table B.10: 13C - chemical shifts of tetramer B II (175 MHz, DMSO-d6).
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